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1002-203 The Relationship between the Framingham 
Cardiovascular Risk Score and C-reactive Protein 
Levels Among Women of Various Race/Ethnic Groups
Fidencio Saldana, Robert J. Glynn, Paul M. Ridker, Michelle A. Albert, Brigham and 
Women’s Hospital/Harvard Medical School, Boston, MA
Background: While data exists on the relationship between the Framingham 
Cardiovascular Risk Score (FCRS) and C-reactive protein levels (CRP) among Whites, 
little data are available in different racial/ethnic groups.
Methods and Results: CRP levels were compared to the calculated 10-year FCRS and 
its components among apparently healthy White (n=24,465), Hispanic (n=254), and Black 
(n=475) women enrolled in the Women’s Health Study. Compared to White and Hispanic 
women, Black women had the highest prevalence of diabetes (7.4%), body mass index 
(28.6 kg/m2), were more likely to be smokers (16.2%), and to have a history of hypertension 
(44.6%), and had the lowest triglyceride levels (122mg/dL + 75 mg/dL). Median CRP 
levels were higher among Black women (2.96 mg/L, interquartile range [IQR] 1.19 to 
5.86) than in Hispanic (2.06 mg/L , IQR 0.88 to 4.88) and White (2.01 mg/L, IQR 0.81 to 
4.36) women. The relationship between CRP and 10-year Framingham Risk Categories 
were signiﬁcant and similar in magnitude among all racial/ethnic groups, among women 
not taking any hormone replacement therapy (HRT) [White r=0.34; Hispanic r=0.25; 
Black r=0.30; all p<0.001]. Among White women, statistically signiﬁcant associations 
were observed between CRP levels and age (r=0.16, ), total cholesterol (r=0.17), HDL 
cholesterol (HDL-C) (r=-0.33), and history of hypertension (r=0.25)[ all p<0.01]. However, 
among Hispanic and Black women, CRP was only signiﬁcantly associated with HDL-C 
(rHispanic=-0.25, rBlack= -0.26; p<0.01) and history of hypertension (rHispanic=0.35, rBlack=0.21; 
p<0.01). Among women taking HRT, the relationship between CRP and Framingham 
Cardiovascular risk categories was similar in magnitude to those not taking HRT.
Conclusions: Overall, CRP levels signiﬁcantly correlated with the calculated 10-year 
FCRS among White, Hispanic, and Black women. HDL-C and history of hypertension 
were the components of the FCRS that had the strongest correlations with CRP in all 
three ethnic groups.
1002-204 Identiﬁcation of Polymorphisms in the Microsomal 
Triglyceride Transfer Protein and Glutamate-Cysteine 
Ligase Catalytic Subunit Genes as Susceptibility Loci 
for Myocardial Infarction
Hideo Izawa, Sahoko Ichihara, Kenji Yasui, Fumimaro Takatsu, Haruo Hirayama, Makoto 
Watarai, Takahito Sone, Akira Yamada, Tomoko Kato, Hiroyuki Asano, Yoshiji Yamada, 
Toyoaki Murohara, Mitsuhiro Yokota, Nagoya University, Nagoya, Japan, Mie University, 
Tsu, Japan
Background: We previously showed that polymorphisms in the connexin 37, plasminogen-
activator inhibitor 1, and stromelysin-1 genes are signiﬁcantly associated with myocardial 
infarction (MI) (N Engl J Med 2002). The aim of the present study was to further identify 
genes that confer susceptibility to MI.
Methods: The study population comprised a total of 6120 unrelated Japanese individuals 
(3845 men and 2275 women), including 3364 patients with MI (2118 men and 1246 
women) and 2756 controls (1727 men and 1029 women). We selected 43 polymorphisms 
of 40 candidate genes that were not examined in our population.
Results: The two-step analysis was performed for men and women independently. In 
an initial screening of the relation between 43 polymorphisms and MI in 860 subjects 
(430 men and 430 women), multivariate logistic regression analysis with adjustment for 
age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, 
hypercholesterolemia and hyperuricemia revealed that 6 and 8 single nucleotide 
polymorphisms (SNPs) were related (P <0.05) to MI in men and women, respectively. A 
large-scale association study with these SNPs was then performed in the remaining 5260 
subjects (2793 men and 1109 women). Similar multivariate logistic regression analysis 
revealed that the -493G/T SNP of the microsomal triglyceride transfer protein (MTTP) 
in men (odds ratio, 0.75; P = 0.002), and the -129C/T SNP of the glutamate-cysteine 
ligase catalytic subunit (GCLC) in women (odds ratio, 1.58; P = 0.009) were signiﬁcantly 
associated with MI.Conclusions: We identiﬁed the MTP gene in men and the GCLC gene 
in women as susceptibility loci for MI, respectively. Genotyping of these polymorphisms 
may prove informative for prediction of the genetic risk for MI, and thereby contribute to 
the primary prevention of this condition.
1002-205 A Polymorphism in the Metabotropic Glutamate 
Receptor 8 Gene is Strongly Associated with 
Myocardial Infarction in Two Independent Studies
Dov Shiffman, Mary J. Malloy, Lance A. Bare, Bradford A. Young, Charles M. Rowland, 
June Cassano, Joseph J. Catanese, Judy Z. Louie, Clive R. Pullinger, Bradley E. 
Aouizerat, Christian Zellner, Thomas J. White, James J. Devlin, Eric J. Topol, John P. 
Kane, Stephen G. Ellis, Celera Diagnostics, Alameda, CA, Cleveland Clinic Foundation, 
Cleveland, OH
Background: Myocardial infarction (MI) is a multi-factorial disease associated with both 
environmental and genetic factors. Although major clinical risk factors are associated with 
most MI events, some patients are at higher risk than indicated by traditional risk analysis. 
Identiﬁcation of genetic polymorphisms associated with MI could lead to a more accurate 
prediction of risk and provide a mechanistic basis for individualized therapy.
Methods: To identify genetic markers associated with MI, we interrogated approximately 
one ﬁfth of the known human genes by determining the allele frequencies of about 8,000 
single nucleotide polymorphisms (SNPs) expected to alter the amount, activity, or stability 
of encoded proteins. Allele frequencies were determined in pooled DNA samples from 
1494 males and females collected by the University of California San Francisco Genomic 
Resource (835 MI cases and 659 controls). The 574 SNPs associated with MI in that 
study (unadjusted p<0.05), were tested in pooled DNA from a second study of 1051 
subjects collected at the Cleveland Clinic Foundation Heart Center (445 MI cases and 
606 controls).
Results: Of the 574 SNPs associated with MI in the ﬁrst study, 36 SNPs in 35 genes were 
also associated with MI in the second sample set (unadjusted p<0.05, same risk allele). 
The most signiﬁcant association, veriﬁed by individually genotyping the samples in the 
second study, was with a SNP in the gene coding for metabotropic glutamate receptor 8 
(GRM8, p=0.00001, OR=1.62). This unadjusted p value remained signiﬁcant even after 
conservative multiple testing correction.
Conclusions: The identiﬁcation of a GRM8 variant associated with MI by testing putative 
functional SNPs in two large sample sets is a step in creating an improved genetic risk 
assessment for MI. GRM8 encodes a group III metabotropic receptor for which in-vitro 
studies have suggested a potential role in regulating glucose homeostasis. The strong 
and plausible association of this GRM8 variant with MI would not have been discovered in 
a candidate gene study; this underlines the importance of extending genetic association 
studies to broad gene scans.
1002-206 Platelet-activating Factor-acetylhydrolase G994t 
(exon 9) And Its Receptor V379 Allele (exon 11) Gene 
Polymorphisms In Relation To The Onset Of Premature 
Myocardial Infarction In Taiwan
Ping-Yen Liu, Jyh-Hong Chen, Yi-Heng Li, Ting-Hsing Chao, Liang-Miin Tsai, Hua-Lin 
Wu, Division of Cardiology, Internal Medicine, National Cheng-Kung University Medical 
Center, Tainan, Taiwan,ROC, Institute of Biochemistry, College of MEdicine, National 
Cheng-Kung University, Tainan, Taiwan,ROC
Background: Oxidation of low density lipoproteins is an initial step of atherogenesis that 
generates pro-inﬂammatory phospholipids, including platelet-activating factor (PAF) and 
its analogs. PAF is degraded by PAF-acetylhydrolase (PAF-AH), a circulating enzyme 
having both pro- and anti-inﬂammatory activities. PAF-AH activity has been postulated to 
be a risk factor for premature myocardial infarction (MI); however, whether PAF-AH has a 
causal role or is simply a marker of risk for MI is unclear.
Methods: All polymorphisms located in putatively functional regions were investigated in a 
cohort of premature MI patients onset less than 46 years of age (n = 150) and a sex-age-
matched control group (n = 150). Their PAF-AH activities were evaluated by ELISA assay.
Results: The frequency of the G994T (exon 9) mutation on PAF-AH gene was similar 
among premature MI and the control group (p>0.1). The V379 allele mutation (exon 11) 
on PAF-receptor gene was less frequent in premature MI patients than in controls (p=0.02) 
and was associated with a lower risk of future cardiovascular events, suggesting that this 
allele might be protective against the development of premature MI or CAD. The V379 allele 
was also associated with a weak increase of plasma PAF-AH activity. The modiﬁcation of 
the enzyme function towards a more anti-atherogenic form by this A379V genetic mutation 
might help explain this paradoxical gene-phenotype association. Multiple logistic regression 
analysis showed that the V379 allele polymorphism was an independent risk factor (Odds 
Ratio (OR) 1.7, 95% CI 1.2 to 7.3, p=0.04) as were as smoking (OR 3.6, 95% CI 1.4 to 5.8, 
p=0.001), diabetes mellitus (OR 3.5, 95% CI 1.5 to 6.7, p=0.003) and hypertension (OR 1.9, 
95% CI 1.7 to 7.7, p=0.001) for the onset of premature MI.
Conclusion: We conclude that a functional and signiﬁcant association between the V379 
allele polymorphism on exon 9 of PAF-receptor gene and premature MI exists in this 
Taiwanese population. This allele may be protective partially via modifying the PAF-HA 
enzyme towards a more anti-atherogenic function.
1002-207 The Polymorphisms in the Interleukin-1 Gene Cluster 
as Protective Factors Against Myocardial Infarction in 
Patients with Coronary Artery Disease
Dao-Fu Dai, Fu-Tien Chiang, Jiunn-Lee Lee, Ling-Ping Lai, Kwan-Lih Hsu, Chuen-Den 
Tseng, Yung-Zu Tseng, Juey-Jen Hwang, National Taiwan University Hospital, Taipei, 
Taiwan, Taiwan,ROC, Taoyuan General Hospital, Taoyuan, Taiwan,ROC
Objectives: Acute myocardial infarction (MI) is caused by ruptured of unstable plaque, 
where macrophages releases several cytokines (including interleukin-1, IL-1) and matrix 
metalloproteinase. The relationship between polymorphisms of IL-1 gene cluster and the 
risk of MI remains unsettled. We want to elucidate the effect of these polymorphisms on 
the risk of MI in coronary artery disease (CAD) patients.
Methods: We recruited 410 subjects with angiographically-proven CAD, and carried out 
a matched case-control study which consisted of 205 cases with a history of MI and 
205 matched controls without MI. Gensini score was applied to evaluate the severity 
of coronary atherosclerosis. Genotyping of IL-1ß +3954C>T,-31C>T, -511C>T and IL-1 
Receptor Antagonist intron 2 VNTR (IL1RN) were performed. Plasma level of CRP and 
IL-1ß were assayed.
Results: After adjustment for age, sex, diabetes, hypertension, hypercholesterolemia, 
hypertriglyceridemia and smoking habit, the genotype IL-1ß -31 C>C is protective against MI 
(OR=0.54, 95%CI:0.32,0.86, p=0.02), independent of the severity of coronary atherosclerosis. 
This result is supported by haplotype analysis (omnibus likelihood ratio, p=0.01), Estimated 
haplotypes showed that the haplotype frequency of IL-1ß +3954C/-31C/-511C is 2 times 
higher in the controls than in the cases (12.7% vs 6.4%, respectively, p=0.006). In addition, IL-
1ß -31 allele C had signiﬁcant effect on the plasma CRP level (carrier vs non-carrier: 8.1± 17.2 
vs 15.0± 28.1 mg/L respectively, p=0.004). Likewise, IL1RN*2 repeat allele is also protective 
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against MI (Allele *2 repeat carrier vs non carrier: OR:0.38, 95% CI: 0.18,0.79, p=0.008) after 
adjustment for the afore-mentioned clinical factors.
Conclusion: This study demonstrates that the polymorphism of IL-1 gene cluster is 
associated with the risk of MI. IL-1ß-31 C/C genotype and IL1RN*2 repeat allele are 
protective factors against MI.
1002-208 NT-proBNP In Symptom Limited Exercise Myocardial 
Perfusion Scintigraphy: Sustained Elevation After 
Exercise And Independent Association With Myocardial 
Ischemia Extent
P. Marc van der Zee, Hein J. Verberne, Jan P. van Straalen, Johan C. Fischer, Gerard 
T B Sanders, Berthe L F van Eck, Robbert J. de Winter, Academic Medical Center, 
Amsterdam, The Netherlands
Background. In patients with overt heart failure, levels of N-terminal pro-BNP (NT-
proBNP) are associated with ventricular dysfunction. Increased levels are also found 
in acute coronary syndromes, suggesting that other mechanisms such as myocardial 
ischemia may also cause elevations of NT-proBNP.
Methods. 38 patients were included undergoing symptom limited exercise myocardial 
perfusion scintigraphy according to a two-day stress/rest protocol using 99m Technetium 
Tetrofosmin and ECG gated single photon emission tomography. Stress and rest 
perfusion images were scored using a 5-point semi-quantitative score for each of 17 
myocardial segments, classifying each segment as normal (0), equivocal abnormal (1), 
mildly abnormal (2), moderately abnormal (3) or severely abnormal (4). The summed 
difference score (SDS) was calculated as the difference between summed stress score 
and summed rest score. A SDS of three or greater was arbitrarily considered to indicate 
clinically relevant ischemia. Left ventricular ejection fraction (LVEF) was calculated using 
a completely automated algorithm. Blood samples were drawn at baseline, at maximum 
exercise (at least 85% of the age predicted heartrate), and at 1, 2, 3, 4, and 6 hours after 
maximum exercise, for assessment of levels of NT-proBNP and creatinine (baseline only). 
For analysis, NT-proBNP levels were logtransformed to a normal distribution.
Results. 15 patients were classiﬁed as having myocardial ischemia. Baseline NT-proBNP 
levels were 75 pg/mL (33-236) (median, IQ range), and were increased at maximum 
exercise (137% of baseline (99-176)) (p<0.001), with a second peak 4 hours later (137% 
(118-173)) (p<0.001). In a multivariate analysis, NT-proBNP levels were independently 
associated with creatinine clearance (Cockroft and Gault), LVEF, and SDS, as assessed 
from the samples at baseline (adjusted R2 of model = 0.537), maximum exercise (adj.R2 = 
0.561), and 4 hours later (adj.R2 =,0.476).
Conclusion. Baseline levels of NT-proBNP, as well as the sustained elevations after 
symptom limited exercise testing are independently associated with extent of inducible 
myocardial ischemia, LVEF and creatinine clearance.
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1003-195 Comparison Of Infarct Size In 1200 NSTE-ACS Patients 
With An Elevated Troponin T Randomized To An Early 
Invasive Or A Selective Invasive Treatment Strategy 
(subanalyses Of The ICTUS Trial)
Fons Windhausen, Jan Tijssen, Jan Hein Cornel, F. W. Verheugt, Peter H. Dunselman, 
Pim de Feyter, H. R. Michels, Robbert J. de Winter, for the ICTUS investigators, 
Academic Medical Center, Amsterdam, The Netherlands
Background:The ICTUS trial compared an early invasive (EI) management aiming at 
coronary angiography (CAG) and revascularization within 24-48 hrs, with a “selective invasive” 
(SI) management, in 1200 nSTE-ACS patients with an abnormal cTnT. In the SI group, CAG 
and revascularization was performed in the event of refractory angina or ischemia on the pre-
discharge exercise test . The primary endpoint, the composite of death, myocardial infarction 
(MI) and rehospitalization for angina at one year, was reached in 21.7% in the EI group versus 
20.4% in the SI group (p=0.59). However, there were signiﬁcantly more MIs in the EI group 
compared to the SI group(14.6 % versus 9.4%, RR 1.55; p=0.006).
Methods: We compared infarct size in spontaneous-, and PCI related MIs between the 
two treatment strategies. Infarct size is expressed as peak CK-MB ratios (peak CK-MB 
level/upper limit of normal [ULN]). Patients with a MI after an episode of chest pain or after 
PCI were stratiﬁed into categories by peak CK-MB ratios of 1-3, 3-6, and >6 × ULN.
Results: The median CK-MB ratio for all MIs in the early invasive (EI) group was 2,3 (IQR 
1.3-5.3) versus 2.3 (IQR 1.4-6.6) in the selective invasive (SI) group (p=0.9). In the EI 
group, the median CK-MB ratio for PCI related MI was 2.25 (IQR 1.5-4.9) and 2.46 (IQR 
1.1-9.4) for spontaneous MI (p=0.94). In the selective invasive group, the median CK-MB 
ratio for PCI related MI was 2.26 (IQR 1.3-6.3) and 2.5 (IQR (1.4-6.8) for spontaneous 
MI (p=0.74). The incidence of MI (spontaneous and PCI related) with peak CK-MB ratios 
between 1 and 3 was 7.3% in the EI-group versus 4.9% in the SI group (p=0.08). In the 
EI group 3.0% had a CK-MB ratio between 3 and 6 versus 1.3% in the SI group (p=0.05). 
In 3.5% of patients in the EI group versus 2.7% in the SI group a CK-MB ratio > 6 was 
observed (p=0.424).
Conclusion: Median infarct size and infarct size categories were similar in both treatment 
groups. Moreover, there was no difference in infarct size between spontaneous and PCI 
related MIs. The higher incidence of MI in both treatment groups compared to previous 
strategy trials is explained by the incidence of small MIs (CK-MB ratio 1-3). The prognostic 
value of these small MIs requires long-term follow-up.
1003-196 Despite the Temporal Increases, Coronary Angiography 
and Revascularization Remain Paradoxically Directed 
Towards Low Risk Non-ST Elevation Acute Coronary 
Syndrome Patients
Andrew T. Yan, Raymond T. Yan, Mary Tan, Anthony Y. Fung, Chi-Ming Chow, Warren J. 
Cantor, Eric A. Cohen, David H. Fitchett, Anatoly Langer, Shaun G. Goodman, for the 
Canadian ACS Registry Investigators, St. Michael’s Hospital, Toronto, ON, Canada, 
Canadian Heart Research Centre, Toronto, ON, Canada
Background: Randomized clinical trials support early invasive risk stratiﬁcation for high 
risk non-ST elevation (NSTE) acute coronary syndromes (ACS).
Objective: To examine the temporal use of invasive strategy in the “real world” 
management of NSTE ACS.
Methods: The Canadian ACS Registries were prospective multicentre observational 
studies of less selected ACS patients. ACS I enrolled 2778 NSTE ACS patients from 
Sept 99 to June 01; ACS II enrolled 2063 patients from Oct 02 to Jan 04. We evaluated 
the use of in-hospital coronary angiography and revascularization in ACS I and II patients 
stratiﬁed into low, intermediate and high risk groups, according to tertiles of their GRACE 
risk scores (validated predictor of in-hospital mortality).
Results: Overall, the calculated GRACE scores (median 114 vs 117) and in-hospital 
death/MI rates (5.6% vs 5.9%) were similar in both ACS I and II. However, ACS II patients 
more frequently underwent coronary angiography (40.5% vs 60.9%, P<0.001), PCI 
(14.3% vs 26.8%, P<0.001), and CABG (4.0% vs 9.5%, P<0.001). 
Registry Low-risk Intermediate-risk High-risk P value
Coronary angio (%)
ACS I 47.6 41.4 32.5 <0.001
ACS II 69.7 63.0 49.9 <0.001
Time to cath (days) *
ACS I 5 (3, 7) 5 (3, 8) 5 (3, 8) NS
ACS II 3 (2, 5) 3 (2,6) 4 (2, 6) 0.01
PCI (%)
ACS I 16.7 14.5 11.8 0.01
ACS II 33.1 28.5 18.8 <0.001
CABG (%)
ACS I 3.8 4.1 4.1 NS
ACS II 8.5 10.2 9.8 NS
In-hospital Death/MI (%)
ACS I 2.8 4.1 9.0 <0.001
ACS II 3.1 4.4 9.6 <0.001
* median (25th, 75th percentiles)
Conclusions: The use of in-hospital coronary angiography and revascularization has 
increased substantially in the management of NSTE ACS. However, this temporal increase 
was not speciﬁcally targeted towards high risk patients, who remained least likely to 
undergo early invasive risk stratiﬁcation, with an associated worse outcome. Future study 
is needed to elucidate the reasons for less frequent intervention in these patients.
1003-197 Use of the Early Invasive Strategy in Older Patients 
With Acute Coronary Syndromes: Insights from the 
PREMIER Registry
Marvin H. Eng, John S. Rumsfeld, Edward P. Havranek, Philip G. Jones, David J. Magid, 
John C. Messenger, John A. Spertus, Saif S. Rathore, Harlan M. Krumholz, Frederick 
A. Masoudi, University of Colorado Health Sciences Center, Denver, CO, Mid-America 
Heart Institute/University of Missouri, Kansas City, Kansas City, MO
Background: Although guidelines recommend an early invasive strategy (EIS) for 
patients with NSTEMI, it is not known if this approach is utilized equally across the age 
spectrum.
Methods: We studied consecutive NSTEMI patients in 19 US centers in the PREMIER 
registry between 1/2003-6/2004. The use of EIS (deﬁned as pre-discharge coronary 
angiography without antecedent stress testing) was assessed in strata according to age 
and TIMI NSTEMI risk scores. In multivariable models, we assessed the relationship 
between age group and EIS, adjusting for TIMI scores and in-hospital events (rest angina, 
heart failure, VT/VF or shock) and accounting for patient clustering by center.
Results: Among all patients, 74.1% were treated with EIS. This strategy was implemented 
more commonly in younger patients in all TIMI categories (Table). After adjustment, EIS 
was used less frequently in patients age 65-74 (OR=0.61, 95% CI 0.44-0.84) and age 
>75 (OR 0.21, 95% CI 0.13-0.32) compared to patients <64 years old (1.00 referent). 
TIMI score was not associated with EIS in all patients (p=0.3) or in age strata (TIMI 
score*age interaction p-value=0.8). Analyses deﬁning EIS as angiography within 48 hours 
of admission yielded comparable results.
Conclusions: Older patients with NSTEMI are less likely to be treated with EIS, even 
after accounting for site-speciﬁc differences and clinical risk features. The implications of 
this practice pattern on clinical outcomes warrant further investigation.
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Percentage of Patients Undergoing Early Invasive Strategy 
% receiving EIS Age Groups
All Ages (n=2,210) <=64 years(n=1,142) 65-74 years(n=505) >=75 years(n=563)
TIMI Risk Scores
All Risk Scores 74.1% 79.0% 78.0% 60.8%
1-2 74.1% 77.2% 72.7% 51.9%
3 72.7% 76.5% 80.8% 57.6%
4 74.8% 85.2% 78.2% 67.8%
5 76.2% 86.8% 78.4% 67.8%
6-7 73.0% 84.6% 76.8% 66.7%
1003-198 Clinical Correlates, Management and Outcome in 
Myocardial Infarction Complicated by Cardiogenic 
Shock at Hospital Admission - A Report from the 
SHOCK Trial and Registry
Raban V. Jeger, Shannon M. Harkness, Krishnan Ramanathan, Christopher E. Buller, 
Matthias E. Pﬁsterer, Lynn A. Sleeper, Judith S. Hochman, New York School of Medicine, 
New York, NY
Background Up to 25% of cardiogenic shock (CS) cases are diagnosed at hospital 
admission. Characteristics, outcome, and effect of early revascularization (ERV) may differ 
between CS on admission (CSA) and delayed CS (CSD) pts, but data are conﬂicting.
Methods Characteristics and in-hospital mortality in both SHOCK trial and registry pts 
with predominantly left ventricular failure were compared for CSA vs CSD. Trial pts were 
randomized to a strategy of ERV (≤18 hrs post CS) vs initial medical stabilization (IMS) 
and followed for 1 year. Pts with suspected CS but not eligible for the trial were enrolled 
in a registry.
Results Overall (n=1053), 20% had CSA. The median time from MI to CS was shorter in 
CSA (1.5, interquartile range 0.5, 4.1, vs 8.1, interquartile range 2.8, 21.0 hrs; p<0.001) 
vs CSD pts. Lowest systolic blood pressure (64±19 vs 69±15mmHg; p=0.008) and 
hemodynamic variables on support measures, ie, systolic blood pressure (84±27 vs 
89±21mmHg; p=0.017), cardiac output (3.3±1.0 vs 3.7±1.5L/min; p=0.001), cardiac power 
output (0.5±0.2 vs 0.6±0.3W; p=0.002), and stroke volume (33±12 vs 40±18ml; p<0.001) 
were lower in CSA vs CSD pts. In contrast, left ventricular ejection fraction, cardiac index, 
cardiac power index, systemic vascular resistance, pulmonary capillary wedge pressure, 
or baseline demographic characteristics did not differ. In-hospital mortality was higher in 
CSA (75 vs 56%; p<0.001) vs CSD pts with lower mortality in ERV vs IMS in CSA (60 vs. 
82%; p=0.001) and CSD pts (46 vs 62%; p<0.001), ie, without interaction between CS 
onset and treatment assignment. Estimated 1-week mortality was higher in CSA (59 vs. 
42%) vs CSD pts. In trial pts (n=263) similar hemodynamic differences between CSA and 
CSD pts were observed as were mortality differences (73 vs. 57% at 1 year; p=0.081) 
despite similar rates of coronary angiography and revascularization in both ERV and IMS 
assigned CSA and CSD pts. 
Conclusion CSA pts have a more severe hemodynamic derangement and higher 
mortality. They beneﬁt equally from ERV for which their precipitous presentation 
demands rapid stabilization. This suggests the need for direct transport to hospitals with 
interventional facilities.
1003-199 Do Patients With Acute Coronary Syndromes Admitted 
to Non-PCI Hospitals Have Worse Outcome? Results 
From the PL-ACS Registry
Mariusz Gasior, Lech Polonski, Marek Gierlotka, Tadeusz Zebik, Teresa Zielinska, 
Zbigniew Kalarus, Janusz Balcarek, Marian Zembala, Grzegorz Opolski, Michal Tendera, 
Medical University of Silesia, Zabrze, Katowice, Poland, Warsaw Medical University, 
Warsaw, Poland
Background: Guidelines recommend early invasive strategy in unstable angina (UA) / 
non ST-elevation myocardial infarction (NSTEMI) and primary angioplasty in ST-elevation 
myocardial infarction (STEMI). We set up a prospective, population-based registry of 
acute coronary syndromes (ACS) in Poland to assess treatment strategy and determine 
the outcome in unselected pts.
Methods: Between October 2003 and June 2004 a total of 81 hospitals in Silesia 
(population of 4,8 million) prospectively collected data of each pt admitted with ACS.
Results: There were 10753 reported admissions of ACS pts in all hospitals. Pts were 
hospitalised for UA in 49.8%, NSTEMI in 15.4%, and STEMI in 34.8%. Seventy-ﬁve 
hospitals without PCI facilities admitted 65.1% of pts; 14.9% of them were transferred 
to one of the 6 PCI centres for further treatment within 48 hours. The remaining 34.9% 
of patients were directly admitted to PCI centres and early angiography was performed 
in 94.3% of them. The rates of in-hospital deaths or myocardial infarctions in relation to 
treatment strategy and type of ACS are shown in the table.
Table 







Immediate coronary angio 
(N= 3 538)
Unstable angina 
[N=5 361] 56.5% 6.2% 2.5% 34.9%
Death or MI 3.9% 1.8% 1.5% 0.8%
NSTEMI [N=1 610] 76.7% 7.1% 1.2% 15.0%
Death or MI 13.4% 7.0% 15.0% 4.6%
STEMI [N=3 728] 44.7% 15.9% 1.6% 37.8%
Death or MI 20.5% 6.0% 24.2% 5.5%
Conclusion: Patients with STEMI admitted to non-PCI hospitals and transported to PCI 
have similar in-hospital outcome to those admitted directly to PCI hospitals. Oppositely, 
patients with UA and NSTEMI have worse outcome in non-PCI hospitals and transport to 
PCI only partially improves the outcome.
1003-200 Major Access Site Bleeding in Acute Coronary 
Syndrome Patients Undergoing Early Invasive 
Management Can Be Reduced With Radial Access and 
Smaller Sheath Sizes. Observations From the SYNERGY 
Trial
Warren J. Cantor, Shaun G. Goodman, Dianne Gallup, Kenneth W. Mahaffey, Dietrich 
C. Gulba, Marc Cohen, Elliott M. Antman, Anatoly Langer, Neal S. Kleiman, Harvey D. 
White, Robert J. Chisholm, Robert A. Harrington, James J. Ferguson, III, Robert M. 
Califf, on behalf of the SYNERGY Investigators, St. Michael’s Hospital, University of 
Toronto, Toronto, ON, Canada, Duke Clinical Research Institute, Durham, NC
Background: An early invasive strategy improves outcomes after acute coronary syndromes 
(ACS), but may be associated with increased bleeding, particularly at the arterial access 
site. The impact of radial access and sheath size has not been evaluated in this setting.
Methods: In the SYNERGY trial, 9978 patients with non-ST elevation ACS were randomly 
assigned to enoxaparin or unfractionated heparin. Of these, 9164 patients underwent 
angiography within 22 (6, 43) hours and 4683 (51%) had PCI within 22 (6, 48) hours of 
enrollment. Glycoprotein IIb/IIIa inhibitors were used in 57% of patients. Access site and 
sheath size were left to operators discretion. Major access site bleeds were those which 
met criteria for GUSTO severe or TIMI major bleeding.
Results: Radial access was associated with less major access bleeding and less 
transfusions. The unadjusted rates of major access site bleeding by sheath size was 2.6% 
for 4/5F, 2.2% for 6F, 3.5% for 7F and 3.6% for ≥8F (p=0.01). After adjusting for baseline 
characteristics, radial access was an independent predictor of transfusions (OR 0.62, 
p=0.002).
Conclusion: In this nonrandomized comparison, major access-site bleeding and the 
need for transfusion occurred less often with an early invasive strategy when radial 
access and smaller sheath sizes were used. In selected patients, smaller sheaths and 









Male 72% 66% 0.02
Caucasian 93% 85% <0.0001
Age 66 (60, 73) 67 (60, 74) 0.24
PCI Success 241/245 (98%) 4231/4376 (97%) 0.15
TIMI Major Bleed (Any Site) 5.8% 8.8% 0.03
Transfusions 13% 19% 0.002
No Access Site Bleed 77% 81%
0.04Minor Access Site Bleed 21% 17%
Major Access Site Bleed 1.7% 2.5%
1003-201 Cardiogenic Shock Complicating Non St Segment 
Elevation Myocardial Infarction. Data From Rico Survey
Marianne Zeller, Jack Ravisy, Gilles Rioufol, Sonia Salmi-Belmihoub, Mohamed Jolak, 
Jean-Claude Beer, Michel Vincent-Martin, Isabelle L’Huillier, Hamib Makki, Philippe 
Buffet, Nawal Moreau, Alexandra Oudot, Yves Cottin, on behalf of the RICO survey 
working group, University of Burgundy, Dijon, France
Background. Many studies have examined the clinical outcome of cardiogenic shock 
complicating ST segment elevation myocardial infarction (STEMI), but its occurrence and 
impact among patients with non STEMI (NSTEMI) remains limited.
Patients. Among the 1945 patients admitted for acute MI in the RICO survey (French 
regional survey for acute MI) between 1st January 2001 and 23rd September 2003, 148 
(7.6%) patients with primary cardiogenic shock complicating acute MI were included in 
the study. Patients with causes of shock other than left ventricle failure were excluded from 
the study. Patients with NSTEMI were compared with STEMI patients.
Results. Among the 148 patients with cardiogenic shock complicating myocardial 
infarction, 35(23%) had a NSTEMI and 113(76%) had a STEMI. Patients from the NSTEMI 
group were older (median 78 vs 73 y, p<0.001) than those in the STEMI group and had 
diabetes mellitus and peripheral arterial disease more frequently (respectively 49 vs 27%, 
p=0.025 and 29 vs 3%, p<0.01). The time delay from symptom onset to admission was 
higher for the NSTEMI group (median 247 vs 165 min, p=0.003). Other risk factors and 
clinical variables were similar for the 2 groups, except for LVEF which was signiﬁcantly 
higher in NSTEMI patients (median 45 vs 34 %, p=0.048). Despite more recurrent MI or 
angina (29 vs 11%, p=0.019), NSTEMI patients had similar recourse to acute therapeutics 
such as IIb/IIIa receptor blockers or coronary angiography. With regard to the proportion 
of patients undergoing primary PCI, there was no signiﬁcant difference between the 2 
groups (23 vs 14%, p=0.057). In-hospital mortality was similar for the NSTEMI and STEMI 
groups (46 vs 58 %, p=0.032).
Conclusion. Patients with cardiogenic shock and NSTEMI have a higher risk proﬁle 
than STEMI patients, in particular for age and diabetes. More recurrent angina or MI 
provides opportunities for earlier intervention in this group of patients without ST segment 
elevation. In-hospital mortality from cardiogenic shock was equally high for patients with 
and without ST segment elevation.
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1003-202 Complications During Spasm Provocation Tests 
Of Acetylcholine - From The Experience Of 927 
Consecutive Cases
Shozo Sueda, Yousuke Izoe, Hiroshi Fukuda, Saiseikai Saijo Hospital, Saijo City,Ehime, 
Japan
Backgroud: There were some reports concerning the severe complications during nonselective 
spasm provocation test of ergonovine and its complication rate was 0.16-4.72%.
Objectives: The purpose of this study was to clarify the complications during spasm 
provocation test of acetylcholine (ACh), retrospectively.
Methods: From 1991 January to 2003 September, we performed 927 consecutive 
provocation tests of ACh to evaluate coronary spasm. ACh was injected in incremental 
doses of 20, 50 and 80 µg into the right coronary artery and of 20,50 and 100 µg into the 
left coronary artery.
Results: (1) Severe complications were observed in 14 patients (1.5%). However, no 
death and no serious irreversible complications were determined. (2) Ten patients (1.1%) 
developed ventricular tachycardia/ﬁbrillation. Two was reversed by direct cardioversion, 
three by thump version and ﬁve resolved quickly with the intracoronary administration 
of ISDN. In all ten patients, spasm occurred. (3) There were three patients (0.3%) who 
developed severe hypotension, loss of consciousness and shock. In three patients coronary 
spasm occurred in both just proximal left anterior descending artery and just proximal 
circumﬂex artery, like the spasm of left main trunks by intracoronary injection of 50/100 
mg ACh. By the administration of both norepinephrine and ISDN, coronary spasm was 
relieved gradually and they recovered from hypotension and shock. (4) Surgical drainage 
was performed in one patient who complicated with cardiac tamponade by inserting the 
temporary pace maker. (5) Paroxysmal atrial ﬁbrillation occurred in 149 patients (16.6%) out 
of 886 patients who had sinus rhythm before the provocation test. Intravenous administration 
of anti-arrhythmic agents were necessary to recover sinus rhythm in 44 patients, while 105 
patients were recovered to sinus rhythm within a few minutes. 
Conclusions: Although the spasm provocation test of ACh was safe and reliable method, 
we should be take care of performing it in spite of selective procedure.
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1004-226 Relative 36% Reduction of Hospital Mortality in 
Diabetics with ST-Elevation Myocardial Infarction 
Between 1994 and 2002 due to Adherence to Guidelines 
in Clinical Practice: Results of MITRA PLUS
Anselm K. Gitt, Harm Wienbergen, Ralph Winkler, Tobias Heer, Rudolf Schiele, Ralf 
Zahn, Martin G. Gottwik, MITRA-PLUS-Study-Group, Herzzentrum Ludwigshafen, 
Ludwigshafen, Germany, Klinikum Nuernberg Sued, Nuernberg, Germany
Background - Diabetics are known to have a high mortality after acute myocardial ST-
elevation myocardial infarction (STEMI). We analysed if the implementation of guidelines 
for the treatment of STEMI improved outcome in diabetics from 1994 to 2002.
Methods - Since 1994 consecutive patients with STEMI were enrolled into German MI-
registries in 319 hospitals (MITRA PLUS). Acute reperfusion and adjunctive treatment of 
STEMI and hospital mortality in diabetics were analysed using 2-year periods.
Results - Between 1994 and 2002, 8516 consecutive diabetics with STEMI were enrolled 
into MITRA PLUS. The prevalence of prior MI slightly decreased, known hypertension 
increased within time. Acute reperfusion increased from 47% to 65% with a more frequent 
use of primary PCI replacing thrombolysis. Adjunctive treatment with betablockers, ACE-I. 
and statins was administered more often in diabetics. This improvement in acute treatment 
was associated with a decrease in hospital mortality from initial 20.5% in 1994/96 to 
13.2% in 2001/2002 (p<0.001 for trend).
Conclusion - Between 1994 and 2002 the acute treatment of STEMI in diabetics in 
Germany signiﬁcantly improved according to existing guidelines. This improvement in 
acute treatment was associated with a 36% relative reduction in hospital mortality for 
diabetics with STEMI.









Age (years) 71 72 71 69
Male Gender 52.3 % 52.5 % 56.7 % 61.0 %
Reperfusion 47.2 % 38.0 % 54.7 % 65.0 %
Thrombolysis 39.1 % 28.0 % 31.7 % 18.7 %
Primary PCI 8.1 % 10.0 % 23.0 % 46.3 %
Betablockers 51.6 % 51.0 % 72.2 % 75.5 %
ACE-Inhibitors 63.8 % 62.9 % 71.2 % 66.6 %
Statins na 46.5 % 47.9 % 62.7 %
Hospital Mortality 20.5 % 20.1 % 18.8 % 13.2 %
1004-227 Bypassing the Emergency Room (ER) impacts care and 
outcomes in ST Elevation Myocardial Infarction (STEMI)
Philippe Gabriel Steg, Olivier Fondard, Patrick Sauval, Didier Blanchard, Jean-Marc 
Lablanche, Jean-Pierre Cambou, Guy Hanania, Laurent Vaur, Nicolas Danchin, for the 
USIK 2000 investigators, Hopital Bichat, Paris, France, HEGP, Paris, France
Background: Most STEMI patients identiﬁed in a pre-hospital setting are initially brought 
to the ER before being admitted in a Coronary Care Unit (CCU). We decided to study the 
impact of direct admission to the CCU (bypassing the ER) vs admission via the ER.
Methods: The USIK 2000 registry was a nationwide registry of acute STEMI collected 
in 369 centers (83% of french CCUs) in November 2000. 1000 patients with STEMI < 24 
h from onset were categorized on the basis of the initial management pathway (direct 
transfer to CCU, vs transfer to CCU via ER).
Patients admitted via the ER had more severe baseline characteristics than those who 
bypassed the ER (Table). Direct transfer to the CCU was associated with a shorter time 
to CCU admission (5.8 vs 7.2 h, p<0.001), a greater frequency of reperfusion therapy 
(70.1 vs 56.8%, p<0.01), a greater use of beta blockers at 48 h and a lower short-term 
mortality. Among patients treated with primary PCI (n=671), there was a greater difference 
in mortality between those who bypassed the ER and those who did not (4.2% vs 17.1%, 
p=0.009). Multivariate analysis showed that admission via the ER was an independent 
predictor of short-term mortality (OR: 3.079, p=0.005).
Conclusions: In this registry, bypassing the ER appeared associated with improved 
processes of care and outcomes, especially among patients treated with primary PCI. 
This suggests that pathways should be established for patients with STEMI to bypass 
the ER.
Direct to CCU CCU via ER p
N 787 213
Male gender (%) 77.6 69 0.005
Age > 70 years 36.2 47.9 0.002
Delay call to CCU (h) 2.7 4.2 0.0001
Lytic therapy (%) 37.2 40.4 0.001
Primary PCI (%) 32.9 16.4 0.001
beta-blockers at 48 h (%) 75.2 67.1 0.032
Death at day 5 (%) 5.1 9.4 0.019
1004-229 Circadian Variation In Myocardial Perfusion And 
Mortality In Patients With ST-Segment Elevation 
Myocardial Infarction Treated By Primary Angioplasty
Giuseppe De Luca, Harry Suryapranata, Arnoud WJ van’t Hof, Jan Paul Ottervanger, 
Jan CA Hoorntje, AT Marcel Gosselink, Jan-Henk E. Dambrink, Menko-Jan de Boer, De 
Weezenlanden Hospital, Zwolle, The Netherlands
Background. Little is known about whether the physiologic factors, that determine 
the circadian variation in STEMI onset and thrombolyis efﬁcacy, may affect myocardial 
perfusion and long-term outcome of patients with STEMI treated with primary 
angioplasty.
Methods. Our study population consisted of 1548 consecutive patients with STEMI treated 
by primary angioplasty between April 1997 and October 2001. All clinical, angiographic 
and follow-up data were collected.
Results. Most of the patients (65.2%) were treated at daytime (between 8 a.m. and 8 
p.m.). Patients treated between 1 and 12 p.m. had a lower prevalence of anterior infarction 
and longer door-to-balloon time, whereas the shortest ischemic time and the highest use 
of stent was observed in patients treated between 0 and 4 a.m. Patients treated between 
4 and 8 a.m. showed the worst outcome in terms of myocardial perfusion, enzymatic 
infarct size and 1-year outcome, whereas patients treated between 8 a.m. and 4 p.m. had 
the best myocardial perfusion and lowest 1-year mortality rate (Figure 1). After correction 
for baseline confounding factors, the time of treatment (between 4 and 8 a.m.) was still 
signiﬁcantly associated with 1-year mortality (relative risk [95% CI] = 1.92 [1.13-3.26], p 
= 0.016).
Conclusions. This is the ﬁrst study showing a signiﬁcant relationship between the 
time of treatment, myocardial perfusion and long-term mortality in patients with STEMI 
undergoing mechanical reperfusion. 
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1004-230 High Mortality In Patients With ST Elevation Myocardial 
Infarction And Prehospital Cardiopulmonary 
Resuscitation Despite Aggressive Reperfusion Therapy. 
Results Of PREMIR.
Uwe Zeymer, Lutz Nibbe, Ralf Zahn, Hans-Richard Arntz, Klaus Ellinger, Harald 
Genzwürker, Burkhard Dirks, Jochen Senges, Herzzentrum Ludwigshafen, 
Ludwigshafen, Germany
Background: Recent studies and registries suggest a low mortality in patients with 
ST elevation myocardial infarction treated with early reperfusion therapy. Little is known 
about the outcome of patients with STEMI and pre-hospital cardiopulmonary resuscitation 
(CPR)treated with early reperfusion therapy.
Methods: In a nationwide prospective registry (PREMIR : PREhospital acute Myocardial 
Infarction Registry) data of consecutive patients with STEMI already diagnosed pre-
hospital in the ambulance by emergency physicans by obtaining a 12-lead ECG were 
collected and processed centrally. A total of 64 ambulance systems in Germany were in 
involved in PREMIR. Patient characteristics, pre- as well as in-hospital treatments and 
events were recorded.
Results: So far 1503 patients with STEMI were included, of whom 197 needed pre-
hospital CPR (13.1%). The mean age of the latter was 64 years, 74% were men, 26% had 
a previos myocardial infarction, 27% were diabetics and 40% were smokers. The median 
time interval between symptom-onset and arrival of the ambulance was 25 minutes. In the 
pre-hospital ECG 41% had an anterior, 54% an inferior infarct and 5% left bundle branch 
block. Over 90% of the patients were given aspirin and heparin. 116 (58.9%) patients 
were treated with pre-hospital thrombolysis. 51 (26%) died before hospital arrival, 46 of 
the latter were treated with pre-hospital thrombolysis. Addional in-hospital reperfusion 
therapy with thrombolysis (n=16) and/or percutaneous coronary intervention (n=77) was 
performed, leaving only 17 (8.6%) patients without any early reperfusion therapy. The 
in-hospital mortality of admitted patients was 33%. In total 96 of 197 patients (48.7%)with 
STEMI and pre-hospital CPR died.
Conclusion: Patients with STEMI already diagnosed in the ambulance by emergency 
physicans and pre-hospital CPR have a high mortality despite an over 90% rate of early 
reperfusion therapy. Therefore the real world mortality of patients with STEMI is higher 
than recent clinical trials and in-hospital registries suggest.
1004-231 Acute Myocardial Infarction: Improving Trends  
in Patient Care
Alan K. Berger, Susan J. Duval, Christopher Armstrong, Patricia A. Janey, Russell 
V. Luepker, University of Minnesota, Minneapolis, MN, Health Evaluation Research 
Foundation, St. Paul, MN
Background: Prior studies have documented poor physician compliance with the 
American College of Cardiology/American Heart Association guidelines for acute 
myocardial infarction (AMI). Regional and nationwide quality improvement programs have 
sought to improve the utilization of aspirin (ASA), beta blockers (BB), and angiotensin 
converting enzyme inhibitors (ACE-I) in AMI but few studies have demonstrated signiﬁcant 
change in real-world practice.
Hypothesis: Among patients hospitalized in the Minneapolis-St. Paul metropolitan area 
with AMI, the utilization of ASA, BB, and ACE-I improved between 1995 and 2001.
Methods: We analyzed data from the Minnesota Heart Survey, a population-based study 
that abstracted random samples of all medical records of hospitalized AMI patients in 
1995 and 2001 in the Minneapolis-St. Paul metropolitan area. AMI was deﬁned using 
an algorithm requiring either elevated serum cardiac biomarkers or ST elevation on 
the electrocardiogram. The utilization of ASA, BB, and ACE-I or angiotensin receptor 
blocker (ARB) in-hospital and at discharge was assessed using a linear regression model 
adjusting for age and gender.
Results: We identiﬁed 1,298 patients with an AMI in 1995 and 1,348 patients in 2001. 
The in-hospital use of ASA (91.8 vs 95.7%, p=0.0013), BB(70.1 vs 84.8%, p<0.0001), 
and combined ACE-I/ARB(35.5 vs 63.9%, p<0.0001) increased between 1995 and 2001. 
Similarly, the prescription of ASA (83.7 vs 85.0%, p=0.48), BB (54.4 vs 78.6%, p<0.0001), 
and combined ACE-I/ARB (27.5 vs 57.4%, p<0.0001) at discharge increased between 1995 
and 2001. In-hospital mortality declined from 7.2% in 1995 to 5.4% in 2001 (p=0.136).
Conclusions: The utilization of standard AMI therapies improved between 1995 and 
2001. This improved quality of care may be partially responsible for the trend toward a 
reduction in hospital mortality.
1004-232 Does Facilitated Percutaneous Coronary Intervention 
Extend Optimal Door-to-Balloon Time in Patients With 
ST-Segment Elevation Myocardial Infarction Presenting 
in Community Hospitals?
Georgios I. Papaioannou, Haris Athar, Sanjeev B. Patel, Marcin R. Dada, Fawad A. Kazi, 
Justin B. Lundbye, Joseph E. Thomas, Leo Marcoff, Roger A. Mennett, Jeffrey F. Mather, 
Edcar D. Messer, Joseph F. Mitchell, Daniel B. Fram, Charles A. Primiano, Jeffrey A. 
Hirst, Francis J. Kiernan, William E. Boden, Raymond G. McKay, Hartford Hospital, 
Hartford, CT, Athens Medical Center, Athens, Greece
Background: Prolonged door-to-balloon (DTB) time >=120 min has a negative impact 
in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary 
percutaneous coronary intervention (PCI). Whether Facilitated PCI extends optimal DTB 
time in community-hospital STEMI patients remains unclear.
Methods: We compared baseline characteristics, and in-hospital major adverse cardiac 
events (MACE) (death, re-infarction, stroke and emergency revascularization), between 
808 consecutive, community STEMI patients, presented within 12 hours of symptom 
onset, without cardiogenic shock, treated either with Facilitated PCI (antecedent use 
of bolus ﬁbrinolytics and/or glycoprotein (GP) IIb/IIIa inhibitors followed by transfer for 
PCI, n=349), or Primary PCI (PCI without antecedent use of thrombolytic or GP IIb/IIIa 
therapy, n=459). Patients in both groups were further divided according to DTB times 
<=120 minutes or >120 minutes.
Results: There were no differences among the 4 groups (stenting >90%). Primary PCI 
patients with DTB <=120 min had lower in-hospital mortality and MACE compared to 
patients with DTB >120 min. Facilitated PCI patients had similar outcomes compared to 
Primary PCI patients with DTB <=120 min, irrespective of DTB time (Table).
Conclusion: Facilitated PCI in STEMI patients transferred from community hospitals 
results in similar clinical outcomes to that achieved in STEMI patients treated with Primary 















Death 1/249 (0.4%)a,e 10/210 (4.8%)b 1/90 (1.1%)d 5/259 (1.9%)
ap=0.002 (I vs. II); bp=0.08 (II 
vs. IV); cp=0.006 (II vs IV)
MACE 6/249 (2.4%)a,e 19/210 (9%)c 2/90 (2.2%)d 8/259 (3.1%)
dp=NS (III vs. IV); ep=NS (I vs. 
III and IV)
1004-233 The Feasibility Of Transport For Primary PCI In The 
Treatment Of STEMI In A Rural American Setting
Thomas A. Haldis, Jr., James C. Blankenship, Geisinger Medical Center, Danville, PA
Background: ACC/AHA guidelines suggest that patients with STEMI transferred for 
primary PCI should undergo PCI within 90 minutes of initial presentation. The feasibility of 
meeting these goals in a rural American setting has not been proven.
Methods: Geisinger Medical Center is the only tertiary care facility in north central 
Pennsylvania. Patients are transferred for PCI from hospitals up to 74 miles away. They are 
routinely re-evaluated by our inpatient service on arrival before the catheterization team 
is called. We retrospectively analyzed all patients transferred for primary PCI to our facility 
between January 1-July 31, 2004. All times from the symptom onset to balloon inﬂation 
were collected from emergency room notes, helicopter dispatch logs, and catheterization 
laboratory logs. We compared the speciﬁc time intervals in our region to those from recent 
randomized controlled trials.
Results: 61 patients with STEMI who were transferred to our facility underwent primary 
PCI over a 7-month period. The mean ﬂight distance from referring hospital to our center 
was 29.2 miles (range 10-74 miles).
Median Time Intervals In Recent Trials Compared  













PRAGUE 215 120 15 52 28 95 7%
PRAGUE 2 429 183 20 48 26 94 6.8%
AIR PAMI 71 na 35 58 25 118 8.4%
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Conclusions: Patients with STEMI in rural Pennsylvania present sooner after onset of 
symptoms than in recent trials. Despite its rural location, transport times are similar 
to those in the clinical trials. A policy of re-evaluation at the receiving center leads to 
unacceptable delays in reperfusion. Even with a door to balloon time under 30 minutes, it 
would be difﬁcult to meet ACC/AHA guideline goals.
1004-234 The ECG Adds Value to Time to Treatment in Predicting 
Aborted Myocardial Infarction
Taha Taher, Suhaib Al-Kurtass, Yuling Fu, Galen Wagner, Shaun G. Goodman, Robert 
Welsh, Christopher Granger, Lars Wallentin, Frans Van de Werf, Paul W. Armstrong, 
University of Alberta, Edmonton, AB, Canada, Duke Clinical Research Institute, Durham, NC
Background: Faster time to treatment enhances the success of pharmacologic 
reperfusion of ST� MI. We recently demonstrated it also increases the likelihood of aborted 
MI. Since time from symptom onset may be an imprecise measure of when ischemic 
injury begins we utilized baseline ECG measures of infarct acuteness score (AS) to 
further explore this.
Objective: To determine if an objective measure i.e. ECG AS (algorithm incorporating 
relative amounts of excess T amplitude and Q duration in ST� leads: AS range 4.0 earliest 
to 1.0 latest) predicts reperfusion success, aborted MI and large MI. 
Methods: ECGs (at baseline, 60 min after lysis) of STEMI pts in ASSENT3 and 3+ 
analyzed by a core lab. Baseline demographics and outcomes were analyzed to determine 
associations with AS.
Results: Of 6,617 pts with CK and ECG data, 14.3% had an aborted MI. Compared to pts 
with AS<3, pts with AS>3 had more frequent aborted MI (15.6% vs 12.4%, p=0.002) and 
fewer large infarcts ie. CK>5x normal (61.3% vs 71.7%, p<0.001). A multivariate analysis 
showed both time to treatment <2h (OR=1.68, CI=1.41-2.00) and AS>3 (OR=1.46, 
CI=1.20-1.77) are independent predictors of aborted MI. In all pts, complete ie. >70% ST 
resolution at 60 min was more likely in pts with higher AS.
Conclusion: The AS adds value to time to treatment in predicting reperfusion, aborted 
MI and large MI’s. A high AS even in pts presenting >2h increased likelihood of successful 
reperfusion and aborted MI thereby broadening the potentially successful treatment 
window.
1004-235 Hospital Stay After Uncomplicated Acute Myocardial 
Infarction in Europe can Be Signiﬁcantly Reduced; 
Observations from The Euro Heart Survey of Acute 
Coronary Syndromes
Maureen J. van der Vlugt, Sanne Hoeks, Eric Boersma, Maarten L. Simoons, Erasmus 
Medical Center, Rotterdam, The Netherlands
Background: Since efﬁcient use of medical resources is a priority for society, early 
hospital discharge after myocardial infarction (MI) has been studied extensively. The aim 
of the study was to evaluate the length of hospital stay (LOS) in patients (pts) with an 
uncomplicated MI across Europe, and to identify pts eligible for earlier discharge.
Methods: During 2001 the Euro Heart Survey of ACS enrolled 6,086 pts with acute MI 
(103 hospitals, 25 countries). During admission the most serious post MI adverse events 
were recorded, including death, asystole, ventricular ﬁbrillation or -tachycardia, heart 
failure, re-infarction and high-graded AV-block. For each hospital day we determined the 
daily event rate and the amount of pts free of any of these events.
Results: The mean age was 65 years, 70 % were male. The median LOS was 9 days 
(6-13). Table demonstrates a signiﬁcant decrease of the event rate during the ﬁrst 6 days. 
From day 7 on daily event rates stabilized around 1.0 %. At day 7 still 40 % were admitted, 
pts eligible for early discharge. Then, 13,588 days (21 % of all hospital days) spend in 
hospital would have been avoided.
Conclusion: Current ACC/AHA/ESC guidelines recommend discharge within 4 days in 
pts with uncomplicated MI. Our data suggested that this might be too early, since the 
event rate (death) decreased further beyond this 4 day period. However, even if pts will be 
discharged within 7 days a considerable reduction in LOS can be achieved. Such policy 
might contribute to an extensive reduction in costs.
hospital day 1 2 3 4 5 6 7 8 9
pts still admitted 6,086 3,948 3,601 3,348 3,117 2,777 2,414 1,998 1,615
death (%) 1.8 0.6 0.3 0.2 0.3 0.3 0.2 0.2 0.1
any event (%) 33.9 6.9 3.9 2.9 2.4 1.8 1.4 1.3 1.0
discharged (%) 0.3 1.9 3.1 4.0 8.5 10.6 14.7 17.9 19.3
1004-236 Participation In Thrombolytic Trials Delays Reperfusion 
Therapy In Acute Myocardial Infarction.
Wojtek C. Wasek, Sebastian Stec, Tomasz Mazurek, Andrzej Budaj, Beata Klosiewicz-
Wasek, Pawel Maciejewski, Bronislaw Bednarz, Cardiology Department, Postgraduate 
Medical School, Warsaw, Poland
Background: Shortening of time delay to the beginning of treatment in ST-segment 
elevation myocardial infarction (STEMI) is proven to be clinically essential. However, 
invasive vs thrombolytic treatment strategy is currently under investigation, particularly 
in terms of time from the onset of chest pain to treatment initiation. It is likely, that 
enrolment to the trials in STEMI may paradoxically prolong the time delay to treatment if 
randomisation procedures are too complex. 
Aim: Evaluation of door-to-needle time (DtN) to the onset of reperfusion therapy in 
patients (pts) randomised to trials or treated routinely with thrombolytics (Thrx).
Methods: We evaluated DtN in a group of 189 consecutive STEMI pts (trials n=96, Thrx 
n=93). The inclusion criteria for the analysis were the same in three groups: 1. STEMI 
diagnosis was given on admission. 2. Pts had no signs of heart failure. 3. There were 
no contraindications for immediate reperfusion therapy. The comparison of DtN between 
evaluated groups was analysed. DtN was separately compared in a subgroup of pts 
admitted within the ﬁrst hour from the onset of chest pain.
Results: DtN was signiﬁcantly longer in pts participated in trials. No differences in DtN 
were found between groups of pts enrolled to various trials.
Conclusion:(1) The participation in trials delays the beginning of reperfusion therapy. (2) 
The delay may be clinically important particularly in pts hospitalized very early from the 
onset of symptoms.




mean ± SD p <
all patients 22 ± 8 41 ± 18 0.0001
Subgroup of pts with chest pain < 1h 22 ± 8 42 ± 22 0.001
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1005-219 Does Plasma Homocysteine Levels Have An 
Independent Impact On Long-term Cardiovascular 
Mortality In Patients With Acute Coronary Syndromes. 
Results From The Biochemical Indices and outcome in 
Acute coronary Syndromes (Bias) Study.
Michael N. Zairis, Demetrios Beldekos, Charalambos Apostolatos, Dionissis Xenos, 
George Bibis, Olga Ampartzidou, Stamatis Makrygiannis, Paraskevi Psarogianni, 
George Psaltiras, Evdokia Adamopoulou, John Hatzissavas, Stefanos Foussas, Tzanio 
Hospital, Piraeus, Greece
Background-Although an elevated plasma total homocysteine (tHcy) level has been 
considered as a cardiovascular disease risk factor, its impact on the long term prognosis 
in patients with acute coronary syndromes remains controversial. We evaluated this 
possible association in the BIAS (Biochemical Indices and outcome in Acute coronary 
Syndromes) study.
Methods-The BIOS study was designed to evaluate prospectively the impact of several 
biochemical indices including tHcy on the long term cardiovascular mortality in patients 
who hospitalised due to either ST elevation myocardial infarction (STEMI) or non-
ST elevation acute coronary syndromes (NSTACS). For the purpose of this study 934 
consecutive pts with STEMI (458 pts) and NSTACS (476) who admitted in the ﬁrst 12 and 
24 hrs of index pain respectively, were recruited. All biochemical indices were estimated 
upon pts’ admission and cardiovascular mortality during 5 years of follow up was the 
primary study endpoint. 
Results-Plasma tHcy levels were signiﬁcantly higher in pts with: diabetes (p=0.02); 
age>=70 years (p=0.01); history of coronary revascularization (p=0.001); and history of 
cerebrovascular or peripheral artery disease (p<0.001). The incidence of cardiovascular 
mortality at the end of the follow up was 23.1% and 21.4% in pts with STEMI and NSTACS 
respectively. By univariate regression analysis high plasma tHcy levels were signiﬁcantly 
related with increased cardiovascular mortality in pts with either STEMI (p=0.01) or 
NSTACS (p=0.01). However by multivariate regression analysis, in which all univariate 
predictors of cardiovascular mortality were included, high plasma tHcy levels were no 
associated with the 5-year outcome in both STEMI (p=0.9) and NSTACS (p=0.8).
Conclusions-The results of the BIAS study suggest that plasma tHcy levels upon 
admission cannot be used as an index of early risk stratiﬁcation in patients with either 
STEMI or NSTACS
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1005-220 Serum 15-F2-Isoprostane Predicts Future 
Cardiovascular Events In Patients With Acute  
Coronary Syndromes
Srikanth Sola, Patrick B. Caneer, W. Craig Hooper, Megan E. Price, Muhammad Q. Mir, 
Joshua M. Larned, Nadya Khan-Merchant, Bobby V. Khan, Emory University School of 
Medicine, Atlanta, GA, Rollins School of Public Health, Atlanta, GA
Background: Isoprostanes are free-radical dependent metabolites of arachidonic acid 
that are used as clinical biomarkers of lipid peroxidation and oxidative stress. Whether 
quantiﬁcation of 15-F2-isoprostane provides prognostic information in unstable coronary 
artery disease is unknown.
Methods: We measured plasma levels of 15- F2-isoprostane, interleukin-6 (IL-6), and 
VCAM-1 on admission in patients who were admitted to the hospital with acute coronary 
syndrome (ACS). Patients were followed prospectively for the occurrence of the primary 
endpoint, which was a composite of cardiac death, non-fatal myocardial infarction (MI), 
revascularization, or hospitalization.
Results: We followed 136 patients for an average of 13 ± 1.3 months. Baseline plasma 
levels of 15-F2-isoprostane, IL-6, and VCAM-1 predicted the
 risk of myocardial infarction, 
even in patients who are negative for troponin T (<0.1 ng per milliliter) at baseline 
(P<0.0001). Furthermore, the incidence of the primary outcome during the follow-
up period was increased in patients in the highest tertile of 15-F2-isoprostane levels 
compared with those in the lowest (see Table). The adjusted odds ratio for occurrence 
of the primary outcome was 1.67 (95% CI 1.32-2.12; p < 0.001) for each tertile of serum 
15-F2-isoprostane levels. 
Conclusions: Serum levels of 15-F2-isoprostane, a marker of oxidative stress, independently 
predicts long-term cardiovascular events in high risk patients admitted with ACS. 






n = 45 P
Composite outcome 7 12 28 < 0.0001
Non-fatal MI 2 6 21 < 0.0001
Hospitalization for heart failure 2 3 8 0.03
Revascularization 4 11 25 < 0.0001
Cardiac death 2 2 2 1
1005-223 Living Alone Is an Independent Predictor of Future 
Cardiac Events Not in Female but in Male Elderly 
Patients After Acute Myocardial Infarction
Daisaku Nakatani, Hiroshi Sato, Yasuhiko Sakata, Kunihiro Kinjo, Hiroya Mizuno, 
Masahiko Shimizu, Hiroshi Ito, Masayoshi Mishima, Masatsugu Hori, Osaka University 
Graduate School of Medicine, Suita, Japan, Sakurabashi Watanabe Hospital, Osaka, 
Japan
Background: Although the number of the adults aged 65 years or older living alone has 
been increasing steadily, few data are available regarding the impact of living alone on 
cardiac events in elderly patients with AMI. Furthermore, there exists a sex difference in 
response to social isolation in rats.
Methods: To examine the impact of living alone on cardiac events in elderly patients with 
AMI and whether it differs between in men and women, we studied 1035 patients aged 65 
years or older who discharged alive after AMI. Cardiac events were deﬁned as composite 
of cardiac death, percutaneous coronary angioplasty, coronary aorta bypass surgery, 
readmission for heart failure, reinfarction, unstable angina, or arrhythmia.
Results: The mean follow up was 699±523 day. The incidence of cardiac events after 
AMI was higher in patients living alone than in those not living alone after AMI (36.2% 
vs. 28.0%, P=0.009). Interestingly, the rate of cardiac events was higher in male patients 
living alone than in the group not living alone (40.4% vs. 28.7%, P=0.002), while it was 
similar between female patients living alone and not alone (26.4% vs. 25.9%, P=0.943). 
Multivariate analysis revealed that living alone was an independent risk factor predicting 
future cardiac events in elderly patients after AMI (HR 1.64, 95% CI; 1.19-2.28, P=0.003). 
According to sex, living alone was independently associated with an increased risk of 
cardiac events in men (HR 1.86, 95% CI; 1.27-2.74, P=0.002), but not in women (HR 1.37, 
95% CI; 0.71-2.62, P=0.345), suggesting sex difference in response to social isolation.
Conclusions: Living alone is associated with an increased risk of future cardiac events in 
elderly male patients after AMI, for whom social support may be needed.
1005-224 Baseline Urinary Albumin Concentration Predicts Long-
Term Cardiovascular Risk in Acute Coronary Syndrome 
Patients: A PROVE IT-TIMI 22 Substudy
Kausik K. Ray, David A. Morrow, Sabina Murphy, Carolyn H. McCabe, C. Michael 
Gibson, Christopher P. Cannon, Brigham and Women’s Hospital, Boston, Harvard 
Medical School, Boston, MA
Background: Urinary microalbuminuria (MA) is postulated to be a marker of vascular 
health and correlates with cardiovascular (CV) risk in patients with diabetes and 
hypertension. Statins have been shown to improve markers of vascular health such 
as ﬂow mediated dilatation and adhesion molecule expression in patients with stable 
coronary artery disease (CAD). 
Aims and Methods: Among ACS patients, we assessed whether urinary albumin 
concentration (UAC) (µg/ml) identiﬁed patients at risk of future CV events, and the effect 
of intensive statin therapy on UAC in the PROVE IT-TIMI 22 study. UAC was measured 
using a spot urine sample at enrollment and at the end of study. 
Results: We measured UAC in 3280 patients. A higher baseline UAC was associated with 
MI, stroke and death or MI during a mean follow up of 2 years (ﬁg1). The % of patients 
with death, MI, stroke or the composite of death, MI or stroke at 2 years each increased 
incrementally with increasing UAC (ﬁgure 2). In 1204 patients who had UAC determined at a 
mean of 2 years after enrollment, neither statin regime signiﬁcantly reduced urinary MA.
Conclusions: Urinary albumin concentration peri-ACS predicts CV risk during long term 
follow up, but is not signiﬁcantly inﬂuenced by statin therapy at 2 years. Measurement of 
vascular health using urinary albumin concentration may be a useful as an additional risk 
predictor in ACS. 
1005-225 Cystatin C is the Most Powerful Predictor of Long-term 
Mortality in Patients With Acute Coronary Syndromes
Stefan K. James, Bertil Lindahl, Anders Larsson, Lars-Olof Hansson, Paul Armstrong, 
Robert Califf, Maarten Simoons, Lars Wallentin, Institute of Medical Sciences, Uppsala, 
Sweden
Background: Measurements of renal function, such as creatinine and creatinine clearance 
(creacl) carry independent prognostic information in patients with acute coronary syndromes 
(ACS). Cystatin-C is a cysteine protease inhibitor involved in the catabolism of proteins and 
a more reliable endogenous marker of glomerular ﬁltration rate.
Methods: The GUSTO IV trial, evaluating abciximab as the medical treatment in non-ST 
elevation ACS without early revascularization, included 7800 patients. Levels of cystatin-C 
at randomization were analyzed in 785 patients and creacl was calculated from creatinine 
with the Cockroft-Gault equation. The results were related to 1-year mortality. 
Results: The median of cystatin-C was 0.99 (cystatin-C derived GFR 75 ml/min). There 
was a signiﬁcant correlation between cystatin-C and creacl, creatinine, Nt-proBNP, CRP 
and troponin T ; r=0.53, 0.47, 0.41, 0.25 and 0.1 respectively.
In a multiple logistic regression analysis including a large number of riskfactors Cystatin-C 
above the median of 0.99 had the highest Odds ratio 3.3 (95% C.I: 1.4-7.75). When creacl 
was added, Cystatin-C remained signiﬁcant with O.R 2.8 (95% C.I: 1.2-6.9) while creacl 
was not; O.R 1.8 (95% C.I: 0.7-4.5).
Conclusion: In non-ST elevation ACS, a single measurement of Cystatin-C at admission 
provides prognostic information on long-term mortality beyond creatinine clearance. In 
combination with NT-proBNP and Troponin-T the risk stratiﬁcation is further improved.
One-year mortality 
% Troponin-T, ug/L p Nt-proBNP, ng/L p
<=0.01 >0.01 <=669 >669
Cystatin-C, mg/L
Quartiles
<0.86 1.2 6.1 0.09 0.7 13.7 <0.001
086-0.99 1.4 5.6 0.14 0.9 9.1 0.007
0.99-1.21 7.0 10.3 0.4 7.1 11.2 0.2
>1.21 9.0 24.4 0.009 7.7 24.6 0.006
0.046 <0.001 0.04 0.08
1005-228 Long-term Prognosis of Patients who Developed 
Hyponatremia During the Acute Phase of ST-elevation 
Myocardial Infarction
Alexander Goldberg, Haim Hammerman, Sergey Yalonetski, Sirouch Petcherski, 
Alexander Zdorovyak, Michael Kapeliovich, Walter Markiewicz, Doron Aronson, 
Rambam Medical Center, Haifa, Israel
Background: Hyponatremia (HNa) is common in hospitalized patients (pts) and is 
associated with adverse short-term prognosis. The prognostic signiﬁcance of HNa in 
acute coronary syndromes, especially beyond the index hospitalization, is not known.
Methods: We studied 1345 pts presenting with ST-elevation myocardial infarction 
(STEMI). Plasma sodium levels (PNa) were obtained on admission and at 24-h, 48-h, 
and 72-h. All pts were followed in hospital and following discharge (median follow-up 
568 days). Cox proportional hazards analysis analyses were performed to determine 
the relation between HNa and mortality adjusting for age, sex, diabetes, hypertension, 
smoking, Killip class on admission, SBP and heart rate on admission, anterior infarction, 
use of diuretics, previous heart failure and reperfusion therapy.
Results: HNa (PNa < 135 mmol/L) was present on admission in 168 pts (12.5%) and 
developed in 234 (17.4%) during the ﬁrst 72-h. Cox analysis revealed that pts with 
HNa were at increased risk of mortality (adjusted RR 2.4; 95% CI 1.8-3.2; P < 0.0001) 
(Figure). Similar results were obtained when analyzing only pts who survived the index 
hospitalization (adjusted RR 1.7; 95% CI 1.1-2.7; P = 0.03). The risk associated with 
severe HNa (≤130 mmol/L) was larger than that of mild (131-134 mmol/L) HNa (adjusted 
RR 4.4 [95% CI 3.0-6.6] vs. 1.8 [95% CI 1.3-2.5]).
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Conclusion: HNa on admission or developing within 72 h from admission is a strong 
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Orange County Convention Center, Hall E1
Presentation Hour: 11:00 a.m.-Noon
1006-215 Effects of Dehydroepiandrosterone Supplementation on 
Coronary Reserve in Men with Coronary Artery Disease
Jerzy Krzysztof Wranicz, Iwona Cygankiewicz, M. Rosiak, J. Slowikowska-Hilczer, P. 
Dejak, M. Maciejewski, W. Koniarek, M. Lipinski, M. Wrona, P. Kukla, I. Poprawska, J. H. 
Goch, K. Kukla, Wojciech Zareba, Medical University of Lodz, Lodz, Poland, University 
of Rochester Medical Center, Rochester, NY
Background. Dietary supplementation with dehydroepiandrosterone (DHEA) has been 
considered as therapeutic modality in coronary patients. We aimed to determine the effect 
of daily supplementation of DHEA on coronary reserve, assessed by clinical evaluation, 
exercise-treadmill test (ETT), and quality of life in men with coronary disease.
Methods. A randomized double blind placebo-controlled crossover trial was designed 
involving 36 coronary patients (mean age 58+/-9 years) who received 12 weeks of 50 
mg/day oral therapy of DHEA and placebo interrupted by a 4-week washout period. Blood 
levels of DHEA sulfate, testosterone, and estradiol were measured and cardiac status 
of the patients was evaluated by quantifying weekly usage of nitroglycerine and by ETT: 
exercise duration and workload. Quality of life was evaluated using SF-36 questionnaire.
Results. Median values of measured parameters after DHEA treatment indicated 
improvement in cardiac status (Table). SF-36 questionnaires also showed signiﬁcant 
(p<0.05) improvement in quality of life (physical function, vitality, bodily pain, limitations 
related to physical and emotional problems).
Conclusions. Administration of DHEA in dose 50 mg per day is associated with signiﬁcant 
improvement of several clinical measures reﬂecting coronary reserve and quality of life in 
coronary patients. This clinically detectable improvement probably relates to an increase 
of DHEAS blood levels together with elevation of blood testosterone and estradiol.
Parameters Baseline Placebo DHEA
DHEA (ug/dl) 103 106 191†
Estradiol (pmol/l) 99 97 196*
Testosterone (nmol/l) 11.9 12.6 16.9*
Nitroglicerine use (tabl/week) 6.1 4.7* 2.9*
ETT workload (METs) 7.5 7.0 9.5*
ETT duration (min) 6.8 6.4 8.2*
* signiﬁcantly different than placebo
† -p=0.07 when comparing to placebo
1006-216 Endothelin-1 Gene LYS198ASN Polymorphism in 
Human Variant Angina Pectoris
Juyong Lee, Jeong-Uk Kim, Kyung Il Song, Yunseok Choi, Sang-sig Cheong, 
Gangneung Asan Hospital, Gangneung-si, South Korea
Background; Endothelin-1 (ET-1) is increased in patients with variant angina pectoris 
(VAP) occurring chest pain. The imbalance of blood vasoconstrictor and vasodilator, such 
as endothelium derived relaxation factor (EDRF) was assumed to be one of the key factors 
causing VAP. Recently, the polymorphisms of EDRF and other vasoreactants have been 
reported for VAP patients. However, there has been no data about genetic polymorphism 
of ET-1 in the patients with VAP. We investigated the frequency of a G/T polymorphism 
with an amino acid substitution (Lys-Asn) at codon 198 in exon 5 of the ET-1 gene in the 
VAP patients and its possible association with coronary spasm.
Methods: Polymerase chain reaction (PCR) restriction fragment length polymorphism 
(RFLP) method was performed in 103 VAP patients and 111 controls. VAP was diagnosed 
with ergonovin (ERG) provocation coronary angiography (CAG)(n=58, 56.3%) and ERG 
stress echocardiography (n=45, 43.7%). Absence of the ﬁxed coronary artery disease 
(CAD) (> 50% of diameter stenosis) was conﬁrmed in the ﬁnding of ERG provocation CAG 
group with normal or minimal CAG result and in ERG stress echocardiography group with 
negative result of treadmill test, thallium scan, normal or minimal CAG result. Age, sex 
matched control who has no history of any angina like chest pain was randomly selected 
from health care screening department. The control has no diabetes mellitus, hypertension, 
hypercholesterolemia, current systemic infection, and elevated SGOT/SGPT. High-sensitivity 
C-reactive protein concentration was checked by immunonephelometry in two groups.
Results: Genotype frequency of Lys198Asn polymorphism of ET-1 in VAP (GG 46(44.7%), 
GT 42(40.8%), TT 15(14.6%)) was signiﬁcantly higher than control group (GG 64(57.7), GT 
41(36.9%), TT 6(5.4%))(p=0.038). Multiple logistic regression analysis using risk factors 
and the Lys198Asn polymorphism showed that the signiﬁcant risk factors for VAP were hs 
CRP(odds ratio 20.68, p=0.03) and the Lys198Asn polymorphism(odds ratio 1.736, p=0.04).
Conclusion: The frequency of Lys198Asn polymorphism of ET-1 gene is higher in VAP than 
normal. It might associate with VAP and seems to be a susceptablity gene for VAP.
1006-217 GLU27 Variant of Beta 2 Adrenergic receptor 
polymorphism is a Risk Factor for Coronary Artery 
Disease
Emanuele Barbato, Alexandre Berger, Leen Delrue, Ganesh Manoharan, Eddy van 
Schuerbeeck, William Wijns, Hans De Beenhouwer, Quirino Ciampi, Jozef Bartunek, 
O.L.V. Clinic, Cardiovascular Center, Aalst, Belgium, Fatebenefratelli Hospital, 
Cardiology, Benevento, Italy
Background. Glu-27 variant of β2-adrenergic receptor (β2-AR) polymorphism is 
associated with several risk factors of coronary atherosclerotic disease (CAD) like 
obesity, high level of plasma trygliceride and hypertension. We tested the hypothesis that 
Gln27Glu β2-AR polymorphism is directly related to coronary artery disease (CAD).
Methods. Seven hundred and ﬁfty-ﬁve consecutive patients were genotyped for 
Gln27Glu polymorphism of β2-AR. Pts were divided into 2 groups: No CAD patients with 
angiographically smooth coronary arteries (n=278) and CAD patients with presence of 
diameter stenosis (DS) >30% in at least one coronary artery (n=477). Control population 
consisted of 110 volunteers from the blood donor center.
Results. In control population, Glu27 allele frequency was 39%. In No CAD patients, allele 
frequency was similar to controls (40%, OR:1.0, 95%CI: 0.6-1.5, NS). In CAD patients, 
incidence of Glu 27 variant was signiﬁcantly higher (47%, OR:1.4, 95%CI: 1.1-1.7, p<0.01 
vs controls and no CAD). The risk for CAD was 1.9 fold higher for Glu 27 heterozygotes 
and 2.4 fold higher for Glu 27 homozygotes Glu 27 patients (Table).
Conclusion. The incidence of coronary artery disease is higher in patients with Glu 27 
variant of the β2- adrenergic receptor. The present data suggest that Glu27 polymorphism 
may play a role in the progression of coronary atherosclerosis and represent a novel risk 
factor for coronary artery disease.















1006-218 The C161T Polymorphism of Peroxisome Proliferator-
Activated Receptor Gamma Gene Is Associated With the 
Occurrence and Severity of Coronary Artery Disease
Ting-Hsing Chao, Yi-Heng Li, Shih-Hung Chan, Jyh-Hong Chen, Hwa-Lin Wu, Guey-
Yueh Shi, Liang-Miin Tsai, Li-Jen Lin, National Cheng Kung University Medical Center, 
Tainan, Taiwan,ROC
Background: Peroxisome proliferator-activated receptor (PPAR) is a nuclear receptor. 
Activation of PPAR γ with ligands could modulate some gene transcription, thereby leading 
to multiple antiatherogenic and ﬁbrinolytic effects. According to our study, an association 
between PPAR γ C161T polymorphism and premature myocardial infarction was observed. 
Lipid peroxidation was signiﬁcantly inﬂuenced with T allele. We hypothesized that C161T 
polymorphism of the exon 6 of PPAR γ is associated with the occurrence and severity of 
coronary artery disease (CAD).
Methods: We recruited 338 patients with angiographically documented CAD (> 50% 
diameter narrowing in one major coronary artery or its major branches) and 310 controls 
in our hospital. The C161T polymorphism was examined using polymerase chain reaction 
and restriction fragment length polymorphism.
Results: The frequencies of the CC, CT, and TT genotypes in controls were 50.3%, 43.9%, 
and 5.8%, respectively, which were in Hardy-Weinberg equilibrium. The frequency of the 
PPAR γ CT+TT genotype among patients with CAD was signiﬁcantly higher than that in 
controls (59.8% vs. 49.7%, p=0.01). By a simple χ2 comparison, there was a signiﬁcant 
association between PPAR γ genotypes and the number of signiﬁcant diseased vessels 
(p=0.002). This association was still signiﬁcant after adjustment of conventional coronary 
risk factors. In multivariate logistic regression analyses, we found CT+TT genotypes (OR 
1.7, 95% CI 1.2 to 2.4), smoking (OR 2.4, 95% CI 1.7 to 3.6), hypertension (OR 3.0, 95% 
CI 2.1 to 4.3), and diabetes mellitus (OR 2.9, 95% CI 1.8 to 4.6) were the independent risk 
factors for the occurrence of CAD.
Conclusions: T allele carriers of C161T polymorphism of the PPAR γ gene had a 
signiﬁcantly higher risk for CAD in terms of the occurrence and severity.
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1006-221 Effects of Sarpogrelate HCl, a Selective 5-HT2A 
Antagonist, on Endothelial Function and Aortic 
Stiffness in Diabetic Patients With Stable Angina
Hideki Watanabe, Kinu Medical Association Hospital, Mitsukaido, Japan, Makabe-
Silvertopia Facilities for Geriatric Care, Makabe, Japan
Background: Sarpogrelate HCl is a novel serotonin blocker, which speciﬁcally 
antagonizes 5-HT2A receptors, and it has potential as an antianginal drug. We assessed 
the effects of sarpogrelate HCl on endothelial function and aortic stiffness in diabetic 
patients with stable angina. 
Methods: Twenty patients with type 2 diabetic mellitus (DM) and stable angina were 
randomized to receive sarpogrelate HCl (sarpogrelate group, 300mg/day, n=10) or not 
to receive sarpogrelate HCl (control group, n=10) after the standard treatment. Flow-
mediated dilatation (FMD) and Nitroglycerin-induced dilatation (NID) of brachial artery 
were measured by using ultrasound system to evaluate endothelium - dependent and 
- independent vasodilation. We also measured aortic pulse wave velocity (PWV) to 
evaluate aortic stiffness by using oscilometric technique (form PWV/ABI, COLIN). 
These measurements were performed at baseline, and then at 3 and 6 months after the 
treatment. Results: At baseline, there was no difference in fasting glucose level, HbA1c, 
FMD, NID, and PWV between two groups. There is no difference in fasting glucose level 
and HbA1c at 3 and 6 months between two groups. FMD was signiﬁcantly increased 
after 3 and 6 months in the sarpogrelate group. PWV was signiﬁcantly decreased after 
6 months in the sarpogrelate group. NID did not change during the study in two groups. 
Conclusion: Sarpogrelate HCl, a serotonin blocker, improves endothelial function and 
aortic stiffness in diabetic patients with stable angina.
Baseline 3 months 6 months
FMD (%) Sarpogrelate 5.7+/-0.4 7.5+/-0.9*# 8.1+/-0.6*#
Control 5.8+/-0.5 5.8+/-0.4 5.8+/-0.5
NID (%) Sarpogrelate 14.9+/-1.0 14.9+/-0.8 14.9+/-0.7
Control 14.8+/-0.8 14.7+/-0.8 14.9+/-0.8
PWV (cm/sec) Sarpogrelate 1750+/-99 1705+/-73 1506+/-62*#
Control 1760+/-105 1712+/-93 1706+/-54
Data are means+/-SD. *p<0.01 vs Baseline, #p<0.01 vs Control
1006-222 Rosiglitazone Improves Myocardial Glucose Uptake in 
Ischemic Regions in Patients With Type 2 Diabetes. A 16 
Week Randomised, Double-Blind, Placebo-Controlled 
Study
Riikka Lautamäki, K.E.Juhani Airaksinen, Marko Seppänen, Jyri Toikka, Matti Luotolahti, 
Elizabeth Ball, Ronald Borra, Risto Härkönen, Juhani Knuuti, Murray Stewart, Pirjo 
Nuutila, University of Turku, Turku, Finland, GlaxoSmithKline, United Kingdom
Background: Rosiglitazone improves insulin sensitivity and skeletal muscle glucose 
uptake in patients with uncomplicated type 2 diabetes. In patients with ischemic coronary 
artery disease, glucose is an important source of energy and preserved myocardial 
glucose uptake is essential for the viability of the jeopardised myocardium. The effect of 
rosiglitazone on myocardial metabolism in type 2 diabetic patients with coronary artery 
disease was thus studied.
Methods: The study was randomized, double-blind and placebo-controlled. Post-hoc 
analysis was conducted excluding 4 subjects who were considered violators. 54 patients 
(38 men, 16 women) with type 2 diabetes (HbA1c 7.2+0.9%) and coronary artery disease 
were studied with PET and [18F]FDG during hyperinsulinemic euglycemic clamp before 
and after 16 week intervention period with rosiglitazone (n=27) or placebo (n=27). 
Ischemic regions of myocardium were determined with rest-stress 99m Tc-SPECT 
imaging and coronary angiography.Statistical analysis was carried out using Analysis of 
Covariance, adjusting for gender and baseline.
Results: Myocardial glucose uptake increased by 6.12 [0.89, 11.34] µmol/100g/min in 
ischemic regions (P=0.023) and by 8.40 [2.99, 13.81] µmol/100g/min in non-ischemic 
regions (P=0.003) on rosiglitazone as compared to placebo. The treatment effect of 
myocardial glucose uptake in ischemic regions based on all subjects was smaller, 4.77 [-
0.37, 9.90] µmol/100g/min. In addition, whole body insulin sensitivity and glycemic control 
were signiﬁcantly improved on rosiglitazone compared to placebo.
Conclusion: Rosiglitazone therapy signiﬁcantly improves myocardial glucose uptake in 
type 2 diabetic patients with ischemic coronary artery disease. These results suggest that 
rosiglitazone therapy may facilitate myocardial glucose storage and utilization in these 
patients.
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1032-203 Effects of Cell Transplantation Using Vascular 
Endothelial Growth Factor-Expressing Mesenchymal 
Stem Cells for Myocardial Infarction
Ryo Matsumoto, Takashi Omura, Minoru Yoshiyama, Tetsuya Hayashi, Yasukatsu Izumi, 
Yasuhiro Nakamura, Kaname Akioka, Kazuhide Takeuchi, Junichi Yoshikawa, Osaka City 
University Medical School, Osaka, Japan
Background: Vascular endothelial growth factor (VEGF) is known to play an important 
role in inducing angiogenesis in ischemic regions. Mesenchymal stem cells (MSCs) may 
have therapeutic potential for restoring cardiac function after irreversible injury. Then, we 
hypothesized that transplantation of VEGF-expressing MSCs could effectively treat acute 
myocardial infarction (MI) by providing enhanced cardioprotective effects, followed by 
angiogenic effects in salvaging ischemic myocardium.
Methods: Bone marrow mononuclear cells of Lewis rats were cultured with low glucose 
DMEM for MSCs outgrowth. The human VEGF165 gene was transfected to cultured MSCs 
using an adenoviral vector. Six million of VEGF- and LacZ-transfected MSCs (VEGF group), 
LacZ-transfected MSCs (Control group), or serum-free medium only (Medium group) were 
injected into syngeneic rat hearts one hour after left coronary artery occlusion.
Results: At one week after MI, the transplanted MSCs were detected by X-gal staining in 
the infarcted region. High expression of VEGF was immunohistochemically observed in the 
VEGF group. At 28 days after MI, infarct size, left ventricular end-diastolic and end-systolic 
dimensions, ejection fraction, E wave velocity / A wave velocity ratio were most improved 
in the VEGF group, compared with the Medium group. Under electron microscopy, small 
cells containing myoﬁlaments and many interstitial cells were observed adjacent to the 
infarcted area, in both the VEGF and Control groups. In addition, immunohistochemically 
stained α-smooth muscle actin-positive cells and capillary density of the infarcted region 
were most increased in the VEGF group.
Conclusions: This combined strategy of cell transplantation with gene therapy could be 
a useful therapy for the treatment of acute MI.
1032-204 Enhancement of The Functional Beneﬁts of Pretreated 
Mesenchymal Stem Cells(MSCs) in a Rat Myocardial 
Infarct Model
Jihyun Yoon, Young Hoon Kim, Wan Joo Shim, Young Moo Ro, Do-Sun Lim, Korea 
University Medical Center, Seoul, South Korea
Background: Mesenchymal stem cells (MSCs) offer a novel therapeutic option in the 
treatment of acute myocardial infarction. MSCs are able to differentiate into myogenic 
cells after 5-azacytitinde treatment. However, 5-azacytidine might have genotoxic effects. 
Recently, it was reported that combined treatment with bone morphogenetic protein-
2(BMP-2) and ﬁbroblast growth factor-4(FGF-4) caused cardiac differentiation in non-
precardiac mesoderm explants. Therefore, we investigated whether MSCs treated with 
combined BMP-2 and FGF-4 showed evidence of myogenic differentiation in vitro, and 
whether these cells resulted in sustained engraftment, myogenic differentiation, and 
improved cardiac function after implantation in infarcted myocardium. 
Methods and Results: In vitro study: MSCs were treated with BMP-2 + FGF-4 (GF-
MSCs) and myogenic phenotype was evaluated immunohistochemically. Cell growth 
curve was used to compare MSC proliferative capacity between the growth factors and 
5-azacytidine treatments. In vivo study: Two weeks after coronary artery occlusion, GF-
MSCs (n = 15), MSCs (n = 5) labeled with PKH26 were injected into infarcted myocardium. 
Control animals (n = 5) received a culture medium into the infarcted myocardium. Two weeks 
after implantation, some engrafted GF-MSCs or MSCs expressed sarcomeric-a-actinin and 
cardiac myosin heavy chain, as was observed in culture. Echocardiography showed that 
GF-MSC group had better (p<0.05) left ventricular performance than the other groups. 
Conclusion: GF-MSCs were induced myogenic differentiation in vitro. Moreover, GF-
MSCs engrafted into the infarcted myocardium appeared to myogenic differentiation, 
prevented dilation of the infarcted region, and eventually improved heart function.
1032-205 Early Treatment With Fluvastatin Enhances the 
Mobilization of CD34+, CD117+, CXCR4+, C-met+ Stem 
Cells Into Peripheral Blood in Patients With Acute 
Myocardial Infarction: LAVA Trial
Wojciech Wojakowski, Anna Michalowska, Marcin Majka, Katarzyna Maslankiewicz, 
Rafal Wyderka, Marek Krol, Andrzej Ochala, Mariusz Z. Ratajczak, Michal Tendera, 
SIlesian School of Medicine, Polish-American Childrens Hospital, Katowice, Krakow, 
Poland, Stem Cell Biology Program at James Graham Brown Cancer Center, University 
of Louisville, Louisville, KY
BACKGROUND: Stem cells can be mobilized into the peripheral blood in the setting of acute 
myocardial infarction. Statins use is associated with improved survival in patients with acute 
coronary syndromes. Aim of the study was to assess the inﬂuence of early (< 12 hours) and 
late (ﬁrst dose given on 4.-5. day after admission) treatment with 80 mg of ﬂuvastatin on the 
dynamics and magnitude of stem cell mobilization in patients with STEMI.
METHODS: 25 patients with STEMI (< 12 hours after chest pain onset) and randomized 
to early treatment (group A, n=13) and late treatment (group B, n=12) with 80 mg of 
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ﬂuvastatin. 20 patients with stable angina were the controls. Peripheral blood samples 
were drawn on admission, after 7 and 30 days. FACSCalibur ﬂow-cytometer was used 
for stem cells assay. RESULTS: Table 1 shows the changes in absolute number of stem 
cells in both groups of STEMI patients in comparison to patients with stable angina. Stem 
cells numbers were signiﬁcantly higher at baseline and after 7 days in all STEMI groups in 
comparison to stable angina and comparable after 30 days. Fluvastatin started early was 
associated with signiﬁcantly higher number of stem cells after 7 days in comparison to 
group treated with ﬂuvastatin later (day 4.-5.). There were no differences in SDF-1, VEGF, 
IL-6 and HFG levels between groups A and B.
CONCLUSION: Early administration of 80 mg ﬂuvastatin signiﬁcantly increases the 
mobilization of CD34+, CD117+, c-met+, CXCR4+ stem cells in acute myocardial infarction.
Table. Data expressed as median and range;  
*p<0.05 vs. group B 









GROUP A GROUP B GROUP A GROUP B GROUP A GROUP B
CD34+ 430 (0-821) 930 (0-1549) 890 (0-1489) 1423 (0-1870)* 860 (0-1584) 571 (131-1121) 498 (0-821)
CD117+ 412 (13-3745) 824 (0-2311) 865 (0-2298) 1031 (0-2087)* 721 (0-1547) 602 (0-1599) 576 (0-2105)
CXCR4+ 1512 (211-2897) 2689 (321-2989) 2543 (0-3011) 2434 (0-2979)* 1724 (0-2475) 1438 (176-2265) 1232 (0-3033)
c-met+ 507 (34-2734) 1789 (0-2458) 1853 (0-2189) 1571 (132-2567)* 932 (0-2312) 677 (0-2060) 729 (283-2120)
1032-206 Autologous Transplantation of a new Generated 
Pluripotent Cells Type of Monocytic Origin Improves 
Damaged Heart Function
Nour Eddine El Mokhtari, Bettina Dresske, Hendrik Ungefroren, Maren Ruhnke, Volker 
Plate, Dirk Janssen, Reiner Siebert, Alexander Reinecke, Fred Fandrich, Rudiger Simon, 
Clinic of Cardiology, Kiel, Germany, Clinic of General and Thoracic Surgery, Kiel, Germany
Aims: Stem cell transplantation has been well demonstrated to improve cardiac function 
after myocardial infarction (MI). Recently, we could generate CD34+,CD90+ and CD117+ 
cells from blood monocytes with pluripotent characteristics that in vitro differentiate into 
various somatic cell types. This study investigated wether these programmable cells of 
monocytic origin (PCMO) succeed to restore LV function postinfarction.
Methods: MI was induced in female LEW rats by ligation of the left coronary artery. PCMO 
of male LEW donors were injected either intramyocardially in the infarcted area or i.v. 24 
hours or 6 days after MI. Infarcted animals receiving no cell treatment or autologous naive 
blood monocytes of male origin served as control. 6 weeks after transplantation, all animals 
underwent transthoracic echocardiography for assessment of LV dimensions and cardiac 
function. Additionally, PCR for the rat sex determing region of the Y-chromosome was 
performed of the different areas of infarcted heart muscle using microdissection technique.
Results: Intramyocardial injection of PCMO signiﬁcantly improved LV function of infarcted 
hearts (ejection fraction (EF) 53.0 ± 15.2% in animals injected 24 hours postinfarction 
and EF 50.8 ± 4.3 % in animals injected after 6 days versus EF 38.3 ± 8.7% in untreated 
rats, p< 0.05) while transplantation of naive blood monocytes failed to restore damaged 
heart function (EF 39.3 ± 17.2%). Interestingly, early i.v. cell transplantation had the same 
effect as intramyocardial injection and improved the ejection fraction to 54.1 ± 14.2%. 
6 days after myocardial infarction systemic application was ineffective in the rat model 
(EF 30.3 ± 2.1%). PCR for the Y-chromosome was positive solely in the area beside the 
infarction while no DNA could be detected in the infarcted area or in the right ventricle. 
Conclusions: Intramyocardial transplantation of autologous PCMO signiﬁcantly improved 
damaged heart function after MI. Moreover, this study demonstrated that also systemic 
application of these cells succeed to restore cardiac function. In combination with the 
superior availability, the transplantation of PCMO promise effective clinical appproach.
1032-207 Dose-Dependent Contribution of CD34-positive Cell 
Transplantation to Cardiomyogenesis, Vasculogenesis 
and Arteriogenesis with Functional Recovery Post-
Myocardial Infarction
Hiroto Iwasaki, Atsuhiko Kawamoto, Masakazu Ishikawa, Akira Oyamada, Shuko 
Nakamori, Hiromi Nishimura, Kazuyo Sadamoto, Miki Horii, Satoshi Murasawa, 
Toshihiko Shibata, Shigefumi Suehiro, Takayuki Asahara, RIKEN, Kobe Institution of 
Biomedical Research and Innovation, Kobe, Japan, RIKEN Center for Developmental 
Biology, Kobe, Japan
Background: Transformation capacity of the CD34+ cells into cardiomyocyte (CMCs) 
and smooth muscle cells (SMCs) is still controversial. Here, we performed a series of 
experiments to prove our hypothesis that cardiomyogenesis and arteriogenesis post 
myocardial infarction (MI) may be dose-dependently enhanced following CD34+ cell 
transplantation.
Methods: Peripheral blood CD34+ cells were isolated from total mononuclear cells of a 
patient with critical limb ischemia by apheresis after 5-day administration of G-CSF, using 
a magnetic cell sorting system. PBS, 1x103 CD34+ cells (Low), 1x105 CD34+ cells (Mid) 
or 5x105 CD34+ cells (High) were intramyocardially transplanted 20 min after ligating LAD 
of nude rats (n=12 in each group). Functional, histological and gene expression outcomes 
were compared among the groups.
Results: Functional assessments using echocardiography and a micro-tip conductance 
catheter at day 28 revealed dose-dependent preservation of LV function by CD34+ cell 
transplantation. Necropsy examination at day 28 disclosed dose-dependent augmentation 
of capillary density by isolectin B4 staining (High group, 714.3±25.0; Mid group, 535.8±31.0; 
Low group, 320.9±36.0; PBS group, 291.3±19.0 /mm2 respectively. P<0.01 for High vs Mid 
and Mid vs Low) and dose-dependent inhibition of LV remodeling by assessing % ﬁbrosis 
area (High group, 16.0±2.6; Mid group, 22.4±1.9; Low group, 30.7 ±3.9; PBS, 31.5±0.7% 
respectively. P<0.01 for High vs Mid and Mid vs Low groups). Immunohistochemistry for 
human-speciﬁc BNP demonstrated that human CMCs were more frequently observed in 
ischemic myocardium at day 28 in High and Mid groups than Low group. Immunostaining 
for smooth muscle actin and human leukocyte antigen or Ulex europaeus lectin type 1 
also revealed dose-dependent vasculogenesis and arteriogenesis following CD34+ cell 
transplantation. RT-PCR indicated that human speciﬁc gene expression of CMC, SMC 
and endothelial cell markers were dose-dependently augmented in MI tissue.
Conclusion: CD34+ cell transplantation may have signiﬁcant and dose-dependent 
potential for cardiomyogenesis, vasculogenesis and arteriogenesis with functional 
recovery from MI.
1032-208 Paracrine Action Accounts for Marked Protection of 
Ischemic Heart by Akt Modiﬁed Mesenchymal Stem 
Cells
Massimiliano Gnecchi, Huamei He, Nicolas Noiseux, Olin D. Liang, Lunan Zhang, Luis 
G. Melo, Richard E. Pratt, Joanne S. Ingwall, Victor J. Dzau, Brigham and Women’s 
Hospital, Boston, MA, Duke University Medical Center, Durham, NC
Background: We reported that transplantation of rat mesenchymal stem cells 
overexpressing Akt (Akt-MSC) limits ventricular remodeling and restores cardiac function 
2 weeks following myocardial infarction. Moreover we showed that the same therapeutic 
effects occur in less than 72 hours. Since this early protective effect cannot be attributed 
to myocardial regeneration, we hypothesised that a paracrine mechanism mediated by 
factor(s) secreted from Akt-MSC is involved. Accordingly, we tested the protective effect 
of conditioned medium from Akt-MSC both in vitro and in vivo.
Methods: Conditioned medium was collected from control MSC (GFP-MSC) and Akt-
MSC grown in normoxia (N-M) or exposed for 12 hours to hypoxia (H-M). Isolated adult 
rat ventricular cardiomyocytes (ARVC) were exposed to 24 hours of hypoxia in presence 
of either standard growth medium (CTR-M), N-M or H-M from GFP-MSC and N-M or 
H-M from Akt-MSC. Myocardial infarction was induced in rats by permanent ligation of 
the left coronary artery. After 30 minutes H-M from GFP- or Akt-MSC was injected in the 
heart. Sham and PBS-injected animals served as controls. At 72 hours cardiac function 
was measured with Langendorff preparation and infarct size was determined with TTC 
staining.
Results: Maximal protection on hypoxic ARVC was seen with H-M. Both GFP- and Akt-
MSC H-M signiﬁcantly decreased caspase 3 activity compared with CTR-M. However, 
the effect of Akt-MSC H-M was greater: compared with CTR-M and GFP H-M a reduction 
respectively of 78% (p<0.05) and 66% (p<0.05) was observed. Moreover, compared with 
CTR-M and GFP-MSCs H-M in the presence of Akt-MSC H-M there were respectively 
62% (p<0.05) and 54% (p<0.05) fewer TUNEL-positive ARVC. In vivo, Akt-MSC H-M 
signiﬁcantly increased left ventricular systolic pressure (Sham: 108±5; PBS: 72±6; GFP-
MSC H-M: 75±5; Akt-MSC H-M: 96±2, p<0.05 vs PBS and GFP-MSC H-M; values in 
mmHg). Infarct size was signiﬁcantly smaller in Akt-MSC H-M group (PBS: 33±5%; GFP-
MSC H-M: 29±4%; AKT-MSC H-M: 15±4%: p<0.05 vs PBS and GFP-MSC H-M).
Conclusion: We conclude that paracrine protective action by released factor(s) is a major 
mechanism in post-infarction healing process observed after Akt-MSC transplantation.
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1033-215 Impact of Prediabetic State on Clinical Outcomes in 
Patients With Acute Coronary Syndrome
Richard Otten, Eva Kline-Rogers, David J. Meier, Rupal Dumasia, Niquole May, 
Yuri Resin, Ranya Sweis, Jianming Fang, Fadi Saab, Mircea Petrina, Kim A. Eagle, 
Debabrata Mukherjee, University of Michigan, Ann Arbor, MI
Background: The American Diabetes Association [ADA] recently redeﬁned the cutpoint 
for normal fasting blood glucose levels from 110 mg/dl to 100 mg/dl, meaning that a 
value of 100 mg/dl or above would lead to a diagnosis of impaired fasting glucose (IFG), 
which is included in the term pre-diabetes. We assessed the impact of the prediabetic 
state on clinical outcomes in patients presenting with acute coronary syndrome [ACS] 
incorporating the new ADA deﬁnition.
Methods: 1763 patients with ACS between Jan 1999 and Aug 2002 were stratiﬁed based 
on their fasting glucose levels as non-diabetic, prediabetic or with known diabetes. We 
compared in-hospital outcomes including death, re-infarction, stroke, cardiogenic shock, 
pulmonary edema, cardiac arrest, atrial dysrythmias and MACE in the different groups.
Results: Adverse clinical events were signiﬁcantly higher in prediabetic and diabetic 
patients compared to those with normal fasting glucose [Table]. Multivariate risk 
adjustment demonstrated a gradient of risk in patients with prediabetes proportional to 
fasting glucose levels.
Conclusions: This pilot study suggests that prediabetic state is a marker for worse 
prognosis in patients with ACS. The new ADA deﬁnition identiﬁes more patients with 
impaired fasting glucose who may be targeted for optimal therapies to improve clinical 
outcomes. This study validated the higher risk proﬁle in patients with impaired fasting 
glucose identiﬁed by the new ADA deﬁnition.
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Clinical event rates in pre-diabetic patients 
Fasting glucose < 
100 mg/dl; n=579
Fasting glucose 100 
-110 mg/dl; n=215






Death 1.04% 0.93% 1.56% 6.69% <0.001
Reinfarction 0.49% 2.21% 0% 0.96% 0.194
Stroke 0.17% 0% 0% 1.16% 0.033
Pulmonary edma 2.21% 3.68% 3.36% 10.8% <0.001
MACE 6.74% 8.84% 14.58% 19.95% <0.001
Multivariate Risk adjusted effect of fasting blood glucose levels on clinical outcome
Fasting glucose 100 -110 mg/dl 1.308 [ 95% CI 0.728 - 2.350] P=0.369
Fasting glucose 110 -126 mg/dl 1.850 [ 95% CI 1.086 - 3.153] P=0.023
Diabetic 2.982 [95% CI 2.034 - 4.371] P<0.001
1033-216 Impact Of Fasting Glucose Abnormality On Heart 
Failure In Patients With Acute Myocardial Infarction. 
Data From Rico Survey
Marianne Zeller, Jack Ravisy, Gilles Rioufol, Hamib Makki, Mohamed Jolak, Alexandra 
Oudot, Luc Janin-Maniﬁcat, Isabelle L’Huillier, Jean Eric Wolf, Bruno Verges, Luc 
Rochette, Yves Cottin, on behalf of the RICO survey working group, University of 
Burgundy, Dijon, France
Objectives: Recent works have described the major effects of fasting glucose 
abnormality, including diabetes mellitus (DM) and Impaired Fasting Glucose (IFG), on the 
onset of in-hospital cardiogenic shock development and mortality after acute myocardial 
infarction (MI). However, very few studies have investigated the inﬂuence of abnormal 
fasting glycemia on the occurrence of heart failure (HF) after MI.
Methods: Between January 2001 and July 2003, all patients hospitalized with acute MI in 
one region of France were included. Patients with prior HF or cardiogenic shock during the 
in-hospital stay were excluded from the study. Patients with HF (Killip class II or III ) were 
compared with patients without HF. Mean fasting blood glucose (FG) was determined at 
day 4 and 5 after admission. FG abnormality was deﬁned for patients with either DM (FG 
> 7 mm/L or clinical history of DM) or IFG (FG 6.1 to 7 mmole/L). Results : Among the 
894 patients, 202 (22%) had HF. Median age was signiﬁcantly higher in the HF group than 
in patients without HF (75 vs 63 y, p<0.0001). Moreover, patients with HF had signiﬁcantly 
higher rate of cardiovascular risk factors. Patients with HF were more likely to have a FG 
abnormality (69 vs 45 %, p<0.001), and had higher HbA1c median level (6.1 vs 5.7 %, 
p<0.01). The incidence of MI with ST elevation (STEMI) or with anterior location was similar 
for the 2 groups (p=ns). Patients with HF had increased median pulse measured at the 
time of admission (85 vs 74 b/min, p<0.01) and higher incidence of altered LVEF (≤40%) 
(28 vs 10%, p<0.05). There was a signiﬁcant increase in hospital mortality in the HF 
group (12 vs 3 %, p<0.001). By logistic regression analysis, HF was a strong independent 
predictor of hospital death (OR, 4.53; 99% CI, 2.01-10.17, p<0.0001). FG abnormality was 
an independent predictor of HF, even after adjustment for covariates (age, gender (male is 
reference), hypertension, prior MI, STEMI, LVEF, and creatinine level) (OR, 2.58; 99% CI, 
1.58-3.96, p<0.0001). Conclusion. Abnormal FG was associated with an increased risk 
of developing heart failure in the setting of acute myocardial infarction. Further studies are 
needed to evaluate the speciﬁc strategies for this population.
1033-217 Does Ejection Fraction Still Predict Mortality in the 
Era of the Troponin-Based Deﬁnition of Myocardial 
Infarction?
Michael C. Kontos, Rajat Garg, F Philip Anderson, Joseph P. Ornato, James L. Tatum, 
Robert L. Jesse, Virginia Commonwealth Univeristy, Richmond, VA
BACKGROUND: A curvilinear relationship between ejection fraction (EF) and mortality 
has been shown in patients (pts) with myocardial infarction (MI). However, most data 
were derived from multi-center randomized controlled trials that included only pts with 
ST elevation MI, and used CK as the MI gold standard. We questioned whether a similar 
relationship holds when troponin is used as the diagnostic criteria for MI in non-ST 
elevation ACS pts. 
METHODS: Consecutive pts without ST elevation admitted from the ED for exclusion 
of ACS underwent serial assessment of cardiac markers (CK, CK-MB, TnI). EF was 
assessed using gated SPECT, coronary angiography, or echocardiography during 
admission. An elevated TnI was deﬁned using the ACC/ESC criteria. One year cardiac 
mortality was compared in those with and without TnI elevations. 
RESULTS: Among the 3,074 consecutive pts admitted without ST elevation MI who had 
EF assessed, MI was diagnosed by TnI elevations in 545 pts (18%). AMI pts were more 
likely to have any systolic dysfunction (EF <50%: 51% vs 30%, p<0.001) and an EF <35% 
(25% vs 11%, p<0.001) than those without TnI elevations. There was a stepwise increase 
in mortality based on both TnI status and EF (Figure). 
CONCLUSIONS: EF is a powerful predictor of mortality in pts admitted for exclusion of MI. 
The presence of TnI elevations increases mortality 2 fold or more for any given EF, even 
when EF is normal. Pts presenting with possible ACS should have EF assessed routinely, 
even in those without troponin elevations. 
1033-218 Obesity Is Associated With Reduced Mortality And 
Complication Rates In Stemi: Results From The National 
Registry For Myocardial Infarction 4
R. Scott Wright, Joseph G. Murphy, Paul Frederick, Allan S. Jaffe, William J. French, 
Mayo Clinic, Rochester, MN, Harbor UCLA Medical Center, Los Angeles, CA
Background: Obesity is a public health crisis in the United States and many parts of the 
world. Preliminary reports suggest an “obesity paradox” in acute myocardial infarction 
(AMI) in that obesity is associated with lower mortality risks.
Methods: Using the National Registry for Myocardial Infarction (NRMI)-4 database, we 
identiﬁed 172,061 patients with STEMI dividing into obese (BMI > 30 kg/m2 n=52,674), 
overweight (25< BMI < 30, n=63,747) and lean (BMI < 25, n=55,640) patients.
Results: Age was signiﬁcantly lower in obese (61.7+ 12.1*,† years) versus overweight (65.4+ 
13.0*) and lean patients (71.4+ 13.6), (* p<0.0001 vs lean, † p <0.0001 vs overweight). 
TIMI Risk Scores (TRS), calculated in non-transfer STEMI patients (n=120,739), revealed 
Low risk TRS in 17.9% of lean patients, 33.5% of overweight patients and 41.7% of obese 
patients. High risk TRS were observed in 55.8 % of lean patients, 37.2% of overweight 
patients and 30.3% of obese patients (p<0.00001 across groups). Use of reperfusion 
therapy was higher in obese (63.6%*,†) and overweight patients (62.4%*) compared to lean 
patients (47.7%). Risks of death, shock and high-grade AV block were signiﬁcantly lower 
in obese and overweight patients (See ﬁgure).
Conclusion: The “obesity paradox” may reﬂect that obese patients are younger and have 
lower TRS at time of presentation for STEMI. They indeed suffer lower risks for death, 
shock and high-grade AV block yet this may reﬂect younger age and risk proﬁle at time 
of STEMI. 
1033-219 Chest Pain At Presentation And Delayed Resolution 
Of Pain In Patients Admitted With Non- ST Segment 
Elevation Acute Coronary Syndromes Predicts Short-
term Outcomes
Benjamin Scirica, Sabina Murphy, Stephen Wiviott, David Morrow, Marc Sabatine, C. 
Micheal Gibson, Christopher Cannon, Brigham and Women’s Hospital, Boston, MA
Background: Ischemic chest pain is the hallmark of non- ST segment elevation acute coronary 
syndromes (NSTEACS). Although the duration of pain is often deemed clinical important, 
there is limited data to suggest that the timing of chest pain resolution has prognostic value.
Methods: Time to chest pain resolution was evaluated in 6963 patients with NSTEACS 
enrolled in the Orboﬁban in Patients with Unstable Coronary Syndromes (OPUS) - TIMI 
16 trial. Outcomes included death, recurrent myocardial infarction (MI), recurrent ischemia 
at 30 days, and baseline levels of creatine kinase-MB(CKMB) .
Results: Patients who had chest pain on arrival to the hospital were at increased risk of death 
or recurrent MI (4.6% vs. 3.3%, p<0.001) and death/recurrent MI/recurrent ischemia (10.8% 
vs. 8.9%, p=0.01). In patients who presented with chest pain, a prolonged time to resolution of 
pain was associated with worse outcomes and increased baseline CKMB levels (Table). The 
groups were comparable in terms of aspirin, heparin, beta-blockers or nitrates use.
30 Day outcomes by time of chest pain resolution 







Pre-hospitalization (n=3426) 1.4 2.2 3.3 8.9
< 30 min after arrival (n=555) 0.7 2.3 2.7 7.0
> 30 min after arrival (n=2332) 2.2 3.3 5.0 11.7
P value 0.012 0.031 0.001 0.0001
Conclusion: In patients presenting with NSTEACS, resolution of chest pain before 
hospital arrival was associated with better outcomes. If the pain persisted beyond 30 
minutes after hospital arrival, patients were more likely to have recurrent MI, ischemia, 
or die by 30 days.
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1033-220 Genetic Polymorphisms C807T and A1648G on Platelet 
Glycoprotein Ia, are Associated With Premature 
Myocardial Infarction in Young Smokers
Charalambos Antoniades, Dimitris Tousoulis, Carmen Vasiliadou, Christos Pitsavos, 
Christina Chrysochoou, Marina Toutouza, Demos Panagiotakos, Costas Toutouzas, 
Kyriakoula Marinou, Christodoulos Stefanadis, Athens University Medical School, 
Athens, Greece
Background: Platelet membrane glycoprotein Ia (GPIa) has an important role in platelet 
function as a receptor for collagen. Silent genetic polymorphism C807T seems to affect 
the expression of GPIa, while A1648G polymorphism leads to a Glu/Lys substitution 
on GPIa. We investigated whether these polymorphisms affect the risk for premature 
myocardial infarction (MI) in young individuals.
Methods: This study enrolled 191 young patients with premature MI (46.6±5.2 years old) 
and 284 healthy controls (48.1±13.5 years old). Distributions of the C807T and A1648G 
polymorphisms were investigated by genotyping DNA by PCR. The allele and genotype 
frequencies in patients and controls were compared using chi-square test. There was no 
deviation from Hardy-Weinberg equilibrium for any of the considered polymorphisms.
Results: The prevalence of 807TT homozygotes was slightly higher among MI patients 
(30 patients, 15.7%) compared to healthy controls (35 subjects, 12.4%, p=NS). The 
807CC genotype was present in 65 MI patients (34%) and in 88 controls (31.0%, p=NS), 
while the 807CT genotype was present in 96 MI patients (50.2%) and 161 controls 
(56.6%, p=NS). However, among smokers, the prevalence of 807TT was present in 27 of 
174 MI patients (15.5%) and in 11 of 114 controls (9.6%, p<0.05). Homozygosity for the 
1648A allele existed in 6 MI patients (3.2%) and in only 1 control (0.3%, p<0.05). 1648AG 
genotype was present in 38 MI patients (19.9%) and in 66 controls (23.2%, p=NS), while 
the 1648GG genotype was present in 147 MI patients (76.9%) and 217 controls (76.5%, 
p=NS). Among smokers, 1648AA genotype was observed in 6 MI patients (3.4%) and in 
none of the controls (p<0.05).
Conclusions: The present study supports that both genetic polymorphisms C807T and 
A1648G on platelet glycoprotein Ia, are associated with the development of premature 
myocardial infarction in young smokers
1033-221 Impact of Diabetes on In-Hospital Mortality Following 
Percutaneous Coronary Intervention for Acute 
Myocardial Infarction: A Report From the New York State 
Coronary Angioplasty Reporting System Database
Ramesh Gowda, David L. Brown, Beth Israel Medical Center, New York City, NY
Background: The presence of diabetes mellitus (DM) confers high risk for adverse 
clinical outcomes following acute myocardial infarction (AMI). Limited information exists 
regarding the impact of DM on short-term outcomes following percutaneous coronary 
intervention (PCI) for AMI. 
Methods: We conducted a retrospective cohort study of all patients undergoing 
angioplasty within 24 hours of an AMI in New York State between 1997 and 1999. The 
primary end point was in-hospital mortality. Diabetes was deﬁned by treatment with oral 
hypoglycemics or insulin. 
Results: Of 9015 patients who underwent PCI for AMI, 1583 (17.6%) were diabetics. 
Diabetics were older (62 years vs. 60 years, P=<0.001), more often female (37.7% vs. 
27.2%, P=<0.001) but less often current smokers (18.7% vs. 30.9%, P<0.001) than 
non-diabetics. Hypertension (72% vs. 52%, P=<0.001), congestive heart failure (CHF), 
(4.7% vs. 1.8%, P=<0.001), stroke (5.5% vs. 3.6%, P=<0.001), chronic renal insufﬁciency 
(2.2% vs. 0.6%, P=<0.001), dialysis (0.9% vs. 0.3%, P=<0.001), prior open heart surgery 
(10.9% vs. 5.9%, P=<0.001) and vascular disease (9.4% vs. 5.1%, P<0.001) were more 
common in diabetics. The mean ejection fraction was reduced in diabetics (45% vs. 47%, 
P<0.001). More patients with DM developed CHF (15.5% vs. 9.9%, P<0.001) and shock 
(5.4% vs. 3.6%, P=0.001). Use of stents was less common (74.2% vs. 79.2%, P<0.001) 
and intraaortic balloon pump more common (9.2% vs. 7.1%, P=0.004) in diabetics. Acute 
vessel closure was more common among diabetics (1.6% vs. 0.7%, P=0.001) while stent 
thrombosis and emergency bypass surgery did not differ signiﬁcantly between groups. 
Unadjusted in-hospital mortality was higher in diabetics than non-diabetics (7.3% vs. 
3.7%, P<0.001). On multivariate logistic regression analysis to adjust for differences in 
baseline characteristics, diabetes was associated with a 50% increase in the risk of in-
hospital mortality (Odds Ratio 1.52, 95% CI 1.094-2.118, P<0.013). 
Conclusion: Diabetics who undergo PCI for AMI are an extremely high-risk population. 
However, even after adjustment for their high-risk features, they maintain a 1.5-fold 
increased risk of in-hospital death.
1033-222 Impact of Cardiac Over-expression of Placental Growth 
Factor on the Improvement of Chronic Phase Left 
Ventricular Function in Patients with Acute Myocardial 
Infarction
Hajime Iwama, Shiro Uemura, Noriyuki Naya, Keiichi Imagawa, Kenji Onoue, Yasuhiro 
Takemoto, Osamu Asai, Satoshi Okayama, Yukiji Takeda, Yoshitomi Kida, Minoru 
Takaoka, Hiroyuki Kawata, Manabu Horii, Tamio Nakajima, Yoshihiko Saito, Nara 
medical university, Kashihara, Nara, Japan
Placental growth factor (PlGF), a speciﬁc ligand for ﬂt-1, is known to stimulate the 
recruitment of monocyte from bone marrow into the injured tissue, and seems to enhance 
wound healing processes by activating monocyte and inducing arteriogenesis. However, 
clinical signiﬁcance of PlGF in myocardial infarction (MI) has not been understood. This 
study investigated expression pattern of PlGF and the impact of PlGF on the clinical 
course in patients and mouse models of acute MI. 
Methods and Results: Human study: Fifty ﬁve patients with acute MI and 43 controls 
were enrolled. Blood sampling was performed from peripheral vein, ostium of coronary 
artery (CA), and coronary sinus (CS), before and after recanalization (RC) of occluded 
CA. Plasma levels of PlGF were measured by ELISA. Transcardiac gradient of plasma 
PlGF ([CS]-[CA]) just after RC of the occluded CA was signiﬁcantly higher than the value 
before RC (14.1±10.6 vs, 0.0±1.1pg/ml p<0.01), indicating cardiac production and release 
of PlGF from infarct heart. Peak plasma PlGF levels (3.2 ± 1.1 days) were signiﬁcantly 
higher than those in control subjects (35.1±26.5 pg/ml vs 13.4±5.7 pg/ml, p<0.001). Peak 
plasma PlGF levels positively correlated with peak peripheral monocyte counts during 
acute phase of MI (r=0.42, p<0.005), although they did not correlated with age, gender, 
time to reperfusion, or peak CK-MB. Furthermore, multiple regression analysis revealed 
that PlGF was the strongest independent predictor for the restoration of left ventricular 
ejection fraction examined at 6-month follow-up study (p=0.0098). Mouse study: In mouse 
models of MI, tissue PlGF mRNA expression was increased 26.6 fold (p<0.001) compared 
with sham operated heart. Immunohistochemical staining showed that PlGF protein was 
over-expressed mainly in endothelial cells of coronary artery in the infarct region, but 
scarcely in non-infarct region. 
Conclusion: PlGF is rapidly produced in the infarct myocardial tissue, especially 
endothelial cells of coronary artery in infarct region during acute phase of MI, and over-
expressed PlGF seems to be involved in the improvement of left ventricular function in 
chronic phase probably by recruiting monocyte from bone marrow.
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1034-195 Effectiveness of Distal Embolic Protection During 
Primary Angioplasty: Final 6-Month Results from the 
Prospective, Randomized, EMERALD Trial
Gregg W. Stone, John Webb, David A. Cox, Bruce R. Brodie, Mansoor Qureshi, Daniel 
Dulas, Anna Kalnych, Mark Turco, Heinz P. Schultheiss, Barry Rutherford, Mitchell 
W. Kruckoff, Raymond Gibbons, Alexandra J. Lansky, Allan Schwartz, Ramona Pop, 
Denise Jones, Roxana Mehran, Columbia University Medical Center, New York, NY, 
Cardiovascular Research Foundation, New York, NY
Background. Distal embolization during PCI for AMI is common, and may result in 
diminished myocardial perfusion, incomplete ST segment resolution (STR), impaired 
myocardial recovery and increased mortality. We therefore performed a multicenter 
randomized trial to determine whether retrieval of distal embolic debris translates into 
improved reperfusion success and clinical outcomes.
Methods. In the EMERALD trial, 501 pts w/i 6 hrs of pain onset with ≥2 mm ST elevation 
or LBBB undergoing primary or rescue PCI were prospectively randomized at 38 sites in 
7 countries to stenting with vs. without distal protection with the 0.028” GuardWire Plus. 
The primary endpoints were STR 30 mins post procedure (measured by 24 hr continuous 
ECG monitoring) and infarct size assessed by tc-99m-sestamibi imaging at day 5-14.
Results. Median age was 59 years, 22% were women, 40% had anterior MI, and median 
peak ST elevation was 4.0 mm. Primary PCI was performed in 81.4% of pts and rescue 
PCI in 18.6%. Median symptom onset to ER time was 77 minutes. In the GuardWire arm, 
balloon occlusion was achieved in 95% of pts, aspiration was performed in 97%, and 
visible debris was retrieved in 72%. Results appear in the table.
Conclusions. The GuardWire distal protection device may be used safely as an adjunct to 
primary PCI in AMI, and effectively retrieves embolic debris in most patients. Nonetheless, 
distal embolic protection did not result in improved microvascular ﬂow or function, nor was 
infarct size reduced or event-free survival improved.
 
GuardWire (n=252) Control (n=249) P value
Final TIMI-3 91.6% 89.2% 0.44
Final blush grade 3 61.1% 52.9% 0.09
STR 30 mins 62.2% 60.6% 0.77
Infarct size (%LV) 18.3 ± 19.4 16.2 ± 19.1 0.26
6 mo death 3.5% 3.5% 0.90
6 mo reinfarction 2.5% 4.0% 0.37
6 mo disabling stroke 0.9% 1.8% 0.37
6 mo TVR 6.4% 6.0% 0.83
6 mo MACE 10.1% 11.5% 0.61
1034-196 Catheter-Based Trans-coronary Myocardial Hypothermia 
Attenuates Arrhythmia and Myocardial Necrosis in Pigs 
With Acute Myocardial Infarction
Hiromasa Otake, Junya Shite, Toshiro Shinke, Ryohei Yoshikawa, Oscar Luis Parades, 
Yusuke Imuro, Satoshi Watanebe, Toru Ozawa, Daisuke Matsumoto, Daisuke Ogasawara, 
Mitsuhiro Yokoyama, Kobe University Graduate School of Medicine, Kobe, Japan
Background: Although lowering myocardial temperature by 3-5°C is effective in 
attenuating myocardial infarction (MI), efﬁcient myocardial cooling could not be obtained 
with systemic hypothermia. We invented a new idea that direct cold saline injection into 
MI-related coronary artery through the over the wire PTCA balloon (OTWB) lumen.
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Methods: Anesthetized pigs received 60min of coronary artery occlusion with OTWB 
and 3hr reperfusion. After 15 min of occlusion, the pigs were randomly assigned to 
either: hypothermia group (H: n=13), or control group (N: n=15). In H animals, cold saline 
(4°C) was given to ischemic myocardium through the wire lumen of OTWB with150 ml/
hr (determined with preliminary study). In N pigs, same volume of normothermal saline 
(36.5°C) was administered through OTWB. Myocardial and systemic temperature, 
incidence of ventricular tachycardia (VT), coronary ﬂow reserve (CFR) by Doppler ﬂow 
wire, serum troponin T variables, and ratio of necrosis to ischemic risk area using blue dye 
and triphenyltetrazolium chloride staining were evaluated.
Result: In H group, myocardial temperature signiﬁcantly decreased from 36.3±1.0 
to 33.1°C±0.5°C (p<0.001) without signiﬁcant reduction of rectal temperature, while 
temperatures in N group did not change. Incidence of VT was 38% in H and 73% in N 
group. At 1hr reperfusion, CFR in H was signiﬁcantly higher than that in N (H:2.44±0.5 
vs N:1.75±02, p=0.010). The values of troponin T was signiﬁcantly lower in H than in N 
(H:0.85±0.61µg/ml vs N:2.84±2.74, p=0.037). Although ischemic risk area were similar in 
both groups, the ratio of necrosis to risk area in H was signiﬁcantly smaller than that in N 
(H:9±7% vs N:36±12%, p<0.001). It was 75% necrosis area reduction.
Conclusion: We successfully obtained regional hypothermia within only ischemic 
myocardium using OTWB. This method dramatically reduced arrhythmia and MI size 
without any complication and is simple enough to permit widespread clinical use.
1034-197 Multivessel Revascularization in the Setting of Primary 
Percutaneous Coronary Intervention for Acute ST-
Elevation Myocardial Infarction
Juhana Karha, Vivek Rajagopal, Mehdi H. Shishehbor, Stephen G. Ellis, Sorin J. Brener, 
Cleveland Clinic Foundation, Cleveland, OH
Background: The goal of primary percutaneous coronary intervention (PCI) is to restore 
ﬂow in the infarct related artery (IRA). The optimal management of severe stenoses in other 
major coronary artery distributions is not clear. We hypothesized that revascularization of 
severe non-IRA stenoses at the time, or within 60 days, of primary PCI is associated with 
improved mortality. 
Methods: We retrospectively evaluated patients undergoing primary PCI for ST-elevation 
myocardial infarction between January 2000 and December 2003. Exclusion criteria 
included cardiogenic shock, CABG performed for complete revascularization, or non-
IRA chronic total occlusions. The ﬁnal study population consisted of 364 patients who 
underwent a PCI on the culprit lesion, and patients were divided into three groups based 
on their coronary anatomy and the strategy of further PCI: patients with attempted PCI of 
>1 non-IRA stenosis of 70-99% within 60 days (group A, n=52), patients with >1 non-IRA 
stenosis of 70-99% on which no PCI was attempted within 60 days (group B, n=50), and 
patients without any non-IRA stenoses of 70-99% (group C, n=262). 
Results: In group A, 34 of the 52 patients (65.4%) underwent PCI on the non-culprit 
lesion during the index procedure. Among the 18 patients who had a staged procedure, 
the median interval between the two PCIs was 6 days. The patients in group A had a 
higher cumulative survival by Kaplan-Meier analysis compared to patients in groups B 
and C: 96.9% vs. 73.4% vs. 89.7% at 2 years, respectively, p=0.0006. Likewise, when 
groups A and C were combined into a group with more complete revascularization, 
the survival was higher compared to group B (less complete revascularization): 90.9% 
vs. 73.4% at 2 years, respectively, p=0.0004. This survival beneﬁt remained signiﬁcant 
(HR 0.34, p=0.017) in a multivariate analysis including important clinical and procedural 
variables. 
Conclusions: Among patients undergoing primary PCI, treatment of non-IRA stenoses 
immediately, or within 60 days, of primary PCI appears to be associated with improved 
survival. Consideration should be given to this strategy in selected patients.
1034-198 Long-Term Follow-Up of Patients With ST-Segment 
Elevation Myocardial Infarction Treated With Sirolumis-
Eluting Stents
Haris Athar, Rachid Elkoustaf, Justin B. Lundbye, Edcar D. Messer, Jeffrey F. Mather, 
Roger A. Mennett, Jill Cloutier-Jarvis, Daniel B. Fram, William E. Boden, Raymond G. 
McKay, Francis J. Kiernan, Hartford Hospital, University of Connecticut, Hartford, CT
Background: Sirolimus drug-elusting stents (DES) have been shown to confer superior 
long-term outcomes in patients undergoing elective percutaneous coronary intervention 
(PCI). To-date, however, the in-hospital and long-term safety and efﬁcacy of Sirolimus 
DES in patients with ST-segment elevation myocardial infarction (STEMI) has been 
incompletely described.
Methods: We assessed baseline clinical and angiographic characteristics, in-hospital and 
9-month major adverse cardiac events (MACE) in 429 consecutive STEMI patients without 
cardiogenic shock undergoing emergency PCI. STEMI patients were divided into 210 
patients treated with one or more Sirolimus DES and 219 patients treated with non-DES 
(bare metal, heparin-coated). GP IIb/IIIa inhibitors were utilized in 88.8% of patients.
Results: Compared to non-DES STEMI patients, DES patients were younger and more 
likely to be Caucasian. Otherwise, there were no signiﬁcant differences between DES 
and non-DES patients with respect to baseline demographics, cardiovascular risk factors, 
co-morbidities, peri-procedural medication use, extent of coronary artery disease and left 
ventricular ejection fraction. In-hospital and 9-month MACE are presented below.
Conclusions: In this single center study, implantation of Sirolimus DES in STEMI patients 
is not associated with any increased risks of adverse in-hospital outcomes, and may 
reduce the need for repeat target vessel revascularization at 9 month follow-up.
DES Non-DES P Value
In-Hospital Death 2.9% 2.3% NS
Stent Thrombosis 0.0% 0.9% NS
Emergent Repeat PCI 0.5% 0.9% NS
Stroke 0.0% 0.5% NS
Renal Failure 0.0% 0.5% NS
9-Month Death 3.4% 4.6% NS
Recurrent Myocardial Infarction 1.9% 5.0% NS
Repeat Catheterization 12.4% 13.2% NS
Angiographic Restenosis 0.5% 4.1% <0.02
1034-199 The Impact of Coronary Stent Placement on Survival in 
Patients Undergoing Angioplasty for Acute Myocardial 
Infarction: A Report From the New York State Coronary 
Angioplasty Reporting System Database
David L. Brown, Jeffrey S. Berger, Beth Israel Medical Center, New York City, NY
Background: Randomized trials have demonstrated the superiority of primary angioplasty 
with stent implantation over balloon angioplasty alone in the treatment of acute myocardial 
infarction (AMI). However, it remains unknown whether beneﬁcial outcomes attained in 
clinical trials can be generalized to community-based practice. This study sought compare 
the outcome for patients with AMI undergoing coronary stent placement to those treated 
with balloon angioplasty alone. 
Methods: We conducted a retrospective cohort study of all patients undergoing primary 
angioplasty for AMI in New York State in 1998 and 1999. A total of 6,010 consecutive 
patients who presented within 23 hours of an AMI were identiﬁed for this analysis. In-
hospital mortality was the primary end point. 
Results: Stents were placed in 5,225 (87%) patients. Patients receiving stents were 
younger (61 vs. 62 years, P=0.011) and less often female (29% vs. 33%, P=0.018). 
Patients receiving stents were less likely to have a history of hypertension (56% vs. 61%, 
P=0.013), diabetes (17% vs. 24%, P<0.001) and chronic kidney disease (0.8% vs. 2.0%, 
P=0.002) compared to patients not receiving stents. Sixty percent of patients in both groups 
presented within 6 hours of the onset of infarction. Ejection fraction was similar between 
groups (46% vs. 47%, P=NS). Patients receiving stents were less likely to present with 3-
vessel disease (14% vs. 19%, P<0.001) and left main disease (2.4% vs. 4.6%, P<0.001). 
Glycoprotein IIb/IIIa inhibitor use was similar in both groups (56% vs. 53%, P=NS). Stent 
use was associated with a signiﬁcant reduction in length of stay (5.9 vs. 8.1 days, P<0.001), 
major adverse cardiac events (4.1% vs. 12%, P<0.001) and in-hospital mortality (3.5% vs. 
9.3%, P<0.001). After multivariate logistic regression analysis to adjust for differences in 
baseline characteristics, stent use was associated with a 50% reduction in the risk of in-
hospital mortality (Odds Ratio 0.474, 95% conﬁdence interval 0.311-0.723, P=0.001).
Conclusion: In a large unselected statewide database, stent use during angioplasty for 
AMI resulted in a signiﬁcant reduction in length of stay, major adverse cardiac events and 
in-hospital mortality.
1034-200 Comparison Between Stent and Balloon in Patients 
Undergoing Primary Angioplasty for ST-Segment 
Elevation Myocardial Infarction due to Proximal Left 
Anterior Descending Coronary Artery Occlusion. A 
Substudy of the Zwolle-6 Randomized Trial
Giuseppe De Luca, Harry Suryapranata, Arnoud WJ van’t Hof, Jan Paul Ottervanger, 
Jan CA Hoorntje, AT Marcel Gosselink, Jan-Henk E. Dambrink, Menko-Jan de Boer, De 
Weezenlanden Hospital, Zwolle, The Netherlands
Purpose. In the Zwolle 6 randomized trial 1683 patients were randomized before 
angiography to stent (S) or balloon (B), without any exclusion criteria. In this study we 
present data form the subanalysis in patients with proximal left anterior descending 
coronary artery (LAD) occlusion.
Methods. A total of 218 patients with STEMI underwent primary angioplasty of proximal 
LAD (107 randomized to S and 111 to B). All angiographic, clinical and 1-year follow-up 
data were prospectively collected.
Results. The cross-over rates from B to S and S to B were 35.1% and 13.1%, respectively 
(p < 0.0001). No difference was observed in 1-year mortality and MACE (Figure 1).
Conclusions. Our study is the ﬁrst randomized trial comparing stenting and balloon 
angioplasty in a large cohort of unselected, consecutive patients. This subanalysis 
showed that routine stenting does not improve clinical outcome in patients undergoing 
primary angioplasty for proximal LAD occlusion. 
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1034-201 Effects Of Hypothermia On Haemostasis And 
Inﬂammation During Myocardial Infarction
Laurent Payot, Jean-Philippe Collet, Gilles Montalescot, Annick Ankri, Farzin Beygui, 
Remi Choussat, Jean-Philippe Metzger, Daniel Thomas, Institut du Coeur, Paris, France, 
Laboratoire d’hémostase, Paris, France
OBJECTIVES: To evaluate the effects of hypothermia on both haemostasis and 
inﬂammation markers during acute myocardial infarction (AMI)
BACKGROUND: Mild hypothermia has been shown to reduce metabolic demand and to limit 
infarct size in experimental models of AMI and in humans. The acute phase reactant proteins 
PAI-1 and vWf are independent predictors of survival in acute coronary syndromes
METHODS: Twelve consecutive patients with anterior AMI were cooled down (target core 
temperature 33°C) via the insertion of an intravascular heat-exchanger catheter (Icy®) 
placed in the common femoral. It was connected to an external temperature control 
system (CoolGard®). Hypothermia was initiated after primary angioplasty. Blood sampling 
was performed before angioplasty (T1), at the target core temperature after 3 hours of 
cooling (T2), and after passive rewarming to normothermia (T3). Von Willebrand factor 
(vWf) and plasminogen activator inhibitor-1 antigen (PAI-1), plasminogen, FVIIIc, tPA 
antigen, alpha 2-antiplasmin, antithrombin III, Protein C, protein S, Partial thromboplastin 
time, prothrombin time test, thrombin time, D-dimer were measured at each time point. 
The acute release of vWF and PAI-1 antigen was deﬁned as the difference between their 
plasma concentrations at T3 and T1
RESULTS: The mean temperature obtained was 35,2°± 0,56. There was neither vascular 
access complication nor cardiac dysrhythmias during the cooling period. An increase of 
all biological parameters was observed between T1 and T2 followed by a decrease at T3, 
except for Ddimer and Protein S. These variations were found to be statistically signiﬁcant 
for vWF, tPA antigen, and antithrombin III. We have paired our patients according to the 
age, the sex, the killip score, Timi ﬂow at the end of PCI with patients who were not treated 
with endovascular cooling. Of interest, vWF and PAI-1 release (T3-T1) was found to be 
lower in patients who received endovascular cooling as compared to controls (1.0 vs 35.3; 
p=ns and - 4,2 vs 12.2; p=ns, respectively)
CONCLUSIONS: Therapeutic hypothermia in AMI seems to blunt the early rise and the 
release of acute phase reactant proteins in AMI. Our results need to be conﬁrmed by a 
largest randomised trial
1034-202 Superiority of Enoxaparin Low-Molecular-Weight 
Heparin Over Unfractionated Heparin in Patients 
With No Prior Antithrombin Therapy or Maintained 
on Consistent Antithrombin Therapy: Results From 
SYNERGY
Marc Cohen, Kenneth W. Mahaffey, Lisa G. Berdan, Craig J. Reist, Louise Traylor, 
Anatoly Langer, Shaun G. Goodman, Elliott Antman, Flavia Dietrich, Robert M. Califf, 
James J. Ferguson, on behalf of the SYNERGY Trial Investigators, Newark Beth Israel 
Medical Center, Newark, NJ, Duke Clinical Research Institute, Durham, NC
Background: Previous trials demonstrated superiority of enoxaparin (Enox) over 
unfractionated heparin (UFH) in patients with non-ST-segment elevation (NSTE) acute 
coronary syndromes (ACS). The recent SYNERGY trial did not demonstrate a signiﬁcant 
difference in outcomes between these 2 antithrombins, although noninferiority was 
shown. Unlike prior comparative trials, 75% of SYNERGY patients received open-label 
antithrombins prior to randomization. Our objective was to compare the outcomes of 
patients treated with Enox versus UFH in a consistent manner from hospital admission 
through randomization in the SYNERGY trial.
Methods: Of 9,978 SYNERGY patients, 2440 did not have any open label antithrombin 
therapy before randomization, and 3698 were randomly assigned to the same antithrombin 
therapy they were treated with prior to enrollment. The primary efﬁcacy outcome was the 
composite of death or nonfatal MI during the ﬁrst 30 days after randomization. Primary 
safety outcome was TIMI major and GUSTO severe bleeding.
Results: In the no-prior-treatment subgroup (n=2440), the primary endpoint occurred in 
12.6% of patients assigned to Enox and 14.8% of patients assigned to UFH (relative risk 
ratio [RRR], 14.9%; odds ratio [OR], 0.84; 95% conﬁdence interval [CI], 0.68-1.05). In the 
subgroup of 6138 patients receiving no prior antithrombin treatment or randomly assigned 
to the same antithrombin received before enrollment, the primary endpoint occurred in 
13.3% versus 15.9% (Enox vs UFH), (RRR, 16.4%; p=0.0039; OR, 0.82; 95% CI, 0.72-
0.94). Rates of TIMI major bleeding (Enox 9.3% vs UFH 7.9%, p=0.05) and GUSTO 
severe bleeding (Enox 2.9% vs UFH 2.1%, p=0.047) were more frequent with Enox.
Conclusions: While the overall trial results showed noninferiority, in the large subgroup 
of patients that had no prerandomization therapy or had the same treatment through 
randomization, Enox was superior to UFH in reducing death or nonfatal MI, with a modest 
excess in bleeding.
1034-233 Survival Beneﬁt Of Primary Angioplasty Over 
Thrombolytic Therapy In Patients With Acute Myocardial 
Infarction Varies According To The Baseline Mortality 
Risk Of Patients With Acute Myocardial Infarction. 
Modelling Across Trials
Giuseppe Tarantini, Angelo Ramondo, Massimo Napodano, Gianbattista Isabella, 
Renato Razzolini, Sabino Iliceto, University of Padova, Padova, Italy
Background According to published meta-analysis, primary angioplasty (PCI) compared 
to thrombolityc therapy (TT) is associated with an absolute early mortality reduction of 2%. 
This result, however, is unlikely to be applied to all patients.
Methods To investigate the beneﬁt of primary PCI as function of mortality risk, we 
examined the treatment effect of PCI compared to TT against the mortality rates in the TT 
groups across the 22 clinical randomized trials comparing PCI to TT in acute myocardial 
infarction, using meta regression technique. When the outcome is mortality, the control 
(TT) mortality rate can be interpreted as a proxy for mortality risk, so far we used control 
rate meta-regression for assessing differences in treatment effect across mortality risk 
that refers to the acute mortality in the TT arm.
Results. Across studies, absolute survival beneﬁt ranged from -4% (favoring TT) to 22% 
(favoring PCI). The graph depicts the absolute beneﬁt in percentage points in the included 
trials. The slope of the regression line is 0.77 and the x-axis intercept is 4.7%, indicating 
that populations at mortality risk below this level are unlikely to demonstrate beneﬁt 
for PCI over TT in term of 30-day mortality and may show harm. These results are not 
modiﬁed by the exclusion of trials with lowest and highest risk of mortality with TT.
Conclusion. Most of the incremental beneﬁt of primary PCI can be achieved by treating 
high risk patients, for which TT is difﬁcult to justify, if nearby PCI is available. 
1034-234 Impact of Early Tiroﬁban Administration on Myocardial 
Salvage in Patients With Acute Myocardial Infarction 
Undergoing Infarct-Related Artery Stenting
Ayse Emre, Ekrem Ucer, Ebru Onturk, Mahmut Cakmak, Dilaver Oz, Muhammed 
Gurdogan, Aycan Esen, Ali Buturak, Birsen Ersek, Siyami Ersek Thoracic& CV Surgery 
Center, Istanbul, Turkey
Background: The timing of GP IIb /IIIa inhibitor administration may be important in 
achieving early epicardial and myocardial reperfusion. We evaluated the effect of early 
tiroﬁban administration on myocardial salvage and cardiovascular outcome in patients 
with acute myocardial infarction (AMI) undergoing infarct-related artery (IRA) stenting.
Methods: Patients (n=42) with a ﬁrst AMI presenting < 6hrs from onset of symptoms 
were randomized to either early administration of tiroﬁban (n=22) in the emergency room 
or later administration (n=20) in the catheterization laboratory (tiroﬁban bolus dose of 
10 mcg/kg, followed by 0.15 mcg/kg for 24 hours). 16.5 mCi of Tc 99m sestamibi were 
injected to all patients in the emergency room. Imaging was performed within 6 hours 
after tracer injection. A follow-up study was performed 5-7 days after stenting. Risk area 
(initial perfusion defect), ﬁnal infarction size (perfusion defect at follow-up study) and the 
salvage index (risk area-ﬁnal infarction size/ risk area) were calculated. The primary end-
point was the degree of myocardial salvage. Thirty-day major adverse cardiac events 
were also assessed.
Results: There were no signiﬁcant differences in patient characteristics or in their 
presentation. The mean door-to-balloon time was similar in both groups (43+/-12 min 
and 53+/-9 min , p=0.08). The early and late treatment groups received tiroﬁban 17+/-
3 min and 52+/-10 min after admission, respectively. Procedural success was achieved 
in all patients. Myocardial risk area were comparable between early and late treatment 
groups (39.3+/-7.0% vs 37.4+/-4.8%, p=0.6). Scintigraphic outcomes demonstrated 
a signiﬁcant reduction in the ﬁnal infarction size (21.7+/-6.4 % vs 9.6+/-4.8%, p=0.01), 
and improvement in the salvage index (44.3+/-13.2 % vs 75.4+/-9.4%, p=0.003) in favor 
of the early treatment group. The 30-day composite end-point of death, recurrent MI or 
rehospitalization also favored the early treatment group (5 % early, 15 % late, p=0.06).
Conclusion: Early tiroﬁban administration enhanced the degree of myocardial salvage 
and clinical outcome in patients with AMI undergoing IRA stenting.
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1035-229 Insulin Resistance is an Independent Predictor 
of Vascular Events in Diabetic Patients with 
Angiographically Proven Stable Coronary Artery 
Disease
Thomas Marte, Christoph H. Saely, Stefan Aczel, Guenter Hoeﬂe, Peter Langer, Heinz 
Drexel, Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, 
Austria, Academic Teaching Hospital Feldkirch, Feldkirch, Austria
Background: Patients with both diabetes and established coronary artery disease are at 
a high risk of cardiovascular events. Insulin resistance (IR) is a central feature of diabetes 
mellitus type 2 (DM2). Therefore, the impact of IR on the incidence of vascular events in 
diabetic patients with established CAD is of particular interest.
Methods: We estimated insulin resistance by the HOMA index in 495 patients with 
angiographically proven CAD and recorded the incidence of vascular events over a mean 
follow-up time of 2.3 ± 0.4 years.
Results: The HOMA index was higher in coronary patients with DM2 (n = 127) than 
in nondiabetic coronary patients (6.5 ± 5.9 vs. 3.0 ± 4.2; p <0.001). Thirty-one (23.8%) 
patients with DM 2 and 60 nondiabetic patients (14.5%) experienced at least 1 vascular 
event. In Cox regression analysis adjusting for age, gender, and baseline extent of 
coronary artery disease (number of angiographic stenoses ≥50%) diabetes was an 
independent predictor for the incidence of vascular events (OR = 1.725 [1.116 - 2.667]; p 
= 0.014). Equally, the HOMA index proved independently predictive for the incidence of 
vascular events in the total study cohort: the standardized OR adjusted for age, gender, 
and baseline extent of CAD was 1.178 [1.026-1.351]; p = 0.010. In subgroup analyses 
with respect to diabetes status, the HOMA index was signiﬁcantly predictive for vascular 
events in patients with diabetes (OR = 1.354 [1.083 - 1.694; p = 0.008]), but not among 
nondiabetic patients (OR = 1.022 [0.729 - 1.432]; p = 0.901).
Conclusions: In the setting of secondary prevention, IR is a strong and independent 
predictor of vascular events among patients with DM2. Thus, the degree of IR signiﬁcantly 
contributes to the adverse effects of diabetes on the prognosis in coronary patients.
1035-230 Association of the Metabolic Syndrome with Worse 
Outcome of Patients with Stable Coronary Disease in 
the Medicine, Angioplasty or Surgery Study (MASS I I)
Neuza Lopes, Aecio Gois, Alexandre Pereira, Antonio Gagliardi, Jorge Borges, Paulo 
Soares, Luiz Cesar, Whady Hueb, Heart Institute (InCor) University of Sao Paulo, Sao 
Paulo, Brazil
Background: In the present study, we examine the association between the metabolic 
syndrome and its components with the incidence of cardiovascular end-points in a group 
of coronary artery disease (CAD) multi-vessel individuals prospectively followed-up in 
the MASS II Study
Methods: We have evaluated individuals enrolled in MASS II for the 5 component 
conditions of the metabolic syndrome: insulin resistance, obesity, hypertriglyceridemia 
, low HDL cholesterol , and hypertension , as well as the full syndrome, deﬁned as at 
least 3 of the 5 conditions. Logistic regression was used to estimate the cross-sectional 
association of the syndrome and each of its 5 conditions separately with each of the 
MASS II end-points (death, myocardial infarction, and recurrent ischemia requiring 
revascularization), as well as the combined end-point.
Results: Among the 611 individuals participating the MASS II Study, there were 52 
(8.5%) individuals with refractory angina requiring revascularization; 40 (6.5%) individuals 
with myocardial infarction; and 43 (7.0%) deaths during the follow-up period of two years. 
No difference between treatment randomization (medical, surgery or angioplasty) was 
veriﬁed regarding metabolic syndrome status (p = 0.24), nor its components (p = 0.42, 
for glucose intolerance; p = 0.89, for low HDL-C; p = 0.78, for high triglycerides; p = 0.22, 
for hypertension). A signiﬁcant difference regarding treatment allocation was veriﬁed for 
obesity (p = 0.02).
Interestingly, when analyzing mortality as the end-point, both the presence of metabolic 
syndrome (p=0.05) and glucose intolerance (p=0.04) were associated with an increased 
mortality in our studied population. Moreover, despite a clear tendency for each of its 
components to increase the mortality risk, only the presence of the metabolic syndrome 
signiﬁcantly increased the risk of mortality among study participants in a multivariate 
model.(p=0.03, RR 2.5, 95% CI 1.1-6)Conclusion: These results indicate a strong, 
consistent relationship of the metabolic syndrome with mortality in patients with stable 
coronary artery disease.
1035-231 Clinical Judgment And Treatment Options In Stable 
Multivessel Coronary Artery Disease: Results From The 
1-Year Follow-Up Of The Mass II Study
Alexandre Costa Pereira, Neuza H. M. Lopes, Paulo R. Soares, Jose E. Krieger, Sergio 
A. Oliveira, José F. Ramires, Whady Hueb, Heart Institute (INCOR), Sao Paulo, Brazil
Introduction: Despite the progress in coronary artery disease (CAD) risk stratiﬁcation 
there is no consensus on the best treatment for patients with stable multi-vessel CAD 
and preserved left-ventricular function. Here, we examine the predictive power of clinical 
judgment in the incidence of cardiovascular end-points in a group of CAD multi-vessel 
individuals prospectively followed in the MASS II Study.
Methods: Preferred treatment allocation was recorded for each of the 611 randomized 
patients in the MASS II Study prior to randomization. We have divided our sample according 
to physician-guided decision and randomization result into two categories: concordant or 
discordant. The incidence of the composite end-point of cardiac death, myocardial infarction 
and refractory angina was compared between concordant and discordant patients.
Results: The number of concordant individuals (physician-guided x randomization) was 
292 (48.2%), and this number was not statistically different between the three studied 
treatments (p = 0.11). A statistically signiﬁcant difference (p = 0.02) was disclosed due to 
an increased incidence of combined end-point events in the group of discordant patients. 
In a multivariate Cox proportional hazard model, clinical judgment was still a powerful 
predictor of outcome (p = 0.01) even after adjustment for age, sex, treatment allocation, 
hypertension, diabetes, smoking status and total cholesterol. The main subgroup 
explaining this difference was a signiﬁcant shift towards a worse outcome in the subgroup 
of discordant patients submitted to PCI (p = 0.003). Angiographic variables were more 
used in the clinical decision regarding PCI than clinical variables and the only independent 
predictor of concordance status in the PCI group was the number of diseased vessels (p 
= 0.01) in a multiple logistic regression model (having three-vessel disease increased the 
odds of a clinical decision against PCI in 2.1 times).
Conclusions: our data is a reminder that physician judgment remains an important 
predictor of outcomes.
1035-232 Cost of Care for Patients with Chronic Stable Angina in 
the United States
Paul A. Heidenreich, Harlan Krumholz, John Spertus, David W. Lee, George A. 
Goldberg, Jennifer B. Watson, Merle Haberman, David J. Cohen, VA Palo Alto Health 
Care System, Palo Alto, CA
Background: Nearly 7 million Americans have chronic stable angina, yet little is known 
about the cost of care for this population.
Methods: We identiﬁed angina patients enrolled in one of two U.S. managed care 
organizations based on the combination of an angina diagnosis and multiple prescriptions 
for beta-blockers, calcium antagonists or nitrates. We compared the cost of care for 
patients with angina to the cost for patients with coronary disease but no angina.
Results: There were 23,892 patients that met the criteria for angina. Their mean age 
was 68 years, 58% were male, 76% had hypertension and 30% had diabetes. Almost 
all patients (95%) were prescribed at least one anti-anginal medication (beta blocker, 
calcium antagonist, or long acting nitrate). Emergency visits for coronary related diagnosis 
during 12 months of follow-up occurred in 9% and revascularization was performed in 
23% of patients. Mean total medical claims over 12 months were $28,836 which included 
$2,224 in drug costs and $26,612 in other medical costs. After adjustment for patient 
characteristics those with an angina diagnosis had total costs that were 25% higher 
and drug costs that were double those of patients with coronary disease but not angina 
(p<0.001). (Table)
Conclusion: When compared to patients with coronary disease and no angina, patients 
with angina use substantially more medical resources. Further studies are warranted to 
determine the degree to which improved anginal control may mitigate this burden.
Increase in Cost of Care for Angina Patients 
Charges: Angina vs. Non-Angina CAD Patients All Charges Medical Drug
Relative Difference 25% 18% 107%
Absolute Difference $10,101 $8,384 $3,411
1035-235 Effects of Intensive Versus Moderate Lipid-lowering 
Therapy on Myocardial Ischemia in Older Patients 
with Coronary Heart Disease: Results of the Study 
Assessing Goals in the Elderly (SAGE)
Prakash Deedwania, on behalf of the SAGE steering committee and investigators, 
UCSF School of Medicine, San Francisco, CA, VACCHCS, Fresno, CA
Background: Few trials have speciﬁcally investigated the effects of lipid-lowering 
therapy with statins in older patients. The Study Assessing Goals in the Elderly (SAGE) 
investigated statin therapy as a novel approach to the treatment of myocardial ischemia 
in this patient population.
Methods: SAGE was a prospective, 12-month, double-blind study conducted at 192 
sites worldwide. Qualifying patients were men and women with stable CHD (aged 65-85 
years; LDL-C between 100 and 250 mg/dL) who had at least 1 episode of myocardial 
ischemia with total ischemia duration ≥3 mins on baseline 48-hour AECG monitoring. 
The AECG was performed while patients conducted routine daily activities and continued 
their usual prescribed anti-anginal medications. In total, 893 patients were randomized 
to either atorvastatin 80 mg/day (aggressive lipid lowering; A) or pravastatin 40 mg/day 
(moderate lipid lowering; P). The primary efﬁcacy parameter was the absolute change in 
the total duration of myocardial ischemia from baseline to Month 12. Secondary efﬁcacy 
parameters included the proportion of patients who were totally free of ischemia.
Results: A signiﬁcantly greater reduction in LDL-C from baseline to Month 12 was 
achieved with A (55% vs. 32% for P; p<0.0001). There was a signiﬁcant reduction from 
baseline to Month 12 for both the primary and secondary parameters (p<0.001) within 
each treatment group. There was, however, no difference between treatment groups 
in ischemia reduction (absolute change in duration, 48 mins for A vs. 46 mins for P; 
proportion of patients free of ischemia, 46% for A vs. 45% for P). Although SAGE was 
neither designed nor powered to assess Major Acute Cardiac Events (MACE), there was 
a favourable trend for A (HR=0.74, A vs. P; p=0.16). The proportions of patients in the 2 
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treatment groups having serious adverse events and non-serious adverse events were 
similar. Withdrawal rates were also similar.
Conclusions: SAGE is the ﬁrst large, multi-center international trial to demonstrate the 
efﬁcacy of lipid-lowering therapy on myocardial ischemia in older patients with CHD.
1035-236 Obesity as a Risk Factor for Major Adverse 
Cardiovascular Events in Patients with Stable Coronary 
Disease and Preserved Left Ventricular Function
Michael Domanski, Kathleen A. Jablonski, Madeline Rice, Sarah Fowler, Marc Pfeffer, 
Eugene Braunwald, National Heart, Lung, and Blood Institute, Bethesda, MD, The 
George Washington University Biostatistics Center, Rockville, MD
Background. Obesity is a risk factor for the development of coronary disease (CAD). 
However, the prognostic impact of obesity on acute events in patients(PTs) with 
established CAD is less clear.
Methods. The Prevention of Events with Angiotensin Converting Enzyme Inhibition 
(PEACE) trial randomized 8290 patients with stable CAD & left ventricular ejection fraction 
> 0.40 to trandolapril or placebo & followed them for a mean 4.7 years. In PEACE patients 
who were non-diabetic at baseline (5693 men & 1170 women), we used proportional 
hazards analysis to study whether obesity, deﬁned as a body mass index (BMI)>30 kg/m2, 
is an independent risk factor for the composite endpoint of stroke, non-fatal myocardial 
infarction, revascularization, or cardiovascular death (MACE-1) and for the composite 
endpoint of stroke, non-fatal myocardial infarction, or cardiovascular death (MACE-2).
Results. A model adjusting for baseline age, gender, current smoking, hypertension, 
hypercholesterolemia, serum creatinine, & treatment group, showed signiﬁcant interaction 
of gender with obesity; 28.5% of men and 29.0% of women were deﬁned as obese. Obesity 
was an independent risk factor for MACE-1 in men (hazard ratio [HR] 1.34; 95% conﬁdence 
interval [CI] 1.19 - 1.51; p<0.001), but not in women (HR 0.97; 95% CI 0.73-1.30; p = 0.86). 
Similarly, BMI-deﬁned obesity was an independent risk factor for MACE-2 in men (HR 1.23; 
95% CI 1.02-1.49; p=0.034), but not women (HR 0.89 ; 95% CI 0.55-1.44 ; p =0.63) .
Conclusion. In the presence of established CAD, obesity was independently associated 
with risk for major adverse cardiovascular events in men.
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1036-223 Ineffectiveness of Precordial Thump for 
Mechanical Cardioversion of Malignant Ventricular 
Tachyarrhythmias
Offer Amir, Jorge E. Schliamser, Neemer Samaniah, Basil S. Lewis, Arie Militianu, Lady 
Davis Carmel Hospital, Haifa, Israel
Background: Although mechanical cardioversion with precordial thump (MCPT) is 
commonly used in patients undergoing cardiopulmonary resuscitation and is recommended 
in major textbooks and guidelines, there are few studies which scientiﬁcally examined 
the effectiveness of MCPT. We evaluated the ability of MCPT to terminate malignant 
ventricular tachyarrhythmia which were induced during electrophysiologic testing (EPS) 
and/or cardioverter deﬁbrillator implantation (ICD).
Methods: The study included 34 patients (mean age 68, range 47-83; 32 males 
and 2 females). All patients underwent EPS (9 patients) or ICD implantation (25 
patients) according to ACC/AHA guidelines and required cardioversion for ventricular 
tachyarrhythmia during the procedure. 31 patients (91%) had coronary artery disease, 26 
patients (76%) were on beta-blockers and 8 (23%) were treated with amiodarone. Mean 
echocardiographic left ventricular ejection fraction was 29% (range 20-45%).
Malignant ventricular tachyarrhythmia was induced as part of the EPS/ICD implantation 
procedure protocol; 17 episodes (50%) of ventricular ﬁbrillation, 12 (35%) of polymorphic 
ventricular tachycardia, and 5 (15%) of sustained monomorphic ventricular tachycardia. 
MCPT was the ﬁrst therapeutic treatment in all patients. MCPT was given once, within 
the ﬁrst 20 seconds following the tachyarrhythmia, and was delivered by one of four 
physicians who participated in the study. In the event that the malignant tachyarrhythmia 
continued after MCPT, external or internal cardioversion was applied.
Results: MCPT was unsuccessful in terminating any of the malignant ventricular 
tachyarrhythmia episodes, and all the patients required other mode of cardioversion. 
There were no complications following the precordial thump.
Conclusion: Precordial thump is ineffective in terminating malignant ventricular 
tachyarrhythmia. We believe that despite its common use, the role of precordial thump in 
both cardiopulmonary resuscitation and guidelines recommendations, should be revised.
1036-224 Continuous Oxygen Insufﬂation is Superior to 
Intermittent Positive Pressure Ventilation During 
Cardiopulmonary Resuscitation
Melinda M. Hayes, Ronald W. Hilwig, Arthur B. Sanders, Robert A. Berg, Nathan Anavy, 
Karl B. Kern, Gordon A. Ewy, University of Arizona Sarver Heart Center, Tucson, AZ
Background: Professional EMS rescuers providing out-of-hospital CPR have been 
observed to ventilate more than 30/min! Such hyperventilation was associated with 
increased intrathoracic pressure (ITP) and decreased survival. This study evaluated 
the effects of intermittent positive pressure ventilation (IPPV), with and without 
hyperventilation, compared to continuous oxygen insufﬂation (COI).
Methods: Thirty swine (25±1 kg) were anesthetized and solid state micromanometer-
tipped catheters were placed to measure aortic, right atrial, and ITP. Following 8 min 
of untreated VF, all animals received manual chest compressions at 100/min and were 
randomized to one of three ventilation groups. Group 1 (standard) received IPPV at a 
rate of 10/min; tidal volume (TV) of 20mL/kg. Gp 2 (hyperventilation) received IPPV at a 
rate of 35/min; TV = 20mL/kg, and Gp 3 received no IPPV but rather COI with a ﬂow rate 
of 10L/min. Chest compressions, with one of the above methods of oxygenation, were 
administered for 2 minutes, at which time deﬁbrillation was attempted.
Results: Return of spontaneous circulation was achieved in 30% in each of the three 
groups. Survival without neurological deﬁcit at 24 Hrs occurred 2/10 in the standard IPPV 
group, 0/10 in the hyperventilation IPPV group, and 3/10 in the COI group (�2 p=.06). 
Mean neurological deﬁcit score was signiﬁcantly less in the COI group (1.3±0.3 vs 2.0±0 
vs 1.0±0; p<.05). Mean ITP was less with COI then either IPPV group (31±6 vs 33±5 
vs 13±4; p<.02). Arterial pH differed among all three groups (7.48±.03 vs 7.65±.02 vs 
7.22±.02; p<.0001), but was not related to outcome.
Conclusion: COI resulted in less increase in ITP during CPR, and produced superior 
neurological outcome to either form of IPPV. COI may be a better choice for ventilation 
during early resuscitation efforts for prolonged untreated VF.
1036-226 Survival and Neurologic Damage in out-of-Hospital 
Cardiac Arrest: Deﬁbrillation or Deﬁbrillation plus CPR?
Alessandro Capucci, Daniela Aschieri, Simona Bennati, Efrosini Iconomu, Maurizio 
Arvedi, General Hospital, Piacenza, Italy
The rate of success of cardiac arrest (SCA) mainly depends on the time to deﬁbrillation. 
Recently the use of automatic external deﬁbrillators (AED)associated with CPR has 
been demonstrated to improve survival from ventricular ﬁbrillation (VF) compared to 
cardiopulmonary resuscitation (CPR) alone in a community project. The use of AED alone 
has not been still investigated.
Methods. 2325 volunteers have been recruited in the of Piacenza Vita Project, including 
policemen, post-ofﬁce personnel, sport centers, hotel, public ofﬁce, railway station 
personnel, lay ambulance volunteers, and worksite. The volunteers were trained only to 
use AED without CPR to reduce time and cost of training. Deﬁbrillation (DP) courses last 
3-4 hours and began four years ago. After one year all certiﬁed lay volunteers undergo a 
1-hour review test and a retraining CD-Rom is given to continue home self-training. The 
volunteers respond to all cases of suspected SCA, simultaneously and in coordination 
with the EMS. The ﬁrst who arrives deﬁbrillates the patients (pts). 
Results. 1188 SCA were recorded with 143 VF as the ﬁrst rhythm. The pts were subdivided 
into two groups: group PV (66 pts), ﬁrstly treated by volunteers and group EMS (77 pts), 
ﬁrstly treated by medical staff who perform CPR. They were similar in age (mean: 69.7+12 
year), proportion of men (63%), rate of witnessed SCA(73%), and location (74% at home). 
Time to deﬁbrillation signiﬁcantly differed between PV and EMS (5.30 min vs 7.30 min; p< 
0.01). The survival rate from shockable rhythms was signiﬁcantly higher for PV vs EMS 
group: 43% (29/66) vs. 22% (17/77), p=0.003. The neurologically intact survival rate to 
hospital discharge (level 1 evaluation)was also higher in PV vs EMS treated pts: 93.9% 
(27/29) vs. 83% (14/17), p=0.008, mainly due to shorter deﬁbrillation time. 
Conclusions. Training volunteers to attempt early deﬁbrillation within a structured 
response system increases the number of survivals to hospital discharge free from 
neurologic lesion regardless to CPR during resuscitation. Trained layperson can use AED 
safely and effectively even after many months from a brief training courses of only 3-4 
hours duration.
1036-227 Prognostic Value of Relative Adrenal Insufﬁciency After 
Out-of-Hospital Cardiac Arrest
Frédéric Pène, Hervé Hyvernat, Vincent Mallet, Alice Ohanessian, Alain Cariou, Pierre 
Carli, Christian Spaulding, Marie-Annick Dugué, Jean-Paul Mira, Cochin Hospital, Paris, 
France
Background: In survivors of out-of-hospital cardiac arrest (OHCA), post-resuscitation 
disease shares common hemodynamic features and a similar immunoinﬂammatory 
response with septic shock, thus identifying a sepsis-like syndrome. Relative adrenal 
insufﬁciency is a poor prognostic factor in patients with septic shock, for whom a 
replacement treatment reduces mortality and duration of vasopressor therapy. We 
performed a prospective observational single-center study to assess the prevalence 
of relative adrenal insufﬁciency in survivors of OHCA, and its prognostic role in post-
resuscitation disease.
Methods: Patients hospitalised after successfully resuscitated OHCA were eligible for the 
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study. A corticotropin-stimulation test was performed between 12 and 24 hours following 
admission: serum cortisol level was measured before and 60 minutes after administration 
of tetracosactide 250µg. Patients with an incremental response < 9µg/dL (non-responders) 
were considered to have relative adrenal insufﬁciency.
Results: Between February 2002 and July 2003, 64 patients were included in the study. 
Thirty three patients (52%) had relative adrenal insufﬁciency. Baseline cortisol level was 
higher in non-responders than in responders (41 IQR [27.2-55.5] vs. 22.8 IQR [15.7-
35.1] µg/dL respectively, p=0.001). A long interval before initiation of cardiopulmonary 
resuscitation was associated with relative adrenal insufﬁciency (5 IQR [3-10] vs. 3 IQR [3-
5] min, p=0.03). Thirty eight patients experienced early post-resuscitation shock requiring 
vasoactive drugs, of whom 13 died of irreversible multiorgan failure. The presence of 
relative adrenal insufﬁciency was identiﬁed as an independent poor prognostic factor of 
shock-related mortality in a multivariate logistic regression analysis (Odds ratio 6.77, CI 
95% 0.94-48.99, p=0.058).
Conclusion:  Relative adrenal insufﬁciency occurs frequently after successful resuscitation 
of OHCA, and is associated with a poor prognosis in case of post- resuscitation shock. 
The role of corticosteroid supplementation should be evaluated in this setting.
1036-228 Adverse Event Reports on Automatic External 
Deﬁbrillators from 1996 - 2003
Oscar H. Tovar, Beverly Albrecht Gallauresi, Food and Drug Administration, Rockville, MD
Background. The estimated growth rate for automatic external deﬁbrillators (AEDs) in 
the USA was 8.2% for 2000 and 2001, 11.5% for 2002 and 22.0% for 2003. Despite this 
growth, there is scarce information about AED-related adverse events.
Methods and Results. We reviewed reports submitted by AED manufacturers to the FDA 
from 1996 - 2003 for AED-related adverse events (Table 1). Manufacturer conclusions 
were grouped in categories to assess association of device failure with a patient death 
(Table 2). 
Table 1. Adverse event reports related to AED use
1996 1997 1998 1999 2000 2001 2002 2003 Total
Deaths 16 45 71 59 65 119 107 108 590
Malfunctions 105 309 537 628 618 1322 1608 1917 7044
Injuries 3 2 1 0 0 3 1 0 10
Table 2. Manufacturers’ conclusions 96-99 00-03
n % n %
No conclusion 111 32.3 467 59.9
Unknown if device contributed to death 77 26.7 118 15.1
No device failure 42 22.4 94 12.0
Device failure caused or contributed to death 92 12.2 75 9.6
User error caused or contributed to death 7 2.0 12 1.7
Device maintenance contributed to death 15 4.3 7 0.9
Device not returned or not related to death 0 0 6 0.8
Total 344 100 779 100
Conclusions. 1) Reported deaths associated with AED failure are more frequent than 
injuries, 2) reported AED malfunctions are increasing, along with increase in AED 
deployment, and 3) increase of AED-reported deaths over time may be associated with 
several factors including increased device availability.
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1059-203 Lower Risk of Cardiac Rupture in CD39 Null Mice Post 
Myocardial Infarction
Mika Ogawa, Norihiko Ogawa, Masaharu Nakayama, Eva Csizmadia, Keiichi Enjyoji, 
Masahiro Kohzuki, Simon C. Robson, Beth Israel Deaconess Medical Center/Harvard Medical 
School, Boston, MA, Tohoku University Graduate School of Medicine, Sendai, Japan
Background: CD39/NTPDase 1 is an extracellular enzyme expressed on the surface 
of vascular endothelium, leukocytes and platelets that hydrolyze nucleotides (ATP, ADP, 
UTP etc.). We have generated cd39/NTPDase 1 null mice (cd39-/- mice) and found the 
disturbance of macrophage chemotaxis and platelet aggregation in this animal model. 
In this study, we analyzed cd39-/- mice to examine the role of cd39/NTPDase 1 in acute 
phase post myocardial infarction (MI).
Methods: Ten-to 13-week-old male wild type mice (wt) and cd39-/- mice underwent left 
anterior descending coronary artery ligation or sham operation. Mortality post MI was 
observed. Physiological data were measured. Immunohistochemistry was performed in 
the excised hearts at day 1 and 3 post MI. Matrix Metalloproteinase (MMP) expression 
and activity were analyzed by immunoblots and zymography in the ischemic area and 
non-ischemic area of left ventricle (LV).
Results: CD39-/- mice showed signiﬁcantly better survival rate than wt by day 8 (38% vs. 
88%, P < 0.05). All of the deaths occurring at day 4 to 7 after MI were caused by LV free 
wall rupture. Systolic blood pressure and LV weight/body weight ratio, however, didn’t differ 
between wt and cd39-/- mice. The ischemic risk area of excised hearts from both groups 
was similar. CD39/NTPDase 1 expression in wt was downregulated at day 1 and changed 
to upregulation on vascular endothelium in ischemic border and inﬁltrated inﬂammatory 
cells in ischemic area as well as MMP9 expression. MMP activation of ischemic area in 
cd39-/- mice was half level as compared to wt (p<0.05).
Conclusion: We demonstrated that cd39-/- mice are protected from the risk of cardiac 
rupture after MI. CD39 and MMP9 have co-localization in the ischemic area and delayed 
activation of MMP in cd39-/- mice are observed. These data suggest that CD39/NTPDase 
1 may modify MMP activation and cardiac remodeling in acute phase post MI.
1059-204 CD36 Plays an Important Role in LV Remodeling After 
Acute Myocardial Infarction
Xiaorong Zhou, Maria Febbraio, Arman Askari, Kai Wang, Marc S. Penn, The Cleveland 
Clinic Foundation, Cleveland, OH
CD36 is a multifunctional membrane-type receptor, mediating the uptake of oxidized LDL 
and development of atherosclerosis as well as anti-angiogenesis through binding TSP-1. 
However, its role in left ventricular remodeling after acute myocardial infarction has not 
been studied. In this study the role of CD36 in LV remodeling was investigated. 
Methods and Results. AMI was induced by chronic ligation of LAD in female CD36-/- and 
wild-type (C57BL/6J). Echocardiography was performed before, 3 and 24 days after AMI 
to assess the effects of CD36 on LV function and remodeling. At 3 and 24 days after AMI, 
CD45 and vWF staining were performed to evaluate the effects of CD36 on inﬂammatory 
response and angiogenesis. There were no differences of LV size and function before and 
3 days after AMI. However, 24 days after AMI, CD36-/- mice showed signiﬁcantly better 
LV function, reduced LV end-diastolic size and increased anterior wall thickness (Table) 
compared to wild-type mice. Along with improved function, we observed signiﬁcantly 
decreased leukocyte inﬁltration (% area) in CD36-/- group 3 days after AMI (25%±8 vs 
8%±3%, P=0.016). Vessel density was increased in CD36-/- group at 24 days (14.5 ± 3.7 
vs 8.2 ± 5.6 vessels/mm2, p<0.05 ) within the infarct border zone. 
Conclusion. CD36 play a critical role in the remodeling process following AMI through 
mediation of the inﬂammatory and angiogenic responses, and blocking CD36 function 
may serve as a novel pathway for optimizing LV function after AMI. 
Groups LVEDD (mm) LVWT(anterior, mm) FS (%)
CD36 -/- 0.329 ± 0.09 * 0.077 ± 0.024 * 0.292±0.10 *
WT 0.443 ± 0.09 0.047 ± 0.020 0.174±0.09
* P < 0.05 vs WT group
1059-205 Tamoxifen Treatment of Post-Myocardial Infarcted 
Adult Female Rats Exerted a Nefarious Action on Scar 
Remodeling
Pedro Geraldes, Hugues Gosselin, Jean-François Tanguay, Robert Clément, Angelino 
Calderone, Montreal Heart Institute, Montreal, PQ, Canada
The Heart and Estrogen/progesterone Replacement Study (HERS) and the Women’s 
Health Initiative (WHI) recently documented that hormonal replacement therapy (HRT) 
increased the incidence of non-fatal myocardial infarction (MI) in postmenopausal women 
with or without coronary artery disease. The partial estrogen receptor agonist Tamoxifen 
(TAM) may represent an alternative pharmacological approach to HRT. In this regard, the 
present study examined the effect of TAM on cardiac remodeling post myocardial infarction 
(MI) in adult female rats. TAM (10 mg kg-1 day-1) was administrated 4 hours post-MI and 
continued for a period of three weeks. In MI rats treated with TAM (n=18), scar surface area 
(TAM+MI=0.67±0.08 versus MI=0.48±0.07 cm2) and scar weight (TAM+MI=0.071±0.007 
versus MI=0.052±0.006 grams) were signiﬁcantly greater (p<0.05), as compared to 
untreated-MI rats (n=25). The nefarious action of TAM on scar remodeling may have been 
attributed to either predisposing cardiac myocytes to apoptosis and/or compromising 
angiogenesis. Serine phosphorylation of the anti-apoptotic molecule protein kinase 
B (PKB) was signiﬁcantly increased (96±4%, n=11;p<0.05 versus sham) in the non-
infarcted left ventricle (NILV) of MI rats, as compared to sham. By contrast, TAM treatment 
completely abrogated PKB phosphorylation in the NILV (n=11) as compared to untreated-
MI rats. In a Matrigel assay, vascular endothelial growth factor (VEGF) (10-9 mol/L; n = 3) 
treatment (48 hr) of rat aortic endothelial cells promoted capillarity-like tubule formation. 
The co-administration of TAM (n=3) caused a dose-dependent suppression of VEGF-
stimulated tubule formation with a maximum effect at 10-7 mol/L. These data demonstrate 
that TAM adversely inﬂuenced scar remodeling post-MI and may have occurred by either 
predisposing cardiac myocytes to apoptosis and/or inhibiting angiogenesis.
1059-206 Alterations In Regional Wall Strain, Enos And 
Microtubulin Concentrations Signaling Left Ventricular 
Remodeling Occur Immediately After Acute Myocardial 
Infarction
Huy Phan, Elizabeth Juneman, Lisa Castellano, Nicholle Johnson, Steven Goldman, 
Mohamed Gaballa, Hoang M. Thai, Southern Arizona VA Health Care System, Tucson, 
AZ, Sarver Heart Center at the University of Arizona, Tucson, AZ
Background: Left ventricular (LV) remodeling after myocardial infarction (MI) leads to 
heart failure (HF). While alterations in LV wall strain are seen in the infarcted regions 
(IR), it is unclear if this also affects the non-infarcted regions (NIR) of the LV. Additionally, 
while LV tissue eNOS and constituitive microtubulin (CM) are altered in chronic HF, it is 
unknown what happens to these biomarkers acutely. We evaluated changes in LV wall 
strain; myocardial eNOS and CM acutely post MI.
Methods: LV wall motion of Sprague Dawley rats (N = 10) was analyzed by echocardiography 
at several time points after MI. Hemodynamic measurements were obtained via a Millar 
catheter. Alterations in myocardial contraction (δ strain) are measured via M-mode 
echocardiography. CM and eNOS were determined via immunoblot techniques.
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Results: Systolic blood pressure decreased (P < 0.05) acutely post MI (127.1 ± 6.1 vs 
101.7 ± 10.1 mmHg). LV end diastolic pressure increased (P<0.05) acutely after MI (5.8 ± 
0.5 vs. 19.9 ± 2.0 mmHg). These changes were accompanied by a decrease (P< 0.05) in 
LV dP/dt after MI (7106 ± 520 vs. 4671 ± 350, mmHg/sec). δ strain was decreased in the 
anterior IR immediately (0.15 ± 0.04 vs 0.1 ± 0.02 mm, P < 0.01); similarly δ strain was 
also decreased in the posterior NIR starting at 1 minute (0.17 ± 0.02 vs 0.1 ± 0.02 mm, 
P < 0.01). A decrease in eNOS was seen with both the IR and NIR of the LV (20.8 ± 3.8 
intensity unit (IU)/50 µg of tissue vs 11.1 ± 3.3 IU/50 µg, P = 0.04) and (26.7 ± 4.8 vs 8.14 
± 1.6 IU/50 µg, P = 0.002), respectively after MI. Conversely, CM was increased in both IR 
and NIR of the LV (10.3 ± 2.4 IU/25 µg vs 26.2 ± 4.6 IU/25 µg, P = 0.0005) and (9.3 ± 1.8 
vs 18.5 ± 3.7 IU/25 µg, P = 0.003), respectively.
Conclusion: Decreases in δ strain occurred in both IR and NIR of the LV acutely after MI. 
This is accompanied by alterations in eNOS and CM levels throughout the LV immediately 
after MI. Our data demonstrate that physical and biomarkers signaling LV remodeling 
occur immediately after MI, rather than over time.
1059-207 Absence of Infarct Regression one Year After Acute 
Myocardial Infarction: Serial Measurements by Contrast 
Hyperenhancement Magnetic Resonance Imaging
Anna KY Chan, Yan Zhang, Gabriel WK Yip, Wynnie Lam, C.M. Yu, John E Sanderson, 
The Chinese University of Hong Kong, Hong Kong SAR., Hong Kong
Background: Late myocardial infarct regression causing a decrease in the proportion 
of the left ventricle occupied by non-viable myocardium has been postulated due to scar 
contraction. Temporal change of infarct size by contrast hyperenhancement magnetic 
resonance imaging (Ce-MRI), in relation to left ventricular (LV) remodeling at 1 year after 
myocardial infarction (MI) is not clear.
Methods: Total 47 consecutive patients with ﬁrst documented MI were evaluated by serial 
Ce-MRI at the following interval: within 7 days, and after 3 and 12 months. MRI infarct size 
was expressed as a percentage of total hyperenhanced regions over left ventricular (LV) 
mass from a stack of short axis views covering the whole LV. Echocardiographic LV end-
systolic, end-diastolic volumes and LV ejection fraction (LVEF) were measured.
Results: Patients were classiﬁed into 2 groups according to the change in LVEF between 
baseline and 1 year. Twenty-seven patients with unchanged or improved LVEF and 20 
patients had LV remodeling with a decline in LVEF ≥ 10%. Patients with LV remodeling had 
signiﬁcantly larger MRI infarct size by Ce-MRI compared to those without remodeling (24.6 
%±3.3 vs 12.6±6.1, p=0.001). There was no temporal change in infarct size at baseline, 
3 and 12 months after index infarction, both in the groups with or without remodeling, 
irrespective of baseline infarct size (Table).
Conclusion: Infarct regression is not evidenced during 1 year follow up in patients with or 
without left ventricular remodeling after MI.
Temporal changes of infarct size by Ce-MRI 
Ce-MRI Infarct Size (%) Without Remodeling(n=27)
With Remodeling
(n=20)
Baseline 12.6 ± 6.1* 24.6 ±13.3
3 Months 12.5 ± 7.2* 25.3 ± 10.6
12 Months 12.3 ± 8.9* 25.9±13.7
1059-208 Quest for a Sensitive ECG Sign Of Myocardial Infarction 
Scar: Beyond Q wave
Bilal Khan, Mithilesh K. Das, Sony Jacob, Avaneesh Kumar, Jo Mahenthiran, Krannert 
Institute of Cardiology, Indianapolis, IN
Background: Pathological Q wave on EKG is a speciﬁc marker with limited sensitivity 
(20-30%) for myocardial scar. Myocardial scar is shown to alter ventricular depolarization 
resulting in terminal QRS conduction delay (RSR’ pattern). We postulate that an abnormal 
fragmented QRS (fQRS) pattern including RSR’ and its variants (ﬁgure), not related to 
bundle branch block (BBB) is highly predictive of a myocardial scar.
Methods: Of 250 patients (pts), baseline ECG and myocardial perfusion imaging (MPI) 
of 239 pts (138 [55%] males, mean age: 58 ±12 years) were studied (11 excluded due 
to BBB or a pacemaker rhythm).The fQRS was deﬁned as QRS with more than one R’ 
(duration <120 ms) on ≥ 2 leads corresponding to individual coronary artery territory. MPI 
scar was deﬁned by a single segment and sum rest score ≥ 3 and a sum difference score 
of stress and rest ≤ 3 using a standard 17-segment, 5-point scale, corresponding to a 
coronary artery territory.
Results: MPI was consistent with scar in 112 (47%) pts. The LAD scar (n=38) had Q in 
6, fQRS in 35 and Q + fQRS in 3 pts. LCx scar (n=19) had Q in 3, fQRS in 13 and Q + 
fQRS in 1 pts. RCA scar (n=100) had Q in 39, fQRS in 101 and Q + fQRS in 29 pts. The 
sensitivity for MPI scar with Q wave increased signiﬁcantly from 28.6% to 82.8% when 
combined with fQRS and speciﬁcity decreased from 99.4% to 92.3% (see table).
Conclusion: The fQRS not related to BBB signiﬁcantly increases the sensitivity of a 
myocardial infarction scar as compared to the presence of Q wave alone on EKG. 
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1060-195 The Presence of Coronary Artery Soft Plaques is 
Associated with Insulin Resistance in Patients with 
Coronary Artery Disease: Assessment by Multislice 
Computed Tomography
Taeko Kunimasa, Masao Moroi, Tatsuhiko Furuhashi, Hiroshi Fukuda, Kaoru Sugi, Toho 
University School of Medicine, Ohashi Hospital, Tokyo, Japan
Disruption of the vulnerable plaque (soft plaque) is thought to be the primary cause of 
acute coronary syndrome. We evaluated the relationship between metabolic syndrome 
and the presence of coronary artery soft plaques detected by multislice computed 
tomography (MSCT). 
Methods: MSCT (Aquillion 16, Toshiba Medical, Tokyo, Japan) was performed in 58 
patients (mean age =63, male/female=50/8) with known or suspected coronary artery 
disease (CAD). On an axial image of MSCT, at least four randomly selected regions 
of interest (1.0mm2) were positioned on the plaque and the density was measured. 
Plaques with the CT density less than 50 Hounsﬁeld Units were deﬁned as soft plaques. 
We assessed the relationship among the presence of coronary soft plaques, metabolic 
syndrome (NCEP ATP III) and the homeostasis model assessment-insulin resistance 
index (HOMA-IR=fasting blood glucose level × fasting serum insulin level /405). 
Results: Coronary artery soft plaques were detected in 29 of 58 patients. The logistic 
regression analysis revealed that HOMA-IR greater than 1.7 was the most important risk 
factor for the development of coronary soft plaques as shown in Table. 
Conclusion: Insulin resistance may be an important risk factor for the development of 
vulnerable plaques in CAD patients.
 
Logistic Regression Analysis 
Odds ratio 95%CI P value
HOMA-IR>1.7 3.2 1.08-9.66 0.04
HDL-Cholesterol<40mg/dl 3.5 0.65-19.2 0.15
Metabolic syndrome 1.9 0.66-5.51 0.24
Body Mass Index>24 1.9 0.60-5.85 0.28
Triglyceride>150mg/dl 1.6 0.53-4.85 0.40
Hypertension 1.2 0.38-3.67 0.77
1060-196 Intravascular Ultrasound Characteristics of Ruptured 
Plaques in the Left Main Coronary Artery.
Jerzy Pregowski, Pawel Tyczynski, Gary Mintz, Mariusz Kruk, Adam Witkowski, Sang-
Wook Kim, Akiko Maehara, Kenneth Kent, Augusto Pichard, Szymon Bieganski, Neil 
Weissman, Washington Hospital Center, Washington, DC, Cardiovascular Research 
Foundatio, New York, NY
Acute coronary syndromes with culprit lesion located in the left main coronary artery 
(LMCA) may be especially life-threatening. Methods We identiﬁed 17 LMCA ruptured 
plaques (RPs) in 16 patients (14 males, ages 69.1±9.7yrs). If the plaque cavity was also 
seen at LMCA bifurcation the rupture was classiﬁed as bifurcated RP. Standard IVUS 
measurements were performed within LMCA at minimal lumen area (MLA), maximal 
plaque cavity (MPC), and proximal reference sites. Results There were 2 patients with 
recent myocardial infarction, 13 with unstable angina, and 1 with stable angina. Thrombus 
was identiﬁed in 4 lesions. Six RPs involved the bifurcation (3 into the LAD and 3 into the 
LCX); 11 RPs were conﬁned to LMCA. The angle between the MPC and the LAD/LCX 
ﬂow divider was 162.3±15.6 º in bifurcation RPs vs 71.3±41.6 º in non-bifurcation RPs, 
2005_5_MyocaIschInfartion.indd   206 12/23/04   10:07:09 AM
Enfocus Software - Customer Support




p=0.004. Mean LMCA RP length was 2.4±1.3mm; cavity area was 3.2±1.8mm2. There 
was no difference between bifurcation and non-bifurcation RPs. LMCA length measured 
11.6±5.6mm; but the distance between MPC and the aortic ostium measured 9.7±5.7mm. 
In bifurcation RPs the MPC tended to be located father from aortic ostium (12.3±5.5mm vs 
7.9±5.0mm, p=0.12). The MLA (6.5±3.8mm2 overall) was within the MPC site in 11 lesions 
and distal to the MPC in 6 lesions. Nine lesions had an MLA <6mm2 - the threshold that 
has been correlated with LMCA-associated ischemia. There was a tendency for a smaller 
LMCA MLA in non-bifurcation lesions: 6.0±3.3mm2 vs 7.4±4.7mm2 (p=0.3), but there was 
no difference in daughter vessel MLA (6.7 ±3.0mm2 vs 6.6 ±3.5mm2, p=0.9). Conclusions 
RPs involving LMCA may occur with various clinical presentations, almost exclusively 
involve the distal LMCA and/or its bifurcation, and are rarely lumen compromising.
1060-197 Long-Term Prognosis of Nonobstructive Coronary 
Artery Disease in the Setting of Acute Coronary 
Syndrome: A TIMI 22 Substudy
Raffaele Bugiardini, Olivia Manfrini, Sabina A. Murphy, Gaetano M. De Ferrari, 
Christopher P. Cannon, TIMI 22 investigators, Brigham and Women’s Hospital, Boston, 
MA, University Alma Mater, Bologna, Italy
Background. The long-term prognostic implication of normal coronary arteries (0% 
stenosis) or mild (>0 to<50% stenosis) coronary artery disease (CAD) at angiography 
is assumed to be benign. Consequently, recurrence of chest pain symptoms in non-
obstructive (<50% stenosis) CAD is often disregarded and, more importantly, there is a 
tendency to not recommend preventive therapy for these patients.
Methods. The TIMI 22 trial enrolled 3580 patients (2788 men and 792 women) who had been 
hospitalized for an acute coronary syndrome within the preceding 10 days and had cardiac 
catheterization. There were 178 (5%) patients with non-obstructive CAD that were used 
for this analysis. The primary end-point was the composite of death, myocardial infarction, 
unstable angina requiring re-hospitalization, revascularization, and stroke at 2-year follow-up.
Results. Patients with non-obstructive CAD included 109 men and 69 women (3.9% and 
8.7%, respectively, of the overall TIMI 22 population). Women were older than men (58.3 
+ 11.8 versus 52.9 + 10.8 years; p = 0.0019). There were 55/178 patients (31%) with 
normal coronary arteries and 124/178 patients (69%) with mild-CAD. Patients with normal 
coronary arteries and those with mild-CAD matched well with regard to the qualifying 
event, gender and baseline characteristics. There was no difference in angiographic group 
by treatment. Kaplan-Meier estimates of the rates of the primary end point at two years were 
8.3% in the normal angiography group and 10.2% in the mild-CAD group. The combined 
hard end point of cardiac death, myocardial infarction, stroke or revascularization was 
6.1 % and 9.4 %, respectively. Revascularization was the most frequent endpoint (50% of 
events) in non-obstructive CAD.
Conclusion. Patients presenting with a clear acute coronary syndrome, but who had 
non-obstructive CAD have a prognosis that is not as benign as previously thought. Normal 
angiography and mild-CAD did not differentiate patients with regard to their prognosis. 
Adverse event rate was driven by revascularization that implies acceleration of the 
underling atherosclerotic process. Aggressive treatment for this “hidden” CAD is timely.
1060-198 Troponin Positive and Creatine-Kinase Negative Acute 
Myocardial Infarction: A Clinical, Electrocardiographic 
and Quantitative Coronary Angiography Analysis
Luis Gruberg, Haim Hammerman, Michael Kapeliovich, Walter Markewicz, Rafael Beyar, 
Rambam Medical Center, Haifa, Israel
Background: Cardiac troponins are part of the new deﬁnition of acute myocardial 
infarction (AMI) by the European Society of Cardiology and the ACC. There is scarce 
data regarding the angiographic characteristics of troponin I (cTnI) positive, creatine 
kinase (CK) negative AMI patients. We assessed the clinical, electrocardiographic and 
angiographic characteristics of these patients.
Methods: Between 1/2002 and 7/2004, a total of 44 consecutive cTnI positive, CK 
negative AMI patients were admitted to the ICCU and underwent coronary angiography.
Results: The mean age was 61±12 years, 40% were diabetics, 37% smokers and 44% 
had hyperlipidemia. Mean cTnI was 11.6±14.1 ug/L and mean CK was 91±40 U/L. 
All patients had normal renal function (serum creatinine: 0.85±0.2 mg/dL). Admission 
electrocardiogram showed inverted T waves in 42%, ST elevation in 35%, ST depression 
in 19% and was normal in 19%. Only six patients (14%) had a totally occluded infarct 
related artery and 37% had one-vessel disease. A total of 129 lesions were analyzed by 
QCA (CAAS II, Pie Medical), as shown in the Table. 
n=129
Percent diameter stenosis (%) 63.3±21.4
Minimal lumen diameter (mm) 0.95±0.72
Reference vessel diameter (mm) 2.52±0.84
Lesion length (mm) 8.05±4.7
Plaque area (mm2) 7.0±7.3
Plaque volume (mm3) 19.4±29.2
Conclusions: This is the ﬁrst detailed QCA analysis of cTnI positive, CK negative AMI 
patients. Contrary to cTnI positive, CK positive patients, a minority of cTnI positive, CK 
negative AMI patients have a totally occluded infarct related artery. Nevertheless, there 
is a high prevalence of signiﬁcant coronary artery disease in these patients, with 63% 
having multiple lesions in at least two coronary arteries.
1060-199 Slow Flow Phenomenon Is Associated With Type of 
Plaque Disruption
Yasunori Ueda, Atsushi Hirayama, Kazuhisa Kodama, Osaka Police Hospital, Osaka, Japan
Background: Distal embolization of thrombus and plaque contents from the culprit lesion 
is supposed to cause slow ﬂow phenomenon and deteriorate left ventricular function but 
can be prevented by distal protection device. Therefore, we examined the predictive 
factors of slow ﬂow phenomenon.
Methods: A series of 202 patients with ischemic heart diseases who received PCI and 
angioscopic examination were analyzed. The effect of patients characteristics, technical 
data of PCI, and angiographic and angioscopic ﬁndings on the occurrence of slow ﬂow 
phenomenon was examined.
Results: Diagnosis of the study patients was acute myocardial infarction, unstable 
angina, stable effort angina, and silent myocardial ischemia in 105, 51, 18, and 28 patients, 
respectively. Slow ﬂow phenomenon was detected in 8.4%. Slow ﬂow phenomenon was 
signiﬁcantly associated with acute myocardial infarction, high fasting blood glucose, 
not taking antiplatele medications, long lesion length, TIMI ﬂow grade=0 before PCI, 
angioscopic detection of massive thrombus, and angioscopic detection of ruptured 
plaque. The incidence of slow ﬂow phenomenon (19% vs. 6%, p=0.008) was higher when 
ruptured plaque was detected by angioscopy than when erosive plaque was detected.
Conclusions: Multiple factors including angioscopic ﬁndings were signiﬁcantly 
associated with slow ﬂow phenomenon. We may be able to know the risk of slow ﬂow 
phenomenon by evaluating these factors.
1060-200 Vulnerability of Coronary Plaques Associates with 
Elevated Cardiac Troponin T in Patients with non-ST 
Elevation Acute Coronary Syndrome: Analysis by Using 
Coronary Angioscopy and Intravascular Ultrasound
Taku Sakai, Yasunori Ueda, Yuji Okuyama, Yuzuru Takano, Atsushi Hirayama, Kazuhisa 
Kodama, Osaka Police Hospital, Osaka, Japan
Background: Elevated troponin T (TnT) predicts adverse outcome in non-ST elevation-
acute coronary syndrome (NSTE-ACS). But the relation between the culprit lesion 
morphology and elevated TnT level are poorly understood.
Objectives: In this study, we analyzed the culprit lesion morphology by using coronary angioscopy 
and intravasclar ultrasound (IVUS) in relation to different TnT levels in patients with NSTE-ACS.
Methods: A series of 57 patients with NSTE-ACS who underwent angioscopic and IVUS 
examinations were enrolled. Patients were divided into three groups based on TnT levels on 
admission. (<0.01µg/l, n=31; 0.01 to 0.1µg/l, n=15; >0.1µg/l; n=11). In angioscopic analysis, 
we assessed the number of yellow plaques, the color grade of yellow plaques (Grade 1:
slight yellow, 2:yellow, 3:intensive yellow), and the prevalence of thrombus. Quantitative 
IVUS analysis was also performed to evaluate the plaque area. The percentage of plaque 
area was calculated as (external elastic membrane cross sectional area-lumen cross 
sectional area / external elastic membrane cross sectional area)×100(%).
Results: Among those patients with TnT<0.01µg/l, 0.01 to 0.1µg/l, >0.1µg/l, the number 
of yellow plaques were 2.0±0.3, 2.4±0.3, 2.1±0.4, respectively (p=ns). The corresponding 
ﬁgures for the plaque color grades were 2.0±0.4, 1.6±0.2, 2.36±0.3 (P<0.05), and for 
the occurrence of thrombus 53%, 61%, 91% (p<0.05). The prevalence of thrombus at 
culprit lesions increased in proportion to the levels of TnT. The percentage of plaque area 
evaluated by IVUS were 57.7±9.9%, 60.2±11.5%, 64.2±8.9% (p=ns), respectively.
Conclusion: In patients with NSTE-ACS, the elevated TnT levels did not associate 
with the plaque burden, but related with the plaque color intensity and the presence of 
intracoronary thrombus. These results may indicate the plaque vulnerability and likelihood 
of thrombus in NSTE-ACS patients with positive TnT.
1060-201 Presence of Soft Plaques in Nonculprit Coronary 
Arteries in Patients With Acute Coronary Syndromes : 
Evaluation by Multislice Computed Tomography
Taeko Kunimasa, Masao Moroi, Tatsuhiko Furuhashi, Hiroshi Fukuda, Kaoru Sugi, Toho 
University School of Medicine, Ohashi Hospital, Tokyo, Japan
Recent clinical observations have suggested that the disruption of the vulnerable plaque is the 
primary cause of acute coronary syndromes (ACS). We hypothesized that ACS patients may 
often have soft plaques in non-culprit coronary arteries compared with non-ACS patients. 
Methods: MSCT (Aquillion 16, Toshiba Medical, Tokyo, Japan) was performed in 22 
patients with ACS (acute myocardial infarction:16, unstable angina:6) and 40 patients 
with non-ACS (stable angina:33, old myocardial infarction:7). On an axial image of MSCT, 
at least four randomly selected regions of interest (1.0mm2) were positioned on the plaque 
and the density was measured. Plaques with the CT density less than 50 Hounsﬁeld Units 
were deﬁned as soft plaques. 
Results: Sixteen of 22 patients (73%) with ACS had plaques in the non-culprit coronary 
arteries whereas 17 of 40 patients with non-ACS (58%) had plaques. There was no 
statistical difference in the number of plaques between ACS and non-ACS patients. 
Among patients with plaques in non-culprit coronary arteries, the incidence of soft 
plaques was signiﬁcantly higher in patients with ACS (13 of the 22 patients, 59%) than 
those with non-ACS (7 of the 40 patients, 18%, P=0.002). 
Conclusion: ACS patients often have soft plaques in non-culprit coronary arteries 
compared with non-ACS patients. This supports the concept of a vulnerable patient but 
not a vulnerable plaque in a patient.
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1060-202 Culprit Coronary Levels of Angiotensin II and Impaired 
Microvascular Reperfusion in Patients With ST-Segment 
Elevation Myocardial Infarction
Makoto Suzuki, Masamichi Tanaka, Eiki Hirose, Hideyuki Saeki, Tsuyoshi Matsunaka, 
Shinichi Hiramatsu, Yukio Kazatani, Ehime Prefectural Central Hospital, Ehime, Japan
Background We investigated the association between culprit coronary levels of 
angiotensin II (AII) and microvascular reperfusion in patients who underwent coronary 
angioplasty for ST-segment elevation myocardial infarction (STEMI).
Methods A total of 30 patients (62±10 years) with an early phase of STEMI due to 
proximal left anterior descending coronary artery obstruction were enrolled. Aspirated 
coronary blood was sampled to measure culprit levels of AII and inﬂammatory markers 
such as high sensitive C-reactive protein (hs-CRP), interleukin (IL)-6, and matrix 
metalloproteinase (MMP)-9. Complete microvascular reperfusion was deﬁned as both the 
angiographic myocardial blush (MB) grade 3 and >50% ST-segment resolution in lead I, 
aVL, and V1 through V6 after coronary angioplasty. Enzymatic infarct size was calculated 
by serial measurements of creatine kinase-MB. 
Results Despite successful coronary angioplasty in all patients, complete microvascular 
reperfusion was obtained in 17 patients (57%). Enzymatic infarct size was large 
in patients with incomplete microvascular reperfusion as compared with complete 
microvascular reperfusion (9916±4318 vs. 6390±4341 IU/L, p=0.041). Culprit levels of AII 
were signiﬁcantly higher in patients with incomplete microvascular reperfusion than with 
complete microvascular reperfusion (19±9 vs. 7±4 pg/mL, p=0.001). Levels of hs-CRP 
and IL-6 but not MMP-9 were also elevated in patients with incomplete microvascular 
reperfusion than with complete microvascular reperfusion (hs-CRP, 4.5±3.6 vs. 1.4±1.7 
mg/L, p=0.004, IL-6, 88±102 vs. 23±34 pg/mL, p=0.021, MMP-9, 134±66 vs. 198±194 
ng/mL, p=0.278). A multivariate regression analysis showed the most association of AII 
with incomplete microvascular reperfusion (r=0.78, p=0.0001). 
Conclusions These results may provide in vivo evidence regarding the culprit link 
between AII and impaired microvascular reperfusion in patients with STEMI.
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1061-215 Predictors of Infarct Size by Technetium-99m Sestamibi 
Imaging After Angioplasty in Acute Myocardial 
Infarction: Meta-analysis From Four Contemporary 
Randomized Trials
Gregg W. Stone, William W. O’Neill, Simon Dixon, David A. Cox, John G. Webb, Bruce 
Brodie, John J. Grifﬁn, Jack Martin, Raymond Gibbons, Martin Fahy, Roxana Mehran, 
Cindy Grines, Columbia University Medical Center, New York, NY, Cardiovascular 
Research Foundation, New York, NY
Background. Radionuclide imaging with Tc-99m sestamibi is frequently used in reperfusion 
therapy trials to assess infarct size. Prior studies have been inadequately powered to fully 
describe all the determinates of infarct size using this technique after angioplasty in AMI.
Methods. We pooled patient level data from 4 contemporary randomized controlled 
trials of PCI in AMI: EMERALD (n=501), COOLMI (n=357), AMIHOT (n=269) and ICE-IT 
(n=228). Of 1,355 total pts, infarct size was determined by Tc-99m sestamibi in 1,234 pts 
(91.1%) at mean time 23 ± 15 days.
Results. The pt population was characterized as follows: Mean age 59.3 years, 76.3% 
male, prior MI 9.6%, 84.6% primary PCI and 15.4% rescue PCI, 42.9% anterior MI, mean 
symptom to balloon time 139 mins and door to balloon 105 mins, TIMI 0/1 pre 73.4%, TIMI 
3 post 91.5%. Mean infarct size was 16.3 ± 18.0% of the left ventricle. The independent 
baseline predictors of infarct size by multivariate linear regression appear in the table; 
factors unrelated to infarct size were investigational device, diabetes, smoking, creatinine, 
stent or GPIIb/IIIa use, discharge use of beta blockers, and time to sestamibi.
Conclusions. Anterior infarction, baseline and ﬁnal TIMI ﬂow, rescue PCI, male gender, 
prior MI and time to reperfusion are important predictors of infarct size after PCI in AMI. 
These variables should be considered when planning future trials of investigational drugs 
or devices designed to enhance myocardial salvage. 
Infarct size with 
variable (%LV)




Pain to door time 
>median (97 min) 17.2 ± 17.9 15.7 ± 18.1 0.02
Door to balloon time 
>median (100 min) 17.7 ± 18.9 14.3 ± 15.8 <0.0001
Male 17.4 ± 17.6 12.9 ± 19.1 <0.0001
Hypertension 17.3 ± 18.5 15.6 ± 17.6 0.04
Prior MI 20.6 ± 19.0 16.0 ± 17.9 0.003
Rescue PCI 17.0 ± 17.8 16.2 ± 18.1 0.03
LAD infarct artery 23.6 ± 20.1 10.1 ± 12.0 <0.0001
Pre TIMI 0/1 18.0 ± 18.0 11.4 ± 16.4 <0.0001
Post TIMI 0-2 27.3 ± 20.2 15.1 ± 17.1 0.0008
1061-216 Continuous 12-lead ST-Segment Recovery Predicts 
Ejection Fraction, Clinical Outcome and Death After  
PCI for Acute ST-elevation MI: Results from the 
EMERALD Study
Mitchell W. Krucoff, Per Johanson, Ricardo Baeza, Bruce R. Brodie, John Webb, 
David A. Cox, Mansoor Qureshi, Daniel Dulas, Anna Kalynych, Turco Mark, Heinz 
P. Schultheiss, Barry Rutherford, Alexandra Lansky, Manuela Negoita, Yingbo Na, 
Roxanna Mehran, Gregg W. Stone, for the EMERALD Investigators, Duke University 
Medical Center/Duke Clinical Research Institute, Durham, NC
Background: After infarct artery recanalization, biomarkers of microvascular reperfusion such as 
ST-segment recovery have been correlated with additional predictive information about outcome. 
In the EMERALD study 591 pts.with acute ST elevation MI (STEMI) underwent direct PCI, 
randomized equally to use of distal protection, with TIMI 3 epicardial ﬂow achieved in 89.6%.
Methods: Acute 24 hours continuous digital 12-lead ECG monitoring (NEMON 180+) 
was performed in all pts. In a blinded core laboratory the most abnormal (peak) ST 
levels (J+60ms) prior to PCI were compared to ST levels 30 min. after the last contrast 
injection to determine ST recovery of <30%, 30-70%, or >70%. Acute ejection fraction and 
independently adjudicated 6 month death and combined death, new heart failure, shock 
or urgent revascularization (MACE) were correlated with ST recovery categories using log 
rank test for trends across ST recovery categories.
Results: There were no differences in clinical descriptors, use of distal protection or use 
of IIbIIIa inhibitors between ST recovery groups. Outcomes correlations were: TABLE
Conclusion: Continuous 12-lead ST-segment recovery reﬂects the cellular response to 
reperfusion in the setting of acute STEMI. In the largest data set ever reported with direct 
PCI in acute STEMI, the EMERALD study results conﬁrm that ST-segment recovery provides 
highly signiﬁcant information about outcome even in the setting of epicardial recanalization.
ST Recovery vs. EFx & Outcomes Correlations
Parameter <30% 30-70% >70% P value
# Pts 42 118 431
EFx (%) 56.00 (49.00, 65.00) 60.00 (51.00, 68.00) 65.50 (57.00, 73.00) <.0001
6 mo MACE (% of pts) 17.70 9.70 5.50 <.006
6 mo Death (% of pts) 9.10 7.10 0.00 <.0001
1061-217 Initial Cumulative ST Segment Deviation Predicts Left 
Ventricular Function and One Year Mortality Strongly 
in Patients With an Anterior Myocardial Infarction, but 
to a Lesser Extent in Patients With a Non-Anterior 
Myocardial Infarction
Peter Elsman, Arthur CP Maas, Jan Paul Ottervanger, Jan-Henk E. Dambrink, Menko-
Jan de Boer, Marcel Gosselink, Jan CA Hoorntje, Felix Zijlstra, Harry Suryapranata, 
Arnoud WJ van ‘t Hof, Isala Klinieken, locatie Weezenlanden, Zwolle, The Netherlands
Background: The initial extent of ST segment deviation (ST dev) is often used for risk 
stratiﬁcation in patients (pts) with acute myocardial infarction (AMI). However, only few 
data exist on the effect of infarct location on the predictive value of ST dev.
Methods: During a 4 year period all consecutive pts who underwent primary angioplasty 
for AMI at our institution were eligible for inclusion in the study. The cumulative extent of ST 
segment deviation was measured on the initial diagnostic ECG’s by an independent core-
lab technician. Successful PCI was deﬁned as TIMI 3 ﬂow and DS<50%. Left ventricular 
ejection fraction (LVEF) was measured using Technetium labelling nuclear technique. The 
cut-off value for pts at high risk was set at 15 mm ST dev.
Results: ECG data were available in 1,163 pts, 566 (49%) had an anterior MI. . ST dev 
> 15 mm was present in 411 pts (35%). Pts with ST dev >15 mm had a lower ejection 
fraction (41 ± 12 % vs 45 ± 11 %, p<0.001) and a higher 1 yr mortality (8.5% vs 3.4%, 
p<0.001), as compared to pts with ST dev < 15 mm. For further results see table (numbers 
are percentages or p-values).
Conclusion: Although cumulative ST dev predicts left ventricular function and outcome in 
all pts undergoing primary angioplasty for AMI, the predictive value is stronger in pts with 
an anterior MI. The combined information of infarct location and extent of ST dev better 
predicts LVEF and clinical outcome as compared to ST dev alone. 
MI location Anterior P Non-anterior P
ST-dev (mm) < 15 > 15 < 15 >15
N 349 (62%) 217 (38%) 403(68%) 194(33%)
Success PCI 88% 89% ns 91% 90% ns
EF 40±11 35±10 <0.001 49±8 48±9 ns
1 yr mortality(%) 5 12 0.003 2 5 0.04
1061-218 The Baseline ECG in ST Elevation Myocardial Infarction 
Provides Powerful Prognostic Insight: Observations 
from ASSENT 2
Saleh Alghamdi, Yuling Fu, Shaun G. Goodman, Weiching Chang, Frans Van de Werf, 
Christopher B. Granger, Paul W. Armstrong, University of Alberta, Edmonton, AB, 
Canada, Duke Clinical Research Institute, Durham, NC
Background: The extent of ST segment elevation and anterior infarct location on 
admission ECG are associated with worse clinical outcomes in patients with ST elevation 
myocardial infarction (STEMI). The prognostic value of reciprocal ST depression has also 
been demonstrated in such pts. To date, little information exists regarding the utility of 
combining these 3 ECG variables beyond their individual prognostic value in predicting 
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adverse event. Accordingly, we undertook a study of 16,949 patients (ASSENT-2 trial) to 
examine this issue.
Methods: The baseline ECGs were evaluated centrally without knowledge of clinical 
outcome at the ECG core lab. Patients were classiﬁed into 8 groups based on the infarct 
location, the presence or absence of reciprocal ST depression, and the extent of ST 
elevation of 3mm or more, 1-2 mm in at least two limb leads or two contiguous precordial 
leads, respectively. Results: composite of outcome (30-day death, in-hospital shock/
CHF) of these groups are depicted in the ﬁgure.
Conclusion: This risk stratiﬁcation tool is simple and easy to use at the bedside, can 
help clinicians identify higher risk populations which will beneﬁt from more aggressive 
management strategies. Furthermore these data permit reﬁnement of pt selection that 
facilitates clinical trial planning in order to better evaluate sample size/ event ratios.
1061-219 Correlations of Infarct Size Assessed by Delayed 
Contrast Enhanced MRI After Primary PCI With Peak 
Levels of Plasma Creatine-Kinase, C-Reactive Protein 
and Time to Intervention
Juergen Haase, Torsten Sommer, Rusen Bayar, Matthias Hackenbroch, Claudia 
Piancatelli, Jule Thomas, Hans Störger, Franz Schwarz, Red Cross Hospital, Frankfurt, 
Germany, University of Bonn, Bonn, Germany
Background: We investigated the relationship between size of myocardial infarctions 
assessed by delayed contrast-enhanced MRI after primary PCI, elevation of plasma creatine-
kinase (CK), c-reactive protein (CRP), and the time from onset of symptoms to intervention.
Methods: Four to 10 days after immediate PCI in 45 acute STEMI patients (<24h) with 
stenting of the infarct-related artery and treatment with abciximab (i.c. bolus injection 
of 0.25mg/kg), we performed gadolinium contrast-enhanced 3D inversion recovery 
gradient-echo MR sequences with complete coverage of the LV-myocardium in short axis 
slices. The mass of infarcted tissue based on the volume of hyperenhanced myocardium 
was calculated and linear regression analysis was performed to assess the correlation 
between absolute size of infarctions (g) as well as relative size (LV%) with peak values of 
CK (U/l), CRP (U/l), and time to PCI (h).
Results: There was a signiﬁcant correlation between absolute size of infarctions (g) and peak 
CK-values (r=0.72; p<0.001) as well as the relative size (LV%) and peak CK (r=0.77; p<0.001). 
No correlations were found between absolute size (r=0.33) as well as relative size (r=0.27) of 
infarctions and peak CRP. There was also no correlation between absolute (r=0.29) as well as 
relative size of infarctions (r=0.27) and the time from onset of symptoms to PCI.
Conclusions: In patients with acute STEMI (<24h) undergoing immediate PCI with 
stenting and treatment with abciximab, peak CK values correlated well with infarct size as 
assessed by delayed contrast-enhanced MRI. There were no correlations between infarct 
size and peak CRP as well as the time to intervention.
1061-220 ST Resolution after Mechanical Reperfusion Closely 
Correlates With Myocardial Salvage And Depends 
on The Severity of Area at Risk Assessed By 99mTc 
Tetrofosmin Imaging
Takeru Shiraki, Hitoshi Matsuo, Takatomo Watanabe, Shun-ichiro Warita, Tai Kojima, 
Takeshi Hirose, Makoto Iwama, Koji Ono, Haruki Takahashi, Tomonori Segawa, Yukihiko 
Matsuno, Sachiro Watanabe, Gifu Prefectural Gifu Hospital, Gifu, Japan
Background: Early resolution of ST-segment elevation is an indicator of ﬁnal infarct size 
and clinical outcomes. However, the relationship between the degree of ST resolution 
and the indexes derived from perfusion scintigraphy such as area at risk(AAR), infarct 
size(IR), and salvaged myocardium(SI) is unclear.
Methods : Consecutive 65 patients with anteroseptal myocardial infarction with successful 
mechanical reperfusion, whose AAR, IS, and SI could be assessed by myocardial 
perfusion imaging, were studied. Serial 12 leads electrocardiograms were performed at 
baseline, 90 minutes after reperfusion. ST resolution was deﬁned as complete (≥70%, 
n=16), partial (<70% to 30%, n=36), or no resolution(<30%, n=13).
Results : Patients with no resolution group tended to be longer time to reperfusion 
(complete: 4.0±7.5 partial: 6.5±8.2 No: 7.4±6.6). Peak CPK inversely correlated with level 
of ST resolution(complete:1689±1395 partial:3078±2577 No:5252±2537 p<0.01).. As for 
the scintigraphical indexes such as AAR, IR, and SI, all these indexes had signiﬁcant 
association with the level of ST resolution(AAR: complete 114±54 partial 145±58 no 
178±51 p<0.05, IS:complete 21±26 partial 66±60 no 131±31 p<0.001, SI: complete 
81.9±16.2 partial 57.6±29.4 no 27.7±23.9 p<0.001)
Conclusion : Early resolution of ST-segment elevation closely correlated with AAR, IS, 
and SI as assessed by scintigraphy. These data validates the use of ST resolution as 
assessment of efﬁcacy of reperfusion therapy. 
1061-221 New Left Bundle Branch Block (LBBB) in Acute 
Myocardial Infarction (AMI) - A Strong Predictor of 
Death Both In-Hospital and in Early Follow-Up
Mircea Petrina, Jianming Fang, Fadi Saab, Richard Otten, Amisha Patel, David F. 
Armstrong, Kim A. Eagle, University of Michigan Cardiovascular Center, Ann Arbor, MI
Background: Much of the recent literature on LBBB complicating AMI has come from 
clinical trials testing reperfusion strategies in ST elevation AMI and has primarily examined 
in-hospital outcomes.
Methods: We studied 1,154 consecutive patients admitted to the University of Michigan 
Cardiovascular Center between January 1999 and August 2003 to asses the incidence 
of LBBB in all forms of AMI and their correlation with comorbid conditions, treatment and 
outcomes, in-hospital and at six months follow-up. Patients with and without new LBBB 
on the index ECG were compared using chi-square test for binary and Students’ t-test for 
continuous variables.
Results (see table): 84 (7.3%) patients had new LBBB; they were older and had higher 
frequencies of DM, HTN, prior AMI, prior CHF and renal insufﬁciency, but received similar 
rates of coronary revascularization and evidence-based medicine as non-new LBBB 
patients. Patients with LBBB were three times more likely to die in the hospital and at six 
months, with an overall admission to six-month mortality of 31/84 (37%).
Conclusion: Patients who develop LBBB in the setting of AMI have worse comorbidities 
and in-patient and six-month outcomes compared to non-new LBBB patients. The striking 
mortality after discharge argues for a careful look to see if such patients may beneﬁt from more 
intensive treatments including revascularization and/or implantable deﬁbrillator or biventricular 
pacemaker in addition to maximized evidence-based therapies and rehabilitation.
Table 
Variable LBBB (n=84) No-LBBB (n=1,070) P value
Mean Age 72±12 65±14 <0.0001
Prior AMI 49 (59%) 401 (37%) 0.0001
Prior CHF 41 (49%) 208 (20%) <0.0001
Diabetes Mellitus 37 (44%) 332 (31%) 0.0147
STEMI 35 (42%) 195 (18%) <0.0001
Killip Class (2-4) 23 (27%) 155 (14%) 0.0018
PCI/CABG 38 (45%) 486 (45%) NS
Death (in-hospital) 11 (13%) 48 (4%) 0.0006
Death (6-months) 20 (29%) 82 (9%) <0.0001
1061-222 Decreased D-dimer Levels Indicate Reduced Risk of 
New Ischemic Events After a Myocardial Infarction - 
Beneﬁcial Effects of Ximelagatran
Christina Christersson, Jonas Oldgren, Anders Bylock, Agneta Siegbahn, Lars 
Wallentin, Uppsala University, Uppsala, Sweden
Background: The ESTEEM trial demonstrated that long-term treatment with the ﬁrst oral direct 
thrombin inhibitor ximelagatran reduced the risk of new ischemic events after a myocardial 
infarction, but without any differences between the four evaluated doses. We related the change 
in D-dimer levels, a marker for ﬁbrin turnover, to the risk of new ischemic events.
Methods and Results: Patients were randomized, at 6 days (mean) after a myocardial 
infarction, to one of four doses of ximelagatran (n=294) or placebo (n=153) together with 
aspirin 160 mg for six months. D-dimer was measured at randomization and after 1 week 
on treatment. In the placebo group 49% of the patients had reduced D-dimer levels after 
1 week compared to 80% in the ximelagatran group (p<0.001). The cumulative rate of 
myocardial infarction, severe recurrent ischemia, ischemic stroke or death at six months 
was 19.7 % in patients with unchanged/increased and 11.5 % in patients with decreased 
D-dimer levels (p=0.01).
Conclusion: Ximelagatran proved to be highly effective in reducing the D-dimer levels in 
patients with a recent myocardial infarction. Early reduced D-dimer levels were related to 
decreased risk of new ischemic events.
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1061-224 Use of Reperfusion Therapy in Elderly Patients with 
Acute Myocardial Infarction
Jeptha P. Curtis, Saif S. Rathore, Yongfei Wang, Mikhail Kosiborod, Joanne M. Foody, 
Frederick A. Masoudi, Harlan M. Krumholz, Yale University School of Medicine, New 
haven, CT, University of Colorado Health Sciences Center, Denver, CO
Background: Although both ﬁbrinolytic therapy and primary PCI improve survival of 
patients with ST-elevation myocardial infarction (STEMI), potential bleeding complications 
limit the number of patients who can safely receive ﬁbrinolytic therapy. Whether the 
availability of primary PCI increases the proportion of STEMI patients who receive 
reperfusion therapy is not known.
Methods: In two national cohorts of 31,339 and 31,759 elderly patients hospitalized 
between 1998-9 and 2000-1 with conﬁrmed AMI, we identiﬁed STEMI patients (n=7,777) 
who presented within 12 hours of symptom onset. To investigate how the availability of 
primary PCI expands the pool of patients receiving reperfusion therapy, we included 
patients who were not ideal candidates for reperfusion therapy. Patients were divided 
into those who presented to hospitals with PCI capability (n=3,317), hospitals with a 
cath lab but not PCI capable (n=2,599), and hospitals with no cath laboratory (n=1,861). 
We determined rates of reperfusion within 12 hours of admission and compared use of 
reperfusion therapy across hospital type.
Results: Overall, only 2,687 (35.6%) patients received reperfusion therapy, with 1,561 
(20.1%) receiving ﬁbrinolysis and 1,206 (15.5%) undergoing primary PCI. A higher 
proportion of patients received reperfusion therapy at PCI capable hospitals compared 
with patients treated at cath lab only hospitals or hospitals without cath capability (48.2%, 
24.5%, and 24.2% respectively, p<0.01).
Conclusions: The proportion of elderly patients with STEMI who receive reperfusion 
therapy is low. The availability of primary PCI is associated with increased use of 
reperfusion therapy.
1061-225 The Inﬂuence of Gender on Survival Following 
Angioplasty for Acute Myocardial Infarction: A Report 
From the New York State Coronary Angioplasty 
Reporting System Database
Jeffrey S. Berger, David L. Brown, Beth Israel Medical Center, New York City, NY
Background: Previous studies have shown that women treated with primary angioplasty 
for acute myocardial infarction (AMI) have a greater morbidity and mortality than men. 
However, it is not clear if the survival disadvantage for women has persisted into a more 
contemporary era of percutaneous revascularization characterized by widespread use of 
stents deployed at high pressures and potent anti-platelet therapies. We therefore sought 
to determine whether gender inﬂuenced short-term outcomes in a cohort of AMI patients, 
all of whom underwent angioplasty. 
Methods: We conducted a retrospective cohort study of all patients undergoing 
angioplasty within 24 hours of an AMI in New York State between 1997 and 1999. No 
patients were excluded. The primary end point was in-hospital mortality. 
Results: A total of 9,015 patients, 2,619 women and 6,396 men, were identiﬁed. Women 
were signiﬁcantly older than men (66±13 years vs. 59±12 years, P<0.01) and had a higher 
prevalence of hypertension (64% vs. 52%, P<0.01), diabetes (23% vs. 15%, P<0.01) and 
peripheral vascular disease (8.1% vs. 5.0%, P<0.01). Women presented more frequently 
with heart failure (15% vs. 9%, P<0.01), pre-shock (6.3% vs. 5.1%, P<0.01) and shock 
(5.8% vs. 3.1%, P=0.02) than men. Ejection fraction was 46% in women and 47% in men 
(P=NS). Stent use was less common in women than men (76% vs. 79%, P=0.001). There 
was no difference in glycoprotein IIb/IIIa inhibitor use between groups. The unadjusted 
in-hospital mortality rate was 6.7% in women and 3.4% in men (P<0.01). After multivariate 
logistic regression analysis, female gender was not a signiﬁcant predictor of in-hospital 
death (Odds Ratio 0.629, 95% conﬁdence interval 0.249-1.589, P=0.327). 
Conclusion: Women have a higher unadjusted mortality following angioplasty for AMI 
than men. However, after adjustment for their higher risk characteristics, female gender 
is not an independent predictor of in-hospital mortality among women undergoing 
angioplasty following for AMI in the contemporary era.
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1062-223 Sustained Prognostic Power of NT-proBNP during 
Hospitalization for Acute Coronary Syndromes.
Mads Riiskjær, Kristian Thygesen, Bjarne Nørgaard, Jens Refsgaard, Lene Heickendorff, 
Aarhus University Hospital, Aarhus, Denmark
Background: An elevated level of N-terminal proBNP (NT-proBNP) indicates increased risk in 
patients with acute coronary syndrome (ACS). However, the optimal timing for determination 
of NT-proBNP during hospitalization as regards risk prediction has not been well established.
Methods: This investigation included 494 patients with unstable angina or non-STEMI. 
Study inclusion was within 24 hours of the latest episode of angina. NT-proBNP and 
CK-MB mass (cutoff: 10 µg/L), TnT (0.10 µg/L) and TnI (2.0 µg/L) were measured on 
blood samples drawn at 0, 6, 12, 24, 36, 48, 72, and 96 hours after admission. All events 
regarding the composite endpoint (death and acute myocardial infarction) during the 
follow-up of 30 days, were adjudicated by an independent Endpoint Committee.
Results: The study shows that patients in the upper quartile (n=124), based on the 
admission NT-proBNP values, had an absolute risk of the composite endpoint of 23.4% 
(15.9-30.8%). That is a 7.8-fold increase as compared to patients with NT-proBNP 
values in the ﬁrst, second and third quartiles (n=370). Furthermore, when comparing 
simultaneously drawn samples of NT-proBNP, CK-MB mass, TnT and TnI by multivariate 
analysis, NT-proBNP was consistently the most powerful risk predictor within 96 hours 
after admission for ACS (Figure). 
Conclusions: NT-proBNP has sustained prognostic power within 96 hours after admission 
for ACS, and when compared to speciﬁc, cardiac, necrosis markers, NT-proBNP is 
consistently the most powerful risk predictor.
1062-226 Value of Serial Measurement of B-type Natriuretic 
Peptide in Patients with Acute Coronary Syndrome: 
An AtoZ Substudy
David A. Morrow, James A. de Lemos, Michael A. Blazing, Petr Jarolim, Marc S. 
Sabatine, Sabina A. Murphy, Joanne Palmisano, Harvey D. White, Keith A. A. Fox, 
Robert M. Califf, Eugene Braunwald, Brigham & Women’s Hospital, Boston, MA, Duke 
University Medical Center, Durham, NC
Measured early after presentation with an acute coronary syndrome (ACS), B-type 
natriuretic peptide (BNP) is a potent indicator of the risk for death or development of 
heart failure (CHF). However, few data are available with respect to the value of 
serial measurements for incremental assessment of risk and the response to therapy. 
METHODS: We measured the plasma concentration of BNP (Bayer Centaur) after initial 
stabilization of ACS (median 3.5 days), and at 4 months in 4273 patients with UA/NSTEMI 
or STEMI enrolled in the Aggrastat to Zocor Trial. A decision-limit of 80 pg/mL was pre-
speciﬁed based on prior work. Outcomes were followed through end-of-study (median 
2 yrs). RESULTS: Patients with baseline BNP >80 pg/ml (“High”, n = 609, 14%) were at 
signiﬁcantly higher 2-year risk of death (HR 2.8; 95% CI 2.1 - 3.7) and death or CHF (HR 
3.2; 95% CI 2.5 - 4.0). Similarly, BNP measured at 4 months was strongly associated with 
subsequent risk of death (HR 4.3; 95% CI 2.6-7.1) and death or CHF (Figure Left, HR 5.1; 
95% CI 3.4-7.6) in patients who were free of events up to four months. Categorized by 
change in BNP (baseline to 4 mo), patients with persistent or new elevation in BNP were 
at signiﬁcantly higher risk than those with persistently low or falling BNP (Figure, Right). 
CONCLUSIONS: Re-assessment of BNP 4 months after presentation with ACS may be 
used to enhance risk assessment for secondary prevention and may provide a basis for 
monitoring the response to therapies effective in modifying the risk of death and CHF.
1062-227 One-Year Rehospitalization and Mortality Rates After 
Hospitalization for Acute Coronary Syndrome.
Stephen Sidney, Michael Sorel, Charles P. Quesenberry, Jr., Patrick L. McCollam, Kaiser 
Permanente Medical Care Program, Oakland, CA, Global Health Outcomes, Eli Lilly and 
Company, Indianapolis, IN
Background: Prevalence estimates of acute coronary syndrome (ACS) vary considerably and 
few data are available on longer-term (e.g., 1-year) outcomes of persons hospitalized for ACS.
Methods: We included patients age > 40 years of the Kaiser Permanente Medical 
Care Program, an integrated health care program, who were hospitalized with an ACS 
diagnosis from 1/1/99-12/31/00. Co-morbidities (hypertension (HTN), hyperlipidemia, 
diabetes mellitus (DM)) were assessed for 6 months prior to hospitalization, and re-
hospitalizations and mortality were assessed for 1-year after the index event.
Results: There were 14,852 patients hospitalized for ACS (7,919 for myocardial infarction (MI), 
6,933 for unstable angina (UA)) representing an incidence of 5.7 cases/1,000 person-years. 
During the ﬁrst year after the index event, re-hospitalization occurred in 13.5% of patients for 
MI, 17.2% for UA, and 38.5% for all coronary heart disease; revascularization was performed 
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in 16.8%. One-year all-cause mortality was 17.2%. Male gender, HTN and DM were associated 
with ACS re-hospitalization (see table). However, acute MI and UA had different associations most 
notable for age and hyperlipidemia. HTN was associated with re-hospitalization for UA only.
Conclusions: Hospitalization for ACS was associated with substantial 1-year re-
hospitalization and mortality. Risk factors for re-hospitalization for MI and UA differ, 
possibly reﬂecting differences in disease severity or pharmacological treatment.
Relative risk of re-hospitalization in the 12 months after  
an ACS event, multivariable analysis 
Demographics 
& prevalence of 
risk factors
Referent group ACS MI Unstable angina
RR (95% CI) RR (95% CI) RR (95% CI)
Age
mean 67.2 + 
12.0 yrs
<65 years old 0.98 (0.92, 1.04) 1.16 (1.06, 1.27) 0.88 (0.82, 0.96)
Gender 63.9% 
male female 1.10 (1.03, 1.17) 1.01 (0.92, 1.11) 1.14 (1.05, 1.24)
Hypertension




hyperlipidemia 1.04 (0.98, 1.12) 0.68 (0.61, 0.76) 1.40 (1.29, 1.52)
Diabetes mellitus 
34.9% without diabetes 1.15 (1.08, 1.23) 1.26 (1.15, 1.38) 1.14 (1.05, 1.23)
1062-228 Early Aggressive Versus Conservative Managment 
On One Year Outcome In Octogenarians Patients With 
Unstable Angina And Non-St-Elevation Myocardial 
Infarction.
Fabio Alfredo Sgura, Elisa Guerri, Roberto D’amico, Emilio Chiurlia, Rosario Rossi, 
Chiara Leuzzi, Maria Grazia Modena, Institute of Cadiology of Modena and Reggio 
Emilia, Modena, Italy
BACKGROUND: Although increasing age is an important risk factor for adverse 
outcome among patients with acute coronary syndromes, elderly patients are more often 
managed conservatively. The goal of our study was to examine, at one year, the outcome 
in patients over 80 years old treated with aggressive management (AM) compared with 
the conservative management (CM).
METHODS: At our institution from January 2000 to April 2003, a total of 396 consecutive 
octogenarians patients were admitted to coronary care unit for Unstable Angina and Non-
ST-Segment Elevation (UA/NSTEMI). Aggressive therapy at 4 to 48 hours vs. conservative 
therapy was analyzed to identify the prognostic factors of mortality. Multivariate analysis 
was performed to evaluated prognostic factors of 1 year survival.
RESULTS: 128 (32%) our patients underwent AM and 268 (68%) received CM. CM had 
higher heart rate at admission (80.2±20.3 vs. 74.5±18.3, p=0.007), lower systolic blood 
pressure (130.5±22.7 vs. 138.2±23.6, p=0.0019), lower creatinine clearance (47.2±22.2 
vs. 55.4±20.6, p= 0.005), creatinine greater than 1.5 mg/dl (31% vs.15% p<0.0001), and 
less anemia (54% vs. 41%, p= 0.015). Gender female, diabetes, hypertension, previous 
MI and TIMI risk score were similar in both groups. After one year of follow up, cardiac 
mortality was 2% in AM and 22% in CM, respectively (p<0.001). Multivariate analysis 
identiﬁed the aggressive treatment as a factor that reduced the odds of mortality of than 
56% (95% CI from 19% to 93%, OR=42%,).
CONCLUSION: This study demonstrated a signiﬁcant difference in mortality regarding 
octogenarians patients treated with aggressive versus conservative therapy. The early 
invasive strategy may signiﬁcantly improve outcome and survival in very old patients with 
NSTEMI Acute Coronary Syndrome.
1062-231 C-reactive Protein Level on Presentation Predicts In-
hospital and Long-Term Mortality in Patients with ST 
elevation Acute Myocardial Infarction in Reperfusion 
Era - From the Heart Institute of Japan Acute Myocardial 
Infarction (HIJAMI) Registry -
Haruki Sekiguchi, Junichi Yamaguchi, Kentaro JuJo, Michitaka Nagashima, Tomohiro 
Kurihara, Yasuhiro Ishii, Atsushi Takagi, Yukio Tsurumi, Hiroshi Ogawa, Hiroshi 
Kasanuki, *for the HIJC Investigators, Tokyo Women’s Medical University, Tokyo, Japan
Backgroud: The inﬂuence of CRP elevation on prognosis in patients with ST elevation 
acute myocardial infarction (STEMI) in recent reperfusion era remains to determine. The 
purpose of this study was to evaluate the impact of the CRP elevation on in-hospital 
and long-term mortality in patients with STEMI. METHODS: From 1999 to 2001, 2363 
consecutive STEMI patients were prospectively registered in Heart Institute of Japan 
Acute Myocardial Infarction (HIJAMI) registry, multi-center, observational cohort study 
investigating real-world treatment practice for AMI in reperfusion era in Japan. We 
analyzed in-hospital and long-term mortality in these patients on the basis of CRP level on 
presentation. The study population was divided into three groups (lowest tertile: <1.0mg/
dl, middle tertile: 1.0 <, < 3.0mg/dl, highest tertile: 3.0mg <). RESULTS: The lowest tertile 
included 1817 patients (76.9%), the middle and highest tertile included 287 patients 
(12.1%) and 259 patients (11.0%), respectively. Unvariate analyses showed statistical 
differences among three groups in age, hyperlidemia, peak creatine kinase, time from 
onset to admission, reperfusion therapy and Killip class. The results of multivariate 
analysis is shown below. During mean follow-up periods of 29 months, the event free 
survival rate was lower in the highest and middle tertile than the lowest tertile (p<0.0001). 
CONCLUSIONS: The CRP level is an independent predictor of in-hospital and long-term 
mortality in patients with STEMI. 
1062-232 Primary Percutaneous Coronary Interventions: 
Predictors of One-year Mortality Among Patients 
Surviving 30 days.
Rajendra H. Mehta, William O’Neill, Kishore J. Harjai, Judy Boura, David Fox, Bruce 
Brodie, Gregg Stone, Cindy L. Grines, On Behalf of the STENT-PAMI and CADILLAC 
Investigators, Duke Clinical Research Institute, Durham, NC, William Beaumont 
Hospital, Royal Oak, MI
Background: Little information exists on factors inﬂuencing the long-term prognosis 
of patients (pts) with ST elevation myocardial infarction (STEMI) treated with primary 
percutaneous coronary intervention (PCI) who survive the acute phase. 
Methods: Accordingly, we examined 3280 pts with STEMI enrolled in Stent-PAMI and 
CADILLAC trials treated with primary PCI and who survived beyond 30-days of their STEMI. 
Results: Death at 1-year occurred among 74 pts (2.3%) who survived beyond 30-days of their 
index STEMI. Univariate associations of the risk of death are shown in Table. Cox Proportional 
Hazard Model identiﬁed: Age >70 years (odds ratio [OR] 3.3 95% conﬁdence interval [CI] 1.7-
5.7); weight <80 Kg (OR 1.9, 95% CI 1.1-3.6); any tachyarrhythmia during index hospitalization 
(deﬁned as ventricular tachycardia/ﬁbrillation or supraventricular tachycardia requiring 
treatment, OR 2.4, 95% CI 1.2-4.8); number of diseased coronary arteries (OR 1.5, 95% CI 
1.1-2.1); and left ventricular ejection fraction (each 10% increase, OR 0.68, 95% CI 0.55-0.86) 
as factors independently associated with risk of 1-year death among 30-day survivors (Model 
C-statistic=0.77, Hosmer Lemeshow Chisquare=13, degrees of freedom=8, p=0.12). 
Conclusions: Our study provides a method for clinicians to advice patients treated with 
primary PCI surviving the acute phase of their STEMI regarding their long-term prognosis, 
thereby enhancing planning and setting up of realistic expectations.
Table 
Clinical factors Alive-1 year, N=3206
Dead-1 






year, N=74 P value
Age>70 682 (21%) 41 (55%) <0.0001 Ejection fraction 49+12 42+14 <0.0001
Weight (Kg) 82+16 76+19 <0.0001 Final TIMI ﬂow <3 179 (5.6%) 9 (12.2%) 0.022
Females 818 (26%) 28 (38%) 0.017 In-hospital events
Prior stroke 111 (3.5%) 6 (8.1%) 0.047 Stroke 12 (0.4%) 2 (2.7%) 0.038
Sum ST elevation (mm) 4.2+2.0 5.2+1.9 0.020 Intubation 8 (0.3%) 2 (2.7%) 0.020
Angiographic factors Pulmonary complications 11 (1.4%) 2 (15%) 0.016
3 vessel disease 506 (15.8%) 26 (35.1%) <0.0001 Vasopressor support 73 (2.6%) 5 (8.3%) 0.022
LAD Infarct 1211 (38%) 41 (55%) 0.0020 Tachyarrhythmia 247 (9%) 13 (22%) 0.0005
POSTER SESSION
1063  Chronic Ischemic Heart Disease:  
Stress Testing
Monday, March 07, 2005, 9:00 a.m.-12:30 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 10:00 a.m.-11:00 a.m.
1063-229 Does a Gradual Exercise Test (Ramp) Attenuate 
Myocardial Ischemia?
Martin Noël, Jean Jobin, Paul Poirier, Gilles R. Dagenais, Peter Bogaty, Institut 
Universitaire de Cardiologie et de Pneumologie de l’Hôpital Laval, Ste-Foy, PQ, Canada
Background: In patients with ischemic heart disease (IHD), it is accepted that the heart 
rate x systolic blood pressure product (RPP) at 1 mm ST depression [ischemic threshold] 
is relatively reproducible on the Bruce protocol treadmill. Would ischemic threshold (IT) be 
higher because of a warm-up effect on a more progressive exercise protocol?
Methods: We compared ischemic parameters on the Bruce protocol treadmill with a ramp 
protocol ergocycle in 18 patients with documented IHD (≥ 70% stenosis) and a previous 
ischemic exercise test. These 2 symptom-limited tests were performed in random order 
2 weeks apart. Respiratory gases, ECG and blood pressure were monitored. The IT and 
maximum ST depression corresponding to the highest RPP common to the 2 tests (Max 
STD) were determined.
Results: While all subjects showed ischemia on the treadmill, 6/18 did not on the 
ergocycle. Despite greater peak RPP and comparable exercise intensity (VO2) at 1 mm ST 
depression and peak exercise, IT was higher and max STD was lower on the ergocycle. 
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Peak VO2 (mlO2* min
-1 * kg-1) 26.76 ± 4.54 25.67 ± 5.43 P<0.05
Peak RPP 25781 ± 6385 28015 ± 6731 P=0.02
Max STD (mm) 1.8 ± 0.9 1.1 ± 0.9 P=0.003
* Peak RPP substituted for IT in the 6 patients with no ischemia on the ergocycle.
Conclusion: Exercise-induced myocardial ischemia is markedly attenuated on the ramp 
ergocycle compared to the Bruce protocol treadmill, an effect unexplained by exercise 
intensity (VO2) or cardiac work (RPP). The more gradually increasing workload of the 
ramp ergocycle protocol may have favoured a “warm-up” ischemic effect despite achieving 
higher RPP than the Bruce protocol treadmill suggesting it may be physiologically 
preferable for exercise prescription in patients with IHD.
1063-230 Long-term Prognostic Value of Dobutamine-atropine 
Stress Echocardiography in 3800 Patients
Boudewijn J. Krenning, Jeroen J. Bax, Elena Biagini, Vittoria Rizzello, Arend F.L. 
Schinkel, Miklos D. Kertai, Olaf Schouten, Ron T. van Domburg, Maarten L. Simoons, 
Don Poldermans, Thoraxcenter, Rotterdam, The Netherlands
Background: Dobutamine-atropine stress echocardiography (DSE) is increasingly used 
to assess the long-term prognosis in patients with proven or suspected coronary artery 
disease. The aim of this prospective study was to investigate the incremental prognostic 
value of DSE for assessment of long-term prognosis.
Methods: Clinical data and DSE results were evaluated in 3,800 patients undergoing 
DSE between 1989 and 2002. Patients were followed for a mean of 6±4 years (range 
0.5-14 year); those who underwent revascularization within 3 months (n= 217) were 
excluded, 50 patients were lost-to follow-up. The value of DSE in predicting cardiac events 
(cardiac death and MI), clinical and DSE data were analyzed using a multivariable Cox 
proportional-hazards model.
Results: In 1255 patients with a normal DSE, cardiac events occurred in 17% during 10 
year follow-up (Figure). 406 of 1691 patients (24%) with stress-induced ischemia suffered 
an cardiac event. However, extensive ischemia was associated with an increased risk 
of 5% for every ischemic segment. Both rest and new wall motion abnormalities were 
present in 1513 (42%). A rest wall motion score > 1.7 is associated with a 2-fold increased 
risk of late cardiac events.
Conclusion: A normal DSE has a relatively good cardiac prognosis. DSE results, such as 
rest wall motion score and number of ischemic segments provide important information 
for predicting subsequent cardiac events.
 
1063-233 The Incidence of Gastro-Esophageal Disease in the 
Patients with Normal or Minimal Coronary Artery 
Disease
Chang-Wook Nam, Kee-Sik Kim, Seung-Ho Seung-Ho Hur, Seong-Wook Han, Yoon-
Nyun Kim, Young-Soo Lee, Sang-Hoon Lee, Young-Soo Lee, College of Medicine, 
Keimyung University, Daegu, South Korea
BACKGROUND The stomach and esophagus may be the origin of chest pain clinically 
indistinguishable from that of myocardial ischemia. When the coronary angiogram shows 
normal or minimal lesion, motility studies are important for adequate diagnosis.
OBJECTIVES This study investigated the identiﬁcation of gastro-esophageal disease in 
patients with chest pain and showing negative coronary angiogram. 
METHODS 126 patients (male 42, 33.3%) who showed negative coronary angiogram 
with typical chest pain were included. All patients underwent UGI endoscopy, and most of 
them were performed Berstein test and esophageal manometry. 
RESULTS Among the 126 patients, clinically stable angina was in 109 (86.5%). Stress 
teat was done in 84 (66.7%; positive 53, 63.1%). Endoscopical ﬁnding was normal or 
nonspeciﬁc gastritis in 78 patients (62.5%), erosive gastritis in 18 (14.3%), gastric ulcer 
in 5 (4.0%), duodenal ulcer in 7 (5.6%), reﬂux esophagitis in 17 (13.5%). One case of 
stomach cancer was detected during endoscopy. Berstein test was done in 122 patients. 
Positive result was 68 patients (55.7%). 59 (48.4%) of them was non-erosive reﬂux 
disease. Esophageal manometry was done 121 patients. 35 patients (28.9%) of them 
had motility disorders. Nutcracker esophagus was in 24 patients (19.8), nonspeciﬁc 
esophageal motility disorder in 5 (4.1%), hypertensive lower esophageal sphincter in 
3 (2.5%). Among the 53 patients of positive cardiac stress test with negative coronary 
angiogram (clinically corresponded to microvascular angina), 46 patients (86.8%) showed 
abnormal ﬁndings in gastro-esophageal studies. 
CONCLUSIONS In our study, 107 (84.9%) of patients with chest pain and showing 
negative coronary angiogram revealed positive result of gastric or esophageal disease. 
In spite of existing microvascular anginal evidence, it will be more advisable to perform 
gastro-esophageal studies.
1063-234 Stress Myocardial Scintigraphy and Dobutamine 
Echocardiography in the Detection of Coronary Disease 
in Asymptomatic Patients with type 2 Diabetes.
Claude Le Feuvre, Olivier Barthélémy, Danielle Dubois, Christophe Maunoury, Agnès 
Mogenet, Gérard Helft, José Timsit, Jean Philippe Metzger, AP-HP, Paris, France
The most appropriate test to detect silent myocardial ischemia (SMI) in diabetic patients 
unable to perform an exercise test is unknown, and few data are available on the long-term 
outcome after aggressive therapy of SMI. This prospective study aimed: (1) to compare 
stress thallium-201 single photon emission computed tomography (SPECT) and dobutamine 
echocardiography (DE) in the detection of SMI in asymptomatic high risk diabetic patients; 
(2) to analyse long-term outcome after intensive care of SMI in these patients.
SPECT was performed in 100 high risk diabetic patients and DE in the ﬁrst 75 patients. 
Coronary angiography was realized in patients with SMI, with systematic revascularization 
for suitable lesions. Intensive treatment of atherosclerosis risk factors was performed in all 
patients. Patients were followed 2+/-0.5 years for the subsequent occurrence of cardiac 
death, myocardial infarction and revascularization.
SMI was detected by SPECT in 62% and by DE in 10% of the patients (p < 0.0001), 
whereas signiﬁcant coronary stenosis at angiography was detected by SPECT in 26% 
and by DE in 5% of the patients (p < 0.02). Independent predictive factors of signiﬁcant 
coronary stenosis were male gender (p < 0.03) and peripheral arterial disease (p < 0.007). 
Nonfatal myocardial infarction occurred during follow-up in 2 patients (2%). Subsequent 
revascularization procedure was needed in 9 patients. Baseline patients’ characteristics, 
as well as stress test results, were not predictive of cardiac event during follow up.
Conclusions: SPECT seems more accurate than DE to detect signiﬁcant coronary 
stenosis in high risk asymptomatic diabetic patients. In this population, aggressive 
treatment of SMI with systematic revascularization combined with intensive care of risk 
factors is associated with a favourable long-term prognosis.
1063-235 Prognostic Value Of hsCRP In Patients With Stable 
Coronary Disease And Angina Of Effort, Univariately 
And In The Presence Of N-terminal BNP And Other Risk 
Factors
Ian Ford, Michele Robertson, David Gaze, Henry J. Dargie, Lisa Garrison, Paul Collinson, 
University of Glasgow, Robertson Centre for Biostatistics, Glasgow, United Kingdom
Background: The independence of the relationship between hsCRP and outcome in 
coronary heart disease has recently been questioned.
Methods: We investigated the association between hsCRP and occurrence of coronary 
events or all-cause mortality in the IONA clinical trial Biobank sub-study (BIONA) of 
nicorandil versus placebo in patients with stable coronary disease and angina of effort. 
1505 patients were included in the sub-study of whom 90 had a non-fatal MI or died 
from CHD causes and 90 died from any cause after an average follow-up of 1.6 years. 
The associations between prognostic factors and outcomes were investigated using Cox 
proportional hazards models, ﬁrst for the logarithm of hsCRP levels (log mg/L) and then 
after adjusting for other cardiovascular risk factors and for the logarithm of N-terminal pro 
BNP levels (log pg/mL). Models were adjusted for randomised treatment allocation.
Results: Estimated hazard ratios and 95% conﬁdence intervals are given below.
 






treatment logCRP (1 unit) 1.23(1.02,1.48) 0.032
CHD death/non-
fatal MI














logCRP (1 unit) 1.14(0.94,1.39) 0.189
All cause mortality LogCRP/randomized treatment logCRP (1 unit) 1.42(1.18,1.71) 0.0002
All cause mortality













logCRP (1 unit) 1.33(1.09,1.63) 0.005
Conclusions: hsCRP levels were signiﬁcantly univariately associated with both coronary 
outcomes and all-cause mortality. The strength of the association was attenuated after 
adjusting for traditional risk factors and for NT proBNP, becoming non-signiﬁcant for coronary 
events but not all-cause mortality. This study conﬁrms the importance of NT proBNP as 
an important independent risk factor for coronary events and for all cause mortality and 
suggests that hsCRP carries additional prognostic value, at least for the mortality outcome.
1063-236 Serum Level of SAA/LDL Complex in Stable and 
Unstable Coronary Artery Disease
Ayumi Goda, Ken Ogasawara, Shinichi Mashiba, Hideki Hashimoto, Kazuo Uchida, 
Tadanori Aizawa, Long-Tai Fu, The Cardiovascular Institute, Tokyo, Japan, Teikyo 
University School of Medicine, Tokyo, Japan
OBJECTIVE: Previously we reported that a serum amyloid A (SAA) and LDL complex 
(SAA/LDL) which is derived by oxidative interaction between SAA and lipoproteins at the 
vascular site in atherosclerotic process can be a novel prognostic marker in patients with 
stable coronary artery disease (CAD). In the present cross-sectional study we attempted to 
determine the relationship between the serum level of SAA/LDL and stable/unstable angina.
METHODS: Consecutive 428 patients who underwent coronary angiography were 
enrolled. Serum levels of lipoproteins, CRP, SAA and SAA/LDL were measured in each 
subject. SAA/LDL was assayed by newly developed ELISA method.
2005_5_MyocaIschInfartion.indd   212 12/23/04   10:07:12 AM
Enfocus Software - Customer Support




RESULTS: The patients consisted of 36 with unstable angina (UA), 252 with stable CAD 
(ST) and 140 without CAD (CON). The values of inﬂammatory markers expressed as 
median (25th, 75th percentile) in each group are shown below.
UA(n=36) ST(n=252) CON(n=140)
CRP(mg/dl) 0.21 (0.11, 0.31) 0.09 (0.06, 0.15) 0.08 (0.06, 0.12)
SAA(µg/ml) 12.4 (6.1, 12.6) 4.2 (2.5, 7.1) 4.4 (2.7, 6.4)
SAA/LDL(µg/ml) 52.0 (36.8, 81.9) 20.5 (14.0, 30.4) 17.9 (11.8, 27.6)
By logistic regression analysis, SAA/LDL and CRP were independent and statistically 
signiﬁcant to predict CAD and to discriminate unstable angina (p=0,001~0.008) even 
after controlling for classical risk factors, while SAA was only marginal (p=0.047~0,076). 
ROC analysis showed that SAA/LDL was equivalent with CRP for the diagnosis of CAD 
(AUC=0.613,0.593, respectively. p>0.20), and that SAA/LDL was superior to CRP in 
discriminating unstable angina (AUC=0.838, 0.733, respectively, p=0.013).
CONCLUSION: The serum level of SAA/LDL can predict the existence of both CAD and 
unstable angina more accurately than CRP.
 
ORAL CONTRIBUTIONS
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803-3 Insulin Improves Myocardial Blood Flow in Patients 
With Type 2 Diabetes and Coronary Artery Disease
Riikka Lautamäki, K.E.Juhani Airaksinen, Marko Seppänen, Jyri Toikka, Matti Luotolahti, 
Ronald Borra, Jan Sundell, Juhani Knuuti, Pirjo Nuutila, University of Turku, Turku, 
Finland, Turku University Central Hospital, Turku, Finland
Background: Intense insulin therapy improves prognosis for type 2 diabetic patients 
(T2DM) with myocardial ischemia. Insulin infusion enhances myocardial blood ﬂow in 
healthy subjects. In this study, the effects of insulin on myocardial perfusion were studied 
in T2DM patients with coronary artery disease (CAD).
Methods: We studied the effects of insulin on myocardial blood ﬂow in regions of 
exercise-induced ischemia evaluated by SPECT and coronary artery stenosis conﬁrmed 
by coronary angiography, and in non-ischemic regions in 43 patients (age 63 +/- 7yrs) with 
T2DM (HbA1c 7.1 +/- 0.9%). Myocardial blood ﬂow was measured in the fasting state and 
during euglycemic hyperinsulinemic clamp at rest (n=43) and during adenosine-induced 
(140 µg/kg/min for 5min) hyperemia (n=26) using positron emission tomography (PET) 
and 15O-labelled water.
Results: In general, myocardial blood ﬂow was signiﬁcantly (P<0.05) attenuated in 
ischemic regions as compared to non-ischemic regions. At rest, insulin infusion increased 
myocardial blood ﬂow by 13% in ischemic regions (P=0.043) and by 22% in non-ischemic 
regions (P=0.003). During adenosine infusion, insulin enhanced myocardial blood ﬂow by 
20% (P=0.018) in ischemic regions, and by 18% (P=0.045) in non-ischemic regions.
Conclusions: Insulin infusion improves myocardial blood ﬂow similarly both in ischemic 
and non-ischemic regions in T2DM patients with CAD. Thus, the acute beneﬁcial effects 
of aggressive insulin therapy in these patients may be partly related to the improvement 
of blood ﬂow in ischemic regions of the myocardium.
9:30 a.m.
803-4 Comparison of Diabetics and Non-Diabetics with 
Chronotropic Incompetence During Dobutamine Stress 
Echocardiogram.
Shrikanth P. Upadya, Sheikh Mahfuzul Hoq, Siu-Sun Yao, Farooq A. Chaudhry, St. Luke’s-
Roosevelt Hospital, New York, NY, Yale University School of Medicine, Bridgeport, CT
Background: When patients do not reach 85% of the maximum predicted heart rate 
(MPHR) for the age during a dobutamine stress echocardiogram (DSE), frequently it is 
reported as a non-diagnostic test due to chronotropic incompetence (CI). In this study, we 
examined the role of DSE between diabetics (DM) and non-diabetics with CI.
Methods: We compared 329 DM to 708 non-DM patients referred for DSE. CI was deﬁned 
as an inability in attaining 85% of the maximum predicted heart rate for the age during 
DSE. Wall motion analysis was performed using a standard 16-segment model. Ischemia 
was deﬁned as new reversible wall motion abnormality and/or biphasic response. Five-
year follow up was obtained for MI and cardiac death and annual event rate calculated.
Results: CI was seen in 340 patients, 212 (29.9 %) non-DM and 128(38.9%) DM patients. 
Results of univariate analysis are as shown in the Table. By multivariate logistic regression, 
BSA (p=0.005), hyperlipidemia (p=0.01) and ischemia on DSE (odds ratio=2.3, p=0.01) 
were predictive of hard events. Annual hard events in non- DM and. DM were 2.7% vs. 
5.6% (P= 0.028).
Conclusions: Diabetics with CI have worse outcomes when compared to non-diabetics 
with CI. Ischemia on DSE in patients with CI was predictive of worse outcomes and 
associated with a 2.3 times increase in adverse outcomes. 
Non- Diabetic (N=212 ) Diabetic ( N= 128) P value
Age (yrs) 59 ± 13 60 ± 11 NS
Males (%) 61.8 62.5 NS
Peak heart rate 116 ± 21 113 ± 22 NS
Hypertension (%) 66 78.9 0.23
Smoking history (%) 36.5 28.5 NS
Hyperlipidemia(%) 37.4 57 0.001
BSA (m2) 1.9 ± 0.3 2.0 ± 0.2 0.012
Prior MI (%) 32.7 41.5 NS
Beta Blockers use (%) 39.8 43 NS
LVEF (%) 46 ± 17 39 ± 17 <0.001
Ischemia by DSE (%) 40.6 61.7 <0.001
Hard events (%) 7.5 15.6 0.028
 
9:45 a.m.
803-5 Chronotropic Resistance to Beta-adrenergic 
Antagonists in Patients with Coronary Artery Disease is 
Greater in Type 2 Diabetes Mellitus
Vivek J. Goswami, John A. Spertus, Robert A. O’Rourke, University of Missouri at 
Kansas City, The Mid-America Heart Institute, Kansas City, MO, University of Texas at 
San Antonio Health Science Center, San Antonio, TX
Background: Although autonomic neuropathy is a common complication of diabetes 
mellitus (DM), little is known about the cardiovascular effects of autonomic neuropathy, 
especially concerning chronotropic resistance to beta-adrenergic antagonists. The result 
may be a persistently elevated heart rate (HR) despite high dose beta-blocker therapy. 
We compared the chronotropic responses to beta-blocker therapy in diabetic and 
normoglycemic patients.
Methods: 265 outpatients in a coronary artery disease (CAD) clinic were included. 
Diabetic patients were deﬁned as those with a fasting plasma glucose > 126 mg/dl or any 
prior documented diagnosis of DM. The control group consisted of normoglycemic CAD 
outpatients in the same clinic. All patients had objective evidence of myocardial ischemia 
with preserved left ventricular function. Only patients who received metoprolol as part of 
aggressive medical therapy were included. Patients taking other medications that may 
have affected heart rate were excluded. Metoprolol was initiated at 100mg and titrated to a 
target resting HR of < 60 beats per minute. After at least 30 days of therapy, HR and doses 
of metoprolol were compared between patients with DM and normoglycemic controls.
Results: The mean HR differed between the 144 diabetics and 121 normoglycemics, 
being 62.8 and 58.8 beats per minute, respectively. The average beta-blocker dose was 
128.8mg for the diabetic patients and 102.9mg for normoglycemic patients. The results 
were analyzed using the Wilcoxon rank-sum test. The metoprolol dosage was divided 
into three groups: less than 100mg, 100mg, and greater than 100mg. The differences 
in HR and dose of metoprolol between diabetic and normoglycemic patients were both 
statistically signiﬁcant (P<0.001).
Conclusion: Thus, patients with DM often have an attenuated chronotropic response 
to beta-adrenergic antagonists despite receiving higher doses than similar CAD patients 
without DM. This inability to adequately reduce HR in diabetic patients is likely due to 
cardiac autonomic dysfunction, which may necessitate more aggressive therapy in order 
to prevent recurrent cardiovascular events.
10:00 a.m.
803-6 The Metabolic Syndrome is Gradually and 
Independently Predictive for Vascular Events Among 
Patients Undergoing Coronary Angiography
Christoph H. Saely, Stefan Aczel, Thomas Marte, Peter Langer, Guenter Hoeﬂe, Werner 
Benzer, Heinz Drexel, Vorarlberg Institute for Vascular Investigation and Treatment 
(VIVIT), Feldkirch, Austria, Academic Teaching Hospital Feldkirch, Feldkirch, Austria
Background: Prospective data on the cardiovascular risk associated with the metabolic 
syndrome (MetS) are limited: the impact of MetS on future vascular events in men with 
established coronary artery disease (CAD) is not known, and data are scarce for patients 
with diabetes.
Methods: We investigated 750 consecutive patients undergoing coronary angiography 
for the evaluation of established or suspected CAD. According to Adult Treatment Panel-
III criteria, we diagnosed the MetS in the presence of three out of: abdominal obesity, 
hypertriglyceridemia, low HDL cholesterol, hypertension, and fasting hyperglycemia.
Results: During a follow-up period of 2.2 ± 0.4 years the MetS was an independent 
predictor of vascular events (adjusted hazard ratio [HR] 2.35; 95% CI 1.47-3.77). 
Importantly, the MetS proved signiﬁcantly predictive of vascular events among men with 
angiographically proven CAD (n = 350; adjusted HR 2.12; 95% CI 1.23-3.66; p = 0.007) 
and among patients with diabetes mellitus type 2 (n = 164; HR 3.89; 95% CI 1.12-3.52; p 
= 0.033). Cardiovascular risk increased gradually with an increasing number of MetS risk 
factors (p for trend <0.001): compared with patients who did not have any MetS risk factor, 
the respective HRs were 1.98 (95% CI 0.66-5.93), 1.91 (95% CI 0.62-5.87), 2.55 (95% 
CI 0.82-7.92), 6.03 (95% CI 2.00-18.17), and 11.11 (95% CI 3.15-39.19) for patients with 
one through ﬁve MetS traits.
Conclusions: The MetS is a signiﬁcant predictor of cardiovascular events in men 
with established CAD and in patients with diabetes mellitus type 2. Cardiovascular risk 
increases gradually with an increasing number of MetS traits.
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803-7 High-Carbohydrate Meal Induced Reduction of Ischemic 
Threshold in Patients with Stable Coronary Disease: 
Effects of Partial Fatty Acid Inhibition by Trimetazidine
Chiara Montano, Gabriele Fragasso, Altin Palloshi, Gianluca Perseghin, Giorgio 
Bassanelli, Giliola Calori, Alberto Margonato, San Raffaele Hospital, Milano, Italy
Background. Previous studies have evidenced a signiﬁcant reduction of coronary ﬂow reserve 
after ingestion of meals of different composition. A possible role of increased free-fatty acids 
levels which are deleterious during acute myocardial ischemia and reperfusion, has been 
hypothesized. We assessed whether the addition of the partial fatty acid inhibitor trimetazidine 
(TMZ) to standard conventional therapy in patients (pts) with stable coronary disease, not 
amenable to revascularization could improve ischemic threshold and stress left ventricular 
function after fasting (F), and after a high fat (HFM) and high carbohydrate (HCM) meals.
Methods. Ten pts (9 males, age 68±7 yrs) were allocated to placebo (P) and TMZ (40 mg 
tid), both administered from 24 hrs before F, HFM and HCM, according to a randomized, 
double-blind design study. All pts underwent stress (treadmill exercise testing-Bruce protocol) 
echocardiography after F (8hrs), HFM and HCM (3 hrs), on P and on TMZ. Time to 1mm ST 
segment depression (time 1mm) and stress wall motion score index (WMSI) were evaluated.
Results. On P, the HFM did not affect exercise variables compared to F, whereas HCM 
resulted in a reduction of the ischemic threshold (time 1 mm from 380±106 to 292±123 
sec, p=0.02). Compared to P, TMZ improved time 1mm after F, HFM and HCM (432±153, 
p=0.04, 438±118, p=0.04, 381±111, p=0.01, respectively). Compared to P, on TMZ stress 
WMSI decreased from 1.55±0.25 to 1.29±0.14, p=0.001 during F, from 1.64±0.21 to 
1.39±0.21, p=0.008 during HCM, and from 1.57±0.10 to 1.39±0.28, p=0.02 during HFM. 
Interestingly, stress WMSI on TMZ was never different from rest WMSI on P.
Conclusions. In conclusion, in pts with coronary disease a HCM results in a greater 
impairment of coronary reserve compared to HFM. The observed beneﬁcial effects of the 
partial fatty acid inhibitor TMZ seem to be independent on meal composition.
ORAL CONTRIBUTIONS
812  Risk Factors and Clinical Outcomes in 
Acute Ischemic Syndrome
Monday, March 07, 2005, 11:00 a.m.-12:15 p.m.
Orange County Convention Center, Room 230D
11:00 a.m.
812-3 Frequency, Timing, and Clinical Correlates of Changes 
in TIMI Risk Score at Emergency Department in Chest 
Pain Patients
Francesco Pelliccia, Paolo Salvini, Domenico Cartoni, Loredana Macali, Fiammetta Albi, 
Bruno Polletta, Giuseppe Mercuro, Pietro Tanzi, San Filippo Neri Hospital, Rome, Italy, 
San Camillo Hospital, Rome, Italy
Background: TIMI risk score is commonly estimated at triage in Emergency Departement 
(ED) in pts with chest pain, but it remains undeﬁned if serial, frequent re-evaluations of the 
score during the following observation period are warranted. Accordingly, the aim of our 
study was twofold: (i) to assess prospectively the frequency and timing of changes in TIMI 
Risk Score during ED stay; (ii) to identify which clinical factors at presentation relate to the 
subsequent change in TIMI risk score.
Methods: Of a total of 4,333 pts who were triaged at ED over a 1-year period because of 
acute chest pain, 1,747 pts (40%) were risk-stratiﬁed as ‘low risk’ on the basis of a TIMI 
risk score 0-2, and were managed further at our CPU according to recently developed 
critical pathways. Pathways include a protocol for ruling out myocardial infarction (i.e. 
q3 hour ECGs and serum markers of myocardial necrosis for 6 hours) as well as pre-
speciﬁed indications for Doppler echocardiography, continuous 12-lead ST-segment 
monitoring, and exercise stress testing. During the observation period at ED, all pts had 
TIMI risk score re-evaluation every 30 minutes over a 6-hour period.
Results: During ED stay, TIMI risk score became 3 or higher in 1,095 pts (63%, Gr.A), 
while it did not change in the remaining 652 pts (37%, Gr.B). Timing of TIMI change vs. 
arrival was <30 min in 128 pts (7.3%), <60 min in 159 pts (9.1%), <90 min in 205 pts 
(11.7%), <120 min in 309 pts (17.7%), and <150 min in 294 pts (16.8%). Compared 
to Gr.B, Gr.A pts were signiﬁcantly (p<0.05) more likely to be female (34% vs 21%), 
hypertensive (44% vs 24%), hyperlipidemic (67% vs 33%) and to have had a prior 
MI (19% vs 6%) or PCI/CABG (21% vs 3%). More Gr.A pts were admitted to CCU or 
transferred to the cath lab (10% vs 2%, p<0.05), while more Gr.B pts were discharged 
home directly from ED (65% vs 32%, p<0.05).
Conclusion: TIMI risk score may change soon after arrival at ED in half of pts with acute 
chest pain initially triaged as ‘low-risk’. Changes in TIMI risk score are more common 
in women with multiple risk factors and/or previous diagnosis of CAD. Serial, frequent 
assessments of the TIMI score during the ED observation period are mandatory 
particularly in these subsets of pts.
11:15 a.m.
812-4 Relationships Between Renal Function, Age, and 
Obesity and Outcomes in High-Risk Patients with Acute 
Coronary Syndromes: Results from SYNERGY
Kenneth W. Mahaffey, Glenn Levine, Richard Gallo, John Ducas, Shaun G. Goodman, 
Yuliya Lokhnygina, Louise Traylor, Elliott Antman, Harvey D. White, Richard C. Becker, 
Jacques J. Col, Marc Cohen, Robert A. Harrington, James J. Ferguson, Robert M. Califf, 
for the SYNERGY Trial Investigators, Duke Clinical Research Institute, Durham, NC
Background: Uncertainty remains about the dosing of heparin in the elderly and in pts 
with renal insufﬁciency and obesity. In the SYNERGY trial, enoxaparin was dosed as 1 
mg/kg every 12 h subcutaneously. Patients undergoing PCI were given a 0.3 mg/kg IV 
bolus if the PCI was >8 h after the last dose. Unfractionated heparin (UFH) was dosed as 
a 60 U/kg bolus and a 12 U/kg/h infusion with a target aPTT of 50-70 seconds.
Methods: The relationships between age, renal function, and outcomes were examined by 
calculating a net clinical beneﬁt (freedom from death, nonfatal MI, urgent revascularization, or 
transfusion through 30 days post-enrollment) by renal function (creatinine clearance [CrCl]) 
and age. Outcomes were assessed by clinically relevant body mass index (BMI) groupings 
(<25 [27.4% of pts], ≥25 and <30 [41.1%], ≥30 and <40 [28.1%], and ≥40 [3.4%]).
Results: The net clinical beneﬁt by renal function and age is shown (Table). Patients with 
the highest BMI tended to have fewer events than those with the lowest BMI (death or 
nonfatal MI [14.3% v 15.4%, p=0.593] and bleeding [4.5% v 8.4%, p=0.013]). No evidence 
of differing efﬁcacy (p=0.700) or safety (p=0.891) existed across BMI groups by treatment 
(enoxaparin v UFH).
Conclusions: Patients with lower CrCl had worse outcomes, but there was no apparent 
increase in events in the elderly. Obese pts tended to do better than those with the lowest 
BMI. No apparent treatment differences between enoxaparin and UFH in these clinically 
important subgroups were seen.
30-day Freedom From Death/MI/Urgent  
Revascularization/Transfusion 
Group N Enoxaparin UFH
CrCl > 60, Age ≤ 75 6589 76.1 76.0
CrCl > 60, Age > 75 870 70.1 69.9
CrCl ≤ 60, Age ≤ 75 1108 61.4 65.1
CrCl ≤ 60, Age > 75 1332 62.7 63.0
11:30 a.m.
812-5 NT-proBNP Is Strongly Related To The TIMI Risk  
Score In ACS
Michael Weber, Albrecht Elsaesser, Christian Kleine, Eva Keil, Matthias Rau, Christian 
Maikowski, Veselin Mitrovic, Christian Hamm, Kerckhoff Heart Center, Bad Nauheim, 
Germany
Background: BNP/NT-proBNP) are synthesised and secreted from the myocardium in 
response to ventricular wall stress and myocardial ischemia. Both markers have proven 
to be of independent predictive value for an adverse outcome in patients with an acute 
coronary syndrome (ACS). Therefore we conducted a prospective observational study to 
investigate the relation of NT-proBNP values to the established TIMI risk score for NSTE-
ACS and STEMI in patients presenting with an ACS. 
Methods and results: We included 609 consecutive patients with an episode of chest 
pain within the last 48 hours and an indication for early invasive diagnostic. In all patients 
NT-proBNP plasma levels were measured at admission. In 261 patients STEMI and in 348 
patients NSTE-ACS was diagnosed. We found NT-proBNP values linked to the respective 
TIMI risk score, either for NSTE-ACS or STEMI (ﬁgure, values are given as median). 
NT-proBNP was correlated to the respective TIMI risk score in NSTE-ACS (Rho=0.43, 
p<0.01) and in STEMI (Rho= 0.49, p<0.01). 
Conclusion: NT-proBNP is elevated in patients with an ACS strongly linked to the 
respective TIMI risk score for either NSTE-ACS or STEMI. These ﬁndings underlines the 
usefulness of NT-proBNP for risk stratiﬁcation in patients presenting with an ACS. The 
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812-6 Placental Growth Factor Level is Not an Independent 
Predictor of Adverse Events in non-ST Elevation Acute 
Coronary Syndrome
Bertil Lindahl, Anders Mälarstig, Agneta Siegbahn, Lars Wallentin, Uppsala Clinical 
Research Center, Uppsala, Sweden
Background: Placental Growth Factor (PlGF) is upregulated in atherosclerotic lesions and 
may be of importance for plaque instability. A previous study has indicated that PlGF may be 
an independent predictor of adverse outcome in non-ST elevation acute coronary syndrome 
(NSTE-ACS). We therefore evaluated the prognostic value of PlGF and compared it with 
other established prognostic factors in patients enrolled in the FRISC-II trial.
Methods: Blood samples were obtained at inclusion in patients enrolled in the FRISC-II 
trial (n=1080), evaluating an invasive vs. a non-invasive strategy in NSTE-ACS. PlGF 
was measured in citrated plasma using a sensitive ELISA (R&D systems). Patients were 
followed regarding myocardial infarction (MI) and death for 2 years.
Results: The median level of IL-10 was 10.6 ng/L [25:th-75:th percentile; 8.6 - 13.8]. 
Events at 2 years PlGF <10.6 ng/LN=533
PlGF ≥10.6 ng/L
N=547 p-value
MI (%) 12.6 11.7 0.66
Death (%) 3.0 5.5 0.043
After adjustment for age, gender, treatment strategy and in addition either troponin 
T, C-reactive protein or NT-pro B-type natriuretic peptide, the Odds Ratio (95 % CI) 
regarding mortality for PlGF was 1.45 (0.76-2.75), 1.30 (0.67-2.50) and 1.52 (0.79-2.92), 
respectively. When all these factors were entered in the model the Odds Ratio was 1.19 
(0.60-2.39).
Conclusions: Increased plasma levels of PlGF are associated with raised mortality in 
univariate analysis, but not in multivariate analysis after adjustment for troponin T, C-
reactive protein or NT-pro B-type natriuretic peptide. There was no association between 
PlGF and myocardial infarction.
Noon
812-7 Increased In-Hospital Mortality in Patients Without 
Traditional Risk Factors Presenting With Non-ST-
Segment Elevation Myocardial Infarction: Insights From 
the CRUSADE Initiative
Abdul R. Halabi, Anita Y. Chen, Robert A. Harrington, Sidney C. Smith, Jr., E. Magnus 
Ohman, W. Brian Gibler, Eric D. Peterson, Matthew T. Roe, Duke Clinical Research 
Institute, Durham, NC
Background: While traditional risk factors increase the risk of developing coronary artery 
disease (CAD), their impact on outcomes for patients with non-ST-segment elevation 
myocardial infarction (NSTEMI) has not been clearly elucidated.
Methods: We compared clinical characteristics and in-hospital outcomes in 74,220 
NSTEMI patients (positive CK-MB or Troponin I/T) included in the CRUSADE Quality 
Improvement Initiative from 476 US hospitals (January 2001-March 2004) according to 
the presence and number of traditional CAD risk factors (hypertension, diabetes mellitus, 
current/recent smoking, and dyslipidemia).
Results: There were no major differences in CAD risk factor distribution across gender 
and age categories. A total of 7,755 patients (10.5%) did not have any CAD risk factors 
and these patients had the highest frequency of unadjusted mortality (Table). The adjusted 
risk of mortality was lower in patients with any combination of traditional CAD risk factors 
(OR 0.92, 95% CI 0.82-1.04, 1 vs. none; OR 0.81, 95% CI 0.72-0.92, 2 vs. none; OR 0.83, 
95% CI 0.73-0.95, 3-4 vs. none).
Conclusion: Patients without traditional CAD risk factors represent 10% of the NSTEMI 
population. Since the absence of traditional CAD risk factors does not yield a favorable 
prognosis for patients with NSTEMI, further study is needed to delineate the interplay 
between CAD risk factors, treatment differences, and novel inﬂammatory risk factors on 
clinical outcomes in this population. 
Number of Traditional Risk Factors*
0 1 2 3 4
Variables n=7,755 n=22,314 n=26,329 n=15,422 n=2,400 P-value†
Patient 
Characteristics
Mean age (yrs) 69.3 68.9 67.8 65.3 60.4 <0.0001
Male sex 61.5 59.5 59.4 61.1 63.9 <0.0001
White race 85.1 82.8 80 77.4 73.4 <0.0001
Prior MI 17.7 23.5 32.7 41.0 46.4 <0.0001
Prior CABG 10.8 13.6 21.8 28.6 27.6 <0.0001
In-Hospital 
Clinical Events‡
Death 6.8 5.9 4.6 4.1 3.4 <0.0001
Death or re-
infarction 9.2 8.1 7.2 6.7 6.0 <0.0001







1088  Predictors of Increased Risk Among 
Patients With ST-Elevation Myocardial 
Infarction
Monday, March 07, 2005, 1:30 p.m.-5:00 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 2:30 p.m.-3:30 p.m.
1088-203 Combination of Admission Troponin I and B-type 
Natriuretic Peptide Levels in Prediction of Mortality and 
Angiographic Success of Procedure in Patients With 
Acute ST-Elevation Myocardial Infarction Treated With 
Primary Angioplasty
Marcin Grabowski, Krzysztof J. Filipiak, Grzegorz Karpinski, Adam Rdzanek, Zenon 
Huczek, Grzegorz Horszczaruk, Janusz Kochman, Przemysław Stolarz, Robert 
Rudowski, Grzegorz Opolski, Medical University of Warsaw, Warsaw, Poland
Background: Troponin I (TnI) and B-type natriuretic peptide (BNP) levels are predictive 
of mortality in patients with acute coronary syndromes. Few data are available for TnI and 
BNP levels obtained on admission in patients (pts) with acute ST elevation myocardial 
infarction (STEMI) treated with primary percutaneous coronary intervention (PCI).
Methods: Blood samples for BNP (median 100 pg/ml) estimation, obtained on admission 
in 126 consecutive pts (mean age 58,8±10,7 years old) with STEMI were measured 
before PCI. Follow-up up to 42 days was performed.
Results: There was a signiﬁcant difference in mortality between the group with positive 
TnI(+) and BNP >100 pg/ml, and the group without TnI(+) and with BNP ≤100 pg/ml: 16,3% 
vs. 0%, p=0,045 and signiﬁcant difference in no-reﬂow phenomenon between the group with 
TnI(+) and BNP >100 pg/ml, and the group without TnI(+)and with BNP ≤100 pg/ml: 24,5% 
vs. 4%, p=0,049. In multivariate model, incorporating BNP, admission TnI and other clinical 
variables, serum BNP on admission had independent prognostic value to predict death 
at 42 days (odds ratio [OR]=8,8; 95% conﬁdence interval [CI] 1,1-73,3), TIMI<3 after PCI 
(OR=3,5; 95%CI 1,2-9,7) no-reﬂow phenomenon (OR=6,2; 95%CI 1,6-23,2).
Conclusion: Combination of TnI and BNP levels obtained on admission are a powerful, 
independent predictor of short-term mortality and angiographic success after PCI in pts 
with STEMI. No-reﬂow phenomenon may be predicted in STEMI on basis of high serum 
BNP values on admission. 
1088-204 Association of Elevated Platelet Counts and Adverse 
Clinical Outcomes in the Setting of ST Segment 
Elevation Myocardial Infarction
Hung Q. Ly, Ajay J. Kirtane, Jacki Buros, Sabina A. Murphy, Christopher P. Cannon, 
Eugene Braunwald, C. Michael Gibson, The TIMI Study Group, Brigham and Women’s 
Hospital, Boston, MA, Beth Israel Deaconess Medical Center, Boston, MA
Background: Platelet activation and aggregation play a pivotal role in the thrombotic 
process leading to myocardial infarction. Prior studies have shown an association between 
mean platelet volume and adverse outcomes in ST elevation myocardial infarction 
(STEMI). However, data on platelet counts and their association with clinical outcomes in 
the setting of STEMI is limited. 
Objectives and Methods: We hypothesized that higher platelet counts on presentation 
would be associated with poorer outcomes. Data was obtained from 10,793 STEMI 
patients pooled from the TIMI trials database. 
Results: Median platelet counts on presentation were 240x103/µL. There was an association 
of increased rates of adverse clinical outcomes at 30 days with increasing platelet counts 
(Figure). Following multivariate analysis for correlates of elevated platelet counts (age, 
gender, weight, diabetes, smoking) as well as standard clinical covariates predictive of 
poorer outcomes in STEMI, increasing platelet counts was signiﬁcantly associated with the 
composite end-point of death, reinfarction, and congestive heart failure: levels between 200-
300 had an OR=1.20 (95% CI 1.01-1.42; p=0.033), levels 300-400 had an OR=1.43 (95%CI 
1.14-1.80; p=0.02) and levels >400 had an OR=1.63 (95%CI 1.05-2.53; p=0.031) compared 
to the reference group with platelet levels of <200 x103/µL. 
Conclusion: In the setting of STEMI, elevated platelet counts on presentation was 
independently associated with adverse clinical outcomes. 
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1088-205 Mitral Regurgitation in Myocardial Infarction 
Complicated by Heart Failure, Left Ventricular 
Dysfunction, or Both: Prognostic Signiﬁcance and 
Relation to Ventricular Size and Function
Maria Amigoni, Deepa Mangalat, Mikhail Bourgoun, Eric J. Velazquez, Frans Van de 
Werf, Jalal Ghali, John J.V. McMurray, Lars Køber, Marc A. Pfeffer, Scott D. Solomon, 
Brigham and Women`s Hospital, Boston, MA
Background: Mitral regurgitation (MR) after myocardial infarction (MI) is associated with 
increased mortality and other cardiovascular (CV) events. We assessed the relationship 
between MR, changes in left ventricular (LV) size and function, and CV outcomes in 
patients (pts) enrolled in the VALIANT echo sub study.
Methods: VALIANT randomized 14,703 pts with heart failure and/or systolic 
dysfunction after MI to valsartan, captopril, or both. We studied 496 pts who underwent 
echocardiography 5.0 ± 2.5 days after MI. MR was quantiﬁed as the jet area/left atrial area 
ratio: < 5%, no MR; 5-20%, mild MR; ≥ 20%, moderate to severe MR. Jet eccentricity raised 
the MR grade by 1 point. MR severity was related to LV size, function, and outcomes.
Results: MR was absent in 231 pts (46.6%), mild in 202 (40.7%), and moderate-severe 
in 63 (12.7%). MR severity was associated with older age, female sex, history of MI, 
hypertension, diabetes, and heart failure (p trend<0.02). LV end-diastolic (no MR: 112.1 ± 
28.2 ml, mild MR: 123.5 ± 29.5 ml, mod-sev: 139.6 ± 43.3 ml.) and end-systolic (no MR: 
67.3 ± 19.8 ml, mild MR: 76.8 ± 23.4 ml, mod-sev: 88 ± 33 ml) volumes increased with 
worsening MR, and ejection fraction decreased (no MR: 40.4 ± 5.1%, mild MR: 38.4 ± 
5.8%, mod-sev: 37.7 ± 7.4%) (p trend<0.0001). Moderate-severe MR was an independent 
predictor of total mortality, CV mortality, or any CV event (p<0.05). 
Conclusions: MR severity is associated with larger LV volumes, worse LV function, and 
adverse outcomes in pts with LV dysfunction after MI.
 
Table. Association of moderate-severe MR with outcomes
Hazard Ratio* 95% - CI P value
Death 2.3 1.2- 4.5 0.016
CV death 2.2 1- 4.5 0.037
Combined end point
(CV death, heart failure hospitalization, 
recurrent MI, cardiac arrest or stroke)
2.1 1.3- 3.5 0.002
(*Adjusted for age, gender, heart rate, Killip class, PTCI, diabetes, history of heart 
failure, history of MI, renal insufﬁciency, ejection fraction, left ventricular diastolic 
volume)
1088-206 Transfer to Acute PCI Improves Outcome for Patients 
With ST-elevation Myocardial Infarction
Michael Oeff, Harm Ohlmeier, Albrecht Hempel, Hartmut Goos, Hartmut Huget, Antje 
Goesswald, Ute Wolf, Staedtisches Klinikum Brandenburg, Brandenburg an der Havel, 
Germany
Early thrombolysis is recommended for the treatment of myocardial infarction with ST-
segment elevation (STEMI), if expected time delay to PCI is more than 90 minutes. But 
discussion about differences in outcome between early thrombolysis and delayed primary 
PCI is ongoing.
Methods: The multicenter hospital-based Myocardial Infarction Registry Brandenburg 
- representing a weakly populated German state - included 2391 patients (pts) with 
acute coronary syndrome (ACS). Survival analysis of pts with STEMI receiving early 
thrombolysis ± PCI vs delayed primary PCI was performed. Mean follow-up in 99,1% of 
pts: 1,5±0,2 yrs.
Results: Of all ACS-pts 1099 presented with STEMI (men 67%; mean age 65.3+/- 12 
yrs) within 24h after symptom onset. Primary thrombolysis was administered in 451 (41%) 
followed by PCI in 330 (30%). Primary PCI was performed in 440 (40%), in 208 (19%) no 
reperfusion therapy was performed within 24h. Median time to thrombolysis was 2.3h to 
primary PCI was 5.4h.
Following subgroups were compared regarding 30-day-mortality: group A: pts receiving early 
thrombolysis (<4h) without subsequent PCI (n=66), group B: pts receiving early thrombolysis 
+ PCI (n= 221) and group C: pts after delayed primary PCI within 4-24h (n=211). 30-day-
mortality was 15,2; 6,8; 6,2%. Difference in mortality was only signiﬁcant comparing group A 
vs C: p=0,02. Comparing the combined group (A+B) vs C mortality was 8.7 vs 6.2% (p=ns).
Logistic regression analysis revealed age (OR:1.09;CI:1.05-1.13), renal failure 
(OR:4.81;CI:1.58-14.68), cardiac shock (OR:3.64;CI:1.10-12.01), heart failure at 
admission (OR:2.65; CI:1.05-6.69) and dyslipidaemia (OR: 0.36;CI:0.16-0.80) as 
independent inﬂuencing factors. There is a tendency towards higher mortality-rates in 
group A, but treatment strategies had no independent inﬂuence on outcome.
Conclusion: Outcome after early thrombolysis within 4 hours after symptom onset 
followed by PCI is comparable to that after delayed primary PCI regarding 30-day 
mortality. This treatment strategy can be recommended in weakly populated areas with 
long distances to centers with angioplasty facilities.
1088-207 High Levels Of Plasma N-terminal Pro-b-Type 
Natriuretic Peptide in Diabetic Patients With Acute 
Myocardial Infarction Are Associated With an Increased 
Risk of In-Hospital Mortality.
Marianne Zeller, Gilles Dentan, Yves Laurent, Jean-Claude Beer, Luc Janin-Maniﬁcat, 
Hamib Makki, Isabelle L’Huillier, Bruno Vergès, Michel Vincent-Martin, Alexandra Oudot, 
Jean-Eric Wolf, Yves Cottin, on behalf of the RICO Survey working group, University of 
Burgundy, Dijon, France, University Hospital, Dijon, France
Background. N-terminal Pro-B-type Natriuretic Peptide (N-BNP), has been shown to 
provide valuable prognostic information on short and long term mortality in patients with 
acute Myocardial Infarction (MI). However, only few data on N-BNP levels in diabetic 
patients after MI are available.
Patients and method. From french regional RICO survey, we measured plasma N-BNP 
(Elecsys, Roche) on admission for MI in 560 patients, including 199 (35%) patients with 
diabetes mellitus (DM). DM was deﬁned by an history of diagnosed DM or by mean of 2 
fasting blood glucose ≥ 7.0 mmol/l (126 mg/l).
Results. In-hospital mortality and cardiogenic shock were strongly associated with supra 
median plasma N-BNP levels (p<0.0001). In mutivariate analysis, N-BNP levels were 
inversely associated with creatinine clearance and Left Ventricular Ejection Fraction (LVEF) 
(both p<0.0001) and directly associated with age (p=0.0002) and diabetes (p=0.002). 
However, there was no association with CK peak level or hypertension. N-BNP plasma 
levels were signiﬁcantly higher in DM patients compared to non-diabetic patients (Median 
(25th-75th): 245 [81-777] vs. 130 [49-299] pmol/l, p<0.0001). The difference remained 
statistically signiﬁcant (p=0.01) even after adjustment for age, creatinine clearance and 
LVEF. In DM patients, we found no signiﬁcant correlation between N-BNP and plasma 
glucose. Moreover, DM patients showed a higher rate of in-hospital mortality (17% vs. 6%, 
p<0.0001) and cardiogenic shock (16% vs. 7%, p=0.0002). In multivariate analysis, when 
DM was not an independent predictive factor, both cardiogenic shock and in-hospital 
mortality were inversely associated with LVEF (p<0.0001 and p=0.0001 respectively) and 
directly associated with log N-BNP (p=0.0002 and p=0.02, respectively).
Conclusions: 1) In acute MI, DM patients show increased plasma N-BNP levels 
independently of age, renal function and LVEF 2). This rise in N-BNP levels appears to be 
strongly associated with the increased incidence of in-hospital mortality and cardiogenic 
shock observed in DM.
1088-208 Primary Coronary Intervention and Prevention of Left 
Ventricular Remodeling: Comparison Between Two Age 
Groups
Chiara Agresti, Francesca Innocenti, Giorgio Jacopo Baldereschi, Francesca Caldi, 
Niccolò Marchionni, Massimo Margheri, Marco Comeglio, Giulio Masotti, Riccardo Pini, 
University of Firenze and AOU Careggi, Florence, Italy
Background: the study was undertaken to compare, between patients of different age 
groups, the efﬁcacy of primary coronary intervention (PCI) on prevention of left ventricular 
(LV) remodeling after anterior ST-elevation myocardial infarction (STEMI).
Methods: one month after PCI for a ﬁrst anterior STEMI, 116 patients (G1: 93 aged<75, 
mean age 59±9 years, males 80%; G2: 23 aged>75, mean age 80±4 years, males 61%) 
underwent standardized dobutamine stress echocardiography (DSE) and measurement 
of left anterior descending (LAD) coronary artery ﬂow reserve (CFR) by transthoracic 
echocardiography during intravenous adenosine infusion (140 �/kg/min for 5’).
Results: Hyperlipidemia and smoking were more frequent in G1, peripheral vascular 
disease in G2. CPK peak was signiﬁcantly higher in G1 (3249±2414 IU/L vs. 1894±1462 
IU/L, p<0.05), while time delay between symptom onset and PCI was similar in the two 
groups (4±2.8 vs. 4±1.5 hours, p=NS). Extension of coronary artery disease, was also 
comparable. LV end-diastolic diameter (EDD) and volume (EDV) were slightly, though 
signiﬁcantly greater in G1, but indexed EDV was similar, probably due to the larger 
proportion of females, with smaller BSA, in G2 (EDVi: 70±18 in G1 vs. 64±13 ml/m2 in 
G2, p=NS). LV ejection fraction was similar and only slightly reduced (G1: 45±11%, G2: 
46±10%, p=NS). Wall motion score index (WMSI) was similar in the two groups during the 
whole stress test, either globally or when calculated separately for necrotic and remote 
area. CFR was within the lower normal range and similar in the two groups (G1 2.0±0.6 
vs. G2 2.1±0.4 p=NS), and LAD diastolic maximal and median ﬂow velocity, both at 
baseline and after adenosine infusion, were similar as well.
Conclusion: The beneﬁcial effect of PCI on microvascular integrity and left ventricular 
remodelling is age-independent and is associated with a substantially preserved global LV 
systolic function after anterior STEMI. This data reinforce the importance of offering older 
people the beneﬁts of invasive treatment of acute STEMI, particularly in consideration 
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1089-195 Admission α1- Antitrypsin Levels Predicts Myocardial 
Infarction Size
Shahar Lavi, Robert Zukerman, Zvi Borochowitz, Oren Zinder, Vardit Adir, Michael 
Kapeliovich, Yoram Agmon, Walter Markiewicz, Haim Hammerman, Rambam Medical 
Center, Haifa, Israel, Bnai-Zion Medical Center, Haifa, Israel
Introduction: α1-antitrypsin (AT) is both an inﬂammation sensitive plasma protein and 
a protease inhibitor. Those, its correlation with acute myocardial infarction (MI) could be 
unique. Our aim was to investigate the time course of α1-AT levels during acute MI and 
correlate it with left ventricular function
Methods: Sixty-two patients with ﬁrst acute ST elevation MI were enrolled. Blood samples 
were obtained for α1-AT levels on admission, and then for 5 consecutive days. Subjects 
were genotyped for Z-E342K and S-E264V mutations to exclude allelic inﬂuence. Patients 
were followed for 30 days. Left ventricular wall motion score index (WMSI) as assessed 
by echocardiography during 2nd-3rd day
Results: None of the patients had the above mutations. Patients were divided into two 
groups according to median α1-AT levels on admission. Patients with higher admission 
levels maintained elevated levels throughout hospital course. Anterior wall MI was more 
frequent in these patients. Other baseline characteristics were similar. α1-AT increased 
less in patients with higher admission levels as compared to patients with lower levels 
(47% vs. 37%, p=ns). Admission α1-AT levels were signiﬁcantly correlated with WMSI 
(R=0.33, p=0.008). Events rates were low and not different between the groups
Conclusions: Higher levels of α1-AT on admission and during acute MI are associated 
with larger infarctions. The known ~ 24h delay of α1-AT rise during stress suggest marked 
inﬂammatory response in large MI prior to admission.
admission α1-AT <130 mg/dL 
(n=31)
admission α1-AT >130 mg/dL 
(n=31) p value
Day 2 α1-AT mg/dL 134±3 162±5 0.0002
Day 3 α1-AT mg/dL 157±4 184±6 0.002
Day 4 α1-AT mg/dL 164±6 196±8 0.002
Day 5 α1-AT mg/dL 166±6 190±7 0.01
WMSI 1.5±0.05 1.71±0.06 <0.01
max CK (U/L) 2016±269 3371±604 0.05
Anterior wall MI (#) 6 12 ns
1089-196 NT-Pro Brain Natriuretic Peptide Levels Predict the 
Rate of Death in Diabetic Patients With Acute Coronary 
Syndromes Without ST Elevation
Oscar Bazzino, Diego Perez de Arenaza, Florencia Rolandi, Jose Navarro Estrada, Juan 
Fuselli, Fernando Botto, J. Santopinto, Maria Ines Sosa Liprandi, Hospital Italiano de 
Buenos Aires, Buenos Aires, Argentina
Background and aims: Patients with diabetes mellitus (DM) with acute coronary 
syndromes (ACS) are at increased risk of further complications. We examined the clinical 
characteristics, levels of N-terminal Natriuretic Peptide(NT-proBNP), troponin T (TnT), and 
C-Reactive Protein (CRP), and clinical outcomes in patients with and without diabetes in a 
cohort of unselected patients admitted with ACS without ST elevation (NSTE-ACS).
Methods: We undertook a prospective, cohort of 1483 patients admitted to 12 centers 
with NSTE-ACS that was followed up for 6 months. Centralized measurements of NT-
proBNP, TnT, and CRP, were performed 3 h (median) after admission.
Results: A prior diagnosis of diabetes mellitus (DM) was found in 275 (18%) patients. These 
patients were younger and had higher rates of prior hypertension, hypercholesterolemia, 
prior myocardial infarction (MI), or peripheral artery disease (PAD) than non-DM patients. 
Rates of elevated levels of NT-proBNP (>586 pg/mL), TnT (>0.03 ng/mL), and CRP (>3 
mg/L) were higher in diabetic compared to non diabetic patients (38% vs 28, p=0.001; 
68% vs 57%, p=0.002; 34% vs 27%, p=0001 respectively). The rate of death was 9.1% 
(n=25/275) in diabetic patients compared to 4.3% (n=52/1208) in non diabetic (p=0.001) 
and the rate of MI was 5.8% (n=16/275) and 3.1% (n=37/1208) (0.02) respectively. In 
diabetic patients, characteristics associated with death or MI were elevated NT-proBNP 
(>586 pg/mL), troponin I (>0.1 ng/mL), ST depression on ECG, age, female sex, prior 
angina and PAD. In a multivariate logistic regression model of diabetic patients including 
clinical, ECG, and biomarkers variables NT-proBNP levels (OR 1.91, 95% CI 1.44-2.53, 
p<0.001) was an independent predictor of death and TnT levels (OR 1.22, 95% CI 1.01-
1.46, p<0.001) was an independent predictor of MI at 6 months.
Conclusions: Diabetic patients with NSTEACS have higher risk proﬁle, biomarker levels 
and clinical outcomes than non diabetic patients. Biomarkers are useful to identify DM 
patients at high risk of clinical events: NT-proBNP identiﬁes patients at high risk of death 
and TnT at high risk of MI.
1089-197 A Multimarker Strategy Predicts Short- and Long-
Term Mortality in Patients Admitted for Exclusion of 
Myocardial Infarction
Michael C. Kontos, Rajat Garg, F Philip Anderson, Charlotte S. Roberts, James L. Tatum, 
Joseph P. Ornato, Robert L. Jesse, Virginia Commonwealth University, Richmond, VA
BACKGROUND: A multi-marker strategy incorporating myoglobin (MYO), CK-MB and 
troponin I (TnI) has been used to rapidly diagnose myocardial infarction (MI). However, 
there is little data comparing the additive value of these markers for predicting short- and 
long-term mortality. 
METHODS: Consecutive patients (pts) without ST elevation on the initial ECG were 
admitted and underwent serial assessment of cardiac markers (CK, CK-MB, and TnI) over 
8 hours for diagnosis of MI. MYO was assessed at the time of admission and/or 3 hours 
later. Pts with positive markers had continued assessment until the markers peaked. 
Thirty day and one year all-cause mortality were assessed for each marker individually 
and in combination. 
RESULTS: A total of 3,461 consecutive pts without ST elevation were included in the 
analysis. Overall 30 day and 1 year mortality was 2.4% and 9.7%. The number of pts 
with (+) markers and mortality are shown in the Table. Mortality was similar and not 
signiﬁcantly different in pts with a (+) TnI, MYO or CK-MB. Each additional positive 
marker was associated with a signiﬁcant increase in mortality, both at 30 days and 1 year. 
CONCLUSIONS: Elevations in any cardiac marker predict mortality. The more markers 
that are positive, the higher the mortality.
Marker # Positive (%) 30 Day Death, % 1 Year Death
Marker (-) Marker (+) Marker (-) Marker (+)
MYO 675 (20) 1.3 # 7.9 7.6 # 22
CK-MB 421 (12) 1.5 # 8.8 8.4 # 20
TnI 517 (15) 1.6 # 7.2 8.2 # 19
0 markers (+) 2490 (72) 1.0 NA 6.6* NA
1 marker (+) 533 (16) NA 3.2 NA 13.7*
2 Markers (+) 234 (6.8) NA 6.8 NA 20
All Markers (+) 204 (5.9) NA 12.7 NA 25.5
*=p<0.05 for 0 vs 1, 1 vs 2 or 2 vs 3 makers (+); p<0.001 (+) vs (-) marker
1089-198 Correlation of Serum Neopterin Levels With Admission 
TIMI Risk Scores in Patients With Acute Coronary 
Syndromes
Marios D. Gagos, Douglas T. Johnston, Nicholas Raio, David Shenouda, Louis Ragolia, 
Kevin Marzo, Mark Davis-Lorton, Joshua DeLeon, Winthrop University Hospital, Mineola, NY
Background: The American College of Cardiology (ACC) and American Heart Association 
(AHA) guidelines include the use of multiple risk scores in the initial assessment of patients 
with acute coronary syndromes (ACS). Macrophage activation has been proven to be a 
vital component of atheromatous plaque disruption resulting in ACS. Serum Neopterin, 
a pterydine by-product of macrophage activation, has been documented to be elevated 
in ACS when compared with control subjects. We evaluated the relationship between 
calculated admission TIMI risk scores and serum neopterin levels in patients with ACS.
Methods: We studied 57 subjects who were admitted with a diagnosis of unstable angina 
(20 men, 14 women; mean age 62.3 +/- 7 years, range 33 to 88) amd non-ST elevation 
myocardial infarction (NSTEMI) (12 men, 11 women; mean age 64.7 +/- 6 years, range 
41 to 93). All blood samples were drawn on admission, 24 and 72 hours of admission. 
Serum neopterin levels were determined with a commercially available enzyme-linked 
immunosorbent assay and compared to admission TIMI risk scores calculated by ACC/
AHA guidelines.
Results: Serum neopterin had a strong correlation with the calculated TIMI risk score on 
admission, r=0.80, n=57, p<0.0001 by the Spearman Correlation. The corresponding mean 
neopterin levels for patients with ACS stratiﬁed with TIMI scores between 1 through 7 were 
the following: patients with TIMI 1 scores had mean neopterin levels of 3.3 +/- 0.4 nmol/L, 
TIMI 2 patients 4.6 +/- 0.6 nmol/L, TIMI 3 patients 5.2 +/- 1.2 nmol/L, TIMI 4 patients 7.0 
+/- 2.2 nmol/L, TIMI 5 patients 10.3+/- 3.5, TIMI 6 patients 18.4.5 +/- 4.5 nmol/L, and TIMI 7 
patients 28.0 +/- 0.0. The sharp rise in Neopterin levels with one-unit increases of TIMI score 
appear to be non-linear (exponential growth, R-square=0.71, p<0.0001).
Conclusions: Serum Neopterin levels drawn on admission have a high correlation with 
ACC/AHA calculated TIMI risk scores. Serum neopterin may be useful in estimating 
coronary disease activity and the non-linearity of the correlation may suggest a more 
sensitive marker for deﬁning risk in ACS.
1089-199 Myoglobin Predicts Mortality Better Than Troponin I, 
Even in Patients With Renal Failure
Michael C. Kontos, Rajat Garg, F Philip Anderson, Charlotte S. Roberts, James L. Tatum, 
Joesph P. Ornato, Robert L. Jesse, Virginia Commonwealth University, Richmond, VA
BACKGROUND: Myoglobin (MYO) can be used as an early marker to diagnose myocardial 
infarction (MI), and while non-speciﬁc for myocardial necrosis, it does appear to be a 
strong predictor of mortality. Elevations of MYO are commonly present in patients (pts) 
with renal failure (RF). Whether the predictive value of MYO is secondary to identiﬁcation 
of pts with RF has not been studied. 
METHODS: Consecutive pts admitted for MI exclusion without ST elevation on the initial 
ECG underwent serial assessment of cardiac markers (CK, CK-MB, and TnI) over 8 
hours. MYO was assessed at the time of admission and/or 3 hours later. Pts with positive 
markers had continued assessment until they peaked. RF was deﬁned as a creatinine 
clearance <60 ml/min. Multivariate analysis was performed to identify predictors of one 
year all cause mortality in all pts and those with RF. 
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RESULTS: A total of 3,461 pts without ST elevation were included in the analysis. Overall 
30 day and 1 year mortality was 2.4% and 9.7%. MYO was elevated in 675 (20%), CK-
MB in 421 (12%), and TnI in 517 (15%). Among the 993 pts with RF, MYO was elevated 
in 43%, CK-MB in 17% and TnI in 21%. MYO was the strongest multivariate predictor of 
mortality in all pts, as well as in pts with RF. TnI had borderline predictive value, while 
CK-MB was not predictive in either group. CONCLUSIONS: Despite absence of cardiac 
speciﬁcity, an elevated MYO still strongly predicts mortality, even in pts with RF.
All Patients (n=3,461) Patients with RF (n=993)
OR (95% CI) P Value OR (95% CI) P value
Age>65 2.8 (2.2, 3.6) <0.001 1.5 (1.0, 2.1) 0.03
Prior MI 1.5 (1.1, 2.0) 0.01 1.6 (1.1, 2.40 0.02
Ischemic ECG 1.6 (1.1, 2.1) <0.001 2.3 (1.6, 3.4) <0.0001
MYO (+) 2.8 (2.1, 3.7) <0.0001 2.3 (1.6, 3.4) <0.0001
TnI (+) 1.4 (0.96, 2.0) 0.08 1.5 (0.95, 2.3) 0.08
1089-200 Increase in Carboxyhemoglobin in Patients With Acute 
Coronary Syndrome
Soon Jun Hong, Hong Seog Seo, Chang Gyu Park, Seung Woon Rha, Jin Won Kim, 
Jung Chun Ahn, Woo Hyuk Song, Dong Joo Oh, Young Moo Ro, Cardiovascular Center, 
Korea University Hospital, Seoul, South Korea
Background: Carbon monoxide (CO), produced within the blood vessel wall, has been 
known for the regulation of vascular smooth muscle tone. CO is synthesized endogenously 
by heme oxygenase type 1 in response to ischemic stress. The relation between CO and 
coronary artery diseases has not been investigated.
Methods: Total of 210 participants (94 women and 116 men) with suspected coronary 
artery diseases were divided into four groups: acute myocardial infarction (AMI) (n=38), 
unstable angina pectoris (UAP) (n=68), stable angina pectoris (SAP) (n=56), and control 
(n=48). All patients underwent coronary angiography (CAG) in evaluation of rest or effort 
angina. Following the CAG, venous carboxyhemoglobin (COHb) was measured.
Results: COHb level in UAP was signiﬁcantly higher than those of SAP and control, 
but COHb level showed no signiﬁcant difference between UAP and AMI (Figure). Total 
cholesterol in UAP was signiﬁcantly higher than that of control (177 ± 40 Versus 144 ± 
29 mg/dL, p=0.03). C-reactive protein (CRP) progressively increased from control to AMI; 
however, only CRP in AMI was signiﬁcantly higher than that of control (6.2 ± 5.7 Versus 
0.8 ± 0.9 mg/L, p<0.01). There were no signiﬁcant differences in age, body mass index, 
fasting blood sugar, HDL-cholesterol, and lipoprotein(a) in all groups.
Conclusion: Our results suggest that acute coronary syndrome is associated with 
higher COHb level, and the increase in COHb may result from the acute compensatory 
mechanism responding to ischemic stress.
1089-201 Levels of Soluble CD40L are Associated With 
Myocardial Infarction, but not Mortality, in Patients With 
Non-ST Elevation Acute Coronary Syndrome
Anders Malarstig, Bertil Lindahl, Lars Wallentin, Agneta Siegbahn, Department of 
Medical Sciences, Clinical Chemistry, Uppsala, Sweden, Department of Medical 
Sciences, Cardiology, Uppsala, Sweden
Background: Recent data suggest that CD40L and its receptor CD40 is involved in the 
pathogenesis of NSTE-ACS by acting in the inﬂammatory and coagulatory systems. The aim 
of this study was to investigate whether levels of sCD40L at study inclusion was associated 
with MI and death during follow-up in a large cohort of patients with NSTE-ACS.
Methods: Citrated plasma samples were obtained at inclusion in patients enrolled in 
the FRISC-II trial (n=2355), evaluating an invasive vs. a non-invasive strategy in NSTE-
ACS. Plasma concentrations of sCD40L were determined using an ELISA assay (Bender 
MedSystems). Patients were followed regarding MI and death for 2 years.
Results: The median level of sCD40L was 0.29 ng/ml [25:th-75:th percentile; 0.19-0.49]. 
A strong association between sCD40L levels and subsequent myocardial infarction 
was observed (p<0.001), whereas the mortality rate was equal in patients with sCD40L 
levels above and below median. The results were similar in patients that received an 
early invasive treatment and in those that did not. Levels of sCD40L did not correlate to 
Troponin T, Interleukin-6 or C-reactive protein.
Conclusions: In patients with NSTE-ACS an increased plasma concentration of soluble 
CD40L is associated with an increased long-term risk of MI , but not with mortality.
 
1089-202 N-Terminal Pro-B-Type Natriuretic Peptide in the 
Prediction of Coronary Artery Disease in Unstable 
Angina Patients with Normal Troponin I and ECG
Youngkeun Ahn, Seo Na Hong, Nam Sik Yoon, Sang Yub Lim, Kyoung Ho Yun, Dong 
Koo Kang, Sang Hyun Lee, Yeon Sang Lee, Kye Hun Kim, Young Joon Hong, Hyung 
Wook Park, Ju Han Kim, Weon Kim, Myung Ho Jeong, Jeong Gwan Cho, Jong Chun 
Park, Jung Chaee Kang, The Heart Center of Chonnam National University Hospital, 
Gwangju, South Korea
Background: Elevation in B-type natriuretic peptide (BNP) and N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) are associated with symptomatic left ventricular dysfunction. 
Myocardial ischemia may also cause elevation in level of BNP and NT-proBNP. 
Methods and Results: To determine whether elevation of NT-proBNP without elevation 
of cardiac speciﬁc marker could predict the coronary artery disease, we measured serum 
(s) NT-proBNP level in 179 unstable angina patients (61.8±44.1 years, male 60.9 %) with 
normal ventricular function (left ventricular ejection fraction > 55 % and no regional wall 
motion abnormality by echocardiography) and normal troponin I level (≤ 0.05 ng/mL). In 
these patients, level of CRP, myoglobin and ECG ﬁnding are normal. Serum-level of NT-
proBNP was higher in patients with coronary artery disease (n=74) than in those without 
coronary artery stenosis (n=105) (196.8±339.8 vs. 78.4±91.0 pg/mL, p=0.005). At the 
standard cutpoint of > 200 pg/mL, elevated BNP show high probability of coronary artery 
disease (odd ratio, 2.98; 95% CI, 1.4 to 8.2; p =0.006).We estimated the extent of coronary 
artery disease by the Gensini score. The Gensini score was computed by assigning the 
severity score to each coronary, according to the degree of luminal narrowing and its 
geographic importance. S-level of NT-proBNP was positively correlated with extent of 
coronary artery disease (r=0.347, p= 0.001). 
Conclusions: NT-proBNP will be a useful screening test for coronary artery disease in 
unstable angina patients with normal troponin I value and normal ECG.
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1090-226 Primary Percutaneous Coronary Intervention Compared 
With Thrombolysis for Acute Myocardial Infarction in 
Diabetes: Results From Randomized Trials of the PCAT 
Collaboration
Jorik R. Timmer, Jan Paul Ottervanger, Menko-Jan de Boer, Eric Boersma, Cindy 
Grines, Cindy Westerhout, Chris Granger, Felix Zijlstra, PCAT collaborators, Isala 
Klinieken, locatie Weezenlanden, Zwolle, The Netherlands, Erasmus Medical Center, 
Rotterdam, The Netherlands
Background: There is growing evidence for a clinical beneﬁt of primary percutaneous 
coronary intervention (PCI) compared to thrombolysis as reperfusion therapy in general. 
However, there are limited data whether this also applies to patients with diabetes.
Methods: Primary PCI was compared with thrombolysis for ST-segment elevation 
myocardial infarction (STEMI) in patients with diabetes, based on individual patient data 
derived from clinical trials on behalf of the PCAT collaboration study group. All patients were 
randomised to thrombolysis or primary PCI. Clinical end-points were mortality, re-infarction, 
and the combined end-point of mortality or non fatal re-infarction (MACE) after 30 days.
Results: A total of 6,315 patients were included of which 947 (15%) had diabetes. 
Patients with diabetes were older, were more often female, had more often previous 
myocardial infarction, and had a longer ischemic time. Mortality (8.8% vs. 5.9%, p<0.001) 
and incidence of MACE (12.4% vs. 9.8%, p= 0.01) were higher in patients with diabetes. 
Compared to thrombolysis, primary PCI was associated with a decreased mortality in 
patients with diabetes (OR 0.5; 95%CI: 0.3 - 0.8) and in patients without diabetes (OR 0.7; 
95%CI: 0.5 - 0.9). Recurrent infarction and MACE were also reduced after primary PCI in 
both patients with and without diabetes.
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Conclusion: Diabetic patients with STEMI treated with reperfusion therapy have an 
increased mortality compared to patients without diabetes. The beneﬁcial effects of 
primary PCI compared to thrombolysis in patients with diabetes, are at least equal to the 
effects in patients without diabetes.
1090-227 Long-Term Mortality of Diabetic Patients in Cardiogenic 
Shock Complicating Acute Myocardial Infarction
Michael E. Farkouh, Krishnan Ramanathan, Eve D. Aymong, John G. Webb, Shannon M. 
Harkness, Lynn A. Sleeper, Judith S. Hochman, NYU School of Medicine, New York, NY
BACKGROUND: The role of diabetes mellitus (DM) in cardiogenic shock (CS) 
complicating an acute myocardial infarction (AMI) is not well understood. Previous studies 
have reported an in-hospital mortality rate for DM patients with CS of > 60%. We sought 
to compare the 1-year mortality rates of DM and non-diabetic (NDM) patients and to 
evaluate the impact of a strategy of early revascularization (ERV) compared to initial 
medical stabilization (IMS) in DM patients with CS.
METHODS: Baseline characteristics, clinical and hemodynamic measures and 
management were compared for 90 DM (31%) and 198 NDM (69%) who were randomized 
to ERV or IMS in the SHOCK Trial. Cox proportional hazards regression was performed to 
evaluate the relationship between DM and treatment strategies for 1-year mortality.
RESULTS: When compared to NDM, DM were of similar age but had higher rates of 
prior MI (44.4 vs. 27.8%, p=0.007) and hypertension (56.2 vs. 42.5%, p=0.04). The DM 
group had lower rates of pulmonary artery catheterization (88.9 vs. 97.5%, p=0.007) 
and ﬁbrinolytic therapy (44.4 vs. 60.1%, p=0.02). For patients randomized to ERV, DM 
patients had a higher rate of coronary artery bypass grafting (CABG) (50.0 vs. 30.9%, 
p=0.03) despite similar rates of triple vessel disease. The rates of intra-aortic balloon 
counterpulsation and coronary angiography exceeded 80% in both NDM and DM.
The 1-year mortality rates in the DM and the NDM groups were equivalent (58.9%). One-year 
mortality was not associated with diabetes (hazard ratio 1.02, 95%CI 0.73 to 1.42, p=0.91). 
The magnitude of the beneﬁt of an ERV strategy was similar in the DM and NDM groups 
[hazard ratio (DM) 0.62, HR (NDM) 0.75, p=0.58]. Even after adjusting for the imbalance in 
CABG rates between DM and NDM, 1-year mortality was not associated with DM.
CONCLUSION: Diabetes mellitus is not a predictor of 1-year mortality in CS after AMI. 
The magnitude of beneﬁt from an ERV strategy is similar for DM when compared to NDM. 
The higher rate of CABG procedures in DM is unlikely to account for the lack of differences 
in mortality between DM and NDM. The inﬂuence of diabetes and the management 
strategies of DM on mortality in CS deserves further prospective evaluation.
1090-228 Automated External Deﬁbrillator Analysis Speciﬁcally 
Designed for Pediatric Patients
Dianne Atkins, Ian Law, Andrew Blaufox, William Scott, McDonald Dick, Wangcai Liao, 
Jamil Sohb, Frederick Geheb, James E. Brewer, University of Iowa, Iowa City, IA, ZOLL 
Medical Corporation, Chelmsford, MA
Background: Electrocardiographic (ECG) rhythm analysis algorithms in automated 
external deﬁbrillators (AEDs) have been evaluated against pediatric patient rhythms 
(patients ≤ 8 years old). However, tested algorithms were designed using adult ECG 
detection criteria. Using adult algorithms to detect nonshockable pediatric supraventricular 
tachycardia (SVT) has been difﬁcult. This study deﬁned shockable and nonshockable 
rhythm detection criteria speciﬁc to pediatric patients, developed a pediatric rhythm 
database (PRDB) of annotated rhythms and a pediatric-based AED rhythm analysis 
algorithm, and determined its accuracy.
Methods: Pediatric rhythm detection criteria were deﬁned for coarse ventricular ﬁbrillation 
(VF), rapid ventricular tachycardia (VT), and nonshockable rhythms, including pediatric 
SVT. Pediatric rhythms were collected as sustained, classiﬁable, rhythms ≥ 9 seconds 
in length, and were annotated by pediatric cardiologists as clinically shockable or 
nonshockable based on pediatric criteria. Rhythms were placed into a publicly-available 
pediatric rhythm database (PRDB); each rhythm was converted to digitally accessible, 
public-domain, MIT rhythm data format with sampling rate and bit resolution. PRDB was 
used to evaluate a pediatric-based AED rhythm analysis algorithm.
Results: There were 124 shockable rhythms from 49 patients (sensitivity (SE); coarse 
VF: 42 rhythms, 100%; rapid VT: 82 rhythms, 94%), for combined SE of 96.0% (119/124). 
There were 585 nonshockable rhythms from 155 patients (speciﬁcity (SP); normal sinus: 
208 rhythms, 100%; asystole: 29 rhythms, 100%; SVT: 161 rhythms, 99%; other sinus 
arrhythmias: 187 rhythms, 100%), for combined SP of 99.7% (583/585). Overall accuracy 
for shockable and nonshockable rhythms was 99.0% (702/709).
Conclusions: New pediatric rhythm detection criteria were deﬁned, and analysis based 
on these criteria demonstrated both high sensitivity (coarse VF, rapid VT) and high 
speciﬁcity (nonshockable rhythms, including SVT). A pediatric-based AED can correctly 
detect shockable rhythms, making it safe and exceptionally effective for children.
1090-229 Speciﬁcity Of Metabolic Abnormalities In Young 
Patients With Metabolic Syndrome And Acute 
Myocardial Infarction. Data From The Rico Survey
Marianne Zeller, Gilles Dentan, Isabelle L’Huillier, Michel Farnier, Luc Janin-Maniﬁcat, 
Jean-claude Beer, Yves Laurent, Alexandra Oudot, Hamib Makki, Bruno Vergès, Luc 
Rochette, Yves Cottin, on behalf of the RICO survey working group, University of 
Burgundy, Dijon, France
Background. Young patients with acute myocardial infarction (MI) are known to have a 
speciﬁc risk factor proﬁle, in particular for tobacco use and dyslipidemia. Little is known, 
however, about the prevalence and impact of metabolic syndrome (MS) in these patients. We 
investigated the occurrence and prognosis of MS in young adults (≤ 45 y) with acute (MI).
Patients. We analysed 663 patients included in the RICO survey (French regional survey for 
acute MI) between 1st January 2001 and 4th May 2004. MS was evaluated at the time of MI 
and was deﬁned according to the NECP/ATP III by 3 or more of the following criteria: fasting 
glycaemia ≥ 6.1 mmol/l, triglycerides ≥ 1.7 mmol/l, HDL-cholesterol <1.04 (M)/1.29 (F) mmol/l, 
blood pressure ≥ 130/85 mm Hg or waist circumference > 102(M)/88(F) cm. Patients were 
classiﬁed according to their age (young (≤ 45y) and old (>45y)) and to the presence of MS.
Results. Of the 663 MI patients included, 63(10%) were young (≤ 45y) (median(25th-
75th) age: 41(38-44) y). The prevalence of MS was similar for young and old patients 
(38 vs 46%, p=0.245). With regard to percentage of females and tobacco use, the data 
for young MS patients were similar to those for young non-MS patients (respectively, 
4 vs 10%, p=0.641 and 79 vs 72%, p=0.566). In contrast, old patients with MS had a 
higher percentage of females (40 vs 15 %, p<0.001) and lower tobacco use (18 vs 34 %, 
p<0.001) than patients without MS. Among patients with MS, abnormal fasting glycemia 
(203(82%)) and hypertension (218(82%)) are predominant in old patients, while low HDL 
(23(96%)) and elevated triglycerides levels (19(79%)) are the major components of MS 
in young adults with acute MI.
Conclusion : The prevalence of MS is high but similar for young and old patients with 
acute myocardial infarction. However, young patients with MS are characterized by a 
predominance of abnormal serum lipid concentrations. These ﬁndings suggest a metabolic 
abnormality proﬁle speciﬁc to young patients with myocardial infarction and therefore 
deﬁne a potential therapeutic target in risk factor management in these patients.
1090-230 Statin Therapy is More Beneﬁcial for Resolving 
Thrombus of the Culprit Lesion Following Acute 
Myocardial Infarction
Takahiro Hayashi, Naoya Kobayashi, Masafumi Ueno, Takuo Ishise, Yukiko Miyamura, 
Takashi Kiyoshima, Masayoshi Matsuura, Hajime Nakamura, Nobutaka Masunaga, 
Hiroshi Yabushita, Atsuhiro Kurooka, Mitsugu Taniguchi, Akio Kimura, Kinji Ishikawa, 
Kinki University School of Medicine, Osakasayama, Japan
Backgrounds: Thrombus at the culprit lesion in acute myocardial infarction (AMI) will 
remain for weeks or months after onset. We hypothesized that statins would help to 
resolve thrombus of the culprit lesions following AMI.
Methods: We studied 188 AMI patients (161 men, 61.2+/-8.9 years) who had percutaneous 
coronary stenting within 24 hours after onset. Stented segments were classiﬁed into those 
with or without thrombus using angioscopy at 1 month (36+/-5 days, n=69), 3 months 
(81+/-40 days, n=49), 6 months (198+/-13 days, n=52) and 9 months later (266+/-42 days, 
n=18). We investigated the effect of statins on the resolution of thrombus at the stented 
segments, retrospectively.
Results: Results are shown in the table. The prevalences of thrombus on the stented 
segments are 73.9%, 53.1%, 26.9% and 16.7% at 1 month, 3 months, 6 months and 9 
months after onset, respectively. The patients taking statins showed a lower prevalence 
of thrombus of the stented segments than those without statins through the observation 
period. 99.5%, 85.6% of patients were taking aspirin, ticlopidine.
Conclusions: AMI patients have thrombus in the culprit lesion over the long term. Statins 
achieved a reduction of thrombus in the culprit lesion, which promoted potent plaque 
stability and antiplatelet and antithrombotic actions.
Table. Prevalences of thrombus on stented segments  
between patients with and without statins 

























1090-231 The Prognostic Impact of Transient Hyperglycemia 
During Acute Myocardial Infarction in Non-Diabetic 
Patients who Undergo Primary Percutaneous Coronary 
Intervention
Shahar Lavi, Michael Kapeliovich, Luis Gruberg, Arthur Kerner, Monther Boulos, Ehud 
Grenadier, Shlomo Amikam, Doron Aronson, Walter Markiewicz, Rafael Beyar, Haim 
Hammerman, Rambam Medical Center, Haifa, Israel
Background: Transient hyperglycemia is common during acute myocardial infarction (AMI) 
in non-diabetic patients. The outcome of patients who undergo primary percutaneous 
coronary intervention (PCI) and have transient hyperglycemia is unknown. 
Methods: Blood glucose was measured after fasting in 387 consecutive patients who 
underwent primary PCI. Patients were divided into three groups: normoglycemic (fasting 
glucose <126mg/dl; n=196); fasting hyperglycemia (fasting glucose≥126mg/dl ; n=113); 
and overt diabetics (n=78).
Results: In hospital mortality was signiﬁcantly lower in normoglycemic compared to 
hyperglycemic and diabetic patients. At one year, the combined endpoint of death and 
target lesion revascularization (TLR) was lower in normoglycemic patients (HR: 0.28, 
CI=0.1-0.44, p<0.0001; vs. diabetics) whereas the outcome of patients who had transient 
hyperglycemia was intermediate (HR: 2.1, CI=1.1-4.3, p=0.02, vs. normoglycemic) and 
non signiﬁcantly different from diabetics. One year mortality was highest in patients with 
transient hyperglycemia (p=0.01). One year TLR rates were identical in normoglycemic 
and hyperglycemic patients (6% vs. 8%) and higher in diabetic patients (19%, p=0.001). 
Conclusions: 1) Transient hyperglycemia in non-diabetic AMI patients who undergo 
primary PCI is associated with higher in hospital and one year mortality. 2) One year 
TLR rates were signiﬁcantly higher in diabetics compared to normoglycemic and transient 
hyperglycemic patients
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1090-232 High Continuation Rate of Statin Treatment Among 
Patients With Acute Myocardial Infarction
Jeppe N. Rasmussen, Gunnar Gislason, Steen Z. Abildstrom, Søren Rasmussen, 
Pernille Buch, Steen Stender, Christian Torp-Pedersen, Mette Madsen, National Institute 
of Public Health, Copenhagen, Denmark, Bispebjerg University Hospital, Copenhagen, 
Denmark
Background: Most population-based studies of statin adherence are hampered by 
studying selected populations only. We have studied the unselected population of all 
acute myocardial infarction (AMI) patients of an entire nation (Denmark).
Method: Via the national patient registry, all patients aged 30 years or older discharged 
alive after a ﬁrst AMI from 1995-2002 were identiﬁed. Via the national prescription registry, 
containing all prescriptions ﬁlled in Danish pharmacies, each patient’s long-term statin 
use was determined.
Results: A total of 58,420 patients were identiﬁed. Of these, 26,810 used statins at some 
point after discharge. In 1995, 10% used statins within 6 months after discharge, this 
increased to 56% in 2002. Between 6 months and 2 years after discharge, an average of 
only further 10% initiated statin,
and this proportion was decreasing during the period (test for linear trend p<0.001).
Among patients using statins, the proportion of days covered (days with a pill available 
divided by days of observation) was 84%. After 4 years of observation, 50% of the patients 
had had no pauses longer than 30 days and 70% had had no pauses longer than 90 
days. After 7 years, only 21% had had a pause of 365 days or more, including those who 
discontinued treatment (Fig.).
Conclusion: If AMI patients receive statin treatment, a large proportion continues 
treatment for many years. If patients are not receiving statin treatment within 6 months 
after discharge, only few additional patients will initiate treatment.
1090-233 The Streptokinase Regimen in Myocardial Infarction 
Should be Changed. Final Report of the Romanian 
Study for Accelerated Streptokinase in ST-Elevation 
Myocardial Infarction (ROMAS).
Gabriel Tatu-Chitoiu, Cristina Teodorescu, Monica Dan, Manuela Guran, Petre Capraru, 
Oana Istratescu, Alexandrina Tatu-Chitoiu, Aurelia Bumbu, Valentin Chioncel, Maria 
Dorobantu, Spitalul Clinic de Urgenta, Bucharest, Romania
Background. The streptokinase (SK) regimen (1.5 MU/30 -60 min.) in the ST-elevation 
myocardial infarction STEMI) remained unchanged for the last 20 years.
Objective. To compare the safety and efﬁcacy of two accelerated SK regimens with the 
one of the classical SK 1.5MU/30-60min. in patients (pts.) with STEMI.
Methods. A group of 1142 consecutive pts. were thrombolised within the ﬁrst 6 hours after 
the onset of STEMI with one of the following four SK regimens: 1.SK1.5MU/60 min. (310 
pts.); 2. SK 1.5MU/30 min. (168 pts.); 3. SK 1.5 MU/20min (377 pts.); 4.SK0.75MU /10 min. 
repeated after 50 min.if non-invasive signs of coronary reperfusion (CR) were detected 
(287 pts.). The CR criteria were: 1.Rapid cessation of the chest pain. 2.Rapid decrease 
of the ST elevation by more than 50% from the initial value. 3.Rapid increase of CK and 
CK-MB with a peak within the ﬁrst 12 hrs.
Results. Similar rates of CR (73.20%, respectively 73.51%) recorded in the SK1.5/20 
and SK0.75/10 were higher that the one of 63.20% obtained with SK1.5/60 (p=0.006 
and p= 0.009) but not signiﬁcant higher that the one of 69.64% obtained with SK1.5/30. 
The in-hospital mortalities were: 13.54% (SK1.5MU/60), 10.71% (SK1.5MU/30), 9.54% 
(SK1.5MU/20) and 10.80% (SK0.75/10) - non-signiﬁcant differences. In pts. younger than 
75 mortalities from the SK1.5/20 (6.93%) and SK0.75/10 (6.91%) groups were lower that 
the one of 12.32% recorded with SK1.5/60 (p=0.027 and p= 0.048). In the SK1.5/30 group 
mortality was 8.60% (not signiﬁcant different compared with the other three SK regimens). 
The incidence of hemoragic stroke was 0.64% (SK1.5/60) 0.0% (SK1.5/20 and SK1.5/30) 
and 0.53% (SK0.75/10). The rates of SK-induced hypotension of 47.33% (SK1.5/20), 
44.11% (SK0.75/10) and 42.51% (SK1.5/30) were signiﬁcant higher that the one of 11.61% 
recorded in the SK1.5/60 group.Hypotension disappeared within 15 min. in all pts.
Conclusions. 1. The classical SK1.5 MU/60 min. is not the best SK regimen.Higher rates 
of CR and lower mortalities can be obtain with two accelerated SK regimens at least 
in pts. younger than 75, without an increased risk. 2. The SK 1.5/30 regimen has an 
intermediate efﬁcacy between the SK1.5/60 and SK1.5/20 or SK0.75/10 ones.
1090-234 Platelet Function Inhibition by Abciximab is Dependent 
on Time to Treatment in ST Elevation Myocardial 
Infarction. ERAMI Substudy.
Luis J. Sargento, Henrique Mesquita Gabriel, J. Marques Costa, P. Canas Silva, J. 
Oliveira, J. Correia Cunha, M. Celeste Vagueiro, Serv. Cardiologia Hosp Sta Maria, 
Lisboa, Portugal
Background: Time dependency is well established for thrombolysis in ST elevation 
myocardial infarction (STEMI), but not for antiplatelet treatment. The aim of the present 
work is to evaluate the relationship between the pain to abciximab(ABC) bolus time (PBT) 
and the level of platelet function inhibition (PltFIn) achieved, in STEMI patients undergoing 
primary PCI.
Methods: Eighty patients (pts) with STEMI participating in ERAMI trial were included in 
the substudy. All pts were submitted to a 0.25 mg/kg ABC bolus. PltFIn determined with 
Ultegra at admission and after the bolus, and the PltAgIn rate determined, and grouped 
according to two pre-speciﬁed rates (80% and 95%). Sixty six pts completed all protocol 
determinations. Pts grouped by PBT into tercis (120 and 240 min). Statistics: Qui square, 
Fisher test’s with odds ratio (OR) determination, and Pearson correlation coefﬁcient.
Results: (1) There is an indirect signiﬁcant correlation between PBT and PltFIn rate (r= 
-0.31 p= 0.022). (2) A PltFIn rate lower than 95% was increasingly frequent with longer 
duration of PBT: 10%, 40.0% and 47.6%, respectively for < 120 min, < 240 min, and 
greater than 240 min. (3) Pts in the lower tercil (< 120 min) were more likely to reach the 
95% PltFIn rate (p= 0.009; OR 0.142 (0.029-0.693)) in relation to the other two tercis.
Conclusion: The earlier the administration of the ABC bolus after STEMI, the greater 
the effect in PltFIn rate.
Fig.- PltFIn rate dependency on pain to abciximab bolus time (tercis). 
1090-235 Relation Between Prothrombotic Markers and Eearly 
Spontaneous Patency in Acute Myocardial Infarction. 
An Acute Study of in Patients Triaged to Primary 
Angioplasty
Marie-Genevieve Huisse, Emilie Lanoy, Annie Bezeaud, Dominique de Prost, Anne 
Dauphin, Eduardo Angles-Cano, Murielle Mary-Krause, Marie-Claude Guillin, Ph. 
Gabriel Steg, Hopital Bichat, Paris, France, INSERM EMI 0214, Paris
Background: The determinants of spontaneous early coronary recanalization in acute 
myocardial infarction (AMI), are poorly understood. We hypothesized that the extent of 
platelet and leukocyte activation, thrombin generation and/or endothelial damage might 
differ between patients with early spontaneous recanalization or persistent occlusion at 
the time of emergent coronary angiography. 
Methods: The study was conducted in 126 consecutive pts admitted with ST elevation 
AMI within 12 hours of pain onset (median 2.2 h) and triaged to primary angioplasty. All 
pts received aspirin, 5000 U of heparin and underwent immediate coronary angiography, 
53 pts had TIMI 2/3 ﬂow and 73 TIMI 0/1 ﬂow in the infarct artery. Blood samples were 
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collected and processed immediately before angiography to measure platelet activation 
markers (P-Selectin and PAC-1) and circulating microparticles (MPs) originating from 
platelets, granulocytes (Gr.) and endothelial cells (Endo.). Soluble platelet glycoprotein 
V (sGPV), thrombin-antithrombin complexes (TAT) were measured as markers of 
thrombin generation. Plasmin-antiplasmin complexes (PAP), tissue plasminogen activator 
(tPA), plasminogen activator inhibitor (PAI-1) were measured as endothelial markers. 
Comparisons used logistic regression adjusting on baseline characteristics.
Results: Baseline characteristics were similar between groups except for more frequent 
history of hypertension (p=0.016)or dyslipidemia (p=0.045) in pts with TIMI 0/1 ﬂow. 
Groups differed by markers oif thrombin generation and endothelial injury which were 
lower among pts with TMI 2/3 ﬂow: speciﬁcally sGPV (53 vs 64 ng/ml,adjusted p=0.002), 
endo.MPs (12 vs 18 N/µl, adjusted p=0.009) and PAP (88 vs 112 ng/ml, adjusted p=0.037). 
Categorization of pts using TIMI 3 vs 0/1/2 provided similar trends.
Conclusion: Spontaneous recanalization of the infarct artery compared to persistent 
occlusion.appears associated with reduced endothelial injury and thrombin generation, 
but not with platelet activation This implies that improved inhibition of thrombin generation 
might be more effective than additional antiplatelet therapy for improving acute 
spontaneous patency.
1090-236 The Inﬂuence of Ximelagatran on Plasma 
Concentration, aPTT and D-dimer in Patients With 
Recent Myocardial Infarction
Christina Christersson, Jonas Oldgren, Anders Bylock, Lars Wallentin, Agneta 
Siegbahn, Uppsala University, Uppsala, Sweden
Background: In the ESTEEM study, the risk for new thrombotic events after a myocardial 
infarction was reduced by placebo controlled long-term treatment with the oral direct 
thrombin inhibitor ximelagatran, but there was no dose-effect response. We evaluated 
the inﬂuence of the four different doses of ximelagatran on plasma concentration of 
melagatran (the active compound), aPTT and D-dimer.
Methods and Results: Patients were randomized 6 days (mean) after a myocardial 
infarction to six months treatment with one of four doses of ximelagatran (or placebo) 
twice daily together with aspirin 160 mg once daily. Venous blood samples were obtained 
after 1 and 26 weeks in 339 out of the 1245 ximelagatran patients. For D-dimer, the 
change (�D-dimer) from randomization was individually calculated for each time-point. 
Results in the table are median levels of plasma concentration, aPTT and �D-dimer after 
1 week, trough and peak, with Spearman rank correlations at peak (*p<0.001) and within-
group comparisons by Kruskal Wallis test†. Similar results were found after 26 weeks.
Conclusion: There was a dose-dependent well-correlated increase in plasma 
concentration of melagatran and aPTT. However all four ximelagatran dose groups 
equally decreased D-dimer levels, without correlation to plasma concentration or aPTT. 
The similar inﬂuence on D-dimer levels, indicating decreased thrombin generation and 
ﬁbrin turnover, corresponded to the equal clinical efﬁcacy of all four ximelagatran doses 
in the ESTEEM study.
P-conc, 
(nmol/L) aPTT, (sec) Conc-aPTT
ΔD-dimer, 
(µg/L) Conc-ΔD-dimer
trough peak trough peak Correlation trough peak Correlation
24 mg 84 291 33 42 r=0.23 -28 -35 r=-0.14
36 mg 141 415 37 47 r=0.67* -33 -40 r=-0.18
48 mg 222 590 40 52 r=0.68* -23 -38 r=-0.15
60 mg 261 760 41 53 r=0.81* -37 -59 r=-0.05
p† <0.001 <0.001 <0.001 <0.001 0.44 0.41
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1091-215 Randomized Trial of Biphasic Atrial Flutter 
Cardioversion
Kai Mortensen, Tim Risius, Tjark F. Schwermer, M. Ali Aydin, Simone Henne, Michelle 
Ortak, Boris Lutomsky, Thomas Hofmann, Andreas Schuchert, Stephan Willems, Heart 
Center, University of Hamburg, Hamburg, Germany
Background: Biphasic shocks have been shown to be potentially beneﬁcial for ventricular 
deﬁbrillation and atrial ﬁbrillation cardioversion. In this prospective trial we evaluated the 
amount of delivered current neccessary for successful cardioversion using rectilinear biphasic 
shocks in patients with common type atrial ﬂutter. Additionally, the electrode conﬁguration 
“anterior-posterior” vs. “anterior-lateral” was determined in a randomized approach.
Methods:  48 consecutive patients (pts.) (61 ± 13 years, male=31) who were admitted to 
our emergency room with acute common type atrial ﬂutter underwent transthoracic DC 
cardioversion using a Zoll M-Series deﬁbrillator with Zoll MFE pads. Patients included 
received a step-up-protocol: 50, 75, 100, 150 or 200 Joule (J.), if necessary. All patients 
were randomized to either “anterior-posterior” (24 pts.) or “anterior-lateral” (24 pts.) 
electrode conﬁguration. Successful cardioversion was deﬁned as the cardioversion of 
atrial ﬂutter to sinus rhythm for ≥30 s after the shock.
Results:  External cardioversion of atrial ﬂutter was successful in all patients. The ﬁrst 
shock with the lowest energy of 50 J was effective in 23 pts. (48%). In 16 pts. (33%) a 
second shock of 75 J was successful, 4 pts. (8%) needed a shock of 100 J. 150 Joule were 
administered to 2 ( 4%), 200 Joule to 2 (6%) pts.
Between the different electrode positions was no signiﬁcant difference concerning the 
mean delivered current (anterior posterior 76 ± 31 J. versus 76 ± 47 J.). The anterior-
lateral was superior to anterior-posterior electrode conﬁguration concerning the ﬁrst 
sucessful shock (62%/24 pts. vs. 33%/24 pts.).
The two groups were similar with respect to age, sex, weight, underlying cardiac disease, 
duration of atrial ﬂutter and use of medication.
Conclusions: Our data shows a low success rate (<50%) for the ﬁrst biphasic shock 
with 50 J. of atrial ﬂutter. 81 % of the pts. were successfully cardioverted with a maximum 
energy of 75 Joule. In conclusion we recommend to start biphasic external cardioversion 
of common type atrial ﬂutter in an emergency room setting with 75 Joule using antero-
lateral electrode position.
1091-216 Disparities by Sex in Timing of Initial Electrocardiogram 
for Patients Presenting with Acute Coronary Syndromes
Deborah B. Diercks, Matthew T. Roe, Anita Y. Chen, Eric D. Peterson, L. Kristin Newby, 
J. Douglas Kirk, Charles V. Pollack, Jr., W. Brian Gibler, James W. Hoekstra, Sidney C. 
Smith, E. Magnus Ohman, Judith S. Hochman, University of California-Davis Medical 
Center, Sacramento, CA
Background: Guidelines for managing patients with non-ST-segment elevation acute 
coronary syndromes (NSTE ACS) recommend that an electrocardiogram (ECG) be 
obtained within 10 minutes of hospital arrival, but data on the impact of sex on the timing 
of the initial ECG are limited.
Methods: Using data from the CRUSADE Quality Improvement Initiative, we compared 
the clinical features of 63,478 high-risk patients (26,615 women [42%]) with NSTE ACS 
(designated by positive cardiac markers and/or ischemic ST-segment changes) presenting 
to the emergency department according to the presence of a delay in initial ECG acquisition. 
Patients were categorized as delayed (>10 minutes from hospital arrival to ECG acquisition) 
or non-delayed. Multivariate predictors of delayed ECG acquisition were determined.
Results: A total of 41,397 patients (65.2%) had a delayed ECG. Women were more likely 
than men to have a delayed ECG (69% vs. 62%). Female sex was the most signiﬁcant 
predictor of delayed ECG, followed by non-cardiology inpatient care, non-white race, 
insurance status, type of institution, and diabetes (Table).
Multivariate Predictors of Delayed (>10 Minutes)  
ECG Acquisition 
Variables Adjusted OR (95% CI) Chi-Square
Female (vs. male) 1.29 (1.25-1.34) 253.0
Off hours (nights and weekends) 0.86 (0.83-0.90) 50.0
Prior PCI 0.86 (0.82-0.90) 48.3
Non-white (vs. white) 1.16 (1.10-1.22) 33.8
No insurance (vs. HMO/private) 0.88 (0.82-0.94) 29.8
Medicaid insurance (vs. HMO/private) 1.07 (1.00-1.14)
Medicare insurance (vs. HMO/private) 1.06 (1.02-1.10)
Current/recent smoking 0.91 (0.87-0.94) 23.3
Diabetes mellitus 1.07 (1.03-1.10) 14.4
Conclusion: Only 35% of high-risk NSTE ACS patients had an initial ECG within 10 
minutes of hospital arrival. Women are more likely than men to have a delayed ECG. 
Since the initial ECG is the earliest triage tool for NSTE ACS and ST-segment elevation 
MI care pathways, emergency departments should focus on reducing the time to initial 
ECG acquisition in women to improve care in these patients.
1091-217 Internal Thoracic Impedance Monitoring: A New 
Possibility in Early Diagnosing and Treatment of Acute 
Heart Failure.
Michael Shochat, Gidon Charach, Aaron Frimerman, Mark Kazatzker, Samir Daka, Paul 
Rabinovich, Avraham Shotan, Simcha Meisel, Hillel Jaffe Heart Institute, Hadera, Israel, 
Ichilov Hospital, Tel Aviv, Israel
Treatment of acute heart failure (AHF) is initiated currently only after the appearance 
of clinical signs such as dyspnea, lung rales (LR), and blood desaturation. These signs 
signify the alveolar stage of pulmonary edema. Identiﬁcation of the interstitial stage of 
AHF, when clinical signs are absent, may enable earlier therapy and prevent the onset of 
overt AHF. We evaluated the newer impedance monitor that allows recognition of small 
ﬂuid shifts in the lung as a means to predict evolving pulmonary edema. Study population 
included AMI patients without clinical and X-ray signs of AHF. Patients were monitored 
and internal thoracic impedance (ITI), respiratory rate (RR), heart rate (HR), level of LR 
and blood oximetry (BO) were measured.
382 patients with AMI were studied. Of these, 313 remained without AHF (group 1), 51 
patients developed AHF throughout monitoring (group 2), 18 received early treatment 
(group 3). Group1 patients did not manifest any signs of AHF and ITI decreased in this 
group by 4.8±2.8% (NS) from initial value (range, 0-11.5%). All group 2 patients developed 
mild AHF, 78% progressed to moderate AHF and 55% advanced to full pulmonary edema. 
ITI in patients with mild AHF decreased from initial value by 21.7±3.8% (13-28.9%), with 
moderate AHF, ITI further decreased by 26.8±5.5% (p<0.05) (range, 19.5-37.9%) and in 
full pulmonary edema showed an ITI decrease of 34.6±7.5% (25.7-53.3%, p<0.05). All 
patients in whom ITI decreased >12% developed AHF. Therefore, an ITI decrease of 12% 
was determined to represent AHF threshold. Time interval from reaching threshold level 
to onset of LR was minimum 30 min.
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Based on this experience we began to treat AMI patients with an ITI decrease>12% despite 
the absence of AHF. Therapy was initiated in 18 patients at ITI decrease of 13.7±1.61%. 
16 patients did not develop AHF. Only 2 patients developed mild AHF. This response was 
considerably different than expected (p< 0.0001 by � 2 test). Conclusions. The extent of 
lung impedance decrease correlated with stage of AHF. The impedance monitor enabled 
the diagnosis of AHF in its preclinical stage, at least 30 before the appearance of LC. Early 
ITI-guided therapy may prevent AHF at its preclinical stage in most patients with AMI.
1091-218 Endografting For Traumatic Aortic Injury
Taro Shimazaki, Shin Ishimaru, Satoshi Kawaguchi, Yoshihiko Yokoi, Kenji Koide, Tokyo 
Medical University, Tokyo, Japan
Purpose: Patients that sustain traumatic aortic injuries often have multiple concomitant 
injuries (e.g., brain contusion, hematopneumothorax, leg fractures), which increases this 
risks associated with conventional open surgery. This study evaluates the safety and 
efﬁcacy of less invasive procedure, endografting, for traumatic aorta injury.
Methods: Between September 1996 and March 2004, 25 patients with traumatic aorta 
injury (20 men, 5 women; age range, 20-79 years; mean age, 47 years) underwent 
endografting. Etiologies of traumatic aortic injury included motor vehicle accidents (n=17), 
falls (n=7), and assault (n=1). The timing of endografting after the precipitating events was 
deﬁned as the acute phase (0-3 days; n=11), the subacute phase (3-30 days; n=6) or the 
chronic phase (greater than 30 days; n=8). Aortic injury occurred at the aortic isthmus in 
all but one case, and a proximal landing zone of at least 15 mm from left carotid artery 
was required before endografting was elected. Endografting was performed under general 
anesthesia, and an original device, constructed from a self-expanding Z shaped stent and 
thin-wall woven polyester fabric, was used in all cases. The activated coagulation time 
was maintained >200 seconds by the administration of 50 unit/kg heparin intravenously 
before the sheath insertion.
Results: Endografting was technically successful in all cases. The mean operating 
duration was 188 minutes, and the mean estimated blood loss was 236 ml. One case with 
subarachnoid hemorrhage sustained during a motor vehicle accident died on the seventh 
postoperative day secondary to rupture of the ascending aorta. Another patient with 
pelvic fractures underwent endografting without resulting endoleak but died secondary to 
exsanguination from a chest drain.
Conclusion: Endografting is an effective method for management of traumatic aortic 
injury and does not require cardiopulmonary bypass with high dose heparin. Therefore, 
endografting may be preferable to conventional surgery for management of traumatic 
aorta injury in select populations.
1091-221 “Cath Alert” and Transmission of a Prehospital 12-Lead 
Electrocardiogram Can Shorten Door-to-Balloon Times 
in Patients With ST-Segment Elevation Acute Myocardial 
Infarction
Howard S. Bush, Allen Brown, Kenneth Fromkin, Gian Novaro, Michael Shen, Craig 
Asher, Sergio Pinski, Cleveland Clinic Florida, Weston, FL, Miami-Dade EMS, Miami, FL
Background: Primary percutaneous coronary intervention (PCI) is the preferred method of 
revascularization for patients with ST-segment elevation acute myocardial infarction (STEMI). 
A main outcome determinant after PCI for STEMI is door-to-balloon time (DBT). DBT can 
be reduced with implementation of strategies for rapid cath lab deployment. This goal could 
be achieved by the “cath alert”, i.e., pre-hospital notiﬁcation/mobilization of a cath lab team, 
especially when combined with transmission of a diagnostic 12-lead electrocardiogram (ECG).
Methods: We tested this hypothesis in 153 consecutive patients (age 61±13, 131 male) 
that presented to our emergency department (ED) with STEMI and underwent primary 
PCI. Exclusion criteria: prior lytics or hospital transfer. Results: 42 patients (pts) self-
presented to the ED and 111 were brought by emergency medical services (EMS), of 
which 106 had pre-hospital notiﬁcation and 90 of these included transmission of a pre-
hospital ECG. The DBT was shorter as more pre-hospital information became available 
to the cardiac team (p<0.001, ANOVA) (Figure). The longest DBT of 106±38 minutes 
occurred in pts who self-referred to the ED; the shortest DBT time of 54±22 minutes 
occurred in those with “cath alert” plus pre-hospital ECG.
Conclusion: The use of “cath alert”, especially when combined with transmission of a 
pre-hospital ECG results in a shorter DBT. The clinical beneﬁt of pre-hospital strategies 
aimed at reducing DBT needs to be prospectively evaluated.
1091-222 Atrial Flutter: Is Biphasic Superior to Monophasic 
External Cardioversion? A Randomized Comparison
Tim Risius, Kai Mortensen, Tjark Schwemer, M. Ali Aydin, Simone Henne, Ralf Köster, 
Thomas Hofmann, Stephen Willems, University Hospital Hamburg - Eppendorf, 
Hamburg, Germany
Biphasic shocks have been shown to be more effective than monophasic shocks for 
ventricular deﬁbrillation and atrial ﬁbrillation cardioversion. In this prospective randomised 
trial we evaluated the efﬁcacy of damped sine wave monophasic to rectilinear biphasic 
shocks in patients with common type atrial ﬂutter. 
Methods: 95 consecutive patients (61 ± 13 years, male=67) who were admitted to the 
emergency room with common type atrial ﬂutter underwent transthoracic DC cardioversion 
using either a Physio-Control Lifepak 8 DC deﬁbrillator with Medtronic Fast-Patch Plus 
Deﬁbrillation/ECG-Electrodes (monophasic) or a Zoll M-Series deﬁbrillator with Zoll MFE 
pads (biphasic). Patients randomized to the monophasic protocol received sequential 
shocks of 100, 150, 200, 300 and 360 J, if necessary. Patients randomized to the biphasic 
protocol received 50, 75, 100, 150 or 200 J, if necessary. Successful cardioversion was 
deﬁned as the cardioversion of atrial ﬂutter to sinus rhythm for ≥30 s after the shock. 
Results: External cardioversion of atrial ﬂutter was successful in all patients, the max. 
energy was necessary in 4 cases of the monophasic group, in the biphasic group in 3 
cases. The ﬁrst shock with the lowest energy was effective in n=23 in the biphasic group 
and n=13 in the monophasic group. Successful cardioversion could be achieved with a 
mean of 76 ± 39 J for biphasic and 175 ± 80 J for monophasic cardioversion. The two 
groups were similar with respect to age, sex, weight, underlying cardiac disease, duration 
of atrial ﬂutter and use of medication.
Conclusions: Monophasic and biphasic cardioversion showed similar high success rates. 
Biphasic shocks signiﬁcantly reduced the amount of delivered current in patients with 
common type atrial ﬂutter. Our data suggests that the preferred method for transthoracic 
DC cardioversion of atrial ﬂutter is the application of biphasic rectilinear shocks.
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1092-219 Short-Term and Long-Term Outcomes of Off-Pump and 
On-Pump Coronary Artery Bypass Graft Surgery: The 
Canadian Off-Pump CABG Registry
Andre Lamy, Forough Farrokhyar, Rosanne Kent, Xiaoyin Wang, On behalf of the 
Registry Investigators, McMaster University, Hamilton, ON, Canada
Background: To examine the early and one-year clinical outcomes of CABG surgery. 
Methods: From 2001 to 2002, 1657 patients had off-pump and 1693 had on-pump 
CABG surgery. At one year, patients were interviewed by telephone (follow-up = 98%). 
Clinical events and memory status were recorded. Treatment bias was controlled for by 
constructing a propensity score. Adjusted rates, odds ratios, and 95% conﬁdence intervals 
are reported. Results: At baseline, the rate of renal dysfunction, previous stroke, carotid 
stenosis, pulmonary hypertension, chronic obstructive pulmonary disease, peripheral 
vascular disease were higher in off-pump CABG and left ventricular (LV) ejection fraction, 
chronic heart failure, previous myocardial infarction (MI) and LV aneurysm were higher in 
on-pump CABG. Hospital length of stay was signiﬁcantly lower in off-pump CABG than in 
on-pump CABG (7.4+8.1 vs. 9.0+11.0, p<0.01). 
Post-operative, Follow-up and One-year Adjusted Rates and Odds Ratios 
Post-operative Follow-up One-year
Off-pump/On-pump Off-pump/On-pump Off-pump/On-pump
Mortality 1.3/1.2(1.04;0.58-1.88) 1.8/1.9(0.96;0.57-1.59) 3.2/3.2(1.00;0.68-1.48)
MI 3.0/1.4(2.18;1.31-3.62)* 0.6/1.3(0.46;0.21-1.00) 3.5/2.7(1.30;0.87-1.96)
Stroke 1.0/1.3(0.77;0.41-1.45) 0.7/1.2(0.60;0.27-1.31) 1.3/2.4(0.55;0.40-1.09)*
Revascularization 0/0 1.7/1.6(1.05;0.60-1.83) 1.7/1.6(1.05;0.60-1.83)
Angiogram 0/0 3.5/4.0(0.87;0.58-1.31) 3.5/4.0(0.87;0.58-1.31)
Recurrent angina 0/0 10.8/17.3 (0.62;0.49-0.72)* 10.8/17.3 (0.62;0.49-0.72)*
* p<0.05
At one-year, the adjusted rates of mortality and MI were similar between off-pump and on-
pump CABG but a 45% reduction of stroke rate was evident in off-pump CABG patients. 
Conclusion: Results from a multicenter registry across Canada demonstrate that 
surgeons use off-pump CABG in patients with more co-morbidities but with a better 
cardiac function. This registry has shown the safety and efﬁcacy of off-pump CABG and 
that the results are comparable to that of on-pump CABG. We propose that off-pump 
CABG should be incorporated into national guidelines as an acceptable technique for 
coronary revascularization.
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1092-220 Outcomes After Coronary Artery Bypass Grafting in 
Non-Dialysis Dependent Renal Failure Patients
Hasmet Bardakci, Veli K. Topkara, Faisal Habib Cheema, Nicholas C. Dang, Timothy 
Paul Martens, Isaac George, Satish Kesavaramanujam, P. B. Namerow, Mehmet C. Oz, 
Donald W. Landry, Columbia University College of Physicians & Surgeons, New York, NY
Background: Preoperative renal insufﬁciency is a risk factor for morbidity and early 
mortality in patients undergoing CABG.
Methods: The New York State Department of Health Multicenter Database (1997-99) 
was analyzed for 56457 patients undergoing CABG without requirement for preoperative 
dialysis. The control group (CTR) with serum creatinine < 2.5 (n=55408) was compared 
with the renal failure group (RF) with serum creatinine > 2.5 mg/dL (n=1049).
Results: RF group had a higher incidence of postoperative dialysis-dependent renal 
failure (10.4% vs 0.8%, p<0.001), stroke (4.6% vs 1.9%, p<0.001), sepsis (2.8% vs 0.8%, 
p<0.001), re-operation for bleeding (3.4% vs 2.2%, p=0.005), gastrointestinal bleeding 
(2.6% vs 0.8%, p<0.001), and respiratory failure (11.5% vs 3.8%, p<0.001). Hospital 
length of stay was longer in the RF group compared to CTR (20.4+/-24.0 days vs 10.8+/-
11.9 days, p<0.001). Early mortality rate was higher and rate of discharge to home was 
lower in RF (4.4% vs 1.5% and 66.0% vs 85.3%, p<0.001). Multivariate analysis identiﬁed 
increased age, female gender, emergent operation, decreased EF and Off-pump CABG 
as independent risk factors for early mortality (Table).
Conclusion: CABG patients with renal failure have signiﬁcantly increased renal and 
non-renal morbidity compared to patients with normal or slightly impaired renal function. 
CABG patients with signiﬁcant renal failure are an appropriate subgroup for aggressive 
strategies such as off-pump CABG and hemodialysis on bypass.
Multivariate Analysis of Non Dialysis Dependent Renal Failure:  
Early Mortality 
Risk Factor Variable Estimate
Standard 
Error p-value Odds Ratio 95% CI
Age 0.478 0.184 0.010 *1.612 1.123-2.314
Female 0.790 0.326 0.016 2.204 1.162-4.178
Hepatic Failure 2.572 1.440 0.074 13.090 0.779-220.061
Emergent 1.253 0.443 0.005 3.501 1.469-8.343
Ejection Fraction % -0.271 0.112 0.016 **0.762 0.612-0.950
Off pump surgery -1.214 0.539 0.297 0.024 0.103-0.854
* Odds ratio for every 10 years of age
** Odds ratio for every 10% of ejection fraction
Hosmer-Lemeshow Goodness of Fit Test: p-value = 0.153
1092-223 The Effect Of Cardiopulmonary Bypass On Cell 
Junctions; Catenins, Cadherins and Connexins
Tamer A. Malik, Cesario Bianchi, Frank W. Sellke, Beth Israel Deaconess Medical 
Center, Boston, MA
Background: The post operative course of patients going for cardiac surgery with 
blood cardioplegia (CP) and cardiopulmonary bypass (CPB) is often associated with 
arrhythmias and increased interstitial ﬂuid content. It is hypothesized that this may be due 
to altered distribution or degradation of gap junctions and/or adherens junctions. Thus, 
we studied the effect of CPB on different cellular junctions in patients going for coronary 
artery bypass grafting (CABG) for advanced coronary artery disease.
Methods: Samples were taken from the atrial myocardium and skeletal muscle before and 
after CPB and immediately frozen in liquid nitrogen. Protein concentration in supernatant 
from homogenized heart tissue was measured spectrophotometrically at 595-nm wave 
length with a BCA protein assay kit. Western blot analysis was used to fractionize total 
protein and to quantify different cell junction proteins using their matching antibodies.
Results: The expression of Gamma-Catenin receptor protein in the human atrial heart 
tissue was reduced after CP/CPB compared to that found before CP/CPB (169.7 ± 8.2 vs. 
183.0 ± 9.5, p=0.04), on the other hand the expression of Beta-Catenin receptor protein 
was increased after CP/CPB (186.8 ± 5.1 vs. 180.5 ± 4.9, p=0.007) as compared to before 
CP/CPB. In the skeletal muscle, a Gamma-Catenin signal could not be detected but there 
was a signiﬁcant reduction in Beta-Catenin expression after bypass compared to that 
observed before CP/CPB (117.5 ± 13.1 vs. 97.2 ± 13.9, p=0.01). Protein expression of 
Connexin-40, Pan-Cadherin or VE-Cadherin were not altered after CP/CPB.
Conclusions: Altered distribution, expression and degradation of cell junctions could 
explain the increased incidence of irregular heart rhythm, altered vascular permeability 
and increased interstitial ﬂuid that is often observed after CP under conditions of CPB.
1092-224 Endothelial Cell Damage Leads To Inﬂammation In On-
pump Coronary Artery Bypass Surgery Patients
Palaniswamy Vijay, Thomas G. Sharp, Yousuf Mahomed, John W. Brown, Indiana 
University School of Medicine, Indianapolis, IN
Background: During open-heart surgery, cells exposed to extra-corporal circulation or 
subjected to relative ischemic conditions can become activated and generate inﬂammatory 
mediators. Endothelial cell markers like the adhesion molecules, ICAM and VCAM, are indicators 
of the degree of damage to myocardial endothelium. We analyzed the release of these markers 
during on-pump(CPB) and off-pump coronary artery bypass(OPCAB) surgery.
Methods: Patients undergoing surgery with or without cardiopulmonary bypass (CPB, 
n=40 and OPCAB, n=25) were included. Plasma soluble VCAM-1 (ng/ml), ICAM-1 (ng/ml), 
and IL-6 (pg/ml) were assayed pre-op, off-pump (end of grafting in the case of OPCAB), 0, 
6 and 24hr after surgery. Clinical information was obtained from hospital charts.
Results: Patients in both groups had similar demographics, co-morbidities and number 
of vessels grafted (2.2±1.4 vs. 2.9±1.8, p=NS). The mean LVEF was 42±15%. The range 
of aortic cross-clamp and bypass times were 54-98 min and 101-143 min. The levels of 
IL-6 were 4 times higher (peak) at 6 hrs after surgery in CPB than OPCAB (854±94 vs. 
242±45, p=0.001) and remained elevated at 24 hrs (184±94 vs.74±30, p=0.001). Both 
sVCAM-1 and sICAM-1 levels were signiﬁcantly greater in CPB than OPCAB patients 
(p<0.05) at 6 and 24hrs after the surgery. The increase in sVCAM was more pronounced 
in CPB than in OPCAB. Evenafter 24hrs, the levels of sVCAM and sICAMs were elevated 
signiﬁcantly in CPB when compared to 0hr (sVCAM: 1248±180 vs.784±104, sICAM: 
563±80 vs.402±90) in CPB, whereas in OPCAB, the levels show a trend to return to 0hr 
levels (sVCAM: 754±47 vs.600±84, p=0.001, sICAM: 384±50 vs.304±52, p=0.001).
Conclusions: Cardiopulmonary bypass in coronary artery surgery results in a greater 
inﬂammatory response as measured by soluble endothelial cell adhesion molecules. This 
may be due to neutrophil activation and the release of inﬂammatory cytokines such as IL-
6. The activation of inﬂammatory mediators is reduced by the off-pump approach, which 
may lead to a smoother postoperative course.
1092-225 Pro-thrombotic Effects Of On-pump Compared With Off-
pump Coronary Artery Bypass Surgery: A Prospective 
Randomized Controlled Trial
Neuza Lopes, David Schneider, Roberto Rached, Ludhmila Hajjar, Aecio F. Gois, 
Deborah Whitaker, Luiz Cesar, Sergio Oliveira, Whady Hueb, Burton Sobel, Jose 
Ramires, Heart Institute (InCor) University of Sao Paulo, São Paulo, Brazil, University of 
Vermont, Colchester, VT
Background: To determine whether of on-pump compared with off-pump bypass surgery 
exerts differential effects on markers of inﬂammation, coagulation, and thrombosis after 
surgery, we performed a prospective, controlled trial in which patients were assigned 
randomly to each.
Methods: All aspects of the surgery other than pump use were the same. The 
concentrations of C-reactive protein (CRP), ﬁbrinogen, D-dimer, and plasminogen 
activator inhibitor type 1 (PAI-1) were determined by ELISA before surgery as well as 1 
and 24 hours after surgery.
Results: At total of 91 patients were randomized to on-pump (n=51) or off-pump (n=40) 
surgery. The concentration of CRP did not change appreciably immediately after surgery 
in either group but was increased 3-fold and comparably 24 hour after either on-pump 
or off-pump surgery (p<0.001). The concentration of ﬁbrinogen tended to be lower 
immediately after surgery and increased comparably in both groups 24 hours later. By 
contrast, the concentration of D-dimer was signiﬁcantly greater immediately after surgery 
in the on-pump compared with off-pump group (p<0.0001). Although the concentration 
of PAI-1 increased signiﬁcantly in both groups immediately after surgery (p<0.0001), the 
increment was greater in the on-pump group (p=0.04).
Conclusion: Bypass surgery induces a comparable inﬂammatory response whether 
performed on-pump or off-pump. However, on-pump compared with off-pump is more 
pro-thrombotic as reﬂected by the increased concentrations of D-dimer and associated 
with constrained ﬁbrinolysis secondary to increased concentrations of PAI-1
ORAL CONTRIBUTIONS
814  Biologic and Physiologic Markers of 
Acute Ischemic Syndrome
Monday, March 07, 2005, 2:00 p.m.-3:30 p.m.
Orange County Convention Center, Room 304A
2:00 p.m.
814-3 Multimarker Approach Predicts Adverse Cardiovascular 
Events in Women Evaluated for Suspected Ischemia:  
A Report From the NHLBI-Sponsored WISE Study
Christopher B. Arant, Timothy R. Wessel, Paul M. Ridker, Marian B. Olson, B. Delia 
Johnson, Barry L. Sharaf, Richard A. Kerensky, Daniel F. Pauly, Eileen Handberg, Issam 
Zineh, George Sopko, Sheryl F. Kelsey, C. Noel Bairey Merz, Carl J. Pepine, University of 
Florida, Gainesville, FL, University of Pittsburgh, Pittsburgh, PA
Both inﬂammatory marker and hemoglobin (Hgb) levels predict cardiovascular (CV) 
events in selected populations.
As part of the Women’s Ischemia Syndrome Evaluation (WISE), we investigated a 
multimarker approach using inﬂammatory markers [high sensitivity C-reactive protein (hs-
CRP), interleukin (IL)-6, serum amyloid A (SAA)] and Hgb for CV risk prediction in women 
with suspected ischemia.
Among 595 women, the mean age was 58 + 12 years, and 26%, 55%, and 58% had 
diabetes, hypertension, and dyslipidemia, respectively. Angiographically, 65% had no 
obstructive CAD and mean ejection fraction was 65 +11%. During a mean follow-up 
of 3.6 + 1.8 years, women with no abnormal inﬂammatory markers had fewer adverse 
CV events* and deaths compared to women with abnormal inﬂammatory markers 
(Table). Adding low Hgb (<12 g/dL) to each category of abnormal inﬂammatory markers 
incrementally increased the rate of adverse CV events and mortality for each category 
(Table). In multivariate analysis women with one, two, three, or four abnormal biomarkers 
were more likely to have an adverse CV event or die during follow-up compared to 
women with no abnormal biomarkers (Table). Diabetes (HR 1.79, 95% CI 1.21-2.65) and 
obstructive CAD (HR 1.65, 95% CI 1.12-2.42) were the only traditional risk factors that 
predicted CV events.
For women with suspected ischemia, a multi-biomarker approach using inﬂammatory 
marker and Hgb levels predicted adverse CV events better than any single biomarker or 
traditional CV risk predictor. 
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Table. Relationships between number of markers 
and outcomes. Number of Abnormal Inﬂammatory Markers
*(Adverse CV Event deﬁned as all-cause death 
or hospitalization for MI, CHF, stroke or other 
vascular events)
0 1 2 3
Proportion (%) with adverse CV events (p<0.001 
for trend) 12% 18.4% 20.9% 37%
Proportion (%) with All-cause Death (p<0.001 
for trend) 1.6% 6.1% 9.1% 17%
Number of Abnormal Inﬂammatory Markers with Low 
Hemoglobin Level (Hgb)
0 + Low Hgb 1 + Low Hgb 2 + Low Hgb 3 + Low Hgb
Proportion (%) with adverse CV events (p<0.02 
for trend) 20.7% 22.2% 34.8% 45.5%
Proportion (%) with All-cause Death (p<0.005 
for trend) 3.5% 6.7% 21.7% 24.2%
Total Number of Abnormal Biomarkers
(Hgb, hs-CRP, IL-6, SAA)
1 2 3 4





















814-4 Association of the BAT1-NFKBIL1-LTA Region on 
Chromosome 6 With Susceptibility to Myocardial 
Infarction
Petra Hoppmann, Vanessa Jung, Elena Michou, Arne Pfeufer, Thomas Meitinger, Adnan 
Kastrati, Albert Schömig, Werner Koch, Deutsches Herzzentrum, Muenchen, Germany
Background: Using single nucleotide polymorphisms (SNPs) as disease markers, a 50 
kb region on the short arm of chromosome 6 (6p21.3) has been found to be associated 
with susceptibility to myocardial infarction in a Japanese population. The locus contains 
the genes BAT1 (encoding HLA-B-associated transcript 1), NFKBIL1 (encoding nuclear 
factor of kappa light polypeptide gene enhancer in B cells inhibitor-like 1), and LTA 
(encoding lymphotoxin-α). We conducted a case-control study to determine whether the 
BAT1-NFKBIL1-LTA region was related to myocardial infarction in Caucasians.
Methods: The group of cases included 3657 patients with myocardial infarction and the 
control group comprised 1211 individuals without signs or symptoms of previous or acute 
myocardial infarction. Nine single nucleotide polymorphisms (3 in BAT1, 3 in NFKBIL1, 
and 3 in LTA) were used as markers for testing the association of the BAT1-NFKBIL1-LTA 
region with myocardial infarction. Genotyping was based on PCR and involved allele-
speciﬁc ﬂuorogenic oligonucleotide probes (TaqMan technique).
Results: Five of the 9 polymorphisms (1 in BAT1, 1 in NFKBIL1, and 3 in LTA) were 
signiﬁcantly associated with a protective effect against myocardial infarction: homozygous 
carriers of the less frequent alleles were signiﬁcantly more abundant in the control group 
than in the group with myocardial infarction (p≤0.045). In addition, we found, that the 9 
SNPs were in strong linkage disequilibrium. Protection against myocardial infarction was 
observed in carriers of a speciﬁc haplotype deﬁned by the 9 SNPs (p=0.016), especially 
in homozygous carriers of the protective haplotype (p=0.0047).
Conclusions: The BAT1-NFKBIL1-LTA region on chromosome 6 is a susceptibility locus 
for myocardial infarction in a population of Caucasian origin. In contrast to previous ﬁndings 
among Japanese, homozygous carriers of the less frequent alleles and carriers of a speciﬁc 
haplotype deﬁned by the 9 SNPs present decreased risk of myocardial infarction..
2:30 p.m.
814-5 Eosinophils May Have Potential To Promote Occlusive 
Thrombus In Acute Coronary Syndrome: Histological 
And Immunohistochemical Analysis
Tetsuo Sakai, Shin Inoue, Taka-aki Matsuyama, Tsukasa Saito, Yuji Hamazaki, Hiroshi 
Suzuki, Hidekazu Ota, Takashi Katagiri, Showa University School of Medicine, Tokyo, 
Japan, Tokyo, Japan
Background: Thrombus aspiration therapy allows us to examine thrombus and 
atheroma fragments in acute coronary syndrome. It was reported that inﬂammatory cells 
and platelet activation play key role in the development of thrombus formation. Among 
inﬂammatory cells, eosinophil granule proteins are thought to facilitate the proliferation of 
thrombus by activating platelets. We performed histological analysis using tissue samples 
that obtained by thrombus aspiration therapy.
Methods: One hundred nineteen samples from 146 consecutive patients were studied. 
Thrombus aspiration therapy was carried out in 34 cases with the RESCUE thrombectomy 
catheter, a PercuSurge GuardWire Plus Temporary Occlusion and Aspiration System 
was used in 31 cases, and a ThromBuster catheter was used in 54 cases. Samples 
were stained with hematoxylin and eosin, Elastica van Gieson and phosphotungstic 
acid hematoxylin. The sample area, percentage of red thrombus (red blood cells and 
ﬁbrin) area, percentage of white thrombus (platelets and ﬁbrin) area and percentage of 
atheroma fragments area were calculated. Samples were stained immunohistochemically 
with antibodies against macrophages, activated platelets (P-selectin) and IL-5 that 
induces eosinophils migration.
Results: Mixed thrombus was observed in 114 of 119 samples, atheromatous tissue was 
included in 53 samples. Macrophages, neutrophils and activated platelets were observed 
in both thrombi and atheroma fragments. Moreover, eosinophil inﬁltration was observed 
in the area between the white thrombus and red thrombus in 79 samples. In the contrast, 
we did not detect eosinophils inﬁltration into atheroma fragments. The number of local 
eosinophils was not related to the percentage of peripheral eosinophils. However, the 
number of eosinophils was signiﬁcantly related to thrombus size and the percentage of 
red thrombus area. IL-5 was expressed on granulocytes and macrophages in thrombi. 
Conclusions: Presumably, eosinophils may play an important role in coronary occlusion 
by promoting the growth of red thrombus. Macrophages and neutrophils may act as 
stimulating eosinophils migration by releasing IL-5.
2:45 p.m.
814-6 Increased Plaque Temperature In Patients With Type 2 
Diabetes Mellitus And Acute Coronary Syndrome: A 
Synergistic Effect?
Konstantinos Toutouzas, Virginia Markou, John Mitropoulos, Maria Drakopoulou, 
Eleftherios Tsiamis, Manolis Vavuranakis, Sophia Vaina, Aris Androulakis, Christodoulos 
Stefanadis, Hippokration Hospital, Athens, Greece
An increased inﬂammatory state is observed in patients (pts) with acute coronary 
syndromes (ACS) and diabetes mellitus (DM). Local inﬂammatory involvement is correlated 
with heat generation, which can be recorded by coronary plaque thermography. In this study 
we investigated whether DM is predisposing in increased plaque temperature in ACS.
Method: In the study we enrolled 108 pts undergoing percutaneous coronary interventions. 
We included 45 patients with DM and 63 pts without DM. The latter group was matched 
for all demographic characteristics. Coronary thermography (Medispes, Switzerland) 
was performed prior to the intervention and temperature difference (DT) between the 
atherosclerotic plaque and the proximal vessel wall was recorded.
Results: Fifty-three pts suffered from ACS and 55 pts had stable angina (SA). Pts 
with ACS had increased DT compared to pts with SA (DT: 0.21±0.04 vs 0.09±0.02ºC, 
p=0.02). Pts with DM had increased DT compared to pts without DM (DT: 0.19±0.04 
vs 0.12±0.02ºC, p=0.03). Pts suffering from ACS with DM had greater DT compared 
to non-diabetic pts (DT: 0.29±0.07 vs 0.15±0.04ºC, p=0.03). In pts with SA there was 
no difference in DT between pts with and without DM (DT: 0.10±0.02 vs 0.09±0.03ºC, 
p=0.67).(Figure; DM:White boxes)
Conclusion: The results of this study suggest that DM predisposes to marked increase of 
local inﬂammatory activation in pts with unstable syndromes. However, in pts with stable 
angina DM does not seem to further increase the local inﬂammatory process. 
3:00 p.m.
814-7 Lipoprotein-Associated Phospholipase A2 
Independently Predicts the Angiographic Diagnosis  
of Coronary Artery Disease
Benjamin D. Horne, Jeffrey L. Anderson, Robert L. Wolfert, Joseph B. Muhlestein, Dale 
G. Renlund, Jessica L. Clarke, Heidi Thomas, Matthew J. Kolek, Tami L. Bair, Robert 
R. Pearson, Krishnankutty Sudhir, John F. Carlquist, LDS Hospital, Salt Lake City, UT, 
University of Utah, Salt Lake City, UT
Background: Inﬂammation in cardiovascular (CV) disease is a much-studied phenomenon 
for which C-reactive protein (CRP) is a non-speciﬁc marker of coronary artery disease (CAD) 
and CV events. Lipoprotein-associated phospholipase A2 (LpPLA2) is an enzyme that may 
be a cardiac-speciﬁc inﬂammatory biomarker. We evaluated the independent association of 
LpPLA2 to CAD and CV events adjusting for standard factors, lipids, and CRP.
Methods: LpPLA2 (PLAC
TM test, diaDexus, Inc.) and CRP were measured from samples 
donated by consenting patients (N=1,493) enrolled in the registry of the Intermountain 
Heart Collaborative Study. All patients underwent coronary angiography (1996-1998) 
to diagnose the presence or absence of CAD. Patients were followed for 6.7±0.5 years 
(range: 5.7-7.9 years) to determine CV events (all-cause death, ischemic death, non-
ischemic CV death, new MI, and cerebrovascular accident [CVA]).
Results: Average age was 63±12 years; 70% were male. LpPLA2 weakly correlated with 
lipids (LDL: r=0.22, p<0.001; HDL: r=-0.13, p<0.001), but not with CRP (r=0.03, p=0.26). 
LpPLA2 levels differed between patients with CAD (geometric mean: 369.5 [SE: 6.3] ng/
mL) and no CAD (315.3 [8.8], p<0.001) and ischemic death (418.3 [26.2] vs. survivors: 
346.4 [6.1], p<0.001). In multivariable logistic regression, increasing quartile (Q) of LpPLA2 
predicted increased risk of CAD (vs. Q1) for Q2 (odds ratio [OR]=1.15, 95% CI=0.78-
1.71, p=0.48), for Q3 (OR=1.53, 95% CI=1.02-2.31, p=0.042), and for Q4 (OR=2.44, 95% 
CI=1.58-3.79, p<0.001), while CRP was also predictive (vs. Q1, Q2: OR=1.47, p=0.057; 
Q3: OR=1.93, p=0.002; Q4: OR=3.43, p<0.001). In multivariable Cox regression, LpPLA2 
also tended to predict ischemic death (vs. Q1; Q2: hazard ratio [HR]=1.27, p=0.55; Q3: 
HR=2.18, p=0.04; Q4: HR=1.73, p=0.14).
Conclusions: LpPLA2 was conﬁrmed to predict increased CAD risk, and extends this 
to patients undergoing coronary angiography. Uniquely, LpPLA2 was found to predict 
longitudinal risk of ischemic death, and did so with a similar effect size. This study 
suggests that LpPLA2 may be considered as an ischemic-speciﬁc inﬂammatory marker of 
clinical CV risk along with the non-speciﬁc CRP.
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814-8 NT Pro-BNP Predicts Clinical Outcomes In Patients 
With Acute Coronary Syndromes And Preserved Left 
Ventricular Function
Florencia Rolandi, Luis Guzman, Jose Gabay, Ricardo Sarmiento, Diego Perez de 
Arenaza, Natalia Vensentini, José Alvarez, Fernando Rubinstein, José Luis Navarro 
Estrada, Hospital Italiano, Buenos Aires, Argentina
NT-proBNP has been associated with adverse outcome in patients with non-ST elevation 
acute coronary syndromes (NSTE-ACS). Little is known about prognostic value of NT-
proBNP adjusted by LV function. Our aim was to assess the capacity of NT-proBNP to 
predict long term events in patients with NSTE-ACS and preserved LV function.
Methods: From a prospective cohort of 1483 patients with NSTE-ACS, 590 underwent in-
hospital angiography (median 2 days). Among these, 393 patients had LV ejection fraction 
>40% and conformed the study population. NT-proBNP was measured at a median of 3 
hours and a pre-speciﬁed cut-off between low and high levels was 586 pg/ml. The primary 
endpoint was death and or myocardial infarction (D/MI) at 180 days.
Results: Of the 393 patients with normal LV function, 310 (79%) had NT-proBNP levels 
< 586 pg/ml and 83 (21%) had = or > 586 pg/ml.
Patients with high NT-proBNP levels had increased risk of death (9.6% vs 2.3%, p=0.002), 
MI (9.6% vs 3.2%, p=0.01), and D/MI (16.9% vs 5.5%, p=0.001) at 180 days compared to 
patients with NT-proBNP < 586 pg/ml. In a logistic regression analysis including clinical, 
ECG and angiographic characteristics, NT-proBNP was an independent predictor of death 
and D /MI, whereas troponin remained the best predictor of MI. (see table)
Conclusions: NT-proBNP is an independent predictor of clinical outcomes in patients 
with NSTE-ACS and preserved LV function. It is possible that prognostic information 
provided by NT-proBNP might be related to other mechanisms than LV dysfunction.
OR 95% IC p value
Death or MI NT-proBNP > 586 pg/ml 2.51 1.12-5.62 0.026
Diabetes 3.37 1.48-7.68 0.004
Troponin T > 0.01 ng/ml 2.80 1.12-7.02 0.028
Myocardial infarction Troponin T > 0.01 ng/ml 3.88 1.06-14.17 0.04
Diabetes 2.87 1.00-8.20 0.049
Complex coronary lesion 2.98 1.01-8.81 0.049
Death Age (per year) 1.06 1.01-1.12 0.029
Diabetes 3.83 1.26-11.65 0.018
NT-proBNP > 586 pg/ml 3.14 1.04-9.45 0.042
 
ORAL CONTRIBUTIONS
822FO  Featured Oral Session...Time to 
Transfer, Time to Treatment and Time  
of Treatment in ST-Elevation Myocardial 
Infarction
Monday, March 07, 2005, 4:00 p.m.-5:30 p.m.
Orange County Convention Center, Hall E2A
4:15 p.m.
822-4 Inter-hospital Delay And Mortality In Patients With ST-
Segment Elevation Myocardial Infarction Transferred 
For Primary Angioplasty
Giuseppe De Luca, Harry Suryapranata, Menko-Jan de Boer, Jan Paul Ottervanger, AT 
Macel Gosselink, Jan-Henk E. Dambrink, Jan CA Hoorntje, Arnoud WJ van’t Hof, De 
Weezenlanden Hospital, Zwolle, The Netherlands
Background. Transferring of patients with STEMI for primary angioplasty has been shown 
to be safe and feasible, with better outcome in comparison with on-site thrombolysis. The 
aim of the current study was to evaluate the impact of inter-hospital delay on mortality in 
STEMI patients undergoing primary angioplasty.
Methods. Our population is represented by 616 patients with STEMI transferred for 
primary angioplasty to our hospital. Patients were divided in 4 groups according to each 
30-minute inter-hospital delay (deﬁned as the time between presentation at the referral 
center and arrival at our hospital): < 30, 30-59, 60-89, >90 minutes.
Results. Patients with longer inter-hospital delay had a higher prevalence of multivessel 
disease, and longer ischemia time. Patient’s delay (from symptom onset to admission at the 
referral hospital) and door-to-balloon time were not different among the groups. Longer inter-
hospital delay was associated with impaired perfusion and larger infarct size (Table 1).
A linear relationship was found between inter-hospital delay and 1-year mortality (Table 1, 
p = 0.01), even after adjustment for major baseline characteristics (age, gender, diabetes, 
Killip class at presentation, infarct location, multivessel disease, pre and postprocedural 
TIMI ﬂow) (RR = 1.6 [1.13-2.27], p = 0.008).
Conclusions. The main ﬁnding of the present study is that inter-hospital delay is linearly 
associated with mortality in patients with STEMI transferred for primary angioplasty.
Table 1. Patients’’ characteristics and outcome according to inter-hospital delay. 
Inter-hospital delay 
(min) < 30 30-59 60-89 > 90 p trend
Number of patients 94 188 194 140
Ischemic time (min) 185 (136-289) 190 (156-247) 220 (172-286) 242 (201-389) < 0.0001
Door-to-balloon time 
(min) 41 (29-60) 38 (27-51) 37 (25-51) 37 (25-51) NS
Patient delay (min) 117 (73-198) 105 (70-155) 110 (60-180) 90 (60-180) NS
Myocardial blush 
grade 2-3 (%) 81.5 79.0 79.7 71.7 0.09
LDHQ48 (U/L) 1150 (698-2510) 1944 (1051-3305) 2131 (1261-3785) 1976 (1103-3300) 0.049
1-year mortality (%) 3.2 6.4 6.2 12.1 0.01
4:30 p.m.
822-5 Does a 90-Minute Door-to Balloon Time Matter? 
Observations From Four Current Reperfusion Trials
William W. O’Neill, Cindy L. Grines, Simon R. Dixon, John J. Grifﬁn, Jack L. Martin, David 
A. Cox, John G. Webb, Bruce R. Brodie, Roxana Mehran, Raymond J. Gibbons, John 
Held, Gregg W. Stone, William Beaumont Hospital, Royal Oak, MI, Columbia University, 
New York, NY
Background: The current AHA/ACC guidelines for percutaneous coronary intervention 
(PCI) therapy of ST-segment elevation MI (STEMI) promote a 90-minute door-to-balloon 
time (DBT) as a target for quality. This recommendation is based largely on retrospective 
observations from clinical registries.
Methods: We sought to determine whether treatment delay has an impact on ﬁnal infarct size 
or mortality in four recent PCI trials aimed at infarct size limitation. Data from the EMERALD 
(n=501), COOL MI (n=357), AMIHOT (n= 269), and ICE-IT (n= 228) were merged and 
analysis of outcome and infarct size, determined by sestamibi imaging, was performed.
Results: DBT (p<0.0001) and onset-to-door time (p=0.025) remained independent 
predictors of ﬁnal infarct size on multivariable analysis
Conclusion: In spite of later time to presentation, patients with short DBT times have 
a lower mortality, lower 30-day MACE and smaller infarct sizes. These data suggest 
that “shorter-is-better” concerning DBT, and provide validation for current guideline 
recommendations.
Results Stratiﬁed By Door-to-Balloon Time 
DBT (mins) <60 60-90 90-120 >120 p-value
N 183 296 304 403
Prior MI 9% 12% 9% 8% NS
Anterior MI 435 40% 45% 41% NS
Onset-to-Door (mins) 197 ± 182 140 ± 140 141 ± 151 113 ± 124 <0.0001
Door-to-Balloon (mins) 44 ± 12 75 ± 9 103 ± 8 156 ± 30 -
Onset-to-Balloon (mins) 235 ± 180 216 ± 140 244 ± 150 269 ± 126 <0.0001
Death 30-days 0.6% 0.7% 4.7% 2.5% 0.0037
MACE 30-days 1.6% 2.4% 7.6% 5.5% 0.0034
Infarct Size (% LV) 14.2 ± 15.8 13.2 ± 14.6 18.0 ± 18.0 17.4 ± 18.0 0.0023
4:45 p.m.
822-6 Door-to-Balloon Time for Acute Myocardial Infarction: 
Where Can We Improve?
Elizabeth Bradley, Robert L. McNamara, Jeph Herrin, Yongfei Wang, Martha Radford, 
David Magid, John Canto, Martha Blaney, Harlan M. Krumholz, Yale University, New 
Haven, CT
Background: While delays in door-to-balloon times for ST-segment elevation myocardial 
infarction (STEMI) patients treated with primary percutaneous coronary intervention (PCI) 
are well-documented, less is known about delays in the speciﬁc subinterval components 
that comprise overall door-to-balloon time. We sought to compare the mean door-to-ECG, 
ECG-to-cath lab, and cath lab-to-balloon subinterval times for the top performing hospitals 
(median door-to-balloon less than or equal to 90 minutes) with those at lower performing 
hospitals (median door-to-balloon times greater than 120 minutes). Understanding how 
these sub-intervals vary can help identify elements of the door-to-balloon process with the 
greatest opportunity for improvement.
Methods: Using patient-level data from the National Registry of Myocardial Infarction 
from 1/2001 through 12/2002 (13,387 patients in 340 hospitals), we estimated hierarchical 
multivariate models and compared hospitals’ geometric mean times for each subinterval 
in door-to-balloon time, adjusted for patient and hospital characteristics.
Results: Top performing hospitals had signiﬁcantly shorter adjusted mean times in 
each subinterval: door-to-ECG (7.8 vs 9.3 minutes, p<0.001), ECG-to-lab (47.3 vs 66.3 
minutes, p<0.001), and lab-to-balloon (29.2 vs 38.3 minutes, p<0.001) compared with 
lower performing hospitals. The subinterval times were positively correlated, indicating 
that hospitals that performed well in one subinterval were more likely to perform well in 
other subintervals (p<0.01).
Conclusion: Our data indicate substantial hospital-level variation in the subintervals 
of door-to-balloon time. Efforts to achieve guideline based door-to-balloon times should 
initially target the ECG-to-lab subinterval time, where the overall variation in, and 
opportunity for, reducing door-treatment times are greatest. Setting benchmark door-
to-balloon subinterval times, identifying and implementing systems for achieving these 
times, and monitoring performance may help hospitals achieve guideline based care for 
patients with STEMI.
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822-7 Time To Treatmant Of Acute Myocardial Infarction (AMI) 
Can Be Optimized By An Integrated Infarction Networtk 
According To Guidelines.
Matthias Rau, Michael Weber, Albrecht Elsaesser, Eva Keil, Christian Maikowski, 
Christian Hamm, Kerckhoff Heart Center, Bad Nauheim, Germany
Background: Recent studies have demonstrated a benﬁt of primary PCI for the treatment 
of patients with an acute ST-segment elevation myocardial Infarction( STEMI). To achieve 
optimised times till PCI, we initiated a network for the treatment of STEMI.
Methods: Our integrated network incorporates the emergency care system, community 
hospitals and a cardiac center with a 24h cathlab intervention facility. A twelve lead 
ECG is recorded preclinically and if STEMI is diagnosed ,the cardiac center is informed 
immediately and the patient is taken directly to the Cath Lab.
Results: From April 2003 till August 2004 a total of 488 patients with STEMI have 
been treated. 283 patients (58 %) were admitted directly by the emergency ambulance 
, 200 (41%) were transferred from community hospitals, n=4 ( 1%) came without 
prior informations. 5 % of patients ( n=24 ) had a cardiogenic shock and 7% had a 
cardiopulmonary resucitation (CPR). Delay from onset of symptoms till arrival in the 
cathlab was signiﬁcantly longer for transferred patients (2.4h ± 6.0 vs 6.5 h ± 8.1; p<0,01) 
Door to balloon- time was short and did not differ between both groops ( 30 ± 51min vs.25 
± 23 min; ns ). In- hospital mortality was 3.2 % excluding those who had CPR. Reinfarcton 
rate was 1 % at six month time.
Conclusion: In a network for treatment of STEMI with undelayed transportation to the 
cath lab based on the preclinically recorded ECG a door to balloon time of < 30 min. 
can be achieved. Short times from onset of symptoms till revascularisation may have an 
impact on low in hospital mortality raates.
5:15 p.m.
822-8 Off-hour Primary Angioplasty: Why Is Mortality Higher?
Srihari S. Naidu, Robert L. Wilensky, Faith Selzer, Warren K. Laskey, Vankeepuram S. 
Srinivas, James N. Slater, Ruchira Glaser, New York Presbyterian Hospital - Cornell, 
New York, NY, University of Pittsburgh, Pittsburgh, PA
Background: Percutaneous coronary intervention (PCI) outcome for ST-elevation 
myocardial infarction exhibits diurnal variation, with higher in-hospital mortality during 
off-hours. It remains unknown whether differences in clinical or angiographic factors are 
responsible.
Methods: The incidences of in-hospital and one-year death were collected on 6,676 
consecutive patients who underwent PCI in 19 centers during three waves of enrollment 
between July 1997 and March 2002. Patients undergoing emergent PCI for acute 
myocardial infarction (n=614, 9.2%) were stratiﬁed according to whether intervention 
occurred off-hour (1900-0659) or during routine hours (0700-1859). Baseline clinical, 
demographic and angiographic characteristics, as well as in-hospital and one-year 
mortality were compared.
Results: The majority occurred during routine hours (n=433, 70.5%). Median time from 
symptom onset to PCI was shorter during off-hours (4.0 vs. 5.1 hours, p=0.05). Clinical 
and demographic characteristics did not differ, including age, gender, race, diabetes, 
hypertension, hypercholesterolemia, smoking, history of coronary disease or heart failure, 
and presentation with cardiogenic shock (off-hours 18.2% vs. 15.0%, p=0.32). Off-hour 
patients more likely had disease of the left anterior descending (LAD, 79.0% vs. 70.0%, 
p<0.05), total occlusion of the LAD (40.3% vs. 27.0%, p<0.01), any total occlusion (76.2% 
vs. 64.0%, p<0.01), and TIMI 0-1 ﬂow (66.8% vs. 55.4%, p<0.01). Stenting rate between 
off-hour and routine hour patients (77.3% vs. 81.5%, p=0.23) and total angiographic 
success (88.4% vs. 92.8%, p=0.07) remained similar. Off-hour PCI was associated with 
higher in-hospital mortality (11.0% vs. 6.0%, OR 1.94 95%CI 1.06-3.58, p<0.05). After 
adjustment for angiographic differences, odds for in-hospital mortality did not change 
signiﬁcantly (OR 2.09, 95%CI 0.96-4.55, p=0.06). Initial differences in mortality persisted 
at one year (14.2% vs. 10.1%, p=0.13), but were no longer signiﬁcant.
Conclusion: Increased in-hospital and one-year mortality after off-hour emergent PCI for acute 





824FO  Featured Oral Session... Recent 
Developments in Myocardial 
Regeneration
Monday, March 07, 2005, 4:00 p.m.-5:30 p.m.
Orange County Convention Center, Room 414A
4:15 p.m.
824-4 Intravenous Infusion of Mesenchymal Stem Cells 
During Early Reperfusion Enhances Regional Perfusion 
and Improves Ventricular Function in a Porcine Model of 
Acute Myocardial Infarction
Michael E. Halkos, Faraz Kerendi, Ning-Ping Wang, Rong Jiang, L. Susan Schmarkey, 
Bradley J. Martin, Arshed A. Quyyumi, Walter L. Few, Hajime Kin, Zhi-Qing Zhao, Robert 
A. Guyton, Jakob Vinten-Johansen, Emory University School of Medicine, Atlanta, GA
Background: The intramyocardial or intracoronary injection of bone marrow stem cells 
after acute MI (AMI) has proven efﬁcacious in improving regional perfusion and LV 
function. Using a closed-chest porcine model of AMI, this study tested the hypothesis 
that bone marrow-derived mesenchymal stem cells (MSCs) delivered intravenously (IV) 
during early reperfusion engraft in ischemic myocardium, augment neovascularization, 
and improve LV function 12 weeks post-infarction.
Methods: The proximal LAD was occluded for 75 min by an angioplasty balloon. At 15 
min of reperfusion, Yorkshire pigs randomly received 1 of 4 treatments: vehicle (Control, 
n=10), 1 x 106 MSCs/kg (1 mill, n=7), 3 x 106 MSCs/kg (3 mill, n=8), or 10 x 106 MSCs/kg 
(10 mill, n=8). MSCs were pre-labeled with DiI and DAPI ﬂuorescent markers. Myocardial 
ﬂow reserve (intracoronary adenosine) in scar and border tissue was determined 12 
weeks after AMI using 15µm microspheres. LV function was assessed at 12 weeks by 
pressure-volume analysis (impedance catheter).
Results: MSCs were observed in the scar zone of MSC-treated pigs 12 weeks after IV 
infusion and expressed muscle-speciﬁc proteins by immunohistochemistry. Flow reserve 
(ml/min/g tissue) in the scar zone was greater in the 1 mill (2.5 ± 0.3), 3 mill (2.9 ± 0.7), 
and 10 mill (2.9 ± 0.5) groups vs Control (1.1 ± 0.3, p<0.001). Flow reserve in the border 
zone was also enhanced in the MSC-treated groups vs Control (p<0.001). Vascular 
density (antibody to vWF) in the scar zone was 23% greater in the 1 and 3 mill groups, 
and 30% greater in the 10 mill group vs Control (p<0.05). Preload-recruitable stroke work 
(mmHg) was greater in the 3 mill (39 ± 4.3) and 10 mill (44 ± 2.4) groups, but not in the 1 
mill group, compared to Control (26 ± 4.0, p<0.05). Systolic performance (slope of end-
systolic pressure-volume relationship, mmHg/ml) was also greater in 3 mill (1.4 ± 0.1) and 
10 mill (1.5 ± 0.2) vs Control (1.0 ± 0.1, p<0.05).
Conclusion: In a chronic porcine model of AMI, MSCs delivered IV during early 
reperfusion engraft into ischemic myocardium, enhance regional perfusion, and improve 
global LV function in a dose-dependent manner. Functional improvements may be a result 
of enhanced neovascularization.
4:30 p.m.
824-5 Autologous Myotissue Transplantation in a Porcine 
Myocardial Infarction Model Results in Improved 
Function and Decreased Infarct Size
Audrey Rosinberg, Pierre Voisine, Guifu Wu, Evan Applebaum, Susan Yeon, Seung Lee, 
Joseph Carrozza, Frank Sellke, Roger Laham, BIDMC/Harvard Medical School, Boston, MA
Background: Myogenesis is emerging as a potential treatment for myocyte loss in 
myocardial infarction and heart failure. Cell based therapy has been proposed as a 
potential treatment strategy. The purpose of this investigation was to determine the safety 
and efﬁcacy of implanting microtissue containing adult cardiomyocytes in an animal 
model of myocardial infarction.
Methods: 13 Yorkshire pigs underwent balloon occlusion of LAD for one hour and were 
randomized to treatment (n=7, septal biopsies via the right ventricle and implantation of 9 
tubular biopsies in anterior wall) or control (n=6, septal biopsies and 9 sham injections in 
anterior wall). Animals were assessed 4 weeks later with hemodynamics, LV function and 
perfusion (MRI), echocardiography, ultrasonic crystals, microspheres, and morphometric 
analysis using tetrazolium (TTC) staining, histology, and molecular studies.
Results: All animals tolerated the procedure well. There were no arrhythmias noted and 
no detectable deleterious effect on basal septum (site of tissue harvest).
TTC staining demonstrated signiﬁcantly smaller infarcts in the anterior wall in treated 
animals compared to controls (10.33±4.57% area of mid slice versus 28.9±5.81% 
respectively, p<0.05). There was no signiﬁcant difference in the size of the infarct in the 
untreated septum between treated and control animals (21.63±5.32% and 21.48±2.53%). 
The volume of infracted myocardium as determined by MRI (delayed enhancement) was 
signiﬁcantly lower for treated animals than controls (2.2±0.5% vs 5.4±1.5% of entire LV 
volume, p=0.04). Anterior/septal wall perfusion ratio (MRI) was signiﬁcantly higher in 
treated animals compared to controls (1.2±0.1 and 0.86±.05, p<0.01). dP/dt improved 
in treated animals vs controls (1235±215 vs 817±91 mmHg/s, p=0.06). There were less 
expression of VEGF, FGF-2, and CD31 in treated animals compared to controls, but more 
expression of the anti-apoptotic factor IAP-2 (p=0.04).
Conclusion: This study demonstrates the safety, feasibility, and efﬁcacy of a novel 
method for myocardial regeneration and protection by implanting autologous myocardial 
microtissue obtained from preserved myocardial regions.
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824-6 Nestin Expressing Neural Stem Cells Identiﬁed in the 
Scar of the Post-Myocardial Infarcted Rat Heart
Angelino Calderone, Jessica Drapeau, Jocelyn Dupuis, Viviane El-Helou, Frederic 
Lefevbre, Montreal Heart Institute, Montreal, PQ, Canada, University of Montreal, 
Montreal, PQ, Canada
Background: Recent studies have delineated the process of neural remodelling in the 
infarcted region of the damaged heart. However, it remains equivocal as to whether nerve 
ﬁber innervation of the scar occurred via either the growth of pre-existing ﬁbers and/or the 
recruitment of neural stem cells. Methods;The present study examined the recruitment 
of neural stem cells to the infarcted region following coronary artery ligation in the adult 
male rat. 
Results: In 1-week post-myocardial infarcted rats, neuroﬁlament-M- and peripherin-
positive ﬁbers were visualized in the scar by immunoﬂuorescence. Co-incident with ﬁber 
formation, numerous scar-derived cells stained positive for the neural stem cell marker 
nestin. By contrast, nestin immunoreactivity was not detected in cardiac myocytes of the 
non-infarcted left ventricle. Following the isolation and culture of scar-derived primary 
passage cells, nestin-positive cells with a neural morphology were identiﬁed, whereas 
nestin staining was absent in myoﬁbroblasts. FACS analysis of primary passage nestin-
expressing neural stem cells indirectly revealed a proliferative capacity as a temporal 
increase of cell number was observed (Day 7, 6%; Day 11, 47%; Day 18, 68%). Consistent 
with a progenitor role, nestin and neuroﬁlament-M immunoreactivity were co-localized 
in primary passage neural cells. To determine the source of nestin-expressing neural 
stem cells, bone marrow-derived cells labelled with green ﬂuorescent protein (GFP) 
were administered to irradiated Wistar male rats two weeks prior to coronary artery 
ligation. Three weeks post-myocardial infarction, numerous GFP-positive cells were 
identiﬁed in the scar, whereas staining was not detected in the non-infarcted left ventricle. 
Unexpectedly, nestin-expressing neural stem cells in the infarcted region did not co-
localize with GFP-positive cells. 
Conclusion: These data have demonstrated that nestin-expressing neural stem cells 
were identiﬁed in the infarcted region of the damaged rat heart, possess a capacity to 
proliferate, were not derived from the bone marrow, and may represent the progenitor cell 
that subsequently differentiates to a neuronal phenotype.
5:00 p.m.
824-7 Improvement of Left Ventricular Function by 
Intramuscular Allogeneic Mesenchymal Stem Cells 
Transplantation in Postinfarcted Rat Myocardium May 
Be Transient
Wangde Dai, Sharon L. Hale, Bradley J. Martin, Jin-Qiang Kuang, Robert A. Kloner, 
The Heart Institute, Good Samaritan Hospital, University of Southern California, Los 
Angeles, CA, Osiris Therapeutics Inc., Baltimore, MD
Purpose: The survival, engraftment and differentiation of allogeneic mesenchymal stem 
cells (MSCs) and their long term effect on left ventricular (LV) remodeling and function 
were investigated.
Methods: MSCs isolated from ACI rats were labeled with DiI. Phosphate buffered saline 
(n=36) or allogeneic MSCs (n=39, 2×106 cells each) were injected directly into the scar of 
a 1 week old myocardial infarction in female Fischer rats. Four weeks or 6 months later, 
LV ejection fraction (LVEF) was assessed by angiogram, and hearts were processed for 
histology. Immunohistologic confocal microscopy examinations of frozen sections were 
performed blindly at 6 months.
Results: At 4 weeks, LVEF was signiﬁcantly greater in MSC treated animals (43.6±1.0 
%, n=12) compared to the control group (38.8±1.1%, n=12; p=0.005). At 4 weeks there 
also was a trend toward smaller post-mortem volumes in the MSC group (0.31±0.01ml) 
versus the control group (0.34±0.01ml, p=0.16); and infarct scar thickness in the MSC 
group was 0.48±0.02mm versus the control group at 0.45±0.04mm, p=0.54. However, at 
6 months the beneﬁts of MSC treatment were gone (LVEF = 41.8±1.1% in MSC group, 
versus 42.0±1.0% in control group, p=0.93; volume =0.40±0.02ml in MSC group versus 
0.44±0.02ml in control group, p=0.2; and scar thickness was 0.41±0.02mm in MSC 
group versus 0.41±0.02mm in control group, p=0.85). At 6 months, DiI positive cells were 
observed in the central scar region of rats in the MSC group, and these cells expressed 
the muscle-speciﬁc markers �-actinin, MF-20, phospholamban and tropomyosin, but did 
not fully evolve into an adult cardiac phenotype. In addition, these cells were found to 
express smooth muscle actin and von Willebrands factor. No DiI positive cells were found 
in the control group.
Conclusion: Allogeneic MSCs survive in infarcted myocardium, and express markers 
suggesting a muscle and vascular phenotype at 6 months after transplantation. MSCs 
did improve global LV function at 4 weeks with a trend towards less remodeling at this 
time; however this beneﬁt was transient. Methods to enhance MSC differentiation and 
continued contribution to contraction are needed to optimize this form of therapy. 
5:15 p.m.
824-8 Indium-111 Oxine Labeling Of Rat Bone Marrow-derived 
Mesenchymal Stem Cells For In Vivo Imaging During 
Autologous Cell Therapy Of Myocardial Infarction
Fatiha Maskali, Nguyen Tran, Joseph Nloga, Marie Héléne Laurens, Pierre-Yves Marie, 
Gilles Karcher, Faiez Zannad, faiez ZANNAD, nancy, France
Aim: Intramyocardial transplantation of bone marrow mesenchymal stem cells (BMSCs) 
was reported improving cardiac function in ischemic cardiac disease. However, data 
concerning the body distribution and the cardiac retention of transplanted cells remain 
poor. This study was Aimed at assessing the use of Indium-111 oxine labeling of BMSCs 
for analyzing the retention and distribution of these cells when injected within myocardial 
infarction areas. 
Material and Methods: In a ﬁrst step, labeling efﬁciency, cytotoxicity and cell retention of 
Indium-111 oxine was analyzed in vitro on BMSCs cultures. In a second step, autologous 
BMSCs labeled with Indium-111 oxine (2x106 cells/50µl) were injected within infarcted 
myocardial walls one month after left anterior descending artery occlusion in 6 rats. 
Body pinhole scintigraphic images were recorded at 2 hours and at 1, 3, and 7 days. 
Cardiac distribution of Indium-111 was also analyzed on cryosections of hearts using a 
microimager. Results: Incubation of BMSCs (2x106 cells in 1 ml) with 15 MBq of Indium-
111 oxyne resulted in a time-dependent labeling efﬁciency and cytotoxicity. Using a 10 min 
incubation-period, labeling efﬁciency was high enough (69%) and cell viability remained 
acceptable (96%). On cell cultures, there were high rates of Indium-111 release from 
labeled BMSCs, especially during the ﬁrst day: retentions of Indium-111 within BMSCs 
were 46% at 2 hours, 28% at day 1, 25% at day 3 and 20% at day 7. After injection 
of autologous labeled BMSCs in infarcted areas, mean heart-activity determined with 
pinhole scintigraphy was 26.4±2.3% of the total injected activity at 2 hours, 17.3±2.4% 
at day 1, 16.8±1.5% at day 2 and 12.7±0.7% at day 7. When these percentages were 
corrected by the rates of Indium-111 release, documented at the same time-points on 
cell cultures, it was found that approximately 60% of injected BMSCs were presumably 
retained within hearts and this, all along the 7 days of in vivo follow-up. 
Finally, microimager and histological analyses showed that at day 7, most transplanted 
BMSCs were still located around the injection sites within infracted areas.
ORAL CONTRIBUTIONS
832  Short- and Long-Term Outcome After 
an Acute Coronary Syndrome: Role 
of Inﬂammatory and Hemodynamic 
Markers
Tuesday, March 08, 2005, 8:30 a.m.-10:00 a.m.
Orange County Convention Center, Room 304A
8:30 a.m.
832-3 Systemic Inﬂammatory Response Syndrome 
Complicating Acute ST-Segment Elevation Myocardial 
Infarction
Rafael Valencia, Salvatore Cavaleri, Christopher B. Granger, Kenneth W. Mahaffey, 
Gudaye Taissa, Pierre Theroux, Paul W. Armstrong, Michael Hudson, Thomas G. Todaro, 
Chris Mojcik, Judith S. Hochman, New York University Medical Center, New York, NY
Large myocardial infarction is associated with an intense inﬂammatory response. The 
systemic inﬂammatory response syndrome (SIRS) may play a role in the development of 
cardiogenic shock (CS).
We analyzed the Complement and ReDuction of Infarct size after Angioplasty or Lytics 
(CARDINAL) program that investigated pexelizumab, a monoclonal antibody against 
C5 complement, in STEMI patients to evaluate the relationship between SIRS and the 
development of CS, CHF and death at 90 days.
The standard deﬁnition of SIRS which is the presence of two or more of the following was 
used: heart rate >90 beats/min, body temperature >38’C or <36’C, respiratory rate >20 
breaths/min, or a white blood cell count >12 x109 / L or <4 x109 / L.
On presentation, 391 of 1903 (21%) patients met clinical criteria for SIRS. Patients with 
SIRS tended to be signiﬁcantly younger (59% vs. 61%), more likely female (32% vs. 26%), 
diabetic (22% vs. 16%) and active smokers (46% vs. 39%). SIRS patients tended to have 
higher systolic (138.5 vs. 132.5) and diastolic blood pressures (84 vs. 80) on admission, 
higher troponin levels (2.0 vs. 1.3), and higher cumulative ST-segment elevation (10.5 vs. 
9.5mm). Unadjusted event rates of CS, CHF, death and the composite of CS or death, with 
and without SIRS are shown below.
SIRS is frequent occurrence in STEMI on presentation and such patients have higher 
rates of CS and death. The presence of a strong inﬂammatory response has potential 
diagnostic and therapeutic implications in the early management of STEMI.





@90 days 26 (6.7%) 58 (3.8%) 0.016
CHF developed
@90 days 34 (8.7%) 95 (6.3%) 0.091
Mortality




54 (13.8%) 118 (7.8%) <0.001
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832-4 Inﬂammation and Acute Hyperglycemia: A Double 
Edged Sword in Diabetics With Non-ST Elevation ACS: 
Analyses From the TIMI Database
Kausik K. Ray, David A. Morrow, Christopher P. Cannon, Jacqueline Buros, Ajay J. 
Kirtane, Carolyn Hoss McCabe, Eugene Braunwald, C. Michael Gibson, Brigham and 
Women’s Hospital, Boston, MA, Harvard Medical School, Boston, MA
Background: Inﬂammation and diabetes (DM) are independently associated with 
cardiovascular (CV) risk in ACS. In vitro glucose augments the adverse effects of CRP.
Methods: We hypothesized that DM would be associated with increased markers of 
inﬂammation & that inﬂammation would enhance the CV risk in DM. We analyzed non ST 
elevation ACS patients in the OPUS TIMI-16 trial & validated the results in the TACTICS-
TIMI 18 trial (invasive arm). 
Results: Median CRP was higher among diabetics (n=541) vs non-diabetics (n=1659) in 
OPUS (9 vs 7.8mg/l p=0.002) & in TACTICS: diabetics (n=267) vs non-diabetics (n=662) 
CRP 6.6 vs 5.2 mg/l (p=0.0005). Stratifying by population median CRP in OPUS (ﬁg 1), 
diabetics with CRP> median were at highest risk of death or MI while non-diabetics with 
CRP>median and diabetics with CRP<median were at similar risk (p for trend across 
range<0.0001). Identical observations were made in TACTICS. In addition, among 
diabetics high glucose levels (tertile 3) increased the CV risk of a high CRP (ﬁg 2). In a 
Cox-regression model of death and MI, that included DM, glucose and CRP, an interaction 
was found between glucose and CRP (PI =0.045).
Conclusion: Diabetics have greater inﬂammation and hyperglycemia may increase the 
CV risk associated with this. In diabetics with ACS future strategies that target both better 
glycemic control and reduction of inﬂammation, may reduce the CV risk in this high risk 
population. 
9:00 a.m.
832-5 Elevated Levels of Interleukin-10 are Strongly 
Associated with Raised Mortality in non-ST Elevation 
Acute Coronary Syndrome
Anders Malarstig, Bertil Lindahl, Lars Wallentin, Agneta Siegbahn, Uppsala Akademiska 
Sjukhus, Uppsala, Sweden
Background: Interleukin-10 (IL-10) is a cytokine with anti-inﬂammatory properties. A 
previous study has suggested that elevated levels of IL-10 are associated with a favorable 
prognosis in non-ST elevation acute coronary syndrome (NSTE-ACS). The aim of this 
study was to evaluate the prognostic value of Il-10 in a large group of patients with NSTE-
ACS and see whether we could conﬁrm the previous ﬁndings.
Methods: Citrated plasma samples were obtained at inclusion in patients enrolled in 
the FRISC-II trial (n=2326), evaluating an invasive vs. a non-invasive strategy in NSTE-
ACS. IL-10 was measured using a highly sensitive ELISA (R&D). Patients were followed 
regarding myocardial infarction (MI) and death for 2 years.
Results: The median level of IL-10 was 1.06 pg/ml [25:th-75:th percentile; 0.63-1.87]. The 
mortality and MI rate in relation to quartiles of Il-10 are shown in the ﬁgure. The relations 
were congruent in both patients randomized to an invasive and a noninvasive strategy.
Conclusions: Increased plasma levels of IL-10 were strongly associated with higher 
mortality in the present study, in contrast to previous ﬁndings.
9:15 a.m.
832-6 Plasma Levels of The Endogenous Nitric Oxide 
Synthase Inhibitor Asymmetrical Dimethylarginine 
(ADMA) Predict Outcome in Patients After Acute 
Myocardial Infarction
Renke Maas, Heeschen Christopher, Friedrich Schulze, Kenneth Dickstein, Lisa Silberhorn, 
Thor Ueland, John Kjekshus, Pal Aukrust, Rainer Böger, University Hopsital Hamburg-
Eppendorf, Hamburg, Germany, Frankfurt University Hospital, Frankfurt, Germany
The endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA) 
has been implicated in the development and progression of cardiovascular disease. 
Elevated plasma ADMA concentrations predict adverse clinical outcome in patients 
undergoing percutaneous coronary intervention. However, whether elevated plasma 
ADMA concentrations also provide important prognostic information in patients after 
acute myocardial infarction (AMI) remains elusive.
Methods: We assayed circulating ADMA levels in 213 patients with AMI and their 
relation to adverse outcomes (death, AMI, stroke, or resuscitation) during follow-up in 
patients randomly assigned to angiotensin converting enzyme inhibition (captopril, n=108 
patients) or angiotensin II receptor antagonism (losartan; n=105 patients). Blood samples 
were collected at baseline (median 3 days following AMI) and 1 year.
Results: Patients were categorized according to the median of ADMA levels (0.59 [range 
0.24-1.13] µmol/l). ADMA levels above the median at baseline were associated with adverse 
cardiovascular events during a median of 27 months follow-up (univariate hazard ratio 2.10 
(95%CI 1.14 - 3.89; P=0.018). Differences in event rates were consistent for all separate 
endpoints including mortality. The crude event rates for patients with low ADMA levels were 
20.8% (combined endpoints), 17.9% (death, AMI), and 10.4% (death) whereas patients 
with high ADMA levels showed event rates of 35.5%, 31.8%, and 20.6%, respectively (all 
P<0.05). ADMA remained an independent prognostic indicator after adjustment for other 
known predictors of mortality and cardiovascular events after AMI (e.g. age, gender, 
diabetes, smoking, BNP, CRP; adjusted hazard ratio (HR) 2.45 [95%CI 1.25 - 4.80); 
P=0.009). Intriguingly, plasma ADMA levels were persistently elevated in patients with 
events during longitudinal testing (baseline: 0.64±0.15; follow-up: 0.67±0.11 µmol/l).
Conclusions: The present study indicates that elevated plasma ADMA concentrations 
can help to identify patients with myocardial infarction being at high risk for adverse 
cardiovascular events independently of other risk markers.
9:30 a.m.
832-7 Natriuretic Peptide Insights in Acute Myocardial 
Infarction
Justin A. Ezekowitz, Pierre Theroux, Wei-ching Chang, Kenneth W. Mahaffey, 
Christopher B. Granger, W. Douglas Weaver, Paul W. Armstrong, University of Alberta, 
Edmonton, AB, Canada, Duke Clinical Research Institute, Durham, NC
Background: While natriuretic peptides have prognostic ability, their relationship to acute 
myocardial necrosis is unclear. We examined the relationship of NT-BNP to infarct size 
(IS), time from symptom onset and prognosis in ST-elevation MI (STEMI) treated with 
primary PCI.
Methods: We studied 331 STEMI pts in the COMMA (COMplement inhibition in Myocardial 
infarction treated with Angioplasty) trial evaluating pexelizumab. NT-BNP (pg/ml) at 0, 24 
and 72 hours; CK-MB area-under-the-curve (AUC) at 72 hours; and discharge QRS score 
were measured. The 90-day composite was death, stroke, shock, and heart failure.
Results: NT-BNP (median & interquartile) was higher with longer time since symptom 
onset (r=0.354, p<0.001) as was baseline CK-MB (r=0.328, p<0.001), Lt Panel. NT-BNP 
was correlated to measures of IS including AUC (r=0.445, p<0.001), and QRS score 
(r=0.354, p<0.001); Pts at the 90-day endpoint had markedly higher NT-BNP at all times 
p<0.001, Rt Panel. NT-BNP at all time points was the strongest independent predictor of 
the 90-day composite endpoint multivariate model: at 24 hrs, only age and 24 hr NT-BNP 
were sig. predictors of 90-day events (c-index 0.825). Similarly, in the 72 hr model, only 
age, Killip class and NT-BNP were predictors of a poor outcome (c-index 0.850).
Conclusions: NT-BNP at presentation is highly correlated with duration of symptoms, 
with IS at 24 hours, and at all timepoints is strongly related to poor outcomes. Sequential 
measures offer powerful prognostic information in STEMI. 
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832-8 Population Studies of Cardiovascular Disease Risk Are 
Limited If They Lack Angiographic Data
Benjamin D. Horne, Joseph B. Muhlestein, Dale G. Renlund, John F. Carlquist, Tami L. 
Bair, Heidi Thomas, Beverly A. Campbell, Jeffrey L. Anderson, LDS Hospital, Salt Lake 
City, UT, University of Utah, Salt Lake City, UT
Background: The predictive strength of novel markers of cardiovascular (CV) risk, such 
as C-reactive protein (CRP), can vary between epidemiological studies. We hypothesized 
that this may result in part from variable presence of asymptomatic CV disease in control 
groups. Speciﬁcally, a recent report claims that CRP only moderately explains CV risk, 
thus we tested whether CRP is a stronger predictor of events when a clean control 
group of event-free, non-coronary artery disease (CAD) patients is used than among an 
admixed control of non-event CAD patients.
Methods: A cohort of 3,688 patients free from acute MI and undergoing angiography for CAD 
assessment had CRP tested. Events during 6.0±1.7 years of follow-up (range: 2.8-9.4 years) 
included MI, cerebrovascular accident, and death (all-cause, ischemic [ICD-9: 410-414], and 
non-ischemic CV). Readmission for congestive heart failure was also determined.
Results: Age averaged 64±12 years; 67% were male. CRP quartiles (Q) 1, 2, 3, and 4 had 
median hsCRP=0.9, 1.7, 3.5, and 13.1 mg/L, respectively. Overall, 717 (19%) patients died 
and 945 (26%) had a non-fatal event. CRP predicted (adjusted p<0.05) ischemic death, all-
cause death, MI, all events combined, and congestive heart failure readmission. Adjusted 
Cox hazard ratios (HR) for death were greater when controls were non-CAD patients (n=882; 
HR=1.0, 1.27, 1.99, 2.23 for CRP Q1-Q4; p<0.001) than when controls had CAD (n=1036; 
HR=1.0, 1.11, 1.60, 1.59; p=0.001). This dichotomy held for the other endpoints (the statistical 
interaction of CRP*CAD for all events had p=0.002 for Q4). ROC AUC for death was 0.60 for 
CRP, 0.70 for CRP and age, and only 0.76 with addition of all 18 other variables.
Conclusions: As demonstrated for CRP, the strength of association for a novel risk marker 
and CV events may differ by presence or absence of CAD. This suggests that control 
groups in CV studies must be well characterized (eg., by coronary angiography). Studies 
where the control group is heterogeneous mixture of both healthy subjects and event-free 
subjects with undiagnosed CAD may underestimate a marker’s predictive power. In this 
case, CRP remains one of the more important indicators of future CV risk
POSTER SESSION
1117  Protecting the Ischemic Myocardium I
Tuesday, March 08, 2005, 9:00 a.m.-12:30 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 9:00 a.m.-10:00 a.m.
1117-203 Human Hibernating Myocardium: Altered Calcium 
Regulatory System Contributes to Contractile 
Dysfunction
Holger M. Nef, Helge Möllmann, Thorsten Dill, Roland Brandt, Woitek Skwara, Birgit 
Bölck, Robert H.G. Schwinger, Jutta Schaper, Albrecht Elsässer, Kerckhoff Heart 
Centre, Bad Nauheim, Germany, Laboratory of Muscle Research and Molecular 
Cardiology, Cologne, Germany
Background: Human hibernating myocardium (HHM) is characterized by a contractile 
dysfunction during chronic ischemia. We tested the hypothesis that a disturbed expression 
of calcium regulatory proteins and an altered SR-Calcium-ATPase activity contribute to 
a reduced function.
Methods: In 14 patients with coronary artery disease and reduced left ventricular function 
HHM was detected preoperatively by thallium scintigraphy, dobutamine echocardiography 
and magnetic resonance imaging. All clinical investigations were repeated three months after 
revascularization. During open-heart surgery transmural biopsies were taken from areas 
deﬁned as HHM. Protein expression of SR-Calcium-ATPase (SERCA2a), phospholamban 
(PLN), sodium-calcium-exchanger (NCX) and ryanodine receptor (RyR2) were evaluated 
by Western blot analysis. SERCA2a activity was determined with an enzyme-coupled assay. 
Donor hearts not used for transplantation represented control myocardium.
Results: In all patients functional normalization of the HHM regions were documented 
after successful revascularization. The protein amount of phosphorylated PLN represented 
by the binding-sites Ser16 and Thr17 was signiﬁcantly reduced (Ser16: 1.0±0.1 vs. 
0.6±0.1, p0.05), and RyR2 (0.9.±0.1 vs. 1.0±0.2, p>0.05). Furthermore in HHM maximal 
SERCA2a activity (Vmax) was signiﬁcantly reduced (419.9±19.9 vs. 526.8±25.4 nmol 
ATP/mg protein/min, p<0.05).
Conclusions: We postulate that in HHM a reduced SERCA2a activity contributes to a 
changed intracellular calcium handling. The regulation of SERCA2a activity depends on 
the phosphorylation of PLN. Therefore the decreased protein expression of Ser16-PLN 
and Thr17-PLN explains impaired calcium uptake into the sarcoplasmic reticulum thereby 
leading to contractile dysfunction in HHM.
1117-204 Beneﬁcial Effects Of Cardiac Denervation On Ischemia-
Reperfusion Injury Result From Decreasing Direct 
Norepinephrine Toxicity, But Not From Decreasing 
Norepinephrine-Derived Free Radical Formation
Makoto Nonomura, Takashi Nozawa, Akira Matsuki, Teruo Nakadate, Norio Igarashi, 
Bun-ichi Kato, Nozomu Fujii, Akihiko Igawa, Hidetsugu Asanoi, Takashi Kondo, Hiroshi 
Inoue, Toyama Medical and Pharmaceutical University, Toyama, Japan
Background: Norepinephrine (NE) released from the sympathetic nerve terminals during 
ischemia is the source of reactive oxygen species and NE-derived free radicals may 
cause the injury of myocyte. Accordingly, we studied inﬂuences of cardiac NE release and 
NE-derived free radicals on myocardial ischemia-reperfusion injury.
Methods: Using Wistar rats, cardiac denervation was induced by painting a solution of 10% 
phenol on the proximal region of left coronary artery 1 week before inducing ischemia. In 
rats without denervation, atenolol (0.5mg/kg) was administered intravenously 10-min before 
coronary occlusion. The proximal portion of left coronary artery was occluded for 30-min 
and thereafter reperfused. Cardiac interstitial levels of NE (iNE) and free radicals were 
determined using microdialysis and electron paramagnetic resonance (EPR) spin trapping 
in cardiac microdialysate containing 5,5-dimethyl-1-pyroline-n-oxide (DMPO), respectively.
Results: During coronary occlusion, there were no differences in cardiac hemodynamics 
between phenol group (n=7) and control group (n=9), but heart rate and blood pressure 
were lower in atenolol group (n=6) than in other two groups. The ratio of infarct size to 
the ischemic area at risk was lower in phenol and atenolol groups than in control group 
(28.5±10.3, 31.8±10.7 vs 49.2±14.5 %, respectively, P<0.05). iNE increased more than 
200 times during 30-min ischemia in rats with innervation but was unchanged in rats with 
denervation, associated with the depletion of myocardial NE contents. EPR signal intensity 
corresponding to ·OH adduct of DMPO was not different between phenol and control 
group at 30-min (0.31±0.01 vs 0.28±0.11) and 60-min (0.45±0.19 vs 0.32±0.15) after 
reperfusion. Conclusions: Cardiac denervation protected myocytes against ischemia-
reperfusion injury primarily through decreasing direct NE toxicity via �-adrenergic signal 
activation, but not through suppressing NE-derived free radical formation.
1117-205 Glutathione Monoethyl Ester Provides Histological, 
Hemodynamic, and Echocardiographic Evidence of 
Cardioprotection in the Rodent Myocardial Ischemia-
Reperfusion Injury Model
Nicholas C. Dang, Veli K. Topkara, Joy Kay, Michael S. Aboodi, Steve Xydas, Shi-Xian 
Deng, Matthew J. Szabolcs, Donald W. Landry, Mehmet C. Oz, Columbia University, 
College of Physicians and Surgeons, New York, NY
Background: Reduced glutathione monoethyl ester (GSHme) is a powerful antioxidant 
that detoxiﬁes harmful oxygen free radicals and peroxides. We sought to examine 
the cardioprotective effects of exogenous GSHme in a rodent myocardial ischemia-
reperfusion (IR) model.
Methods: Forty-eight adult Sprague-Dawley rats were divided into 4 groups: sham-
thoracotomy + dextrose (Group 1), sham-thoracotomy + GSHme (Group 2), left anterior 
descending (LAD) artery ligation-release + dextrose (Group 3), and LAD ligation-release + 
GSHme (Group 4). Subjects were survived to 4 weeks and underwent echocardiographic 
and hemodynamic assessment. Hearts were sectioned for histological analysis.
Results: End-diastolic pressure (EDP) was higher (24.08 mm Hg) in Group 4 than in 
Groups 1 and 2 (20.71 and 19.73 mm Hg, respectively; p<0.05), but lower than in Group 3 
(30.58 mm Hg, p<0.05). Myocyte size (hypertrophy) was increased in Group 4 compared 
to Group 2 (116.91 µ2 vs. 101.70 µ2, p=0.02), equivalent to Group 1 (104.58 µ2, p=0.06), 
and decreased compared to Group 3 (133.68 µ2, p=0.01). Left ventricular free-wall sum/
sample collagen content was lower in Group 4 than in Group 3 (61% vs. 71%, p<0.05), 
but comparable to Groups 1 and 2 (61% and 61%, respectively; p=0.87 and p=0.88). 
Fractional shortening (FS) was higher in Group 4 than in Group 3 (30.26% vs. 22.07%, 
p<0.05), but comparable to Groups 1 and 2 (33.83% and 31.71%, respectively; p<0.05 
and p=0.67). Vascular density and mean aortic pressure were similar among all groups.
Conclusions: These ﬁndings suggest GSHme has a sustained cardioprotective effect in 
a rat IR model manifest as lower EDP, preserved myocyte size, decreased collagen scar 
formation, and higher FS. Future studies may determine a clinical role for this compound 
in common IR syndromes.
1117-206 Cardioprotective Effect of KP-102, a Synthetic Growth 
Hormone-Releasing Peptide, in Ischemia-Reperfusion 
Injury
Tadashi Ohyama, Sadayoshi Furuta, Toshimitsu Hori, Haruyoshi Ueo, Noriko Shiraishi, 
Masahiro Amakawa, Takahiko Murata, Kaken pharmaceutical Co., Ltd., Kyoto, Japan
Background: KP-102 (GHRP-2: pralmorelin) is a synthetic growth hormone (GH)-releasing 
peptide that not only induces GH release but also exerts a variety of cardiovascular effects. 
The aim of the present study was to determine the direct protective effects of KP-102 on 
cardiomyocytes and the effects of acute treatment following myocardial infarction in dogs.
Methods and Results: 1) Ischemia/hypoxia-induced injury to rat cardiomyocytes was 
elicited by incubating the cells for 4 h in an ischemia buffer under hypoxic conditions. 
Cardiomyocyte apoptosis and death were then respectively evaluated using the TUNEL 
method and by visual assessment of detached cells. Treatment with KP-102 (0.1 -10 
µM) after induction of ischemia/hypoxia reduced the number of apoptotic and detached 
cells in a concentration-dependent manner by exerting a direct, GH-independent 
cardioprotective effect. 2) Myocardial infarction was induced in dogs by occluding the 
left anterior descending coronary artery (LAD) for 90 min; this was followed by 3 h of 
reperfusion. Intravenous administration of KP-102 (1 µg/kg + 0.1 µg/kg/min) was begun 50 
min after LAD occlusion and continued to the end of the experiment. Collateral blood ﬂow 
to the ischemic region was measured 30 min after occlusion using colored microspheres. 
2005_5_MyocaIschInfartion.indd   229 12/23/04   10:07:22 AM
Enfocus Software - Customer Support



















Infarct size was determined by TTC staining and was expressed as a percent of the 
area at risk based on collateral blood ﬂow of <0.03 mL/min/g. Treatment with KP-102 
signiﬁcantly reduced infarct size, as compared to saline-treated controls (38.7±4.6 %, n=7 
versus 55.2±4.0 %, n=7, p<0.05). Plasma troponin T levels, which served as an index of 
myocardial injury and were measured after 60 min of reperfusion, were also signiﬁcantly 
reduced in KP-102-treated dogs (0.93±0.27 ng/mL versus 1.59±0.20 ng/mL, p<0.05).
Conclusions: KP-102 protects against ischemia-induced cardiomyocyte injury via a 
GH-independent mechanism. It also reduces infarct size when administered following 
ischemia in a canine model of acute myocardial infarction. These ﬁndings suggest that 
KP-102 could be beneﬁcial in the management of ischemic cardiovascular disease, 
including acute myocardial infarction.
1117-207 Brief Renal Ischemia Applied Before Coronary 
Reperfusion (Remote Postconditioning) Protects 
Against Myocardial Reperfusion Injury via Adenosine 
Receptors
Faraz Kerendi, Hajime Kin, Michael E. Halkos, Rong Jiang, Zhi-Qing Zhao, Robert A. 
Guyton, Jakob Vinten-Johansen, Emory University School of Medicine, Atlanta, GA
Objectives: A series of brief coronary artery reperfusions and reocclusions applied 
during the early minutes of coronary reﬂow (myocardial “postconditioning”) attenuates 
reperfusion injury. Using a model of infarct-inducing coronary artery occlusion-reperfusion, 
this study tested the hypothesis that a single 5 minute episode of renal artery (RA) 
occlusion and reperfusion applied immediately before the onset of coronary reperfusion 
(“remote postconditioning”, or RPC) would be cardioprotective by mechanisms involving 
adenosine receptor activation.
Methods: Anesthetized rats undergoing 30 min of left coronary artery occlusion and 3 
hours of reperfusion were randomized to: 1) CON (control, no RA occlusion); 2) RPC (RA 
was occluded for 5 min and released 1 min before coronary reperfusion); 3) Permanent RA 
occlusion (RA was permanently occluded 5 min before coronary reperfusion); 4) Delayed 
RPC (RA was occluded for 5 min, but its release was delayed until 1 min after coronary 
reperfusion); 5) CON+SPT (same as CON, but received 10 mg/kg IV of the adenosine 
receptor antagonist 8-sulfophenyltheophylline [SPT] 5 min before coronary reperfusion); 
and 6) RPC+SPT (same as RPC, but received 10 mg/kg IV SPT 5 min before coronary 
reperfusion). Results: Infarct size (percentage necrosis/area at risk, expressed as mean 
± SEM) was reduced by 50% in RPC (25 ± 4%) compared to CON (49 ± 4%, p=0.003), 
consistent with reductions in plasma CK activity (44 ± 5 vs. 67 ± 6 U/ml, p=0.023). In contrast, 
permanent RA occlusion failed to reduce infarct size (47 ± 5%). Delaying the release of the 
RA in delayed RPC abrogated the protective effect of RPC (48 ± 6%). SPT alone had no 
effect on infarct size (47 ± 4% in CON+SPT vs. 49 ± 4% in CON); however, RPC+SPT 
reversed the protective beneﬁt of RPC (50 ± 3% in RPC+SPT vs. 25 ± 4% in RPC).
Conclusions: Remote renal postconditioning applied immediately before the onset 
of coronary reperfusion provides potent cardioprotection likely exerted during the ﬁrst 
minutes of coronary reperfusion. This phenomenon is likely mediated by adenosine 
receptor activation as the protective beneﬁt is inhibited by the simultaneous administration 
of a non-selective adenosine receptor inhibitor.
1117-208 Mixed L-amino Acids Provide Cardioprotection 
Mediated By Translational And Transcriptional 
Regulation Of De Novo Protein Synthesis
Carol Chen-Scarabelli, Zuhair Allebban, Ruggero Ama’, Howard Rosman, Louis 
Saravolatz, Julius Gardin, Tiziano Scarabelli, VA Ann Arbor/University of Michigan, Ann 
Arbor, MI, St John Hospital/Wayne State University, Detroit, MI
Background: We previously showed that long-term oral supplementation with mixed L-
amino acids (AA) attenuates the extent of ischemia(I)/reperfusion(R) injury in the rat heart 
(Am J Cardiol. 2004;93(8A):35A-40A). Aims of this study were a) to determine whether a 
single dose of L-AA protects the rat heart against I/R; b) to investigate the mechanisms 
of this hypothesized cardioprotection; and c) to address whether it is mediated by 
transcriptional and/or translational effects.
Methods and Results: Isolated rat hearts were randomly divided into 5 groups (n=8): Control: 
perfused for 60 mins; I/R control: exposed to 35 mins I and 120 mins R; treated group: given 
a single oral dose (1g/Kg) of 11, mainly essential, mixed AA, and exposed, after 6 hours, to 
IRI; actinomycin D (ActD) and cycloheximide (Chx) groups: pretreated with ActD (1.5 mg/
kg, i.p.), inhibiting transcription (DNA→mRNA), or Chx (1 mg/kg, i.p.), inhibiting translation 
(mRNA→protein), 1 hour prior to AA supplementation, and exposed to IRI. AA reduced infarct 
size and release of creatine kinase, promoting postischemic recovery of cardiac function; 
lessened myocyte apoptosis, processing of caspase-9, although not caspase-8, and reduced 
mitochondrial leakage of cytochrome c (all p<0.05). AA also enhanced ATP content and rate 
of ATP production in isolated mitochondria, increased O2 consumption rate in myocardial 
skinned bundles, and elevated ratio of Bcl-2 to Bax (all p<0.05). These effects were reduced 
by pretreatment with both Chx (~80%), and ActD (~60%). Although differences in dry/wet 
weight ratios between hearts from different groups were not signiﬁcant, AA induced an 
increase in myocardial protein content (5930±76 ug/g vs 4732±175 ug/g), which was averted 
by pretreatment with both Chx and ActD (all p<0.05).
Conclusions: AA reduced postischemic cardiac cell loss, with recovery of cardiac 
function, and preservation of mitochondrial production of high-energy phosphates. These 
effects are largely dependent upon protein synthesis, regulated at both transcriptional and 
translational level. However, since cardioprotection was not fully abolished by blocking 
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1118-215 Enoxaparin is Consistently More Effective Than 
Unfractionated Heparin Across the Spectrum of Risk in 
Non-ST Elevation Acute Coronary Syndrome Patients: 
Insights from the INTERACT Trial
Andrew T. Yan, Raymond T. Yan, Mary Tan, Paul W. Armstrong, Christopher B. Granger, 
Omar Dabbous, Keith A.A. Fox, Kim A. Eagle, Thao Huynh, David H. Fitchett, Anatoly 
Langer, Shaun G. Goodman, St. Michael’s Hospital, Toronto, ON, Canada, Canadian 
Heart Research Centre, Toronto, ON, Canada
Background: The Global Registry of Acute Coronary Events (GRACE) risk score 
accurately predicts in-hospital mortality across the broad spectrum of acute coronary 
syndromes (ACS).
Objective: To determine whether GRACE risk score predicts recurrent ischemia and 
different treatment response in ACS.
Methods: In INTERACT, 746 ACS patients receiving aspirin and eptiﬁbatide were 
randomized to enoxaparin or unfractionated heparin (UH). Holter (48-hour) monitoring 
was analyzed by an automated algorithm and reviewed by a blinded cardiologist. Events 
at 30 days were centrally adjudicated in a blinded fashion. We examined the prevalence 
of Holter-ischemia (HI) and enoxaparin effect among patients stratiﬁed by the median 
GRACE risk score.
Results: The median GRACE score was 117 (range 53 to 233); HI was detected in 19.3% of 
patients. The GRACE score was positively correlated with HI and death/MI (both P<0.001).
 
GRACE Score Adjusted Odds Ratio




HI 12.6% 26.2% 2.63 (1.75-3.96) <0.001
Death/MI (30d) 4.5% 9.9% 2.37 (1.28-4.39) 0.006
Major bleeding (30d) 5.1% 7.4% 1.24 (0.69-2.24) 0.47
The beneﬁcial effects of enoxaparin were uniform on HI (pooled OR=0.43, 95% CI 0.29-
0.64, P<0.001) and on death/MI (pooled OR=0.49, 95% CI 0.27-0.90, P=0.02) across the 
high and low-risk subgroups (P for heterogeneity =0.53 and 0.16, respectively).
Conclusions: The GRACE risk score identiﬁes ACS patients at increased risk for early 
recurrent ischemia detected by Holter monitoring, and death/MI at 30 days. When combined 
with eptiﬁbatide, enoxaparin is consistently more effective than UH regardless of baseline 
risk and thus the greatest absolute treatment beneﬁt is seen in higher risk patients.
1118-216 Effects of Tiroﬁban Plus Clopidogrel Versus Clopidogrel 
Alone on Biomarkers of Myocardial Necrosis in 
Aggressively Treated Patients With Non-ST-Elevation 
Acute Coronary Syndromes Treated With Early 
Aggressive Approach: Results of the CLOpidogrel, 
Upstream TIroﬁban, in Cath Lab Downstream Abciximab 
(CLOTILDA) Study
ALESSANDRO POLITI, Mario Leoncini, Anna Toso, Francesco Bellandi, Mauro Maioli, 
Fabio Frascarelli, Stefano De Servi, Roberto Piero Dabizzi, S.Anna Hospital, Como, 
Italy, Misericordia e Dolce Hospital, Prato, Italy
Objectives. In non-ST-elevation (NSTE) acute coronary syndromes (ACS) patients 
undergoing early invasive strategy (coronary angiography within 48 hrs) and pre-treated 
with aspirin, heparin, and clopidogrel, we evaluated whether the adjunctive treatment with 
upstream tiroﬁban signiﬁcantly reduced the peak levels of troponin (cTn) I and creatine 
kinase (CK) - MB fraction.
Background. In NSTE-ACS a strong correlation has been found between adverse clinical 
events and peak values of myocardial necrosis markers.
Methods. A total of 250 patients were randomized to receive (group 1; n =128 ) or not (group 
2; n = 122) tiroﬁban administered “upstream”. Serial blood samples were collected before 
and after coronary angiography or pecutaneous coronary intervention (PCI) if performed.
Results. Between the 2 groups no differences in clinical and angiographic ﬁndings were 
observed. PCI was globally performed in 163 patients (86 of group 1 and 77 of group 2). 
Twenty (26%) out of 77 group 2 patients undergoing PCI received abciximab just prior to 
PCI because of high-risk clinical and angiographic characteristics. Mean cTn I and CK-MB 
values at admission, 6, 12, 24 hrs thereafter, peak values before coronary angiography, 
and peak values of index event were not signiﬁcant different between the 2 groups. Major 
bleeding rate was 2.3% in group 1 and 1% in group 2 (p = ns). Composite incidence of death, 
myocardial infarction or re-hospitalization for ACS at 30-day was 10% in both groups.
Conclusions. In NSTE-ACS patients undergoing early invasive strategy, the adjunctive 
administration of upstream tiroﬁban did not reduce the peak values of cTn I and CK-MB 
compared to a regimen including aspirin, heparin, and clopidogrel given on admission and 
associated with a selective use of abciximab just prior to PCI in high risk patients.
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1118-217 Celecoxib Reduces Angina Episodes and Inﬂammatory 
Markers in Refractory Unstable Angina by Down-
Regulating Monocyte COX-2 Expression
Donatella Lomaglio, Luigi M. Biasucci, Giovanna Liuzzo, Matteo Santamaria, Giovanna 
Di Giannuario, Valeria Colafrancesco, Julia Mela, Michela Narducci, Maddalena Piro, 
Filippo Crea, Attilio Maseri, Institute of Cardiology-Catholic University of the Sacred 
Heart, Rome, Italy
Background. Treatment of refractory unstable angina (RUA) in patients (pts) not suitable 
for revascularization is a clinical challenge. In this setting COX-2 inhibition may provide 
profound anti-inﬂammatory activity without interfering with ASA antiplatelet effects. 
Accordingly, we sought to assess whether celecoxib (C) may reduce angina episodes and 
inﬂammation in patients with untreatable RUA. 
Methods: Nine pts (age 71±8; 7 males) with RUA not suitable for revascularization 
were treatred with C 800 mg/d for 1 week. In all pts number of ischemic episodes before 
and after treatment and CCS classes were recorded. Pts were followed for 3 months. 
Before C and after 1 week, 1 and 3 months, CRP levels, interleukin (IL)-6 production after 
Lypopolysaccaride (LPS) stimulation and monocyte COX-2 expression by Western Blot 
(WB) assay were assessed in order to evaluate the anti-inﬂammatory effect of treatment. 
Results. All 9 pts were in CCS IV class at entry, with a mean of 3.1 daily ischemic 
episodes: all but 2 had a subjective improvement at one week that was still present at 3 
months in 5 pts (CCS class II, mean number of ischemic episodes 0.4±0.2), 1 pts died 2 
months after the end of treatment, 3 had no improvement. None of the pts had myocardial 
infarction, episodes of heart failure or hematological abnormalities during treatment. CRP 
decreased rapidly and markedly during the ﬁrst week (from a median level of 10.9 mg/L 
at admission to 4.6 at 48 hours, and 3.1 at 1 week) persisting low in pts with symptomatic 
improvement at 3 months. IL-6 production after LPS signiﬁcantly decreased at 48 hours, 
remaining signiﬁcantly reduced at 1 week, and 3 months (4053 pg/mL at admission, 1805 
at 48 hours, 1305 at 1 week, 1328 at 3 months respectively; p<0.05). In pts with reduction 
of symptoms and of inﬂammatory markers after C, monocyte COX-2 expression by WB 
was intense at baseline but was markedly reduced at 48 hours, 1 week and 3 months. 
Conclusions. One week of treatment with the selective COX-2 inhibitor C is safe and 
effective in improving symptoms in RUA. The clinical effects are persistent in the majority 
of pts and are associated with suppression of monocyte COX-2 expression and reduction 
in CRP levels, IL-6 production after LPS.
1118-218 Consistent Therapy With Enoxaparin Is Superior to 
Unfractionated Heparin in SYNERGY
Kenneth W. Mahaffey, Robert M. Califf, Marc Cohen, Karen S. Pieper, Harvey D. White, 
Louise Traylor, James J. Ferguson, for the SYNERGY Trial Investigators, Duke Clinical 
Research Institute, Durham, NC
Background: Of patients in the SYNERGY trial, 75% were on antithrombin therapy prior 
to enrollment, 12% assigned enoxaparin were treated with unfractionated heparin (UFH), 
and 4% assigned UFH received enoxaparin post-randomization (“crossovers”).
Methods: To explore the potential impact of switching therapy, a prespeciﬁed analysis 
was planned to analyze the rates of death or nonfatal myocardial infarction (MI) at 30 days 
and the incidence of bleeding among patients that received consistent therapy (deﬁned 
as no prerandomization therapy, prerandomization therapy same as assigned therapy, 
and no crossovers). Censored and time-dependent covariate analyses were performed to 
adjust for potential confounders.
Results: Of the 9978 patients in SYNERGY, 5637 (56.5%) received consistent therapy. 
Outcomes in the overall trial and in the consistent therapy group with and without modeling 
are shown. The results were similar after adjustment for baseline demographics (death/MI 
hazard ratio [HR] of 0.86 [95% conﬁdence interval {CI}, 0.75-0.99; p=0.032] and TIMI 
major bleeding HR of 1.17 [95% CI, 0.97-1.42; p=0.1]) and using the time-dependent 
covariate techniques (death/MI HR of 0.93 [95% CI, 0.84-1.03]).
Conclusions: In patients in SYNERGY treated with consistent therapy, a signiﬁcant 
reduction in death or nonfatal MI with enoxaparin was observed with no excess of 
bleeding with and without modeling. These data suggest that consistent use of enoxaparin 
is superior to UFH in acute coronary syndromes.
 
30-Day Death / MI 
(%)Enoxaparin vs UFH
Death / MI
HR and 95% CI
TIMI Major Bleeding 
(%)Enoxaparin vs UFH
Overall 14.0 vs 14.5 0.96 (0.86-1.06) 9.1 vs 7.6 (p=0.008)
Consistent 
Therapy 12.8 vs 15.6 0.81 (0.70-0.93) 8.1 vs 7.5 (p=0.374)
Adjusted - 
Censored Analysis 8.4 vs 8.5 0.82 (0.71-0.93) 5.1 vs 4.1 (p=0.378)
1118-219 Effect Of Dual Antiplatelet Therapy On Platelet Activation 
In Patients With Acute Coronary Syndromes In The 
Presence Of Elevated Crp And Soluble Cd 40 Ligand.
Manolis Vavuranakis, Dimitris Aggelis, Sophia Vaina, Maria Drakopoulou, Konstantinos 
Toutouzas, Irini Bosinakou, Theodoros Papaioannou, John Mitropoulos, Christodoulos 
Stefanadis, Hippokration Hospital, Athens, Greece
In patients (pts) with unstable angina and acute myocardial infarction without ST elevation 
(ACS), an increase risk for adverse outcome has been observed if high sensitivity C-
reactive protein (hs-CRP) and serum soluble CD 40 Ligand (sCD-40L) are elevated. 
Platelet activation, as reﬂected by soluble p-selectin(s-PS) has been used in clinical trials 
for the in vivo evaluation of platelet activity in patients with ACS. Aspirin is an effective 
therapy for ACS but the addition of clopidogrel, further improves clinical outcome. 
However, s-PS a marker of platelet activation has not been predictably altered.
Aims: We evaluated the effect of clopidogrel on s-PS in association with hs-CRP and 
sCD-40 L levels.
Methods: From 86 consecutive pts who were admitted for ACS, 43 pts (mean age 70±4 
years, 36 males, 7 females) were randomized to receive aspirin (325 mg, daily) and 
clopidogrel (300 mg loading dose followed by 75 mg daily) (group: Asp+Clop), and 43 pts 
(mean age 67±6 years, 34 males, 9 females) to receive aspirin (group: Asp), additionally 
to usual medical therapy. Blood samples were collected at 0, 8, 48 hours and on day 6. 
hs-CRP, s-PS and sCD-40 L were determined by immunoturbidimetric assay and ELISA 
as appropriate.
Results: Pts on Asp+Clop compared to pts on Asp alone had at baseline similar clinical 
characteristics. Overall, s-PS levels were similar among the two groups at 0, 8 and 48 
hours and at day 6 (Asp+clop vs Asp: 55.6±23 vs 53.75±22.9 ng/ml p=0.4, 52.41±16 vs 
54.14±20 ng/ml p=0.5, 50.17±13.7 vs 60.8±37.9 ng/ml p=0.1, 50.53±17.5 vs 54.64±18.97 
ng/ml p=0.4). However, pts with levels of sCD-40 L > 5.0 µg/dl who also belonged to the 
highest CRP quartile (CRP >2.26 mg/l) had a signiﬁcant increase in s-PS at 8 hours, if 
they received Asp only (53±12 to 68.41±21 ng/ml, p=0.043), and levels of s-Ps were 
greater than in pts on Clop+Asp (Clop+Asp vs Asp: 47.6±14 vs 68.41±21 ng/ml, p=0.01). 
This difference was not maintained at 48 hours and 6 days.
Conclusions: In pts with ACS and high hs-CRP and sCD-40 L, treatment with Asp+Clop 
is better than Asp alone in prohibiting early P-selectin elevation. This could be related to 
the greater intensity of platelet activation in these pts.
1118-220 Impact of Glycoprotein IIb/IIIa Inhibitors in Patients With 
Acute Coronary Syndromes Without ST-Elevation in the 
“Real World”
Pedro Monteiro, on behalf of the Portuguese Registry for Acute Coronary Syndromes 
investigators, Coimbra University Hospital, Coimbra, Portugal
Background: Glycoprotein IIb/IIIa inhibitors (GPI) are a major advance in the treatment 
of acute coronary syndromes (ACS) without ST-elevation. However, their real impact in an 
unselected population of ACS patients (pts) is still poorly documented.
Aim: To evaluate, in pts admitted with ACS without ST-elevation, the impact of GPI therapy 
in the in-hospital clinical outcome.
Population and Methods: Retrospective analysis of a nationwide database with data 
from 7067 pts, admitted for ACS in CCU´s or Cardiology wards since 2002; 3871 pts were 
found to be admitted for ACS without ST-elevation EMI and had data regarding in-hospital 
therapy. This subpopulation was divided in two groups, as they had (Group A: n=1252) or 
had not (Group B: n=2619) received GPI. Groups were analyzed regarding demographic, 
epidemiological and clinical data (see table).
Results: Pts treated with GPI had a higher risk proﬁle, with a higher incidence of previous 
revascularization and a more adverse coronary anatomy (left main and/or 3-vessel disease 
- 24% versus 14%; p<0.05). Although GPI-treated pts had a worse clinical proﬁle and a 
higher incidence of non-ST elevation AMI (NSTEMI) (71% versus 59%; p<0.05), they had 
a lower in-hospital mortality (3% versus 5%; p=0.03) - see table. A multivariate analysis 
showed that this was mainly due to a lower incidence of LV dysfunction (p=0.029).
Conclusions: Even in an unselected ACS without ST elevation patient population, the 
use of GPI is associated with better in-hospital mortality.
Table I - Results 
Groups/Parameters Group A (GPI) Group B (without GPI) p
Male Gender 71% 65% <0.05
Hypercholesterolemia 51% 43% <0.05
Smoking habits 26% 17% <0.05
Previous PCI 10% 8% <0.05
NSTEMI 71% 59% <0.05
Unstable angina 29% 41% <0.05
Left main and/or 3-vessel disease 24% 14% <0.05
In-hospital Mortality 3% 5% 0.03
1118-221 Treatment With the Selective Serotonin Reuptake 
Inhibitor Sertraline in the Early Phase of Acute 
Coronary Syndromes: A Double-Blind, Placebo-
Controlled, Pilot Study
Francesco Pelliccia, Antonio Picano, Paolo Salvini, Bruno Polletta, Domenico Cartoni, 
Maria Paola Cicini, Giuseppe Mercuro, Pietro Tanzi, San Camillo Hospital, Rome, Italy, 
University of Cagliari, Cagliari, Italy
Background: Selective serotonin re-uptake inhibitors (SSRIs) can improve outcome of 
pts with coronary artery disease and depression, but it remains unknown if they can be 
given in acute coronary syndromes (ACS). We planned a pilot randomized study to verify 
the effects and safety of the early administration of sertraline, a SSRIs, in patients with 
ACS and depression.
Methods: We studied 20 pts who arrived to our ED because of acute chest pain and 
were found to have ACS and depressive symptoms. Depression was assessed using 
the 21-item self-report Beck Depression Inventory (BDI) and was deﬁned as a score>10. 
Within 6 hrs from arrival, pts were randomly assigned to a double-blind treatment with 
50 mg b.i.d. of sertraline (n=10) or placebo (n=10). All pts had clinical and biochemical 
evaluation, echocardiography and coronary angiography within 48 hrs from admission 
to ED. In-hospital major adverse cardiac events and pre-discharge BDI scores were 
recorded in all pts.
Results: At entry, there were no differences between the two groups in age, sex, smoking 
(50% vs 60%, NS), diabetes (30% vs 20%, NS), hypertension (40% vs 30%, NS), and 
previous MI (20% vs 10%, NS). The two groups had similar BDI scores (13+5 vs 14+6, 
NS). Also, pts exhibited similar TIMI risk score (5+3 vs 4+2), peak CK-MB (125±35 vs 
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139±80 ng/ml, NS), peak Troponin I (20±11 vs 25±15 ng/ml, NS), LV ejection fraction 
(53±15% vs 50±17%, NS), and number of diseased vessels at coronary angiography 
(1.4±0.8 vs 1.6±0.7, NS). During hospital stay, no deaths occurred and recurrence of 
myocardial ischemia was seen in 1 patient on sertraline but in 4 pts on placebo. No 
differences in the frequency of arrhythmia or in QTc interval were detected between the 
two groups. At time of discharge, BDI score was signiﬁcantly lower in sertraline-group 
than in the placebo-group (6+5 vs 13+4, p<0.05). Notewhorthy, a BDI score<10 was seen 
in 6/10 pts on sertraline and in 1/10 pts on placebo (p<0.05).
Conclusion: Early treatment with sertraline in this pilot study was safe and effective 
for treating depressive symptoms in pts with ACS and was associated with a better in-
hospital outcome. A multicenter randomized study is now ongoing and complete results 
will be available by 2005.
1118-222 Blood Transfusions in Patients Admitted With Non-ST-
Segment Elevation Acute Coronary Syndromes: Results 
From CRUSADE
Eric D. Peterson, Anita Y. Chen, Xin Yang, Matthew T. Roe, Sunil V. Rao, Ralph G. Brindis, 
W. Brian Gibler, E. Magnus Ohman, Duke Clinical Research Institute, Durham, NC
Background: The management of non-ST-segment elevation acute coronary syndromes 
(NSTE ACS) now includes more aggressive antithrombotic therapies and interventional 
procedures. Meanwhile, the NSTE ACS patient population has grown older with more 
comorbidities. The degree to which these factors have affected the need for blood 
transfusions has not been well studied in community practice.
Methods: We examined 74,271 patients with NSTE ACS (positive cardiac markers 
and/or ischemic ST-segment changes) admitted to 430 U.S. hospitals participating in 
the CRUSADE quality improvement initiative from 2002-2003. Bypass surgery-related 
bleeding was excluded. We identiﬁed the percentage of patients requiring one or more in-
hospital red blood cell transfusions as well as the multivariable baseline patient predictors 
of transfusion. Variation in transfusion rate among hospitals was also analyzed.
Results: The overall in-hospital blood transfusion rate was 9.4%. The top ﬁve patient 
predictors of blood transfusion included the following: renal insufﬁciency (odds ratio [OR] 
of 2.35 [95% conﬁdence interval {CI}, 2.21-2.50]), systolic blood pressure (per 10 mmHg 
drop) (OR of 1.08 [95% CI, 1.06-1.09]), female gender (OR of 1.49 [95% CI, 1.41-1.59]), 
diabetes mellitus (OR of 1.40 [95% CI, 1.33-1.48]), and age above 75 (vs below 55) 
(OR of 2.82 [95% CI, 2.48-3.20]). There was a concurrent rise in transfusion rate with 
increasing number of antiplatelet and anticoagulant agents used in combination among 
those above age 75. This was not observed among those below age 55. There was >3-fold 
variation in transfusion rate among participating hospitals.
Conclusion: Blood transfusion is often required in contemporary NSTE ACS management. 
Patient factors associated with antithrombotic drug distribution and clearance are highly 
associated with transfusion risks and emphasize the need for individualized dosing to 
improve the safety of ACS care. Furthermore, wide inter-hospital variability in transfusion 
emphasizes the need for more studies to quantify the risk and beneﬁt of transfusion in the 
management of NSTE ACS.
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1119-195 The Impact of Contrast-Induced Nephropathy on 
Survival Rate in Patients after Acute Myocardial 
Infarction
Jacek Kowalczyk, Radoslaw Lenarczyk, Zbigniew Kalarus, Janusz Prokopczuk, 
Grzegorz Honisz, Teresa Zielinska, Joanna Stabryla-Deska, Patrycja Pruszkowska-
Skrzep, Oskar Kowalski, Agata Musialik-Lydka, Mariusz Gasior, Lech Polonski, Medical 
University of Silesia, Zabrze, Poland, Silesian Centre for Heart Diseases, Zabrze, Poland
Renal insufﬁciency is associated with poor prognosis in patients (pts) with coronary heart 
disease.
Aim: to determine impact of contrast-induced nephropathy (CIN) on long-term outcome in 
pts with acute myocardial infarction (AMI), who underwent coronary angioplasty (PCI).
Methods: CIN was deﬁned by serum creatinine level < 133 µmol/l on admission and its 
25% increase, with value > 133 µmol/l within 24 hours after PCI. One-center analysis 
of 1027 consecutive AMI pts who underwent PCI was performed. 89.8% of them had 
proper renal function (controls, n=922) and 5.9% had CIN (n=61). CIN group was divided 
into diabetic (CIN DM, n=28) and non-diabetic pts (CIN nDM, n=33). Cumulative survival 
during mean 26.4 months follow-up was compared using log-rank, independent predictors 
of death selected with multivariate Cox regression model.
Results: Remote survival in CIN pts was lower than in controls (68.4% vs 90.0%, 
p<0.001). CIN pts were older, more often diabetic, hypertensive, with lower EF and 
greater prevalence of cardiogenic shock (all p<0.05). When incorporating the signiﬁcant 
parameters into multivariate analysis, CIN was shown to be still an independent predictor 
for any-cause death only among CIN DM pts. Adjusted hazard ratio (HR) for death in CIN 
DM vs controls was 2.35 (CI: 1.95-2.75, p<0.05), in CIN and CIN nDM vs controls HR 
was not signiﬁcant.
Conclusion: CIN in diabetic pts signiﬁcantly and independently inﬂuences survival in 
AMI pts treated with PCI and is associated with increase of death hazard.
1119-196 Excellent Clinical Outcomes in High Risk Non-Shock 
Acute Myocardial Infarction Patients Treated in the 
Contemporary Mechanical Reperfusion Era: A Pooled 
Analysis of 4 Clinical Trials
William W. O’Neill, Simon R. Dixon, Gregg W. Stone, John J. Grifﬁn, David A. Cox, John 
G. Webb, Roxana Mehran, Bruce R. Brodie, Jack L. Martin, Raymond J. Gibbons, John 
Held, Cindy L. Grines, William Beaumont Hospital, Royal Oak, MI, Columbia University, 
New York, NY
Background: Recent reports have suggested that the excellent clinical results observed 
in the CADILLAC trial was attributable to enrollment of low-risk patients. We therefore 
examined the early clinical outcomes in 1,122 high-risk non-shock acute myocardial 
infarction (AMI) patients enrolled in 4 contemporary mechanical reperfusion trials.
Methods: We performed a pooled analysis of the EMERALD, COOL-MI, ICE-IT and 
AMI-HOT randomized clinical trials. These studies were conducted from September 2001 
to December 2003. All trials required electrocardiographic evidence of acute anterior or 
large infero-posterior myocardial infarction for enrollment. Patients with cardiogenic shock 
were excluded. In three trials, patients presented within 6-hours of symptom-onset; in 
AMIHOT patients were eligible for up to 24-hours from AMI onset. Clinical outcome was 
evaluated at 30-days.
Results: 1,122 patients were enrolled in the 4 trials (mean age 59 ± 12yrs; 77% male). 
Baseline demograhics included: diabetes 14%, hypertension 43%, and prior MI 28%. 
Almost all patients (99%) had a native vessel culprit. 43% patients had anterior wall 
infarction and 52% had multi-vessel coronary disease. Stenting was performed in 96% 
patients; 83% received a glycoprotein IIb/IIIa inhibitor. The mean infarct size at 30-days 
was 16% of the left ventricle. Following PCI, TIMI-3 ﬂow was achieved in 92% of patients. At 
30-days, the incidence of major adverse cardiac events was 4.5% (death 2.0%, myocardial 
infarction 1.5%, TVR 2.1% and stroke 0.8%).There was no signiﬁcant difference in MACE 
rates between anterior and non-anterior patients (4.6% vs. 3.3%, p=NS).
Conclusion: In the current era, mechanical reperfusion is associated with excellent 
clinical results even in high risk non-shock AMI patients, with similar outcomes in anterior 
and non-anterior infarct patients.
1119-197 Impact of Plaque Characteristics on Myocardial Tissue 
Reperfusion in Acute Myocardial Infarction.
Shigeo Kawano, Hiroshi Ito, Katsuomi Iwakura, Atsunori Okamura, Toshiya Kurotobi, 
Motoo Date, Koichi Inoue, Yoshimune Hiramoto, Noriyuki Hanibuchi, Norihiro Hayashi, 
Takahiro Hashimoto, Hiroyuki Nagai, Masao Takeda, Kenshi Fujii, Sakurabashi 
Watanabe Hospital, Osaka, Japan
Background: Previous studies have demonstrated that the microvascular embolization 
of intracoronary thrombus and plaque components reduces the beneﬁt of reperfusion 
therapy for AMI. However, it is unknown whether the plaque burden of culprit lesion 
impacts the microvascular embolization and the tissue reperfusion.
Methods: In 83 consecutive patients (pts) with AMI within 6 hours after symptom onset, 
we performed IVUS to evaluate the plaque characteristics after thrombectomy with 
RescueTM PT catheter. All pts underwent the subsequent angioplasty with or without 
stenting after IVUS assessment. Myocardial tissue reperfusion was assessed based on 
TIMI perfusion grade (TMPG)
Results: TIMI-3 ﬂow was observed in 53 pts (64%) after thrombectomy alone and 65 
pts (78%) after adjunctive angioplasty. There were 58 pts (70%) with TMPG-3 in ﬁnal 
angiography. In a logistic regression model, RCA culprit was the strongest predictor 
of TMPG<=2. Large plaque area, presence of lipid-pool like image and angiographic 
collateral grade were independent predictors of poor tissue reperfusion (Table).
Conclusions: These results suggest that the PCI induced embolization of unstable 
plaque materials impacts on microvascular dysfunction. Intracoronary thrombus removal 
is not enough to prevent microvascular embolization and the evaluation of plaque 
characteristics by IVUS is promising to determine the indication of distal protection 
strategy to obtain tissue reperfusion in AMI.
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RCA culprit, n(%) 14(24%) 15(60%) 10.7(1.04-110)
Plaque area, mm2 14.5±4.4 18.5±4.9 1.4(1.03-1.9)
Lipid pool like image, n(%) 9(16%) 6(24%) 9.6(1.2-79)
Collateral grade 0.9±0.9 0.6±0.6 0.17(0.04-0.74)
1119-198 Long-Term Prognostic Implications of Nonoptimal 
Primary Angioplasty for Acute Myocardial Infarction
Guido Parodi, Renato Valenti, Gentian Memisha, Nazario Carrabba, Angela Migliorini, 
Giovanni Maria Santoro, David Antoniucci, Careggi Hospital, Florence, Italy
Background: The long-term outcome of a non-optimal result of a primary percutaneous 
coronary intervention (PCI) for acute myocardial infarction (AMI) has not been investigated. 
Methods and Results: An optimal PCI result was deﬁned as TIMI ﬂow grade 3 and 
residual stenosis < 20%, otherwise the procedure result was considered non-optimal. 
Long-term (51±21 months) clinical follow-up data were collected from 1,009 consecutive 
patients with AMI who underwent primary PCI.
Overall, an optimal primary PCI result was achieved in 958 patients (95%). Cardiogenic 
shock (OR 2.921, 95% CI 1.462-5.837; p=0.002) and age (OR 1.029, 95% CI 1.002-
1.058; p=0.033) were independent predictors of non-optimal primary PCI result. Patients 
with a non-optimal PCI had a higher (3588±3716 U/L versus 2443±2143 U/L, p=0.002) 
and delayed (11±6 hours versus 7±4 hours, p=0.0001) peak creatine kinase values, as 
compared to patients with optimal PCI. At 5-year follow-up, patients with non-optimal PCI 
showed higher rate of all cause mortality (47% vs 19%; p<0.00001 by log-rank test) than 
those with an optimal mechanical reperfusion. Fifty-two percent of the deaths in the non-
optimal PCI group occurred within the ﬁrst month. Interestingly, after this period, estimated 
survival of 30-day alive patients was not signiﬁcantly different to that of patients with an 
optimal PCI (p=0.06 by log-rank test). Moreover, at long-term follow-up, comulative rates 
of nonfatal reinfarction, hospitalization for heart failure, and additional revascularization 
procedures were similar in the 2 groups (4% vs 5%, p=0.695; 4% vs 5%, p=921; and 22% 
vs 20%, p=0.816, respectively).
Conclusion: A non-optimal primary PCI result is an uncommon occurrence, but it 
represents a very serious event because of the high early mortality.
However, in patients surviving the early phase, long-term patient care should be the same 
of successfully reperfused AMI patients, since the incidence of clinical events is similar.
1119-199 Blood Loss After Primary Percutaneous Intervention 
Is Associated With Death and Major Adverse Cardiac 
Events in Acute Myocardial Infarction
Beth A. Bartholomew, Cindy L. Grines, Gregg W. Stone, Eugina Nikolsky, Judith A. 
Boura, David A. Cox, Bruce R. Brodie, William W. O’Neill, William Beaumont Hospital, 
Royal Oak, MI
Background: Hemorrhagic complications are not infrequent after primary percutaneous 
coronary intervention (PCI) in acute myocardial infarction (AMI). The clinical impact of 
blood loss after primary PCI has not been studied.
Methods: Data was pooled from 4,357 patients undergoing primary PCI from 7 
randomized trials from the PAMI and CADILLAC databases. The impact of decline in 
hematocrit (HCT) from baseline to nadir on clinical outcomes was examined..
Results: The absolute HCT drop from admission to nadir was >10% in 18.7% of pts, and 
was >15% in 4.7% of pts. Independent predictors of HCT drop included dialysis (odds 
ratio (OR) = 44, p<0.0001), ﬁnal thrombus present (OR=3.0, p<0.0001), ejection fraction 
<50% (OR=2.2, p=0.0006), no stent (OR=2.2, p=0.0014), female gender (OR=2.0, 
p=0.03), and age >70 (OR=2.1, p=0.001). In-hospital major adverse cardiac events 
strongly correlated with the degree of blood loss (Table). By multivariate analysis, HCT 
drop was an independent predictive of mortality (OR=3.5, p=0.001), reinfarction (OR=7.8, 
p<0.0001), target vessel revascularization (OR=3.1, p=0.0009), and composite major 
adverse events (OR=4.1, p<0.0001).
Conclusions: Signiﬁcant blood loss after primary PCI in AMI occurs in nearly one in 
ﬁve patients, and is strongly associated with adverse clinical events. Future studies are 
warranted to examine whether alternative routes of vascular access or anti-thrombotic 
agents can reduce blood loss after primary PCI to improve event-free survival.
Adverse Events are Increased with Increased Blood Loss 
Event < 10% HCT Drop 11-15% HCT Drop >15% HCT Drop P value
Death 1.2% 3.3% 8.3% <0.0001
Reinfarction 0.6% 1.7% 6.4% <0.0001
Revascularization 1.7% 4.8% 5.9% <0.0001
Disabling Stroke 0.08% 0.3% 1.0% 0.011
MACE (combined) 3.2% 8.1% 16.2% <0.0001
1119-200 Higher Presentation Acuity and Medical Comorbidities 
Limit Utilization of Early Invasive Therapies in Acute 
Myocardial Infarction With Cardiogenic Shock, 
Decreasing Survival to Hospital Discharge
Oliver DSilva, Sandeep Nathan, Akshay Gupta, Amit Amin, Shaun Senter, Arun Kumar, 
Lloyd W. Klein, Rush University Medical Center, Chicago, IL, Cook County Hospital, 
Chicago, IL
Background: Although early invasive therapies are beneﬁcial in myocardial infarction (MI) 
complicated by cardiogenic shock (CS), the interaction between clinical factors, selection 
for angiography and mortality is unclear. Current treatment patterns and predictors of 
early mortality in CS were investigated in a retrospective cohort analysis.
Methods: Data from 181 pts admitted for MI with CS over 54 months at 2 tertiary care 
centers, were compiled and analyzed via multivariate logistic regression. MI pts with CS, 
deﬁned as sustained peri-infarct SBP<90 or MAP<60 mm Hg, were identiﬁed by DRG 
code and adjudicated by chart review.
Results: 56.9% of pts survived to hospital discharge. 84.0% pts underwent angiography, 
37.6% pts received IABP support and 69.1% pts were revascularized (53.6% PCI, 15.5% 
CABG). Deferral of angiography, ﬁrst SBP<100, any SBP<70 or DBP<30 mm Hg and 
LVEF<30% each independently predicted in-hospital mortality (Fig.1a). Prior CABG 
or CHF, earlier development of CS after admission and pressor use were linked with 
deferral of angiography (Fig. 1b). No interaction between age, DM and death was noted, 
irrespective of revascularization status.
Conclusions: Deferral of angiography was more likely in pts with earlier onset of 
hypotension, prior CABG, CHF or pressor needs, which in turn was strongly predictive 
of early mortality. This suggests that selection bias may limit utilization of life-saving 
therapies in the most critically ill pts, who have the most adverse prognosis overall. 
1119-201 The Safety of Antithrombin Therapy in Non-ST-Segment 
Elevation Acute Coronary Syndromes Patients: Results 
From the CRUSADE Initiative
Kanwar P. Singh, Matthew T. Roe, Eric D. Peterson, Anita Y. Chen, Kenneth W. Mahaffey, 
Shaun G. Goodman, Robert A. Harrington, E. Magnus Ohman, W. Brian Gibler, Charles 
V. Pollack, Duke Clinical Research Institute, Durham, NC, University of Pennsylvania, 
Philadelphia, PA
Background: In the SYNERGY trial, the use of low molecular weight heparin (LMWH) was 
associated with a higher risk of bleeding than unfractionated heparin (UFH), particularly 
when treatment crossover occurred. The relative safety proﬁles of these antithrombin 
therapies have not been examined in routine clinical practice.
Methods: Using data from the CRUSADE Initiative, we compared treatment patterns in 
patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS) 
receiving LMWH and UFH at 311 U.S. hospitals with full revascularization capabilities 
between January 2001 and December 2003. Eligible pts had positive cardiac markers 
and/or ischemic ST-segment changes. Unadjusted and adjusted in-hospital clinical 
outcomes were compared in pts treated with LMWH vs. UFH vs. LMWH and UFH.
Results: Of 38,601 pts, 38.4% received LMWH only, 54.4% received UFH only, and 7.3% 
received both within 24 h of admission. Clinical characteristics were similar among all 
pt groups. Transfusion rates were lowest in pts treated with LMWH only (Table). These 
results persisted after adjusting for clinical factors and revascularization.
Conclusions: High-risk NSTE ACS pts in routine clinical practice have lower rates of 
transfusion when treated with LMWH compared with UFH or both LMWH and UFH in 
the ﬁrst 24 h. These results suggest that the safety proﬁle of antithrombin therapies may 
be different in community practice than those seen in selected trial patients receiving 
protocol-driven regimens.





LMWH and UFH 
(n=2,797) Adjusted OR (95% CI)*
RBC Transfusion Rates
All pts 13.8% 15.2% 17.0% 0.81 (0.76-0.87)
Non-CABG pts 7.1% 8.5% 8.7% 0.77 (0.70-0.84)
Concomitant Treatment Rates
GP IIb/IIIa inhibitors 31.7% 45.1% 49.0% n/a
Clopidogrel <24 h 41.7% 47.0% 52.7% n/a
Cardiac cath 71.0% 81.0% 82.7% n/a
PCI 36.8% 49.1% 51.2% n/a
CABG 13.0% 13.7% 16.3% n/a
* For LMWH alone versus UFH alone. CABG = coronary artery bypass grafting; GP = glycoprotein; cath = 
catheterization; PCI = percutaneous coronary intervention.
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1119-202 Approach to Post-Myocardial Infarction Ventricular 
Septal Defect: Conservative, Percutaneous Device 
Closure or Surgical Repair
Pankaj Gupta, Atul Mathur, S. Radhakrishan, S. Srivastava, A. Seth, R. Kapoor, N. 
Chandra, Z. S. Meherwal, A. Omar, R. R. Kasliwal, N. Trehan, Escorts Heart Institute And 
Research Centre, New Delhi, India
Background: Ventricular septal rupture complicating acute myocardial infarction (MI) has 
extremely poor prognosis. Percutaneous Ventricular Septal Defect (VSD) device closure 
aims at improving the outcome in this subset of patients.
Methods: Between July 2000 to August 2004, 33 patients (pts) presented to us with acute MI 
complicated with ventricular septal rupture, mean age 64.18 ± 11.14 years (43-89 years).
Result: Of these 33 patients, 16 were managed conservatively (group A), 12 by 
percutaneous device closure (group B) and 8 by surgical closure (group C). Both surgical 
repair and percutaneous device closure was performed in 3 pts. Presentation was with 
anterior MI in 11 pts in group A, 8 pts in group B and 6 pts in group C. Gross pulmonary 
edema and or cardiogenic shock was present in 13 pts in group A, 10 pts in group B 
and 6 pts in group C. Angiographically triple vessel disease and double vessel disease 
was present in 6 and 4 pts in group A respectively, 4 and 5 pts in group B respectively 
and 3 and 1 pts in group C respectively . The mean VSD size was 12.9 + 5.8 millimeters 
(mm) in group A, 12.3 ± 4.5 mm in group B and 11.7 + 4.9 mm in group C respectively. 
The mean left ventricular ejection fraction was 35.3 + 9.9% in group A, 35.8% ± 8.5% 
in group B and 35 + 8.9% in group C. Percutaneous device closure was performed via 
right internal jugular vein using the Amplatzer VSD (9) or Atrial septal defect(3) closure 
devices, mean size 22.5 ±3.6 mm (18-30 mm). Mean duration of device implantation 
after MI was 8.9 ± 18.9 days and for surgical closure was 21.4 + 12.3 days. Procedural 
success was achieved in 10 pts in group B and 5 pts in group C. In hospital mortality was 
11 in group A, 7 in group B and 1 in group C. At a mean follow up of 2-44 months in 15 
discharged pts, survival was 2 in group A, 4 in group B and 4 in group C. Follow up was 
lost in 2 pts in group A and 3 pts in group C.
Conclusion: Percutaneous device closure of post MI VSD is feasible and is a less invasive 
modality for treating this sick subset of patients. However a low survival was noted in this 
group as the patient selection was biased towards inclusion of more acutely sick patients.
1119-233 Predictors of Death in Patients Treated by Facilitated 
Percutaneous Coronary Intervention for Acute 
Myocardial Infarction
Philippe Garot, Thierry Lefèvre, Yves Louvard, Jean-Yves Le Tarnec, Alain Margenet, 
Claude Pougès, Pierre Dumas, Dominique Thebert, Ivan Laurent, Marie-Claude Morice, 
Institut Cardiovasculaire Paris Sud, Quincy, France
Background: Facilitated PCI has become the treatment of choice for acute MI. However, 
the predictors of death after facilitated PCI still need to be investigated .
Objectives: We sought to determine the predictors of in-hospital death after facilitated PCI 
for acute MI in a large cohort of consecutive patients referred to the cath-lab of our institution.
Methods and results: From 1995 to 2004, a large cohort of > 2000 consecutive patients 
were referred to the cath-lab of our institution for acute MI. Among them, a total of 553 
(28%) underwent facilitated PCI after prompt out-of-hospital management including the 
administration of thrombolysis and/or IIBIIIA inhibitors. 
In-hospital death 
N=43
Alive at discharge 
N=510 P
Males 70% 80% 0.16
Age, y-o 65±12 60±14 < 0.05
Diabetes 23% 14% 0.19
Shock on admission 70% 7% < 0.0001
Pain to admission, minutes 331±202 255±188 < 0.05
Anterior MI 53% 46% 0.27
Initial TIMI-3 ﬂow 19% 38% < 0.01
Thrombus containing lesion 51% 39% 0.09
Direct stenting 37% 49% 0.07
Ejection fraction, % 39±17% 53±14 < 0.05
PCI success 65% 92% < 0.01
Re-MI (early IRA reocclusion) 10% 1% < 0.001
Peak CK, IU/L 3028±2378 2184±2037 < 0.05
By multivariate analysis, shock on admission (0.18, 95%CI [0.00-0.36]) and re-MI (0.41, 
95%CI [0.20-0.63]) were independent predictors of death after facilitated PCI for AMI.
Conclusion: Patients who died after facilitated PCI for acute MI had less favourable 
clinical and angiographic characteristics (older pts with larger infarcts and late coronary 
re-opening). Shock on admission and early re-MI were independent predictors of death 
after facilitated PCI for acute MI.
1119-234 Beneﬁcial Effect of Reperfusion Therapy Beyond 
Preservation of Left Ventricular Function In Patients 
With Acute ST Elevation Myocardial Infarction: Support 
for the Open Artery Hypothesis
Uwe Zeymer, Anselm Gitt, Ralf Zahn, Rudolf Schiele, Ralph Winkler, Martin Gottwik, 
Jochen Senges, Herzzentrum Ludwigshafen, Ludwigshafen, Germany
Background: Left ventricular ejection fraction (LVEF) is one of the most important 
predictors of mortality during follow-up in patients with acute ST elevation myocardial 
infarction (STEMI). While randomized clinical trials have shown a reduction of mortality 
by early reperfusion therapy, the effect of ﬁbrinolysis and primary PCI on the preservation 
of left ventricular function was only modest. Therefore we sought to determine the impact 
of early reperfusion therapy on 1-year mortality in patients with STEMI and a comparable 
LVEF before discharge. 
Methods: We used data from the prospective MITRA-PLUS registry containing nearly 
10.000 patients with STEMI and 1-year follow-up. Results: From a total of 9934 patients 
3103 were treated with primary PCI, 3856 with ﬁbrinolysis and 2975 without early 
reperfusion therapy. The 1-year mortality related to LVEF and reperfusion therapy is given 
in table 1 and revealed signiﬁcant differences between patients with and without early 
reperfusion therapy in the groups with the same LVEF. Reperfusion therapy remained an 
independent predictor of survival even after adjusting for confounding parameters such as 
age, gender, prior MI, diabetes, killip class, etc.
Conclusion: Early reperfusion therapy improves mid-term mortality compared to patients 
without reperfusion therapy despite similar LEVF at discharge. These results support the 
open-artery hypothesis which suggests a clinical beneﬁt of reperfusion therapy for STEMI 
beyond preservation of LEVF.
1-Year mortality related to LVEF at discharge 
No reperfusion therapy Fibrinolysis Primary PCI p-value
LVEF > 55% 8.4 % 2.8 % 2.2 % < 0.0001
LVEF 41-55% 14.1 % 6.6 % 4.4 % < 0.0001
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1120-229 Has the Impact of a Recurrent Acute Myocardial 
Infarction on Mortality Changed Within the Last Two 
Decades?
Pernille Buch, Steen Abildstrom, Søren Rasmussen, Gunnar Gislason, Jeppe 
Rasmussen, Mette Madsen, Christian Torp-Pedersen, Bispebjerg University Hospital, 
Copenhagen, Denmark, National Institute of Public Health, Copenhagen, Denmark
Background: Recurrent acute myocardial infarction (re-AMI) has been shown to be 
a strong predictor of subsequent mortality in the past. But the impact of a re-AMI on 
prognosis in more recent years is unknown. We therefore analyzed trends in the mortality 
from a re-AMI during 1985-2002.
Methods: Patients aged 30 years or older with a ﬁrst acute myocardial infarction (MI) were 
identiﬁed through the Danish National Patients Registry during 1985-2002. International 
Classiﬁcation of Diseases was used to identify all re-AMI’s within the ﬁrst month after 
admission from a ﬁrst AMI. Estimates of mortality were obtained from the Kaplan Meier 
method. A time dependent Cox regression model with adjustment for sex and age was used 
to compare relative risk (RR) of mortality from ﬁrst re-AMI with patients without an event.
Results: A total of 167,260 patients had a ﬁrst AMI and 5363 had a re-AMI. One year-
mortality was 39% after admission for a ﬁrst MI and 49% for patients with a re-AMI in 
1985-1989. The respective percentages were 34% and 35% in 1990-1994, 29% and 25% 
in 1995-1999 and 25% and 18% in 2000-2002. A re-AMI carried a poor prognosis in 1985-
1989, particularly in relation to the acute event. The RR of mortality declined throughout the 
period and was no longer of signiﬁcance 60 days after a re-AMI in 2000-2002 (see Table).
Conclusion: The predictive power of a ﬁrst re-AMI within 30 days of an infarction has 
weakened during the last 17 years. After 2 months the subsequent prognosis is as good 
as for patients without a re-AMI.
Relative risk of mortality within ﬁrst year after a re-AMI  
during 1985-2002 
RR (95% CI) of mortality - days after re-AMI*
Year 0 - 7 days 8 - 60 days 61 - 365 days




















*Risks are calculated as lifetime since admission from a ﬁrst re-AMI. Reference group is 
patients with a ﬁrst AMI who did not suffer a re-AMI in the same period.
1120-230 Prediction of Depressive Disorder Following Myocardial 
Infarction; Data From the Myocardial Infarction and 
Depression - Intervention Trial (MIND-IT)
Joost P. Van Melle, Peter de Jonge, Astrid M. Kuyper, Adriaan Honig, Aart H. Schene, 
Harry J. Crijns, Maarten P. van den Berg, Johan Ormel, University Hospital Groningen, 
Groningen, The Netherlands
Background- Depression following myocardial infarction (MI) is associated with 
complicated cardiac rehabilitation, non-compliance and poor cardiovascular prognosis. 
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Whether depression following MI can be predicted from variables routinely assessed 
during hospitalization for MI is unknown.
Methods - Using data from the Myocardial INfarction and Depression - Intervention 
Trial (MIND-IT), we identiﬁed 2177 patients (mean age 63 years; 23% female) who were 
hospitalized for MI. Patients were randomly divided into a derivation and a validation 
sample. In the derivation sample, we analyzed, demographic, cardiac, and medical 
variables potentially associated with the development of post-MI depressive disorder, 
which were tested in the validation sample.
Results - In the year following MI, 199 patients (18.5%) suffered from depressive 
disorder according to ICD-10 criteria. In a multivariate model, the factors associated with 
depressive disorder were younger age (OR 1.94; CI 1.38-2.74), hypercholesterolemia 
(OR 1.68; CI 1.08-2.61), the use of calcium channel blockers at discharge (OR 1.80; CI 
1.20-2.71), and especially left ventricular ejection fraction (LVEF) (OR 4.14 for patients 
with LVEF<30%; CI (2.42-7.10). The derived predictors were tested in the validation 
sample. The ﬁnal model yielded two clinical predictors, i.e. younger age and LVEF<30%, 
which correctly predicted post discharge depression status in 82.9% of the MI patients. Of 
note, this model has a high negative predictive value (89%).
Conclusions - During hospitalization for MI and using common clinical variables, i.e. 
younger age and severe LV-dysfunction, it is possible to identify MI patients with a high 
risk for subsequent development of a depressive disorder.
1120-231 The Magnitude of ST-Segment Depression at Hospital 
Admission for a Non-ST Acute Coronary Syndrome 
Identiﬁes the High-Risk Patients Among Those in Low-
Risk Score Categories. 
Thao Huynh, James Nasmith, The Minh Luong, Martin Bernier, Chantal Pharand, Robert 
Giugliano, Pierre Theroux, McGill Health University Center, Montreal, PQ, Canada, 
Montreal Heart Institute, Montreal, PQ, Canada
Background: The prognostic value of the TIMI score has been well validated in non ST-
elevation acute coronary syndromes. Although ST-segment shifts are incorporated in the 
score, their characteristics are not. This study looked at the prognostic value of the direction 
and magnitude of ST-shifts in perspective with TIMI scores in the PRISM-PLUS patients.
Methods: The pre-randomization 12-lead ECGs were all re-analyzed blindly by a 
cardiologist, excluding confounding ECGs with pacemaker activity, left ventricular 
hypertrophy, or left bundle branch block. Of 1299 patients, 806 (62.0%), 225 (17.3%) 
and 268 (20.6%) showed ST depression (STD), elevation (STE) and no deviation (noST) 
respectively. Among these patients, TIMI scores were ≤4 in 70.3% and > 4 in 29.6%.
Results: STD and STE were associated with a signiﬁcantly higher 6-month rate of death/
myocardial infarction (MI) with the highest rate of adverse events highest in patients with 
STD≥2 mm. This was most apparent at TIMI score ≤4; patients with higher (≥2 mm) STD 
had more events: 17.6% vs 8.5% with STD < 2 mm (p<0.001). Those with a combination 
of TIMI score>4 and STD ≥2 mm had an OR of 1.83 for 6-month death/MI (95% CI: 1.21-
2.76, p=0.004). The c-index of this combination was 0.64 vs 0.61 and 0.59 for TIMI index 
alone and STD, respectively.
Conclusion: The magnitude of ST-segment depression confers additional prognostic 
information over the TIMI risk score; a 2 mm ST-segment depression helps identify high-
risk individuals from lower-risk score groups.
Six-month death/MI rates (%)
TIMI score NoST STD STE
1 mm ≥2 mm 1 mm ≥ 2 mm
Any 6.3 11.8** 18.5** 4.9* 14.7*
1-4 5.2 9.8* 17.6** 3.4 12.7*
> 4 13.9 17.8 19.9** 8.3 19.0
P-values vs noST: * <0.05, ** <0.0001
1120-232 Prognostic Importance of Post Procedural Systemic 
Blood Pressure Following Mechanical Reperfusion For 
Cardiogenic Shock Complicating Acute Myocardial 
Infarction
Hassan Kafri, Simon R. Dixon, Amr E. Abbas, James A. Goldstein, Judith A. Boura, 
William W. O’Neill, William Beaumont Hospital, Royal Oak, MI
Background: Despite the beneﬁt of early mechanical revasculariztion in cardiogenic 
shock (CS) in-hospital mortality remains high. Predictors of survival after percutaneous 
coronary intervention (PCI) for CS have not been well deﬁned.
Methods: From 1995-2002, 110 patients with CS due to left ventricular failure 
complicating acute myocardial infarction were admitted to William Beaumont Hospital and 
were selected to undergo early PCI. Reperfusion success was deﬁned as restoration of 
TIMI-3 ﬂow and < 50% diameter stenosis.Clinical variables were examined to identify 
predictors of survival after PCI.
Results: The overall in-hospital mortality was 46%. After PCI, 86% of patients had 
intra-aortic balloon pump (IABP), and 80 % of patients were on intravenous pressors. 
Revascularization success was achieved in 61/110 (56%) of cases. Patients who died 
after PCI were more likely to have multi-vessel disease, diabetes, a lower creatinine 
clearance (CrCl), a lower rate of successful reperfusion and a lower systolic BP (SBP) 
at the end of PCI. Infarct location, age, stent and use of IIb/IIIa inhibitors did not correlate 
with in hospital death. Independent clinical predictors of in-hospital death after PCI were: 
lower SBP (OR 0.84, CI 0.76-0.91, p<0.0001), and multi-vessel disease (OR10.3, CI 
1.003-1.02, p=0.008).
Conclusion: Patients with refractory hypotension after mechanical reperfusion have a poor 
prognosis. New therapeutic strategies are required to improve outcome in this high risk group. 
1120-235 Long-Term Outcome of Patients Presenting With Acute 
Myocardial Infarction And Normal Coronary Arteries Is 
Just As Bad As Those With Advanced Coronary Artery 
Disease
Matthew T. Rondina, Joseph B. Muhlestein, Benjamin Horne, Tamie Bair, Jeffrey L. 
Anderson, University of Utah, Salt Lake City, UT, LDS Hospital, Salt Lake City, UT
Background: Previous case series and small series reports have described situations 
in which patients have presented with acute myocardial infarction (AMI) but have normal 
coronary arteries by angiography. It has been proposed that their long-term clinical 
outcome is better than AMI patients with signiﬁcant coronary artery disease (CAD), but 
this has not been well documented.
Methods: We identiﬁed 244 patients who presented to LDS Hospital with AMI 
(characteristic symptoms and troponin-I [TnI] >2.1 ng/ml) but with normal coronary 
arteries by angiography and compared their clinical presentation and long-term mortality 
to 3,376 AMI patients with advanced (>50%) angiographic CAD. The two groups were 
compared with respect to their clinical presentation, demographics, and long-term 
survival at 3-years follow-up.
Results: AMI patients with normal coronary arteries were younger (54±17 years versus 
64±13 years [p<0.001]) and more likely to be female (42% versus 70% [p<0.001]) than 
those with advanced CAD and had lower peak levels of TnI (53 ng/ml versus 131 ng/ml 
[p<0.001]). They were also less likely to have hypertension (40% versus 60% [p<0.001], 
hyperlipidemia (22% versus 57% [p<0.001] and diabetes (13% versus 23% [p<0.001]). 
Long-term survival did not signiﬁcantly differ between the two groups (death: 10.9% vs. 
15.3% [p=0.06] for normal vs. CAD patients, respectively). When new non-fatal AMI events 
were also considered in a long-term combined endpoint of death/new AMI, outcomes did 
differ (25.0% vs. 39.9% [p<0.001]).
Conclusion: Patients presenting with AMI with normal coronary arteries are more 
often younger women and without traditional CAD risk factors. However, their long-term 
survival is not signiﬁcantly different than those with advanced CAD. Whether this similar 
risk relates to the presence of angiographically silent CAD or other undetermined factors 
requires further study. In any event, these patients should not be dismissed as being at 
low future cardiovascular risk.
1120-236 Practice Variations in Treatments and Outcomes of 
Acute Myocardial Infarction From 1995 to 2000. The 
PRIAMHO Registries
Magda Heras, Jaume Marrugat, Fernando Arós, Xavier Bosch, Joan Vila, Miguel Ángel 
Suárez, Hospital Clinic, Barcelona, Spain, IMIM, Barcelona, Spain
Background: To analyse practice variations and their incidence in outcome in patients 
with acute myocardial infarction (AMI) included in the PRIAMHO I and II Registries, 
performed in years 1995 and 2000.
Methods: Forty-seven in 1995 and eighty-one in 2000 of the 168 Spanish public hospitals 
with a coronary care unit participated in the PRIAMHO Registries. Hospitals underwent 
quality data control.
Results: In PRIAMHO II (n= 6221) compared with I (n=5242), patients were older (65.4 
vs 64.4 , p <0.001), more women (25.3% vs 22.6%, p= 0.001), more diabetics (29.4% vs 
24.2%, p <0.001), smokers (44.1% vs 37.6%, p <0.001), dyslipemia (40.3% vs 28.6%, 
p <0.001), hypertension (46.1% vs 42.4%, p <0.001), previous MI (15.7% vs 17.5%, p= 
0.013). Drug therapy is given in table 1. Mean time to reperfusion was 12 minutes shorter 
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in PRIAMHO II ( 48 vs 60, p<0.001). Patients were followed-up during one year. Mortality 
at 28-day was 11.3% vs 14.2%, p <0.001 and at one-year 16.4% vs 18.5%, p<0.001, 
respectively.The adjusted odds ratio of death at one year for patients included in the 
PRIAMHO II compared with those in PRIAMHO I was 0.71 (95% CI 0.63-0.81) p=0.003 
(adjusted for patients characteristics and clinical parameters).
Conclusions: In Spain within a 5 year-interval, there has been a 29% reduction on 
one-year mortality in patients with an AMI, despite patients admitted in year 2000 were 
a higher risk group. More and quicker reperfusion and a better use of antithrombotic, 






Reperfusion 41.9% 45.7% <0.001
Antiplatelet 89.1% 96.1% <0.001
Heparin 65.4% 86.9% <0.001
Betablockers 30.1% 51.1% <0.001
ACE-inhibitors 24.9% 41.6% <0.001
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1121-223 Sustained One Year Beneﬁt of Enhanced External 
Counterpulsation in Relieving Mild Angina in Patients 
with End Stage Coronary Disease
William E. Lawson, Elizabeth D. Kennard, John CK Hui, Sheryl F. Kelsey, State University 
of New York, StonyBrook, Stony Brook, NY, University of Pittsburgh, Pittsburgh, PA
Background: Most enhanced external counterpulsation (EECP) patients have disabling 
angina refractory to medical therapy and are poor CABG or PCI candidates. The success 
of EECP in relieving angina and freedom from adverse events at 1 year in the end stage 
CAD patient with mild versus severe angina has not been reported.
Methods: Data of 1,989 consecutive pts with refractory angina not amenable to PCI/CABG 
in the International EECP Registry were divided into 2 groups: CCS angina Class I/II (Mild) 
and CCS Class III/IV (Severe). Patient demographics, immediate and 1 year outcomes, 
freedom from MACE (death/MI/CABG/PCI) were compared. Signiﬁcant differences by 
students t test and on Kaplan Meier survival plots were deﬁned by p < 0.05.
Results: Mild and Severe angina groups were similar in age, race, gender, hyperlipidemia, 
smoking, diabetes, prior MI or revascularization. Mild and Severe groups differed 
signiﬁcantly in HBP [66.1 vs 72.4 %], non-cardiac vascular disease [23.9 vs 32.8 %], 
CAD duration [9.5 vs 11.5 years], multivessel CAD [72.4 vs 80.4%], EF [48.8 vs 45.9%]. 
Baseline angina [11.9 vs 4.1 times/week] and Ntg use were signiﬁcantly greater in the 
Severe group. After comparable EECP [33.8 ± 9.0 vs 33.2 ± 10.0 hours], angina was 
reduced by ≥ 1 class in 57.8% of Mild and 77.2% of Severe pts with similar decreases 
in angina [2.9 and 8.6 times/week] and Ntg use. Post EECP 31.5% of Mild and 14.3% of 
Severe pts were angina free. Angina reduction was preserved in both Mild and Severe 
groups at 1 year [44.7 vs 24.1 % with no angina; 21.8 vs 18.2 % with Class I angina] 
with parallel reductions in angina and Ntg use. MACE at 1 year in Mild vs Severe groups 
differed signiﬁcantly: death [3.1 vs 6.9%], MI [2.7 vs 7.2%], overall MACE [11.9 vs 21.4 %]. 
CABG [4.1 vs 3.2%] and PCI [4.9 vs 8.4 %] rates were similar.
Conclusions: End stage non-revascularizable CAD pts with severe angina have more 
“room for improvement” and were more likely to have an immediate reduction in angina. 
However, pts with mild angina initially were more likely to be angina and event free one 
year following EECP. Mild, but limiting angina, in the pt with end-stage CAD may be 
effectively treated with EECP.
1121-224 Low-Dose Pioglitazone Safely Provides Clinical 
Antiatherosclerotic Effects For Patients With Coronary 
Artery Disease and Metabolic Syndrome
Tatsuaki Murakami, Sumio Mizuno, Fukui Cardiovascular Center, Fukui, Japan
Background: Thiazolidinedione is one of potential agents to treat patients with coronary 
artery disease and metabolic syndrome, but the concern about its safety and cost 
hesitates clinical administration. We assessed hypothesis that low-dose pioglitazone 
provides both effectiveness and safety for patients with coronary artery disease and 
metabolic syndrome.
Methods: Twenty-six patients with coronary artery disease and metabolic syndrome were 
randomized to group-L where they received low-dose pioglitazone (7.5mg/day, a quarter 
dose of standard dose) for 4 months, or to group-C where they continued therapy without 
thiazolidinedione. We evaluated serum lipid and glycemic variables. We noninvasively 
ultrasonic quantiﬁed ﬂow mediated endothelium-dependent dilation of brachial artery after 
5 minutes forearm occlusion (FMD) and quantiﬁed brachial-to-ankle pulse wave velocity 
(PWV). Changes in serum variables and FMD were compared between the 2 groups. 
Results: Patients in group-L (n=13) manifested good compliance to the treatment without 
adverse events such as edema and liver dysfunction and improvements in some of serum 
variables (mg/dL) associated with insulin resistance while those in group-C showed no 
improvement (group-L versus group-C: triglycerides: from 205±75 to 151±62, p=0.01, 
versus, from 198±89 to 194±91, p=ns, HDL: from 42±11 to 50±9, p<0.01, versus, from 
41±12 to 40±11, p=ns). They manifested improvements in high sensitive CRP (high 
sensitive CRP: from 0.14±0.07 to 0.08±0.04, p=0.04, versus, from 0.13±0.08 to 0.14±0.09, 
p=ns). FMD (%) improved after medication in group-L (4.1±1.6 to 6.5±2.8, p<0.01) but not 
in group-C (4.1±1.8 to 4.2±1.5, p=ns). PWV also improved after medication in group-L 
(1727±269cm/sec. to 1664±234cm/sec., p=0.03) but not in group-C (1711±284cm/sec. 
to 1714±294cm/sec., p=ns).
Conclusion: Low-dose pioglitazone use in patients with coronary artery disease and 
metabolic syndrome safely improves serum insulin resistant variables and vascular 
function, which may have beneﬁcial potentials for management of atherosclerosis.
1121-225 Racial Determinants Of Premature Coronary Artery 
Disease And Predictors Of Early Mortality In Young, 
Inner-city Patients Undergoing Coronary Angiography 
- Results Of An Open Cohort Study
Sandeep Nathan, Amit Amin, Steve Attanasio, Vijay Mehta, Russell F. Kelly, Rush 
University Medical Center, Chicago, IL, Cook County Hospital, IL
Background: The epidemiology of premature CAD (PCAD) is poorly deﬁned in the 
inner-city population. We investigated the relationship between race, cardiac risk factors 
(CRFs), and PCAD risk and assessed predictors of early mortality in these patients.
Methods: Data from 416 pts < 40 yrs of age, undergoing coronary angiography at 
Cook County Hospital (1993-2001) were compiled prospectively and analyzed as an 
open, retrospective cohort. The primary outcome measure was mortality analyzed via 
Kaplan-Meier analysis. Risk of CAD (deﬁned as > 50% stenosis in >1 coronary artery) 
by race and CRFs was estimated via stepwise logistic regression. Angiographic data was 
adjudicated by blinded ﬁlm review.
Results: 1,444 pt-yrs of follow-up were attained. Of 416 pts, 33% (136) had PCAD, of 
which 96% (131) had severe CAD ( > 70% stenosis). White and Indian pts, dyslipidemics, 
smokers, diabetics and older pts all evidenced increased PCAD risk (Fig. 1). Total mortality 
at 3.47 yrs mean follow-up was 5.8% and was higher with severe CAD (9.2% if CAD vs 
4.2% if no CAD, p=0.044). Diabetes mellitus (DM) (OR 3.71 [1.13-12.2], p=0.031) and 
systolic dysfunction (OR 3.13 [1.0-9.81], p=0.05) independently predicted mortality.
Conclusions: This data suggests a previously unrecognized risk associated with certain 
ethnic subgroups of the inner-city population, independent of that conferred by traditional 
CRFs, with CAD linked to higher mortality. DM and systolic dysfunction were predictive of 
early mortality, independent of CAD. 
1121-226 The Prevalence of Impaired Functional Status in 
Unrecognized Myocardial Infarction: A Population 
Based Study
Khawaja A. Ammar, Ravindrakumar Makwana, Barbara Yawn, Jan Kors, Margaret M. 
Redﬁeld, Steven J. Jacobsen, Richard Rodeheffer, Mayo Clinic, Rochester, MN, Olmsted 
Medical Center, Rochester, MN
Background: Unrecognized Myocardial Infarction (UMI), diagnosed by a surveillance 
ECG, has a poor prognosis equal to that of recognized myocardial infarction (RMI). The 
impact of UMI on quality of life, functional status and cardiac symptoms other than angina 
has not been evaluated.
Methods: A population based random sample of 2042 Olmsted County residents, age 
>=45 years, were studied by self-administered questionnaire, chart review, ECG and 
echocardiogram. UMI (n=81) were diagnosed if ECG-MI criteria were met without the 
history of a documented myocardial infarction. RMI (n=101) were diagnosed if Gillum 
criteria were met. Functional Status was measured by Goldman Speciﬁc Activity Scale 
(SAS) and 6 minute walk test. 
Results: In the No MI/UMI/RMI groups, there was a stepwise increase in the prevalence of 
cardiac symptoms and abnormal functional status. The relationship of UMI with abnormal 
functional status persisted after stratiﬁcation for age, sex, obesity, smoking and pulmonary 
disease, but became insigniﬁcant after stratifying for wall motion abnormalities, and left 
ventricular systolic or diastolic dysfunction. 
Conclusion: UMI subjects have a signiﬁcantly higher prevalence of cardiac symptoms, 
resulting in an abnormal functional status. These symptoms may be mediated via structural 
damage demonstrable on echocardiography. These ﬁndings signify the impact of an ECG 
based diagnosis of UMI in adults with otherwise unexplained cardiac symptoms and 
abnromal functional status. 
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No MI UMI RMI
Dyspnea on exertion (%)* 29 49 53
Paroxysmal Nocturnal Dyspnea (%)* 4 6 11
History of ﬂuid overload (%)* 1 6 8
Angina (%)* 9 24 78
Palpitations (%)* 15 20 31
Abnormal Functional Status by SAS (%)* 11 22 39
Average Distance Covered in 6 Minute Walk Test(meters)* 526 476 446
*p <0.001
1121-227 N-Terminal Pro-BNP Predicts Coronary Stenosis
Thomas Wolber, Micha Maeder, Ramin Atefy, Walter Riesen, Peter Ammann, Hans 
Rickli, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background: B-Type Natriuretic Peptide (BNP) and its precursor, N-terminal proBNP 
(NT-ProBNP), are released from cardiac myocytes in response to various stimuli. In acute 
coronary syndromes, BNP is a strong predictor of mortality independent of ventricular 
function. Recent data suggest that BNP elevations can be attributed to myocardial 
ischemia in the absence of heart failure. The use of BNP to predict coronary stenosis could 
improve non-invasive diagnosis of coronary heart disease. We tested the hypothesis, that 
elevated levels of NT-ProBNP are associated with signiﬁcant coronary disease in patients 
with normal systolic left ventricular function.
Methods: We measured plasma NT-ProBNP levels in 62 consecutive patients (30% 
female) with stable angina pectoris referred for coronary angiography. Patients with 
valvular heart disease or abnormal systolic left ventricular function (ejection fraction < 
60%) were excluded.
Results: Coronary angiography showed relevant coronary artery disease (CAD) with 
at least one ≥50% stenosis in 43 (69%) patients. NT-ProBNP levels were signiﬁcantly 
increased in patients with CAD compared to patients without CAD (plasma NT-ProBNP 
251 ± 215 ng/L vs. 126 ± 88 ng/L, p=0.026). Receiver operating curve analysis showed 
an area under the curve of 0.68. NT-ProBNP levels above 300 ng/L had a speciﬁcity of 
90% for CAD. Systolic left ventricular function was similar in both groups (ejection fraction 
0.69 ± 0.6 vs. 0.72 ± 0.6, p=0.10). Patients requiring percutaneous coronary interventions 
(PCI) (n=13) or bypass surgery (CABG) (n=13) had signiﬁcantly higher NT-ProBNP levels 
than patients (n=35) who were managed with medical treatment only (plasma NT-ProBNP 
167 ± 149 ng/L vs. 276 ± 230 ng/L, p=0.05).
Conclusions: Coronary artery disease is associated with elevated levels of NT-ProBNP 
in patients with stable angina pectoris and normal systolic left ventricular function. 
NT-ProBNP may play an important role in non-invasive assessment of patients with 
suspected coronary disease. As elevated NT-ProBNP levels are predictive of signiﬁcant 
coronary stenosis and of the need for PCI and CABG, invasive testing might be warranted 
in these patients.
1121-228 Resting Magnetocardiographic Imaging Can Accurately 
Detect ObstructiveCoronary Artery Disease in Patients 
with Chronic Ischemia
Yuanlu Chen, Xiaocheng Liu, Xiangqian Qi, Kirsten Tolstrup, Yi Lian, Fang Liu, Yu Song, 
Jian Zhang, TEDA International Cardiovascular Hospital, Tianjin, People’s Republic of 
China, Cedars-Sinai Medical Center, Los Angeles, CA
Background: Magnetocardiographic (MCG) imaging is a new noninvasive mapping 
technique that measures and records cardiac electric activity. It has been suggested that 
the MCG provides independent information for the detection of myocardial ischemia. We 
evaluated the utility of MCG for the diagnosis of coronary artery disease (CAD) in patients 
with chronic ischemic heart disease. 
Methods: We studied 77 patients (56 men,21 women, mean age 58 ±9.4 years old) 
with CAD conﬁrmed by coronary angiography (≥70% stenosis in ≥ one branch of main 
coronary arteries). Patients with concomitant hypertension, left ventricular hypertrophy, 
bundle branch block, complex rhythm disturbances and NYHA functional class III and IV 
were excluded. The control group consisted of 36 healthy subjects (12 men, 24 women, 
mean age 31.5 ± 8.9 years) who all underwent 12-lead ECG, stress testing,transthoracic 
echocardiography, and Electron Beam-CT. All MCG images were acquired with a 9-
channel MCG system (CardioMag Imaging, Schenectady, New York), in an unshielded 
location. The scans were performed at rest with an acquisition time of 6 minutes. 
Ventricular repolarization was analyzed using 7 parameters set by an automated software 
program, and scores for normal and abnormal were obtained. 
Results: All 7 interrogated parameters demonstrated signiﬁcant differences between 
CAD group and control group (p<0.001 and <0.002 for all). The sensitivity of each of the 
parameters for the diagnosis of CAD was 71.1%, 71.4%, 71.1%, 50.6%, 20.7%,29.9% 
and 46.7%, respectively.The corresponding speciﬁcities were 91.6%, 86.1%, 97.2%, 
97.2%, 97.2%,94.4% and 100%, respectively. The accuracy of the scan was 51% to79% 
depending on the chosen parameter. With ≥ 3 parameters positive, the speciﬁcity of the 
test was ≥ 97% and the accuracy was 85%-88%. 
Conclusion: Resting magnetocardiographic imaging is an accurate and rapid test for 
the detection of obstructive coronary artery disease in patients with chronic ischemic 
heart disease.
ORAL CONTRIBUTIONS
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846-4 Dose Timing Dependent Effects of GCSF administration 
on Left Ventricular Remodeling and Global Function
Nirat Beohar, Jayesh Mehta, Charles J. Davidson, Seema Singhal, Daniel Lee, James D. 
Flaherty, Mladen Vidovich, Jonathan Rapp, Adam Brodsky, Chad Rammohan, Francis J. 
Klocke, Edwin Wu, Robert O. Bonow, Northwestern University, Chicago, IL
Background: We evaluated the effect of immediate or delayed administration of IM 
granulocyte colony stimulating factor (G-CSF) on LV performance and remodeling in a 
porcine model of acute MI and reperfusion. Two administration regimens were assessed: 
1) immediately after MI and reperfusion or 2) delayed until 5 days. 
Methods: MI was induced percutaneously (n=35) with 90 min proximal LCX balloon 
occlusion followed by reperfusion. Controls (C): n=11. Early treatment (ET): n=17, G-CSF 
300 µg IM QOD for 20 days immediately after reperfusion; Delayed treatment (DT): n=7, 
G-CSF 300 µg IM QD for 10 days starting day 5 post MI. Cine and contrast MR were 
performed at 5 (MR1) and 56 (MR2) days post MI. EDV, ESV, LVEF, Expansion Index (EI), 
Systolic and Diastolic Sphericity Index (SI) were calculated. 
Results: EDV, ESV and LVEF were similar between groups at MR1. Mean infarct size 
was similar: (Infarct mass/LV mass) 6.5 ± 2.6% (C), 7.0 ± 2.8% (ET), 7.2 ± 2.5% (DT) (p= 
NS, C vs ET, C vs DT, ET vs DT). Systolic and diastolic SI were similar at baseline and 
followup between groups. 




Δ EDV ml 17± 9 8±7 0.005 21±10 NS
Δ ESV ml 10.6±7 10.1±7 NS 16.8±7 NS
LVEF% (MR2) 47±7 44±7 NS 38±6 0.008
Expansion Index (MR2) 0.32±0.15 0.37±0.2 NS 0.62±0.2 0.003
Conclusions: While early treatment with GCSF after myocardial infarction does not 
improve overall left ventricular ejection fraction, it favorably affects LV remodeling by 
decreasing post MI ventricular dilatation. However, delayed treatment appears to have 
a deleterious effect on LV remodeling by causing infarct expansion and decreased LVEF. 
These important timing dependent treatment effects should be considered in designing 
clinical trials with GCSF.
11:00 a.m.
846-5 Extravasation Of Intracoronary Administered Bone-
marrow Derived Cd34+ Stem Cells In Patients With 
Acute Myocardial Infarction Evidenced By In111 Cell 
Labelling
Tomasz Siminiak, Rafal Czepczynski, Dorota Fiszer, Olga Jerzykowska, Olga 
Jerzykowska, Grygielska Beata, Sowinski Jerzy, Kurpisz Maciej, Kalmucki Piotr, District 
Hospital, Department of Cardiology, Poznan, Poland
Background. Increasing experimental and initial in-man experience indicate that 
autologous bone marrow stem cells (AMB) do have a potential for myocardial regeneration. 
The protocols of currently ongoing clinical phase 2/3 trials evaluating functional beneﬁts 
of AMB do involve their intracoronary administration, although a direct evidence of AMB 
cells extravasation and tissue migration after intracoronary administration is missing.
Aim. To evaluate the extravasation and tissue migration of autologous CD34+ stem cells 
after intracoronary administration in patients with acute myocardial infarction (AMI).
Material and methods. 8 patients that underwent AMI treated with primary PTCA were 
included into the study. In all patients, at day 2-6 after AMI onset, under local anesthesia, 
ca 30 ml of bone marrow aspirate was obtained by sternal puncture. CD34+ cells were 
isolated from bone marrow aspirate by magnetic cell sorting using the Dynal® CD34 
Progenitor Cell Selection System. Cells were subsequently labeled with 0.4-0.8mCi 
(15-30MBq) of 111-Indium-oxinate (Mallinkrodt). Cell suspension was administered sub-
selectively intracoronary into the infarct-related artery at the time of a brief coronary ﬂow 
decrease. An over-the-wire balloon was inﬂated for 120 seconds and cells were delivered 
via the internal catheter lumen. Whole-body scans using a double-head Varicam gamma 
camera were performed in each patient after 24 hours.
Results. Main regions of uptake were detected over liver, spleen and heart. Based on 
evaluation of tissue activity in the regions of interest, we estimated that 1-11% of injected 
activity was concentrated in the heart, whereas uptake in the spleen and the liver was 
3-17% and 12-45% of total injected activity, respectively.
Conclusion. Our preliminary data provide evidence for stem cell extravasation and 
tissue migration after intracoronary administration in patients with AMI. Detailed studies 
evaluating possible correlations of stem cell tissue migration with cell administration 
protocol used as well with clinical data, including the time of primary PTCA after AMI 
onset and timing of cell administration, are needed.
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846-6 Granulocyte-Colony Stimulating Factor in the Acute 
Myocardial Infarction (The Rigenera Study)
Antonio Maria Leone, Leonarda Galiuto, Giovanna Liuzzo, Alessandro Giordano, Maria 
Lucia Calcagni, Barbara Garramone, Maria Benedetta Giannico, Fiammetta Cirillo, Luigi 
M. Biasucci, Antonio G. Rebuzzi, Filippo Crea, Università Cattolica del Sacro Cuore 
Institute of Cardiology, Rome, Italy, Università Cattolica del Sacro Cuore Institute of 
Nuclear Medicine, Rome, Italy
Background: recent data suggest that of bone marrow derived stem cells (BMSC) can 
improve post-infarction LV function. The Granulocyte-Colony Stimulating Factor (G-CSF) 
induces mobilization of transplantable BMSC and its administration could improve LV 
function.
Methods: we enrolled in a pilot open label study 12 patients with a large anterior AMI as 
ﬁrst manifestation of IHD and a LVEF <45% after 5 days from a successfully performed 
revascularization. Nine patients (8 males, 54±11 yrs) were treated with G-CSF (250 mcg 
s.c./b.i.d.+ enoxaparin 80Ui/Kg s.c/b.i.d) and compared to 3 patients (3 males; 57±3) 
treated with conventional therapy. LV function was evaluated by Gated-SPECT scan 
during hospitalization and after 3 and 6 months.
Results: during hospitalization none of the 9 G-CSF patients experienced major adverse 
events, two reported mild bone pain and one 2 episodes of nocturnal dyspnea. Eight 
patients underwent 3 months follow up (6 in the G-CSF group and 2 in the control group) 
and 5 underwent 6 months follow up (all in the G-CSF group). None of the patients had any 
cardiac recurrence. One G-CSF patient preferred to drop out from the study after completed 
administration of G-CSF, however she’s alive and came back to her normal life.
After G-CSF the CD34+ BMSC increased from 5.36±3.57 to 47.71±31.02 cell/µl. After 
5 days from the end of the G-CSF therapy CD34+ cells’ concentration came back to 
4.32±2.71 cellule/µl. At 3 months LV function was improved in the group of patients 
treated with G-CSF, in terms of LVEDV (from 207±47 to 180±58 ml, p=0.06), LVESV (from 
150±46 to 115±45 ml, p=0.03), LVEF (from 28±8 to 38±8 %, p=0.03), summed motion 
score (SMS) (from 43±13 to 28±11 p=0.03) and summed thickening score (STS) (from 
34±10 to 22±12, p=0.03). At 6 months LV function parameters remained substantially 
unchanged (LVEDV 184±55 ml, LVESV 115±45 ml, LVEF 39±9 %, SMS 24±10, STS 
22±10). No signiﬁcant improvement in LV function was observed in the 2 patients treated 
with conventional therapy at 3 months FU.
Conclusions: in our initial experience G-CSF therapy in patients with large anterior AMI 
seems to be safe and well-tolerated and potentially able to improve post-infarction left 
ventricular function.
11:30 a.m.
846-7 Feasibility, Safety And Efﬁcacy Of Bone Marrow-derived 
Cell Mobilization With G-csf And Gm-csf In Patients 
With Acute Myocardial Infarction: A Pilot Study
Sebastiano Marra, Paolo Scacciatella, Corrado Tarella, Giacomo Tamponi, Tullio 
Usmiani, Maurizio D’Amico, Giorgio Millesimo, Marco Sicuro, Mauro Giorgi, Luca 
Checco, Pierluigi Sbarra, Massimo Baccega, Mario Campana, Irene Ricca, Paola 
Omedè, Fiorella Sanavio, Mario Boccadoro, Michele Casaccia, Azienda Ospedaliera 
San Giovanni Battista, Torino, Italy
Background. Myocardial regeneration and neovascularization of the ischemic 
myocardium may be obtained either in animal models or in human by intracoronary or 
intramyocardiac injection of growth factor-mobilized peripheral blood stem cells (PBSC) 
and growth factor PBSC only. Aims of this pilot study were: i) to verify feasibility and safety 
of PBSC mobilization in patients (pt) with acute myocardial infarction (AMI); ii) to monitor 
clinical effects of PBSC mobilization in terms of myocardial perfusion and function. 
Methods. Eight male pt (mean age: 51,7±5,6 years) were enrolled. All were treated with 
a primary PTCA for an anterior (5 pt) or an inferior (3 pt) AMI. The mobilization regimen 
consisted of G-CSF 5 g/kg/12h from day 1 to day 3 and GM-CSF 2.5 g/kg/24h from day 
1 to day 5 (starting within 24 hours from PTCA).All pt underwent coronary angiography, 
intracoronary doppler ﬂow study, echocardiography, and nuclear Thallium scan before 
treatment and at 6 months apart. 
Results. WBC and PBSC peaked during the 3th day of mobilization. Mean WBC and 
PBSC peaks were 34960±10794 leukocytes/ L and 29.71±30.8 CD34+/ L. Five in hospital 
adverse events were recorded: severe hypotension in 3 pt, atrial fybrillation in 1 pt, recurrent 
ischemia in 1 pt. No death was observed. At present 7 pt completed a 6-months follow-
up evaluation: target lesion revascularization rate was 14,3% (1 patient) and target vessel 
revascularization rate was 42,8% (3 pt). Angiographic mean ejection fraction increased from 
49,8±11,9 to57,1±8,9 (p=NS), and mean coronary ﬂow reserve raised from 1,63±0,42 to 
2,45±0,36 (p=0,005). Perfusion improvement was observed by nuclear study in 66% of pt. 
Conclusion. We conclude that: a) cytokine-induced stem cell mobilization is feasible in 
AMI pt; b) myocardial perfusion clearly improved within the ﬁrst six months of follow-up; c) 
even if not statistical signiﬁcant we observed a global myocardial function improvement; 
d) the 3 cases of progressive coronary disease give a concern about a potential negative 
effect of hematopoietic cytokines (particularly GM-CSF) on silent coronary lesions. 
However, PBSC mobilization is worthwhile of further investigation.
11:45 a.m.
846-8 Bone-Marrow Stem Cell Mobilization Induced By 
Granulocyte-Colony Stimulating Factor In Patients 
Undergoing Delayed Revascularisation For ST Segment 
Elevation Myocardial Infarction: Early Results From The 
G-CSF In STEMI Trial
Markus G. Engelmann, Hans D. Theiss, Christine Hennig, Bernd J. Wintersperger, 
Armin Huber, Stefan O. Schoenberg, Gerhard Steinbeck, Wolfgang M. Franz, Ludwig 
Maximilian University, Klinikum Grosshadern, Munich, Germany
Background: Recently, adult human stem cells were considered to improve regional and 
global contractility after ST elevation myocardial infarction (STEMI). This interim analysis 
of an investigator driven, prospective, randomized, double-blinded, Placebo-controlled 
Phase II study compares the effects of G-CSF on the improvement of myocardial function 
in patients undergoing delayed percutaneous coronary intervention (PCI) for STEMI.
Methods: Eighteen patients (CKpeak 3260±450 U/L) with late revascularised STEMI 
(angina to PCI interval 42±16 hours) were treated either with G-CSF (n=12) or Placebo 
(n=6) over 5 days after successful PCI. Inﬂammatory and safety parameters were 
monitored and mobilized stem cell populations characterized using ﬂow cytometry. 
Primary endpoints were global and regional myocardial function assessed by magnetic 
resonance imaging.
Results: G-CSF was generally well tolerated, with no signiﬁcantly higher rate of in-stent 
restenosis when compared to Placebo. G-CSF treatment led to mobilization of several stem 
cell populations (CD34+/CD31+, CD34+/CD133+, CD34+/c-kit+). Expression of CXCR4, which 
is essential for stem cell homing in target tissue, was slightly increased onto CD34+ cells. 
Left ventricular ejection fraction was not signiﬁcantly changed from baseline over 3 months 
of follow-up in both treatment groups. However, regional wall thickening of the main infarct 
segment was improved in G-CSF treated patients in comparison to Placebo (p=0.05).
Conclusion: G-CSF treatment in STEMI patients is safe following PCI with no increased 
rate of in-stent restenosis. G-CSF mobilizes several stem cell populations considered 
to improve myocardial regeneration via homing by CXCR4. The more rapid recovery of 
regional function in late revascularised STEMI patients treated with G-CSF encourages 
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1145-203 Remote Ischemic Preconditioning modiﬁes Coronary 
ﬂow and Resistance Via Katp-dependent Mechanism
Mikiko Shimizu, Igor Konstantinov, Jia Li, Rajesh Kharbanda, Andrew Redington, 
Hospital for Sick Children, Toronto, ON, Canada
Introduction: Ischemic preconditioning (IPC) is an innate protective mechanism that 
attenuates myocardial ischemia-reperfusion injury. Remote IPC (rIPC) may be more 
clinically relevant. It being induced by transient ischemia of distant tissue such as a limb.
Objective: To assess whether rIPC can modify coronary circulation.
Methods: Nineteen pigs were randomized to control group (n=5), rIPC group (n=8) or 
glibenclamide pretreated rIPC group (n=6). rIPC was induced by four 5 minutes cycles 
of lower limb ischemia. Mean arterial pressure (MAP) and coronary sinus pressure (CS) 
were measured via indwelling cannulae. Left anterior descending (LAD) artery ﬂows were 
monitored by transonic ﬂow probe placed on proximal portion of LAD. Coronary resistance 
was calculated as: Coronary resistance = MAP- CS / LAD ﬂow All pressure and ﬂow data 
were collected at baseline and during incremental pacing between 100 -180bpm.
Result: There were no differences in MAP between three groups. Coronary resistance 
was signiﬁcantly lower (p<0.0001, 2-way ANOVA) and LAD ﬂow was signiﬁcantly higher 
in the rIPC group (p=0.0008). In the Glibenclamide pretreated group, coronary resistance 
was higher and LAD ﬂow was lower compared to rIPC group (p<0.0001, p<0.0001).
Conclusion: rIPC increases coronary ﬂow and lowers coronary resistance via a Katp 
channel-dependent mechanism. This may be an important factor in the protective effect of 
rIPC against subsequent IR injury. 
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1145-204 Brief Ischemia Before Sustained Ischemia Attenuates 
The Deterioration Of Cardiac Sympathetic Neuronal 
Function In The Remote Period After The Ischemic 
Insult
Teruo Nakadate, Takashi Nozawa, Akira Matsuki, Makoto Nonomura, Norio Igarashi, 
Bun-ichi Kato, Nozomu Fujii, Akihiko Igawa, Hidetsugu Asanoi, Hiroshi Inoue, Toyama 
Medical & pharmaceutical University, Toyama, Japan
Background: Recent studies demonstrated that a brief episode of transient myocardial 
ischemia reduced cardiac norepinephrine (NE) release from the sympathetic nerve 
terminals during the subsequent sustained ischemia. However, the inﬂuence of brief 
ischemia on sympathetic neuronal function in the remote period after the sustained 
ischemia remains unclear. 
Methods: In rats with (group I) and without (group II) 5-min left coronary occlusion and 
5-min reperfusion preceding the 30-min prolonged occlusion, cardiac interstitial NE (iNE) 
during 30-min ischemia and early after reperfusion was determined using microdialysis 
method. In rats without preconditioning, K-channel opener, nicorandil (group III) was 
administered at rate of 50µg/kg/min from 20-min before 30-min coronary occlusion 
to the release of ischemia. In separate animals, the NE uptake function at cardiac 
sympathetic nerve terminals was assessed by quantitative autoradiography using 131I-
metaiodobenzylguanidine (MIBG), an analogue of NE, 3 days after the 30-min ischemia 
produced in the same method as in group II. 
Results: Thirty-min coronary occlusion increased levels of iNE more than 200 times in 
group II, as compared to that before ischemia. However, the levels of iNE were less in 
group I (n=8) and group III (n=7) than in group II (n=7) at the latter half of 30-min ischemia 
(6.3±2.3, 4.9±3.0 vs 19.4±5.9 ng/ml, respectively, p<0.01) and just after the reperfusion 
(1.5±0.9, 2.3±1.8 vs 8.4±3.6 ng/ml, respectively, p<0.01). MIBG uptake in ischemic region 
was greater in group I (n=8) than in group II (n=9) (0.062±0.030 vs 0.031±0.011 %kg 
dose/g, p<0.05) and its uptake ratio of ischemic region to the remote region was greater 
in group I than in group II (37.4±7.4 vs 24.6±8.1%, p<0.05). 
Conclusion: A brief episode of ischemia before sustained ischemia attenuated 
sympathetic neuronal dysfunction in the remote period after the ischemic insult, i.e., the 
phenomenon of neural preconditioning, in association with marked reduction in iNE during 
ischemia. Suppression of increasing iNE during ischemia induced by nicorandil suggests 
that K-channel may be involved in the mechanism of neural preconditioning.
1145-205 Exogenous Nitric Oxide Inhibits AMP-activated 
Protein Kinase (AMPK) Phosphorylation and GLUT4 
Translocation to Sarcolemma in Ischemic Myocardium
Biao Lei, Ken Matsuo, Volodymyr Labinskyy, Anna Ahn, Margaret P. Chandler, Martin 
Altarejos, William C. Stanley, Fabio A. Recchia, New York Medical College, Valhalla, NY, 
Case Western Reserve University, Cleveland, OH
Background: NO donors such as nitroglycerin (NG) have been used for about a century 
to treat cardiac ischemia (ISC) and are commonly believed to indirectly reduce myocardial 
metabolic demand by lowering left ventricular preload, however we hypothesized that 
exogenous NO directly limits the increase in glucose uptake that normally occurs in the 
ischemic heart. 
Methods: In 18 open-chest dogs, the left anterior descending coronary artery (LAD) was 
artiﬁcially blood-perfused in a ﬂow-controlled mode. Paired blood samples were withdrawn 
from the perfusion line and from the left anterior cardiac vein at baseline and during ISC 
induced by 66% reduction in LAD ﬂow. 9 dogs received 0.5 µg/kg/min of NG in LAD 
during ISC and 9 served as control. Isotopic tracers were infused i.v. After 45 min of ISC, 
portions of ischemic and non-ischemic ventricular tissue were harvested and fractionated 
to measure the translocation of the glucose transporter GLUT4 to sarcolemma. 
Results: NG did not cause any change in LAD myocardial ﬂow distribution and systemic 
hemodynamics. At 45 min of ISC, myocardial O2 consumption, free fatty acid and glucose 
oxidation were signiﬁcantly decreased vs baseline by the same amount in both groups. 
However, myocardial glucose uptake increased signiﬁcantly less in ISC+NG compared 
to ISC (0.38±0.03 vs 0.54±0.05 µmol/min/g), which corresponded to signiﬁcantly less 
translocation/activation of GLUT4 (73.7±6.9% vs 164.8±16.9%). GLUT4 translocation is 
stimulated by phosphorylated AMPK and in fact we found that AMPK phosphorylation 
was inhibited in ISC+NG compared to ISC (76.7±11.8% vs 167.1±17.0%). An important 
consequence of these effects of NG was the signiﬁcant reduction in net myocardial lactate 
production (0.04±0.03 vs 0.28±0.05 µmol/min/g) and the limited depression of regional 
contractile function (fractional shortening: -6.2±1.4% vs -11.2±1.9%) in ISC+NG vs ISC. 
Conclusion: Exogenous NO, a molecule employed in the treatment of angina, causes a 
direct reduction of glucose transport/uptake in severely ischemic myocardium, likely due 
to inhibition of AMPK phosphorylation. This metabolic effect is beneﬁcial, since it limits 
lactate production and contractile depression.
1145-206 Intermittent Limb Ischemia During Myocardial Ischemia 
Preserves Cardiac Function in the Reperfusion Phase
Michael R. Schmidt, Morten Smerup, Andrew Redington, Rajesh Kharbanda, Aarhus 
University Hosptal, Aarhus, Denmark, Hospital for Sick Children, Toronto, ON, Canada
Background: Remote ischemic preconditioning (rIPC) by intermittent limb ischemia 
reduces myocardial infarction in animal models. We hypothesized that systemic 
protection induced by rIPC may be effective when administered during ischemia, prior 
to reperfusion.
Methods: Fourteen 15-kg pigs were randomized (7 in each group) to a 40-minute period 
of left anterior descending artery (LAD) occlusion with (rIPC group) or without (control 
group) four 5-minute cycles of limb ischemia during LAD occlusion followed by120-minutes 
reperfusion. Left ventricular (LV) function was assessed using a conductance catheter.
Results: The extent of myocardial infarction compared to area at risk did not differ 
between rIPC and control groups (43.6±13.0% vs. 52.2±16.4%, p=0.30). There were 
no differences in indices of LV systolic (preload-recruitable stroke-work (PRSW) and 
dP/dtmax) or diastolic (tau) function at baseline. However, systolic and diastolic function 
was signiﬁcantly better in the rIPC group at 30-minutes and 120-minutes reperfusion. 
There was no signiﬁcant difference between the two groups in absolute dP/dtmax-values 
at 120-minutes reperfusion, but the results reﬂect a 46.8±6.7% reduction from baseline in 
controls compared to 24.3±13.1% reduction in the rIPC group (p<0.001).
Conclusion: Intermittent limb ischemia during myocardial ischemia preserves global 
cardiac function during reperfusion. This novel observation has potential implications for 
reducing LV dysfunction after reperfusion 
1145-207 Either Pretreatment or Treatment at Reperfusion With 
Pyrroloquinoline Quinone Reduces Lipid Peroxidation 
and Is Cardioprotective in a Rat Model of Ischemia/
Reperfusion
Boqing Zhu, Hui-zhong Zhou, John R. Teerlink, Joel S. Karliner, University of California 
San Francisco, VA Medical Center, San Francisco, CA
Background: The essential nutrient pyrroloquinoline quinone (PQQ) has been newly 
identiﬁed as a redox cofactor vitamin for mammals. As PQQ has shown neuroprotective effects 
in vitro and vivo, we asked if PQQ is cardioprotective in a rat model of ischemia/reperfusion. 
Methods: Intact rats were subjected to 30 min of LAD occlusion and 2 hours of 
reperfusion with LV hemodynamic monitoring. PQQ (15 mg/kg) was given either 30 min 
before LAD occlusion by i.p. injection (Pretreatment) or by i.v. injection at the onset of 
reperfusion (Treatment). Controls received vehicle (2% NaHCO3). 
Results: Either Pretreatment or Treatment with PQQ resulted in reduced infarct size (infarct 
mass/risk area). PQQ protected against ischemia-induced LV dysfunction after 1-2 hours 
of reperfusion and resulted in fewer episodes of ventricular ﬁbrillation (VF). In separate 
experiments, PQQ 5-20 mg/kg given as Pretreatment was inversely related to infarct size 
(r=0.96, P<0.01). In ischemic tissue, levels of malondialdehyde (MDA), a measure of lipid 
peroxidation, were reduced by PQQ. Additional rats received PQQ (5, 10, 15 mg/kg, 4 rats 
each dose). Renal and liver functions after 4 and 10 days of treatment remained normal. 
Conclusions: PQQ given as pretreatment before ischemia or as treatment at the onset 
of reperfusion following ischemia is highly effective in reducing myocardial infarct size and 
improving cardiac function in a dose-related manner in intact rats. PQQ appears to act as 
a free radical scavenger in ischemic myocardium.













I/R 38±3 84±5 4415±349 -3415±306 71 316±88
Pretreatment 18±2*** 115±3** 6300±311* -4750±150* 31** 99±14**
Treatment 26±4** 108±2** 5571±268* -4429±156* 42* 123±17*
1145-208 Gp91-Phox Expression Increases in the Remote 
Noninfarcted Myocardium After Myocardial Infarction in 
Rabbits: Association With Myocyte Apoptosis
Fuzhong Qin, Megan Simeone, Chang-seng Liang, University of Rochester, Rochester, NY
Background: NADPH oxidase subunit gp91-phox expression is increased in the infarct 
site 1 week after myocardial infarction (MI). In this study, we proposed to test whether 
gp91-phox expression was increased in the remote non-infarcted myocardium (RM) late 
after MI and whether the change was associated with myocyte apoptosis.
Methods: Rabbits were randomly assigned to MI or sham operation. The animals were 
sacriﬁced 4 weeks after MI. We measured cardiac function, hemodynamics, infarct size, 
gp91-phox protein and mRNA expression by Western blot and RT-PCR, oxidative stress by 
examining the ratio of reduced to oxidized glutathione (GSH/GSSG), myocyte apoptosis 
by TUNEL assay and p38 mitogen-mediated protein kinase (p38 MAPK) activity.
Results: MI rabbits exhibited an increase of left ventricular (LV) end-diastolic dimension 
(EDD) and a decrease of LV dP/dt. The infarct size was 29.0±2.5 %. Gp91-phox protein 
and mRNA expression was increased in RM after MI. Immunolabeling revealed that 
gp91-phox was present in myocytes. We also found a decrease in GSH/GSSG ratio and 
increases in p38 MAPK activity and myocyte apoptosis after MI.
Conclusion: Gp91-phox expression was increased in RM late after MI. The change was 
associated with increased oxidative stress, p38 MAPK activation and myocyte apoptosis. 
The ﬁndings suggest that increased gp91-phox expression may play a role in myocyte 
apoptosis and LV remodeling by contributing to increased oxidative stress.
Group gp91-phox protein (arbitrary unit) GSH/GSSG
P38 MAPK 
(arbitrary unit)




Sham 1.03±0.03 133±10 1.01±0.02 4.6±0.7 15.2±0.1 4554±181
MI-4W 1.92±0.22* 64±9* 1.35±0.05* 20.4±2.7* 16.8±0.6* 3845±180*
n=8-12. Values are mean±SE. *P<0.05 vs Sham. W: week.
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1146  Inﬂammation, Infection, and Novel 
Observations and Acute Ischemic 
Syndrome
Tuesday, March 08, 2005, 1:30 p.m.-5:00 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 1:30 p.m.-2:30 p.m.
1146-215 Association Between Systemic Inﬂammation and 10-
Year Risk for Coronary Heart Disease Among Healthy 
U.S. Adults
Hee-Yeol Kim, Don D. Sin, Jae-Hyung Kim, St Paul’s Hospital, The Catholic University 
of Korea, Seoul, South Korea, St Paul’s Hospital, University of British Columbia, 
Vancouver, BC, Canada
Background: The association between estimated 10-year risk for coronary heart disease 
(CHD) and systemic inﬂammation, which is a known risk factor for cardiovascular events, 
remain largely unknown. We sought to determine whether the distribution of the 10-year risk in 
a dose-dependent way is associated with novel inﬂammatory markers among U.S. adults. 
Methods: We applied the risk prediction algorithm used by the National Cholesterol 
Education Program Adult Treatment Panel III guidelines to data from 6,371 participants 
(age 40 to 79 years) without self-reported heart attack, stroke, peripheral vascular 
disease, and diabetes in NHANES III. 
Results: After adjustments for age, sex, BMI, race, and various co-morbidities, participants 
with high risk had circulating leukocyte, platelet, ﬁbrinogen and homocysteine levels that 
were 914/µL (95% conﬁdence interval [CI], 672 to 1,156/µL), 10,222/µL (95% CI, 2,837 
to 17,607/µL), 21.9 mg/dl (95% CI, 12.5 to 29.4 mg/dl) and 1.5 µmol/L (95% CI 0.8 to 2.3 
µmol/L) higher, respectively, than in those with low risk. They were also more likely to have 
elevated levels of CRP, ﬁbrinogen and homocysteine (Table). There were dose-dependent 
increases in circulating levels of markers across 3 risk groups. 
Conclusions: These ﬁndings indicate that low-grade systemic inﬂammation and 
hyperhomocysteinemia were present in participants with high 10-year risk for CHD. These 
observations may in part explain the high rates of cardiovascular events in a high-risk 
population.
 
Relative odds(95% CI) of having elevated level of circulating markers 
Intermediate risk High risk
CRP >0.21 mg/dl 1.12 (1.00, 1.26) 1.61 (1.30, 2.01) **
CRP >1.00 mg/dl 1.07 (0.89, 1.30) 1.41 (1.03, 1.93) *
Fibrinogen ≥377 mg/dl 0.97 (0.83, 1.14) 1.36 (1.05, 1.78) *
Homocysteine ≥13.3 µmol/L 1.11 (0.89, 1.38) 2.11 (1.48, 3.01) **
Elevated ﬁbrinogen and homocysteine levels were deﬁned as ≥85th percentile of either 
variable.
*P<0.05, **P<0.0001 compared with low risk group, adjusted for confounding factors
1146-216 Elevated Wbc Count Not Associated With Obstructing 
Coronary Lesions In Patients Presenting With Non-st 
Elevation Acute Coronary Syndromes.
Maliha Zahid, Ali F. Sonel, Lauren Wall, Chester Bernie Good, Center for Health 
Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, 
Cardiovascular Institute, University of Pittsburgh, Pittsburgh, PA
Background: Elevated peripheral white blood cell (WBC) count has been shown to 
predict adverse events in patients presenting with unstable angina or non-ST segment 
elevation MI. The value of elevated WBC in predicting degree of coronary artery disease 
(CAD) is unknown.
Methods: To determine the relationship between WBC count and degree of coronary 
artery disease on catheterization, we prospectively studied 251 consecutive patients 
without ST elevation, admitted with suspicion of MI and who subsequently underwent 
coronary angiography during hospitalization. Clinical information was determined by 
medical record abstraction. All patients had a WBC count determined at time of admission. 
Elevated WBC count was deﬁned as >10K/mm3. Signiﬁcant CAD was deﬁned as any 
stenosis of >70% and/or left main stenosis >50%. Univariate logistic regression modeling 
was performed to analyze the relationship between different parameters and presence 
of signiﬁcant CAD.
Results: Mean age was 63 years, with majority of patients being male (99.2%). 26.3% 
had signiﬁcant CAD. Patients with elevated WBC count were less likely to have signiﬁcant 
CAD (OR=0.40, 95% CI=0.18-0.91, p=0.029). This relationship persisted and in fact was 
stronger after correcting for presence of diabetes, hypertension, hypercholesterolemia 
and tobacco use (OR=0.36, 95% CI=0.16-0.84, p=0.018).
Conclusion: Patients presenting with acute coronary syndromes and elevated WBC count 
were much less likely to have obstructing CAD on catheterization. These results suggest 
that ruptured plaque rather than severity of coronary stenoses may be responsible for 
poor outcomes in patients with non-ST elevation acute coronary syndromes and elevated 
WBC counts. Further research is needed to clarify the value of WBC count as a predictor 
of plaque stability and inﬂammation.
1146-217 Inﬁltration of Neutrophils Directly Relates to the Clinical 
Severity in Patients with Unstable Angina Pectoris
Taichi Adachi, Takahiko Naruko, Akira Itoh, Kazuo Haze, Michihiko Hirayama, Takehisa 
Suekane, Hiroko Fukushima, Yoshimi Sugama, Nobuyuki Shirai, Shoichi Ehara, 
Yoshihiro Ikura, Masahiko Ohsawa, Makiko Ueda, Osaka City General Hospital, Osaka, 
Japan, Osaka City University Graduate School of Medicine, Osaka, Japan
Background: Neutrophils in unstable atherosclerotic lesions have not received much 
consideration, despite accumulating evidence suggesting a link between systemic 
inﬂammation and acute coronary syndromes. We have recently demonstrated that 
neutrophils play a role in mediating destabilization of atherosclerotic plaques (Naruko T 
et al, Circulation 106, 2002). However, the relationship of neutrophil inﬁltration to clinical 
severity of unstable angina pectoris (UAP) has not been adequately explored. For this 
reason, we immunohistochemically studied the inﬁltration of neutrophils in coronary 
atherectomy specimens obtained from patients with stable angina pectoris (SAP) and 
patients with diverse clinical presentation of UAP. 
Methods: All patients underwent atherectomy at primary atherosclerotic lesions 
responsible for SAP(n=30) and UAP(n=25). Based on Braunwald’s class, the patients 
with UAP were divided into two groups: Braunwald’s IB+IIB and Braunwald’s IIIB. Frozen 
samples were studied with antibodies against smooth muscle cells, macrophages, 
endothelial cells, and neutrophils (CD66b, CD11b, myeloperoxidase, and elastase). The 
presence of macrophage and neutrophil immunoreactivity was quantiﬁed, respectively, 
using computer-aided planimetry. 
Results: Quantitative analysis demonstrated that macrophage positive area and the 
number of neutrophils in UAP patients was signiﬁcantly (P<0.001) higher than in SAP 
patients. Furthermore in culprit lesions obtained from UAP patients, the number of 
inﬁltrated neutrophils was signiﬁcantly (P<0.001) higher in the Braunwald’s IIIB group 
than in the Braunwald’s IB+IIB group. 
Conclusions: These ﬁndings strongly suggest a correlation between the magnitude of 
neutrophil inﬁltration and the clinical severity of UAP.
1146-218 Levels of Inﬂammatory Markers at the Site of Plaque 
Rupture in Acute Myocardial Infarction Depend on 
Preceding Symptoms
Lukas A. Altwegg, Arnold von Eckardstein, Roberto Corti, Gabor SÃ¼tsch, Marco Rofﬁ, 
Franz Robert Eberli, Thomas Felix Luescher, Willibald Maier, Cardiology, University 
Hospital, Zurich, Switzerland, Institute of Clinical Chemistry, Zurich, Switzerland
Background: Clinical practice experiences two groups of patients with acute myocardial 
infarction (AMI): those with preceding, intermittent symptoms over a longer period of time 
prior to the event, and those without any previous warning signs (sudden onset). Since 
evidence is accumulating that inﬂammation plays an important role in the pathogenesis of 
AMI, we analyzed inﬂammatory markers in the local and the systemic circulation during 
PCI for AMI with respect to the onset characteristics (more versus less than 24 hours).
Methods: In sixty-one patients undergoing primary percutaneous coronary intervention 
(PCI), the acute phase reactants C-reactive protein (hs-CRP), interleukin 6 (IL-6), and 
serum amyloid A (SAA) were assessed in the aorta and at the immediate site of the 
culprit lesion with occlusion of the distal part of the artery by means of a protection device 
(PercuSurge GuardWire) for prevention of distal embolization. Patients with preceding 
symptoms (n=26, 43%) were compared to those without (n=35, 57%). The Mann-Whitney 
rank test was applied, since inﬂammatory markers were not normally distributed.
Results: The systemic inﬂammatory markers were signiﬁcantly higher in patients with 
preceding symptoms. These differences prevailed at the site of plaque rupture (medians 
[IQR] in AMI with preceding symptoms versus sudden onset): IL-6 was 11.1[7.8-38.3] 
versus 5.0 [5.0-14.4] ng/L, SAA was 26.8 [22.8-324.3] versus 23.3 [14.6-34.3] mg/L, and 
CRP was 5.5 [1.8-15.5] versus 1.7 [0.8-3.6] mg/L, all p<0.05.
Conclusion: In patients with AMI and preceding symptoms, not only systemic, but 
also local levels of inﬂammatory markers at the site of plaque rupture were signiﬁcantly 
elevated compared with sudden onset AMI. This difference in inﬂammatory activation 
might reﬂect two different mechanisms of disease: one primarily inﬂammation-driven, and 
another with spasm and thrombus formation as primary trigger.
1146-219 Disagreement in the Interpretation of the Admission 
Electrocardiogram in Acute Coronary Syndromes and 
Association With Clinical Outcome: Real-World Insights 
From GRACE
Shaun G. Goodman, Andrew T. Yan, Jeanna Allegrone, Jose Lopez-Sendon, Christopher 
B. Granger, Joel M. Gore, Andrzej Budaj, Alina A. Georgescu, Quamrul Hassan, Janna 
Luchansky, Frans Van de Werf, for the GRACE ECG Substudy Investigators, Canadian 
Heart Research Centre, Toronto, ON, Canada, St. Michael’s Hospital, Toronto, ON, 
Canada
Background Clinically relevant differences in ECG interpretation between site and central 
core laboratory have been demonstrated in clinical trials but the extent and impact of this 
variability in a “real-world” setting is unclear.
Methods Pts in a prospective substudy (n=7900, 39 hospitals, 7 countries) of the GRACE 
registry were stratiﬁed according to admission ECG ﬁndings in the following hierarchy: 
left bundle branch block (LBBB), ST-segment elevation (ST↑)*, ST-depression (ST↓)*, 
T-wave inversion (T↓)*, and other changes/normal (*≥0.1 mV, ≥2 contiguous leads). The 
proportion of potential agreement achieved between the site and core lab (noncardiologist 
physician readers) categorization beyond chance was calculated (kappa [κ]).
Results Overall agreement between the sites and core lab was moderate (κ=0.48); 
agreement was good in pts with LBBB (κ=0.70), moderate in ST↑ (κ=0.55), and fair in 
ST↓ (κ=0.40) and T↓ (κ=0.38). In-hospital death/MI was high in core lab-categorized pts 
with LBBB (19.3%), ST↑ (16.1%), ST↓ (17%), T↓ (10.3%), and others (11.4%). In-hospital 
death/MI was higher in the ST↓ subgroup identiﬁed by both sites and core lab vs those 
categorized by the sites but not conﬁrmed by the core lab.
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Conclusions Only moderate agreement was evident when comparing site and core 
lab interpretations of the admission ECG in ACS. Consistent with clinical trial settings, 
important differences in even a simple categorization of the admission ECG ﬁndings may 
be associated with different outcomes.
1146-220 Hypertensive Patients Have Increased Sensitivity To 
Meteorological Parameters For Myocardial Infarction 
Occurrence. Analysis From Rico Database
Clothilde Royer, Jean-Claude Beer, Marianne Zeller, Jean-Pierre Besancenot, Jack 
Ravisy, Isabelle L’Huillier, Michel Vincent-Martin, Yves Laurent, Alexandra Oudot, Jean-
Eric Wolf, Hamib Makki, Yves Cottin, on behalf of RICO survey working group, University 
of Burgundy, Dijon, France
Background: Cold temperatures are known to be associated with an increase in 
vascular resistance. However, the seasonal distribution of acute myocardial infarction (MI) 
occurrence in hypertensive patients is unknown.
Methods: RICO is a French regional survey for patients hospitalized with acute MI. From 
01 January 2001 to 31 December 2002, date of MI onset, hypertensive (HT) status of 
each patient, and daily mean climatic parameters (atmospheric pressure, temperature 
and passage of weather cold or warm fronts) obtained from Meteo-France for the region 
corresponding to RICO covering area were collected. Non parametric Mann-Whitney rank 
sum test was performed to assess the relationship between daily occurrence of MI and 
climatic variables in HT and normotensive (NT) patients.
Results: Among the 748 patients included during the study period, 373 (50%) were HT. A 
peak in MI onset was observed in overall population at lowest temperatures (-6.9 to -4.0°C) 
vs warmer (-3.9 to 27°C), which was nearly exclusively due to HT patients (respectively 
1.20 vs 0.51 MI/day, p<0.023, increased risk = 96%). In contrast, MI onset was similar for 
temperatures for NT patients (respectively 0.80 vs 0.52 MI/day, ns). Also, HT patients have 
increased risk (+62%) of MI when the difference in temperature between the day before 
and the day of MI onset was >5°C (0.81 vs 0.5 MI/day, p=0.04), while NT patients had 
similar occurrence of MI (0.58 vs 0.53 MI/day, ns). Mean pressure gap > 8 hPa between 
the day before and the day of MI onset had no inﬂuence on NT patients (0.56 vs 0.50 
MI/day, ns) but induced an increased risk of MI in HT patients (+54%, 0.74 vs 0.49 MI/day, 
p=0.039). Moreover, increased MI onset observed at the passage of cold fronts in overall 
population was mainly due to HT patients (0.79 vs 0.46 MI/day, p<0.03) with no inﬂuence of 
this variable in NT patients (0.57 vs 0.50 MI/day, ns). Inversely, no signiﬁcant deviation from 
chance expectation was observed between HT and NT after warm fronts.
Conclusion: Our results show for the ﬁrst time the increased sensitivity of hypertensive 
patients to several climatic parameters for myocardial infarction triggering, when compared 
to normotensive patients.
1146-221 Human Immunodeﬁciency Virus (HIV) Infection as an 
Independent Risk Factor for the Development of Severe 
Coronary Artery Disease
Amar D. Patel, Srikanth Sola, Divya Gupta, Muhammad Mir, Megan Price, Patrick 
Caneer, Faiz Cheema, Bobby Khan, Tarek Helmy, Emory University, Atlanta, GA
Background: The use of Highly Active Anti-Retroviral Therapy (HAART) has signiﬁcantly 
reduced the morbidity and mortality associated with HIV infection. However, the limited 
angiographic data in several studies questions whether HIV positivity is independently 
associated with an increased risk for the development of angiographically severe coronary 
artery disease (CAD).
Methods: All patients who had undergone cardiac catheterization at Grady Memorial 
Hospital, Atlanta, Georgia between January 2001 and December 2001 for evaluation of 
an acute coronary syndrome or an abnormal cardiac stress test were studied. Patients 
were evaluated for the presence or absence of HIV infection, common cardiac risk factors, 
HAART, and ﬁndings on coronary angiography. Multivariate analyses were conducted to 
determine the relationship between HIV status and angiographically severe CAD (major 
epicardial coronary artery stenosis ≥70%).
Results: 525 patients were enrolled in the study; the average age was 55.7 ± 10.9 years; 
304 (58%) were male; 462 (88%) had hypertension; 237 (45%) had diabetes mellitus; 
333 (63%) had dyslipidemia; 178 (34%) used tobacco; 27 (5%) were HIV positive; 
and 111 (21%) were admitted with a myocardial infarction. Of the latter group, only 7 
(1.4%) were HIV positive. Cardiac catheterization revealed that 213 patients (45%) had 
≥ 70% stenosis of a major epicardial coronary artery; of these, 14 patients were HIV 
positive. On unadjusted analysis, HIV status was found to be signiﬁcantly associated 
with angiographically severe CAD (p = 0.05). However, after adjusting for age, gender, 
hypertension, diabetes, hyperlipidemia, and tobacco use, HIV status was no longer 
associated with severe CAD (OR 1.88, 95% CI 0.86 - 4.11; p = 0.12). Furthermore, there 
was no signiﬁcant relationship between angiographically signiﬁcant CAD and HAART, 
CD4 count, or viral load.
Conclusions: Although HIV infection was common in an urban population referred 
for cardiac catheterization, it was not a signiﬁcant risk factor for the development of 
angiographically severe CAD. This suggests that other factors play a signiﬁcant role in the 
pathogenesis of severe CAD in patients who are HIV positive.
1146-222 Opposite Effects of CX3CR1 Receptor Mutants I249 
and M280 on the Development of Acute Coronary 
Syndrome: A Possible Implication of Fractalkine in 
Inﬂammatory Activation
Alexander Niessner, Rodrig Marculescu, Arvand Haschemi, Georg Endler, Gerlinde 
Zorn, Cornelia M. Weyand, Gerald Maurer, Christine Mannhalter, Johann Wojta, Oswald 
Wagner, Kurt Huber, Medical University of Vienna, Vienna, Austria, Wilhelminen-
Hospital, Vienna, Austria
Background: Several lines of evidence suggest that the chemokine fractalkine (FKN) and 
its receptor CX3CR1 contribute to the accumulation of leukocytes in the atherosclerotic 
plaque. The CX3CR1 mutation M280 modulates leukocyte recruitment and is associated 
with lower prevalence of cardiovascular disease. The effect of I249, another CX3CR1 
mutation, is discussed controversially. We investigated the association of the mutations 
M280 and I249 of CX3CR1 with coronary artery disease (CAD) and with acute coronary 
syndrome (ACS). Furthermore, we examined the relationship of the receptor mutations to 
the concentrations of soluble ligand FKN and high-sensitivity C-reactive protein (hsCRP).
Methods: 1152 patients with suspected CAD were genotyped for M280 and I249. We 
applied multivariate logistic regression analysis to assess the independent effect of 
mutations on CAD and ACS while adjusting for age, sex and cardiovascular risk factors. 
Circulating FKN and hsCRP were measured in a subgroup of 67 subjects during ACS. Due 
to non-normal distribution continuous variables were expressed as median [interquartile 
range] and analyzed using the Mann-Withney U test.
Results: 63% of individuals (n = 720) showed signiﬁcant CAD (stenosis > 60%) with an 
ACS life-time prevalence of 59% (n = 427). We found a harmful inﬂuence of I249 (adjusted 
odds ratio 1.8, 95% conﬁdence interval [CI]: 1.1-3, P = 0.023) and a protective effect of 
M280 (adjusted odds ratio 0.6, 95% CI: 0.3-1, P = 0.037) on the occurrence of ACS in 
patients with CAD. Correspondingly, patients with CAD carrying I249 but not M280 (17%) 
were at elevated risk of ACS (odds ratio 1.6, 95% CI: 1-2.5, P = 0.039) compared to 
those lacking both mutations. During ACS these patients (carrying only I249) had higher 
concentrations of FKN (997 [659-2047] vs. 532 [374-960] pg/mL, P = 0.033) and hsCRP 
(14.2 [9.8-36.1] vs. 8.6 [2.6-14.2] mg/L, P = 0.042). We found no effect of M280 and I249 
on the occurrence of CAD.
Conclusion: I249 and M280 have opposite independent effects on the occurrence of 
ACS. The presence of I249 “unbalanced” by M280 confers an elevated risk of ACS in 
patients with CAD. A FKN-mediated enhanced inﬂammatory activation may in part explain 
this increased risk.
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1147-197 Protection of LV Remodeling by Intravenous Infusion 
of Human Atrial Natrieuretic Polypeptide in the Patients 
with Acute Anteroseptal Myocardial Infarction. - 
Prospective Randomized Trial Assessed by Quantitative 
Gated Spect Imaging-
Hitoshi Matsuo, Tomonori Segawa, Takatomo Watanabe, Shunichiro Warita, Shunichiro 
Warita, Tai Kojima, Takeru Shiraki, Takeshi Hirose, Makoto Iwama, Kouji Ono, Masahiko 
Kouda, Haruki Takahashi, Yukihiko Matsuno, Sachiro Watanabe, Gifu Prefectural Gifu 
Hospital, Gifu, Japan
Purpose: The aim of this study is to demonstrate HANP administration combined with 
acute revascularization prevent LV remodeling independent of myocardial salvage.
Methods: Consecutive 44 patients with acute anteroseptal myocardial infarction were 
randomly assigned to either continuous infusion of HANP at a dose of 0.025 µg/kg/min 
for 3 days, or control. Myocardial salvage, infarct size, and LV volume was assessed by 
99mTc-tetrofosmin imaging.
Results: No differences in patients backgrounds were observed. HANP suppressed 
LVEDVI increase in comparison with placebo (HANP:3.2±16.8 control:16.0±23.4 p<0.05) 
with no difference in salvage index (HANP:55.6±24.9% control:55.5±34.1%). A close 
correlation was observed between delta LVEDVI and infarct size in both group as shown 
in ﬁgure. This relationship means the linear correlation between the severity of infarct size 
and the degree of LV remodeling. The regression line is steeper and shifted to upward 
in control group than HANP infusion group, suggesting supprsive effect of HANP for 
LV volume expansion. Multilinear regression analysis to test the signiﬁcance of HANP 
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infusion independent of infarct image severity score yielded a signiﬁcant relationship 
between delta-LVEDVI and infusion of hANP (p<0.05) as well as infarct severity score 
(p<0.001).
Conclusion : This study clearly demonstrate that HANP can suppress LV volume 
expansion despite no difference of infarct size. 
1147-198 Effects Of Early Ace-inhibition In Patients With Non-
STEMI Acute Myocardial Infarction.
Claudio Borghi, Stefano Bacchelli, Daniela Degli Esposti, Ettore Ambrosioni, University 
of Bologna, St.Orsola-Malpighi Hospital, Bologna, Italy, Menarini Research S.p.A., 
Firenze, Italy
Background. The early use of ACE-inhibitors is among the recommended treatments in 
patients with ST-elevated acute myocardial infarction (AMI) where it improves the clinical 
outcome.
Objective and methods. The aim of the present study is to evaluate the effects of 
the early administration of an ACE-inhibitor in a population of 526 non-STEMI patients 
enrolled in the SMILE study and randomly allocated to the treatment with zofenopril (30-
60 mg/day) or matched placebo within 24 hours from the onset of symptoms of acute MI.
Results. The two populations were comparable for demography, baseline clinical 
characteristics and concomitant pharmacological treatment, and none of them underwent 
thrombolysis. Blood pressure decreases in a similar fashion in response to treatment with 
zofenopril or placebo. The primary end-point (6-week death+severe CHF) occurred in 
10.3% of patients treated with placebo and in 3.6% of those allocated to ACE-inhibition 
(adjusted 2p=0.003). The 6-week rate of severe CHF was reduced from 4.0% to 0.4% 
(p=0.006) whereas 1 year mortality was signiﬁcantly lower in patients treated with 
zofenopril (7.9% vs.13.9%: 2p=0.036) with a relative risk reduction of over 43.1%. Kaplan-
Meier estimate of survival showed a reduced mortality in patients treated with zofenopril 
with an affect that was already evident after 6-weeks of treatment and increased after 12 
months of follow-up (p=0.013). The beneﬁt of early ACE-inhibition was conﬁrmed in both 
males and females and in the different age groups and infarct locations.
Conclusions. The results of the present study clearly conﬁrm the extensive role of ACE-
inhibitors in patients with MI and support their primary role in patients with non-STEMI 
where they could interfere with the angiotensin II-mediated mechanisms responsible for 
coronary vasoconstriction and myocardial ischemia.
1147-229 Aqueous Oxygen Therapy for ST Segment Elevation 
Myocardial Infarction; Final Results and One Year 
Follow Up of the AMIHOT Trial
Jack L. Martin, Pranobe V. Oemrawsingh, Antonio B. Bartorelli, Simon D. Dixon, Mitchell 
W. Krukoff, Barbara S. Lindsay, Douwe A. Atsma, William W. O’Neill, Main Line Health 
System, Bryn Mawr, PA, William Beaumont Hospital, Royal Oak, MI
Background: Although rapid reperfusion in ST segment elevation myocardial infarction 
(STEMI) reduces mortality, epicardial vessel patency does not insure full restoration of 
nutrient ﬂow at the tissue level. Animal and Phase I testing of the TherOx® Aqueous Oxygen 
(AO) System suggest that percutaneous coronary infusion of autologous blood mixed with 
hyperoxemic saline may overcome the downstream barrier to oxygen delivery and improve 
myocardial salvage after percutaneous coronary intervention (PCI) for STEMI.
Methods: A Phase II randomized trial to evaluate the efﬁcacy of regional AO therapy 
in STEMI. A sub-selective catheter positioned in the infarct artery delivers AO for 90 
minutes at 75 ml/minute. Contrast echocardiography performed after PCI and before 
randomization is repeated at 24 hours, and days 30 and 90. Primary endpoints include 
regional wall motion scores, ST segment resolution and day 14 SPECT defects.
Results: Patients with anterior MI (n=144) had signiﬁcantly less resolution of ST elevation 
after PCI alone than those with non-anterior (n=125) MI (57.8 ± 22.7 vs 75.4 ± 2.3 %, 
p< 0.05). Anterior MI patients randomized to AO therapy (n=70) after PCI demonstrated 
more complete resolution and less marked (area >5000) persistence (47 vs 35% and 9 
vs 21%, p= 0.023). Core laboratory data demonstrates more improvement in regional wall 
motion scores at 3 months in the anterior MI group assigned to AO therapy (0.78 ± 0.56 
vs 0.57 ± 0.49, p< 0.03) particularly those (n=40) treated <6 hours from symptom onset 
(8.1 ± 0.58 vs 0.56 ± 0.48, p=0.01). There is a trend to 6% smaller SPECT defects (p=ns). 
Twelve-month follow up will be available by 3/05.
Conclusion: AO after PCI for anterior MI signiﬁcantly improves ST segment resolution 
suggesting enhanced reversal of ischemia at the tissue level. This is associated with 
improved convalescent regional wall motion.
1147-230 Caldaret (MCC-135) Lowers the Frequency of Severe 
Systolic Left Ventricular Dysfunction in STEMI patients 
undergoing PCI
Mark Hibberd, Dan Tzivoni, Fritz Bar, Johannes Brachmann, Hans Reiber, Mitchell 
Krucoff, Martin Davies, Jun Tatsuno, on behalf of the (CASTEMI) Study Group, Shaare 
Zedek Medical Centre, Jerusalem, Israel
Background: Recently we demonstrated that caldaret, a novel compound that modulates 
myocardial calcium handling, given before PCI for STEMI lowered infarct size and 
increased early LVEF in anterior MI. We investigated whether the frequency of severe LV 
dysfunction (LVD) (LVEF <30%) will be reduced in caldaret-treated STEMI patients.
Methods: CASTEMI enrolled 387 patients with STEMI and >10 mm total summed ST 
elevation (12 leads) undergoing primary PCI, receiving 48hr IV caldaret 57.5 mg (LD), 
172.5mg caldaret (HD) or placebo (PL). Global LVEF was assessed by resting gated 
SPECT on Day 7/discharge and Day 30 post MI. Populations were analyzed by infarct 
location and pre-PCI TIMI ﬂow.
Results: HD caldaret produced modest reductions in frequency of patients with LVD at day 
7 with any TIMI ﬂow and any MI location(Table 1). However, in anterior MI patients signiﬁcant 
dose-dependent lowering of LVD was seen at Day 7 and 30 compared with PL.
Table 1: Percentage of patients in each treatment  





























D 7 19.4 (98) 25.7 (70) 18.8 (96) 25.0 (64) 15.5 (84) 19.2 (52)
Anterior
MI
D 30 17.4 (86) 22.6 (62) 9.5 (95) 13.6 (66) 7.7 (78) 9.6 (52) p=0.080
D 7 34.5 (55) 48.6 (37) 28.3 (53) 36.1 (36) 19.7 (61) p=0.093
23.7 (38) 
p=0.031









Conclusions: Pre-PCI caldaret in STEMI patients lowered the frequency of severe LVD 
and could help reduce high mortality in patients with large infarcts.
1147-231 Intracoronary Hyperbaric Oxygen Administered During 
Primary Percutaneous Coronary Intervention Prevents 
One Month Left Ventricular Remodeling
Hazem M. Warda, Johan G. Bosch, Jeroen J. Bax, Douwe E. Atsma, Wouter J. Jukema, 
Ernst E. Van der Wall, Martin J. Schalij, Pranobe V. Oemrawsingh, Leiden University 
Medical Center, Leiden, The Netherlands
Background: Initial experience with the TherOx® Aqueous oxygen (Ao) system (TherOx 
Inc) in AMI patients (pts) post primary PCI shows rapid recovery of LVEF and improvement 
of wall motion primarily due to functional recovery within the infarct zone. We tested 
whether hyperbaric Ao infusion (Ao) prevents unfavorable LV remodeling.
Methods: We studied 42 pts presenting within 6 hours of onset of an anterior AMI. 
Angiographic inclusion criteria were initial TIMI 0-1 ﬂow in the IRA and TIMI ﬂow 2-3 
post PCI. Pts were randomized to either treatment group (Ao group, n = 20) or control 
group (Non-Ao, n = 22). Ao group patients received Ao infusion for 90 minutes through a 
selective catheter positioned in the stent. Myocardial contrast echo was performed after 
24 hours and at 1 month follow up (FU).
Results: Patients did not show any differences in baseline clinical characteristics. In the 
non-Ao group, EDV and ESV were signiﬁcantly increased at 1 month FU demonstrating 
clear remodeling (p=0.004 for EDV and p=0.017 for ESV). In the Ao-group group, EDV 
and ESV did not signiﬁcantly change at 1 month FU (p=0.600 and 0.196 respectively). 
In addition, ejection fraction signiﬁcantly increased in the treatment group (p=0.041) but 
remained relatively constant in the non-Ao group (p=0.433) (see table).
Conclusion: Intracoronary hyperbaric oxygen as an adjunct to primary PCI prevents 
LVED dilatation and preserves LVES volume at 1 month follow up. Also, patients with Ao 
therapy showed improved ejection fraction at 1 month follow up.
LV volumes (ml) at 24h and 1 mo
24 hours 1 month Delta P value
EDV non Ao 114.2 ± 25.0 129.6 ± 31.4 15.4 ± 22.6 0.004
EDV Ao 119.6 ± 28.0 116.5 ± 34.2 -3.1 ± 25.8 0.600
Delta EDV Ao vs nonAo 0.018
ESV non Ao 56.0 ± 15.9 65.8 ± 22.6 9.8 ± 17.6 0.017
ESV Ao 62.6 ± 24.6 55.9 ± 27.3 -6.7 ± 22.3 0.196
Delta ESVAo vs nonAo 0.011
EF non Ao 50.5 ± 10.1 19.5 ± 9.2 -1.0 ± 5.9 0.433
EF Ao 48.8 ± 10.6 53.7 ± 11.3 5.1 ± 10.1 0.041
Delta EFAo vs nonAo 0.023
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1147-232 Beneﬁcial Effect Of Folic Acid On Endothelial 
Dysfunction In Patients With Normo- And 
Hyperhomocysteinemia After An Acute Myocardial 
Infarction.
An L. Moens, Marc J. Claeys, Inge Goovaerts, Christiaan J. Vrints, University of Antwerp, 
Antwerp, Belgium
Background: Folic acid (FA) has multiple mechanisms of action. It not only lowers 
homocysteine (HCY), e.g. it also enhances the bioavailability of tetrahydrobiopterin and 
it directly interacts with eNOS. In this study, we investigated the effect of folic acid on 
endothelial dysfunction after an acute myocardial infarction (AMI).
Material en methods: A randomized, double-blind crossover study was performed in 
35 patients with AMI. In group A, FA(10mg/d) was administered for 6 w, followed by a 
washout period (2 w) and by a placebo period (6w). Group B received ﬁrst the placebo, 
thereafter FA. Endothelial function was assessed by ﬂow-mediated dilation (FMD), using 
high-resolution ultrasound at t1(basal), t2(week 6) and t3(week 14). All subforms of 
homocysteine were determined using HPLC.
Results: FMD values at t1, t2 and t3 for group A and B are shown in ﬁg1. This effect 
signiﬁcantly decreases after stopping folic acid administration.
The basal levels of all HCY forms were comparable between the groups. There was no 
correlation between all forms of HCY (baseline and Δ) and FMD (baseline and Δ).
Repeated measures ANOVA indicated a interaction effect (p=0.003).Using the different 
forms of HCY (baseline and Δ) as covariates in this analysis didn’t abolish the interaction-
effect, indicating that the beneﬁcial effect of FA on FMD in AMI is independent of HCY.
Conclusion: Folic acid has a beneﬁcial effect on endothelial dysfunction in patients with 
normo- and hyperhomocysteinemia after an AMI.
1147-233 Efﬁcacy of Eplerenone in Killip Class II-III Post AMI 
Patients: Results from EPHESUS
Jeffrey Anderson, Faiez Zannad, Henry Solomon, Robin Mukherjee, Rajiv Patni, 
Bertram Pitt, LDS Hospital, Salt Lake City, UT
Introduction: The risks of adverse outcomes following acute myocardial infarction (AMI) 
are believed to be associated with the presence of heart failure (HF) (Wu et al. J Am Coll 
Cardiol. 2002;40:1389), but the relationship is incompletely deﬁned. Thus, we performed 
a post-hoc analysis of the Eplerenone Post-Acute Myocardial Infarction Heart Failure 
Efﬁcacy and Survival Study (EPHESUS) to evaluate the efﬁcacy of eplerenone in patients 
who were Killip Class II or Killip Class III.
Methods: Patients with clinical HF (Killip II or III) and left ventricular systolic dysfunction 
(ejection fraction ≤40%) were randomized 3-14 days after index AMI to eplerenone (25 mg 
titrated to 50 mg QD; N=3319) or placebo (N=3313) used with standard therapy, and followed 
for up to 2.5 years. Study endpoints included all-cause mortality (ACM), cardiovascular (CV) 
mortality (CVM), CV hospitalization (CVH), CVM/CVH, and sudden cardiac death (SCD).
Results: Among the total intent-to-treat EPHESUS population, 81% were classiﬁed as 
Killip Class II (64.6%) or Killip Class III (16.5%). In these patients, eplerenone reduced 
the risk of ACM by 19% (P=0.002), CVM by 20% (P=0.002), CVH by 9% (P=0.116), CVM/
CVH by 14% (P=0.003), and SCD by 26% (P=0.009).
Conclusions: When compared with placebo, eplerenone reduced the risk of these 
endpoints in post-AMI patients who were Killip class II or III at presentation.
1147-234 Does Facilitated Percutaneous Coronary Intervention 
Improve Angiographic and Clinical Outcomes in ST 
Elevation Myocardial Infarction? A Quantitative Review
Thomas T. Tsai, Brahmajee K. Nallamothu, P. Michael Grossman, Debabrata Mukherjee, 
Stanley Chetcuti, Mauro Moscucci, Eric R. Bates, University of Michigan, Ann Arbor, MI
Background: Facilitated percutaneous coronary intervention (PCI) combines the 
rapidity and availability of ﬁbrinolysis with the infarct-artery stabilization of PCI in STEMI. 
Randomized clinical trials (RCTs) comparing this strategy to primary PCI alone have 
yielded inconsistent results. We performed a quantitative review to evaluate the efﬁcacy of 
facilitated PCI on early TIMI-3 ﬂow and short-term mortality in STEMI.
Methods: We searched MEDLINE, PREMEDLINE, Current Contents and recent scientiﬁc 
session databases to identify relevant RCTs. A RCT was included if it: 1) involved 
ﬁbrinolysis with planned PCI versus primary PCI for STEMI; and 2) reported “early” TIMI-
3 ﬂow (i.e., prior to PCI) and/or short-term mortality.
Results: Six studies with 1809 patients met the above criteria. The likelihood of TIMI-3 
ﬂow was signiﬁcantly higher in patients receiving facilitated PCI (41.1% versus 12.8%; 
pooled relative risk-ratio [RR], 3.0; 95% CI, 2.2-4.0). However, facilitated PCI was not 
associated with a lower risk for short-term mortality (5.5% versus 5.1%; RR, 1.1; 95%, 
CI 0.7-1.8) (Figure). In the 4 studies reporting the outcome, major bleeding was not 
signiﬁcantly increased with facilitated PCI (RR, 1.6; 95% CI, 0.7-3.9)
Conclusions: Facilitated PCI results in higher rates of early TIMI-3 ﬂow when compared 
to primary PCI, but this advantage has not yet been associated with improved clinical 
outcomes. Larger trials are needed to evaluate this strategy more deﬁnitively. 
1147-235 Single High-Dose BoluS TiRoﬁbAn and Sirolimus 
Eluting STEnt Versus Abiciximab and Bare Metal Stent 
in Acute MYocardial Infarction (STRATEGY) Study
Marco Valgimigli, Gianfranco Percoco, Giordano Cicchitelli, Patrizia Malagutti, Gianluca 
Campo, Fabrizio Ferrari, Dario Barbieri, Lucia Ansani, Roberto Ferrari, University of 
Ferrara, Ferrara, Italy
Background: Primary bare metal stenting and abciximab infusion are currently considered 
the best available reperfusion strategy for acute ST-segment elevation myocardial 
infarction (STEMI). Sirolimus eluting stents (SES), compared to bare metal stent (BMS), 
greatly reduce the incidence of binary restenosis and target vessel revascularisation 
(TVR), but their use on a routine basis results in a signiﬁcant increase in medical costs. 
With current European list prices, the use of tiroﬁban instead of abciximab would save 
enough money to absorb the difference between SES and BMS. 
Aim: To assess whether in patients with STEMI the combination of SES with a single 
high dose bolus (SHDB) tiroﬁban regimen results in a similar incidence of death and 
myocardial infarction (MI) but in a lower rate of TVR and binary restenosis (BR) after six 
months compared to BMS and abciximab. 
Methods and Results: 175 patients (mean age: 63 ± 12; 128 M) with STEMI have been 
randomised to a SHDB tiroﬁban regimen (bolus of 25 µg/Kg/3-min, followed by an infusion 
of 0.15 µg/Kg/min for 18-24 h) plus SES (n=87) vs. standard dosing of abciximab and BMS 
(n=88). Seventy-ﬁve patients in the SHDB tiroﬁban-SES and 77 patients in the abciximab-
BMS group ultimately received the prespeciﬁed treatment combination (n=152). Analysis is 
based on the intention-to-treat principle. At 6 months, 115 patients underwent clinical and 
angiographic follow-up. The rate of major cardiovascular events (MACE) and BR were both 
lower in the in the tiroﬁban-SES (15% and 9.6%, respectively) than in the abciximab-BMS 
group (26% and 40%, p<0.04 and p<0.001, respectively). Cumulatively, the primary end-
point, which included the summation of death, myocardial infarction and BR, occurred in 24 
(41%) patients randomized to abciximab-BMS compared to 13 (23%) patients randomized 
to the SHDB tiroﬁban regimen-SES (p=0.03). In the tiroﬁban group, there were 1 major and 
7 minor bleeds, while they were 2 and 8 in the abciximab group, respectively. 
Conclusions: The combination of the SHDB regimen of tiroﬁban and SES is a new 
promising strategy for STEMI, resulting in similar cost but lower MACE and BR when 
compared to abciximab and BMS.
1147-236 Transport for Abciximab Facilitated PCI Versus 
Onsite Thrombolysis With a Liberal Rescue Policy: A 
Randomized Trial in Large ST-Elevation MI Presenting 
Early in a Referral Hospital: The Holland Infarction 
Study (HIS)
Hendrik-Jan Dieker, Elvira V. van Horssen, Ferry M.K.J. Hersbach, Marc A. Brouwer, 
Arnoud W. van ‘t Hof, Ad J. van Boven, Wim R.M. Aengevaeren, Freek W.A. Verheugt, 
Frits W.H.M. Bär, University Medical Center, Nijmegen, The Netherlands, University 
Hospital, Maastricht, The Netherlands
Introduction: HIS studied transport for abciximab facilitated primary PCI versus on-site ﬁbrin-
speciﬁc thrombolysis in patients presenting in a referral hospital. In contrast to DANAMI-2, a 
liberal protocol-driven rescue PCI policy was advocated in case of failed thrombolysis.
Method and Results: Patients presented with ST-elevation in a referral center having < 
4.5 hrs of chest pain and ≥12 mm ST-segment shift. These patients were randomized to 
transport for abciximab facilitated primary PCI (FP) or to on-site thrombolysis (TT) with 
advocated rescue angioplasty in case of failed reperfusion (< 50% ST-resolution at 60 
min. after start TT). Of the originally planned 900 patients only 48 were included, due to 
suspension of ﬁnancial funding.
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time to randomization, min, median, (IQR) 130(81 - 146)
150
(115 - 181) 0.15
time to treatment, min, median, (IQR) 230(195 - 250)
170
(123 - 191) < 0.01
complete ST-segment resolution (>70%) 58% 35% 0.10
CK-peak, U/l, median, (IQR) 2091(914 - 3005)
2582
(1327 - 3370) n.s
In the FP-group all patients received abciximab pretreatment for a median duration of 85 
min. The rate of preprocedural TIMI-3 ﬂow was 17% (TIMI 2+3, 35%) and postprocedural 
TIMI-3 ﬂow was 85%. In the TT-group 48% underwent urgent catheterization of which 58% 
had TIMI-3 ﬂow at angiography and 55% underwent immediate PCI.
At 30 days 1 patient (4%) died in the FP-group, in the TT-group 2 (9%) patients died and 
one (4%) had non-fatal MI.
Conclusion: Patients treated with abciximab facilitated primary PCI tended to have more 
complete ST-resolution and smaller infarctions than thrombolytic treated patients with a 
liberal rescue strategy. Larger studies should address the optimal treatment strategy for 
patients presenting in hospitals without intervention facilities.
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1148-223 Risk of First Coronary Ischemic Events Following First 
Atrial Fibrillation: Data from 2 Decades (1980-2000)
Yoko Miyasaka, Marion E. Barnes, Stephen S. Cha, Kent R. Bailey, James B. Seward, 
Walter P. Abhayaratna, Bernard J. Gersh, Teresa S.M Tsang, Mayo Clinic, Rochester, MN
Background: Although coronary artery disease (CAD) is known to be a risk factor of AF, 
the risks of symptomatic CAD following ﬁrst AF are not well characterized.
Methods: The medical records for residents of Olmsted County, MN, with an ECG-
conﬁrmed diagnosis of ﬁrst AF between 1980 and 2000 were reviewed. Cox proportional 
hazards modeling was used to assess overall and sex-speciﬁc incidence of new 
symptomatic CAD following incident AF. Time dependent Cox modeling was used to 
assess prognosis following coronary events.
Results: Of 4618 residents (mean age 73 + 14 years, 51% men) who developed ﬁrst 
AF in 1980-2000, 1771 (38%) had prior CAD, and 180 (4%) diagnosis of ﬁrst ischemic 
coronary event and ﬁrst AF was made on the same day. Of the remaining 2667 patients 
without CAD at the time of AF onset, 818 (30%) developed a ﬁrst coronary ischemic event 
during a mean follow up of 6 ± 5 years, and1580 died. Age (P<0.0001), but not sex, and 
multiple other factors were independently predictive of ischemic coronary events within 
5 years (Table). The Kaplan-Meier estimate of cumulative probability of the development 
of a ﬁrst coronary ischemic event was 25% and 41% at 5 and 10 years, respectively. 
The occurrence of post-AF ischemic coronary events was associated with signiﬁcantly 
increased mortality risk (HR=11.20, p<0.001).
Conclusions: Symptomatic CAD developed in a signiﬁcant proportion of patients 
following ﬁrst AF, which conferred substantial mortality risk. Age, but not sex, was 
predictive of such events.
Table: 
Variable HazardRatio Lower95% CI Upper 95% CI P-value
Calendar Year 1.03 1.022 1.038 <.0001
BMI (kg/m2) 1.014 0.998 1.029 0.0797
History of ASO 1.522 1.103 2.101 0.0106
History of diabetes mellitus 1.451 1.077 1.955 0.0144
History of dyslipidemia 1.139 0.92 1.411 0.2316
History of hypertension 1.982 1.545 2.544 <.0001
Current and past smoker 0.947 0.779 1.151 0.583
1 / Creatinine (dl/mg) 0.868 0.62 1.215 0.408
Log glucose 0.991 0.642 1.53 0.9669
1148-224 Creatinine Clearence Independently Predicts Extent 
And Severity Of Coronary Atherosclerosis In Patients 
With Stable Coronary Artery Disease
Johann Auer, Thomas Weber, Gudrun Lamm, Robert Berent, Elisabeth Lassnig, Michael 
Porodko, Edwin Maurer, Bernd Eber, General Hospital Wels, Wels, Austria
Background: Although there is accumulating evidence that renal insufﬁciency is 
associated with an increased risk for cardiovascular events in patients with coronary 
artery disease (CAD), it is not known whether creatinine clearence rates a the time of 
hospital admission is associated with the extent and severity of coronary atherosclerosis 
assessed angiographically.
Patients and Methods: We studied 1062 consecutive white subjects (336 women and 
726 men; mean age 65.6 +/- 18.8 years) undergoing coronary angiography for stable CAD 
at a single referral center. In addition to conventional risk factors and clinical characteristics 
as predictors of extent and severity of coronary atherosclerosis, we assessed creatinine 
clearence rates at the time of admission. Two experienced cardiologists blinded to the 
clinical and laboratory data reviewed the angiographic ﬁlms and deﬁned severity of CAD on 
the basis of the sum of three scoring systems, whose total score could range from 0 to 27.
Results Patients were devided into three groups according to CAD severity score. 
Creatinine clearence rates were 67.5+12.8, 60.1+15.9, and 57+18.3 mL/min for group 
I (410 patients; CAD score 0 to 3), group II (316 patients; CAD score 4-8), and group 
III (336 patients; CAD score >8), respectively (p<0.05). Signiﬁcant renal dysfunction, as 
deﬁned by the National Kidney Foundation as an estimated glomerular ﬁltration rate of 
<60 ml/min/1.73 m2, was signiﬁcantly more common in groups II and III compared to 
group I (p<0.01). When grouped according to levels of creatinine clearence (group A: 
>75 mL/min; group B: <75 to >68; group C: <68 to >58; group 4: <58), scores of the 
angiographic CAD severity were 5.0+3.7, 5.64+3.6, 6.63+4.1, and 7.35+4.0, respectively 
(p for trend <0.0001). After adjustment for baseline characteristics including age, gender, 
and CAD risk factors, patients in groups C and D had signiﬁcantly higher scores of CAD 
severity as compared to group A and B patients (p<0.01).
Conclusion: Creatinine clearence on admission independently predicts extent and 
severity of coronary atherosclerosis in patients with stable CAD. Thus, increased serum 
creatinine may be a marker for non-traditional proatherogenic factors.
1148-225 Evaluation of Patients with Dyspnea Without Chest 
Pain: Prevalence and Predictors of Coronary Artery 
Disease ( CAD) Using Myocardial Perfusion Imaging 
(SPECT) and Coronary Angiogram (CATH)
Su Min Chang, Regina Chu, Douglas Russell, Timothy F. Christian, University of 
Wisconsin, Madison, WI
Background: Dyspnea could precede angina as manifestation of CAD.
Objectives: In dyspneic patients (pts) with no chest pain (CP) , examine the prevalence 
and predictors of CAD as myocardial perfusion abnormality (MPA) by SPECT and 
angiographic coronary stenosis (> 50 %) (CAS).
Method: SPECT was performed in 915 pts with dyspnea alone and 1357 pts with CP 
alone . CATH was done in 238 and 452 pts respectively. High risk MPA was deﬁned as >15 
% LV perfusion defect size( LVPDS) , multivessel or LAD distribution and Severe CAS as 
left main, 3 VD or 2VD involving LAD.
Results: Compared to pts with CP, dyspneic pts were older ( 65 +-12 vs 61+-12 y/o ) , had 
less MI (17 % vs 24 %), similar risk factors but less likely to exercise (35 % vs 48 %) (all p < 
0.01). Prevalence of MPA (44% vs 45 % p =0.8) , high risk MPA (27 % vs 29 % p =0.6) and 
LVPDS (18.8+-14 % of LV vs 19.8 +- 15 % p =0.7) were about equal. No statistical signiﬁcance 
on CATH ﬁnding : 73 % of dyspneic pts had CAS vs 79 % of pts with CP and 33 % vs 37% 
were severe.( p= ns). Both groups had similar univariate predictors of MPA : age > 65, male, 
h/o MI, diabetes (DM), abnormal ECG, inability to exercise and positive stress ECG. Of CAS 
were DM, hyperlipidemia and MPA for dyspneic pts , and DM, positive stress ECG and MPA 
for pts with CP.  Independent predictors of severe CAD were shown on table.
Conclusion: In dyspneic pts referred for SPECT/CATH, the prevalence and predictors of 
CAD appeared similar to pts with CP alone. Inability to exercise, positive stress ECG and 
high risk MPA identiﬁed pts at high risk for severe CAS.
all p< 0.05 
Pts with Dyspnea alone Odds Ratio (95% CI) Pts with CP alone Odds Ratio (95% CI)
Severe CAS
Inability to exercise 2.24 (1.03 - 4.9)
Severe CAS
Diabetes 1.96 (1.14-3.4)
Positive stress ECG 5.5 (2.1 - 14.3) Positive stress ECG 1.85 (1.02-3.3)
MPA 3 (1.2 - 7.2) MPA 3.2 (1.7 -6)
High risk MPA 2.6 (1.3 - 5.2) High risk MPA 3.1 (1.8 -5.1)
High Risk MPA
Male 2.4 ( 1.7 - 3.5)
High Risk MPA
Male 2.05 (1.5-2.8)
h/o MI 4.1 (2.8 - 6.2) h/o MI 1.55 (1.08-2.2)
Diabetes 2 (1.36 - 2.9) Diabetes 1.64 (1.16-2.3)
Inability to exercise 2 (1.34 - 3) Inability to exercise 1.96 (1.4-2.7)
Positive stress ECG 2.4 (1.4 - 4.2) Positive stress ECG 2.5 (1.6 -3.8)
1148-226 Should Erectile Dysfunction Be Considered as a Sign of 
Occult Coronary Artery Disease?
Charalambos Vlachopoulos, Nikolaos Ioakeimidis, Konstantinos Rokkas, Konstantina 
Aggeli, Andreas Michaelides, Konstantinos Aznaouridis, Athanassios Askitis, 
Christodoulos Stefanadis, Athens Medical School, Athens, Greece
Background: Erectile dysfunction (ED) shares many risk factors with coronary disease 
(CAD) and in most of the cases of ED the underlying abnormality is endothelial dysfunction 
in the penile arteries. The aim of this prospective study was to evaluate the incidence of 
asymptomatic CAD in men with ED of vascular origin.
Methods: Twenty-six consecutive asymptomatic men, aged 40-70 years, with non-
psychogenic and non-hormonal ED were compehensively evaluated using medical 
history, exercise teadmill test and stress echocardiography. Patients who had positive one 
or both of the two non-invasive procedures were referred for coronary arteriography in 
order to document CAD and evaluate the severity of the disease.
Results: The mean time interval between the onset of ED and cardiological assessment 
was 14 months (range 2-36). Smoking (17 pts/65%), hypertension (15 pts/58%) and 
hyperlipidemia (13 pts/50 %) were the most common risk factors, followed by diabetes 
mellitus (5 pts/20 %) and family history (3 pts/11%). Moreover, 19 (73 %) men had two or 
more risk factors. One patient presented with myocardial infarction before he completed 
the non-invasive investigation and coronary arteriography was performed during 
hospitalization. In addition, eight (32 %) patients with ED had positive one or both of 
the two non-invasive procedures. Coronary arteriography performed in 6 patients with 
positive one or both of the two non-invasive procedures and in the patient with myocardial 
infarction demostrated that 5 patients had single-vessel disease (1 pt LAD, 3 pts LCx, 1 
RCA) and 1 patient had coronary artery ectasia.
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Conclusions: A considerable proportion (23%) of patients with ED of vascular origin have 
angiographically documented CAD. These ﬁndings support the strategy that patients with 
ED should undergo further cardiovascular evaluation.
1148-227 Prognostic Value of N-Terminal Pro-Brain Natriuretic 
Peptide in Patients with Chronic Stable Angina
Gjin Ndrepepa, Siegmund Braun, Kathrin Niemöller, Julinda Mehilli, Nicolas von 
Beckerath, Olga Gorchakova, Wolfgang Vogt, Albert Schömig, Adnan Kastrati, 
Deutsches Herzzentrum, Munich, Germany
Background: Patients with stable angina are poorly characterized in terms of biomarkers 
that may help in the assessment of prognosis. We investigated whether N-Terminal Pro-
Brain Natriuretic Peptide (NT-proBNP) may be used as a prognostic marker in patients 
with stable angina treated with coronary stenting.
Methods: Plasma NT-proBNP was measured in 1059 patients with stable angina and 
angiographic conﬁrmation of signiﬁcant coronary artery disease. The primary end point 
was mortality at one year.
Results: Using receiver operating characteristic curve analysis, the best cutoff value of 
NT-proBNP maximizing sensitivity and speciﬁcity for prediction of one-year mortality was 
1048 pg/ml. Patients were divided into 2 groups: the group with NT-proBNPgreater than 
1048 pg/ml (the high NT-proBNP group, 208 patients) and the group with NT-proBNP 
less than1048 pg/ml (the low NT-proBNP group, 851 patients). At one year there were 
17 deaths (8.2%) among the patients in the high NT-proBNP group and 7 deaths (0.8%) 
among the patients in the low NT-proBNP group (odds ratio 10.4, 95% conﬁdence interval 
[CI] 5.1 - 21.1, P<0.001). Plasma NT-proBNP was the strongest independent correlate of 
one year mortality (adjusted hazard ratio [HR] 1.4, 95% CI 1.07 - 1.22, P<0.001) followed 
by left ventricular ejection fraction (HR 0.52, 95% CI 0.31 - 0.88, P=0.01) and age (HR 
2.23, 95% CI 1.11 - 4.51, P=0.024).
Conclusions NT-proBNP is a strong prognostic biomarker in patients with chronic stable 
angina.
1148-228 Long-term Prognosis Of Dobutamine-atropine Stress 
Echocardiography: The Impact Of Heart Rate Response
Boudewijn J. Krenning, Jeroen J. Bax, Elena Biagini, Vittoria Rizzello, Arend F.L. 
Schinkel, Ron T. van Domburg, Maarten L. Simoons, Don Poldermans, Thoraxcenter, 
Rotterdam, The Netherlands
Background: During dobutamine-atropine stress echocardiography (DSE) atropine 
is frequently added to overcome the negative chronotropic effect of concomitant anti-
ischemic therapy. The aim of this study was to assess the long-term prognostic value of 
atropine addition and a sub-maximal DSE.
Methods and results: 3,800 patients undergoing DSE between 1989 and 2002 were 
evaluated for heart rate response, test results, and long-term cardiac events (cardiac 
death and myocardial infarction). Patients were followed for 6±4 years; 217 underwent 
revascularization within 3 months and were excluded, 50 patients were lost-to follow-up. 
Patients were divided into three groups; group 1 THR using dobutamine (n=1917); group 
2 THR achieved after the addition of atropine (n=1247), and group 3 THR not achieved 
(n=419). Test end-points in group 3 were: maximum dose (47%), severe ischemia (21%), 
and side effects (32%). The 5-year cardiac event rate in patients in group 1 and 2 with and 
without new wall motion abnormalities (NWMA) was comparable, 5.6% vs 4.8%, and 1.5% 
vs 1.5%, respectively, p=NS. However, a sub-maximal test had a 5-year cardiac event rate 
of 18% in the absence of NWMA, while in the presence of ischemia the prognosis was 
poor (5-year cardiac event rate 30%).
Conclusion: A completed DSE has an excellent prognostic accuracy, irrespective of the 
addition of atropine. A sub-maximal DSE carries a high risk for cardiac events despite a 
normal test outcome, while patients with severe ischemia have a poor prognosis. 
POSTER SESSION
1149  Novel Methods in CABG Outcomes
Tuesday, March 08, 2005, 1:30 p.m.-5:00 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 1:30 p.m.-2:30 p.m.
1149-195 Effectiveness of N-3 Fatty Acids for the Prevention of 
Atrial Fibrillation After Coronary Artery Bypass Surgery
Leonardo Calo’, Leopoldo Bianconi, Antonella Meo, Filippo Lamberti, Maria Luisa 
Loricchio, Ermenegildo de Ruvo, Furio Colivicchi, Claudio Pandozi, Massimo Santini, 
San Filippo Neri Hospital, Rome, Italy
Background: Postoperative atrial ﬁbrillation (AF) is a common complication of coronary 
artery bypass surgery (CABG) and several studies have explored the effectiveness of 
pharmacological and non-pharmacological interventions for prevention of AF. Recently, 
there is growing clinical evidence that n-3 polyunsaturated fatty acids (PUFA) have cardiac 
antiarrhythmic effects. Aim of this study was to assess the efﬁcacy of preoperative and 
postoperative treatment with n-3 PUFA in preventing the occurrence of AF after CABG.
Methods: A total of 150 patients were prospectively randomized to control group (76 
patients, 13 female, 65 ± 9 years) or PUFA 2 g/day (74 patients, 11 female, 66 ± 8 
years) for a minimum of 7 days before elective CABG and until the day of discharge 
from the hospital. Exclusion criteria included prior AF, concurrent therapy with class I 
or III antiarrhythmic drugs, or concomitant valve surgery. The primary endpoint was the 
development of AF in the postoperative period.
Results: The clinical characteristics of the patients in the 2 groups were similar. 
Postoperative AF developed in 27 patients of control group (35.5%) and in 11 patients 
of PUFA group (14.9%) (P=0.006). Non fatal postoperative complications occurred in 5 
patients who received n-3 PUFA (6.8%) and in 6 controls (7.9%, P=NS). Postoperative 
mortality was not signiﬁcantly different in n-3 PUFA-treated patients (1 patient, 1.4%) 
versus controls (1 patient, 1.3%). After CABG, the patients in the n-3 PUFA group were 
hospitalized for signiﬁcantly fewer days than those in the placebo group (7.2 ± 1.9 days 
versus 8.3 ± 3.2 days, P < 0.05).
Conclusions: This study ﬁrst demonstrates that the preoperative and postoperative 
administration of n-3 PUFA (2g/day) was associated with a signiﬁcant decrease (58%) in 
postoperative AF in patients undergoing CABG without side effects.
1149-196 Mid-Term Clinical and Hemodynamic Outcome 
Following Surgical Ventricular Restoration in Patients 
with Ischemic Cardiomyopathy
Marisa Di Donato, Serenella Castelvecchio, Alessandro Frigiola, Lorenzo Menicanti, San 
Donato Hospital, San Donato Milanese, Milano, Italy
Background. Pts with ischemic cardiomyopathy and EF =/< 30% are at high risk of death, 
mostly of arrhythmic origin. We followed-up (FUP)122 pts (65±10 yrs,20F) operated by 
surgical ventricular restoration (SVR) for post-anterior infarction and symptoms of angina 
and/or heart failure.
Aim: to assess survival and the rate of events following SVR at mid term follow-up (18±8 
months,min 3 max 33).
Patients: Group 1(G) with pre-op EF=/<30% , median 24% (n=53) and Group 2 with pre-
op EF>30%, median 36%(n=69). All had SVR with the use of a shaper device and coronary 
graftings.All pts had pre and post-op echocardiogram and 46 had late echo at 18±8 m. On 
telephone interview we assessed: functional status,death,rate of hospitalization,cardiac 
procedures,cardiac events.
Results: FUP was completed in 88% of pts. NYHA class from 2.4±0.6 to 1.2±0.6 
p=0.0001. EF from 24+/-4 to 35+/-4 in G 1 and from 38±6 to 45±8 % in G 2 (p 0.0001). Two 
operative cardiac deaths in G1 (3.6%) and 3 in G 2 (4.3%). Two late deaths in G1 (at 3 and 
5 months; 1 for sudden death). No late deaths occurred in G 2. In G 1 seven pts (13.5%) 
had cardiac hospitalization: 3 pts had implantable deﬁbrillator for ventricular arrhythmias 
(5.8% of survivors); 1 pt had biventricular pacing (2%) and 1 had stroke. Seven pts in G 2 
required cardiac hospitalization (10.6%): 1 pts had PTCA for myocardial infarction (1.5%) 
and one had pace maker (1.5%).
Conclusions: SVR improves pump function and functional status. Survival is excellent 
and the rate of events is low even in pts with </=30 EF% . 
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1149-199 Sustained Regional Improvement in Myocardial 
Perfusion One Year After Transplantation of Autologous 
Bone Marrow Cells in Patients With Diffuse Coronary 
Artery Disease
Luis Henrique W. Gowdak, Isolmar T. Schettert, Carlos Eduardo Rochitte, Luiz Antonio 
M. Cesar, Protasio L. da Luz, Jose Eduardo Krieger, Jose Antonio Ramires, Sergio A. de 
Oliveira, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil
Background: Adult bone marrow cells (BMC) have recently been tested as a novel 
therapeutic option for patients (pt) with severe coronary artery disease (CAD). However, little 
data is available regarding the duration of the angiogenic effect shortly seen after the cell 
injections. The aim of this study was to verify whether the increase in myocardial perfusion 
after intramyocardial injection of autologous BMC could be sustained in the long-term.
Methods: 10 pt (8 men), 59±6 years-old, with limiting angina and 3-vessel CAD, not 
amenable to complete CABG due to the diffuseness of the disease were enrolled. 
BMC were obtained immediately prior to surgery, and the lymphomonocytic fraction 
separated by density gradient centrifugation. During surgery, 4mL containing 13±3x107 
BMC (CD34+ = 1.3±0.4%) were delivered by multiple injections in the ischemic non-
grafted myocardium. Before (B), 1 (1M), 3 (3M), 6 (6M) and 12 (12M) months after 
surgery, myocardial perfusion (at rest and after pharmacological stress with adenosine) 
was assessed in 17 segments by magnetic resonance imaging (MRI). Each segment 
was blindly graded as normal (0), or having mild (1) or severe (2) perfusional defect. 
An ischemic score (IS) comprising all 17 segments (total IS) or only those injected non-
grafted segments (regional IS) was calculated.
Results: Injected myocardial segments (n=12) included the inferior (n=7), anterior (n=2), 
septal (n=1), apical (n=1) and lateral (n=1) walls. No complications or deaths occurred. 
As expected, MRI showed a sustained reduction in total IS (B=0.65±0.14, 1M=0.15±0.08, 
3M=0.24±0.10, 6M=0.11±0.06 and 12M=0.17±0.05; P=0.002) but more interestingly also 
in the regional IS (B=1.11±0.20, 1M=0.28±0.21, 3M=0.51±0.25, 6M=0.35±0.18, and 
12M=0.34±0.13; P=0.0009).
Conclusions: In this small series of pt, one-year after a single procedure of intramyocardial 
injection of autologous BMC combined to CABG, a sustained increase in myocardial 
perfusion could be veriﬁed. Provided the angiogenic effect seen in this trial is conﬁrmed 
in a larger randomized trial, this strategy could be used for myocardial angiogenesis in pt 
with a more advanced CAD not suitable for complete surgical revascularization.
1149-200 Electrocardiographic Left Ventricular Mass and 
Conduction and Long-Term Survival Following 
Coronary Bypass Surgery
Derlis Martino, Eugene Blackstone, Ken Baker, Michael Lauer, Cleveland Clinic 
Foundation, Cleveland, OH
Objective: Electrocardiographic left ventricular (LV) mass and QRS duration predict 
adverse outcomes in healthy populations. We sought to determine if QRS duration and 
ECG LV mass predict survival in patients undergoing primary isolated CABG.
Methods: Digital data on preoperative ECGs on 13,427 patients undergoing primary 
isolated CABG between 1991 and 2002 were analyzed for QRS duration and the Cornell 
voltage criteria for LV mass (sum of R wave in avL and S wave in V3). Excluded were 
patients with pacemakers and Wolff-Parkinson-White syndrome. The primary endpoint 
was all-cause mortality during a median of 6.3 years of follow-up.
Results: There were 2,749 deaths. Increased QRS duration was strongly associated 
with death (Figure 1). 
After adjusting for demographics, cardiovascular risk factors, surgical characteristics, LV 
function, severity of coronary disease, renal function, and other ECG ﬁndings (including 
heart rate, Q waves, and bundle branch block), QRS duration remained a strong predictor 
of risk (P<0.0001). Cornell voltage also provided additional prognostic information to QRS 
duration.
Conclusions: The ﬁnding that increasing QRS duration is a strong independent risk 
factor for late mortality in patients undergoing CABG has not previously been reported. 
This effect was seen even at the low end of the spectrum of QRS durations, and was not 
dependent on left or right bundle branch blocks or evidence of myocardial infarction. The 
Cornell criteria were also predictive of mortality, but less so.
1149-201 Postoperative Troponin I is a Better Predictor of 30 Day 
Mortality Following Coronary Artery Bypass Compared 
to the Postoperative Electrocardiogram.
Henry S. Loeb, Donald Depinto, Donald D. Thomas, II, William P. Gunnar, Edward Hines 
Jr. Veteran’s Administration Hospital, Hines, IL, Loyola University Stritch School of 
Medicine, Maywood, IL
Background: The EKG is routinely used after coronary artery bypass (CABG) to identify 
patients with perioperative myocardial infarction (MI) for whom closer monitering might be 
indicated. After CABG however the EKG often is difﬁcult to interpret due to non speciﬁc 
changes. Elevation of troponin i (TROP) is a highly speciﬁc and sensitive marker for 
myocardial damage and therefore could be useful in identifying patients at risk for an 
adverse outcome following CABG.
Methods: We studied 693 consecutive patients undergoing isolated elective CABG in 
whom at least one postoperative TROP was obtained. The sensitivity of TROP and of 
postoperative EKG changes for prediction of 30 day mortality were compared.
Results: Of the 693 patients undergoing CABG, 27 patients ( 3.9%) expired within 30 
days of surgery. Maximum postoperative TROP was =>15ng/mL in 17 of these patients 
(63%) where as only 6 of these patients (22%) had an EKG diagnosis of perioperative 
MI. Of the 666 survivors 25% had a post operative TROP =>15ng/mL and 8.6% had 
perioperative MI by EKG.
Thirty day mortality was directly related to the maximum postoperative value of TROP . 
Conclusions: Elevation of TROP =>15ng/mL following CABG is a much better predictor 
of 30 day mortality than is the postoperative diagnosis of perioperative MI by EKG. The 
direct relationship between the extent to which TROP increases following surgery and 
30 day mortality suggests that such patients have signiﬁcant myocardial damage not 
identiﬁed by postoperative EKG changes.
1149-202 A Novel C5-Binding Nucleic Acid Aptamer That 
Protects Isolated, Perfused Mouse Hearts From Human 
Complement-Mediated Damage and Inhibits Primate C5 
Activity In Vivo
James Rottman, Claude Benedict, Jeffrey Kurz, David M. Epstein, Archemix, 
Cambridge, MA
Background and Aims: Activation of the complement (C’) cascade during coronary 
artery bypass (CABG) surgery causes morbidity and mortality mediated by C5 cleavage 
products C5a and C5b-9. We synthesized a nucleic acid aptamer that binds human and 
primate C5 with high afﬁnity (human KD = 600 +/- 100 pM) and inhibits zymosan-mediated 
C5 cleavage and C’-mediated lysis of sheep erythrocytes. We studied the ability of this 
aptamer to inhibit human C5-mediated damage of isolated, perfused mouse hearts and 
to inhibit primate C5 activity in vivo.
Methods: Mouse hearts were perfused with Krebs-Heinseleit buffer containing 
6% human plasma + / - aptamer. During each experiment, hearts were observed for 
myocardial dysfunction (increased end-diastolic pressure, and asystole). Heart sections 
were examined by immunohistochemistry (IHC) for deposition of C5b, and the heart buffer 
efﬂuent was assessed for C3a, C5a and C5b-9 levels by ELISA.The aptamer was then 
administered to macaques by bolus and C5 inhibition assessed by zymosan activation of 
serial plasma samples.
Results: When the C5 aptamer was added to the heart perfusate in a 50-fold or 10-
fold molar excess over plasma C5 (25 µM or 10 µM), myocardial dysfunction and C5b 
deposition were observed in 0/5 and 0/4 hearts, respectively. At C5 aptamer concentrations 
equivalent to plasma C5 levels (0.5 µM), or with irrelevant aptamer (25 µM) or in the 
absence of any aptamer, C5b deposition and myocardial dysfunction were observed in 
3/3, 3/3 and 5/5 mice, respectively. The heart perfusion efﬂuent contained equivalent 
amounts of C3a in all groups, but the C5 aptamer inhibited C5a and C5b-9 generation in a 
dose-dependent manner. The aptamer completely inhibited zymosan-mediated activation 
of primate plasma C5.
Conclusion: The C5-aptamer may be useful to protect human CABG patients from 
complications of complement activation.
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850  Treatment Approaches in Acute 
Ischemic Syndrome
Tuesday, March 08, 2005, 2:00 p.m.-3:30 p.m.
Orange County Convention Center, Room 414A
2:00 p.m.
850-3 Intensive Statin Therapy Reduces CRP in Acute 
Cornonary Syndrome Patients With Metabolic 
Abnormalities and Adverse Lifestyle Features:  
An Analysis From PROVE IT-TIMI 22
Kausik K. Ray, Christopher P. Cannon, Richard Cairns, Ajay J. Kirtane, David A. Morrow, 
Carolyn Hoss McCabe, C. Michael Gibson, Paul M. Ridker, Eugene Braunwald, Brigham 
and Women’s Hospital, Boston, MA, Harvard Medical School, Boston, MA
Background and Aims: CRP is an important prognostic indicator of cardiovascular risk 
and statin therapy has been shown to reduce CRP. A number of factors such as adverse 
lifestyle and components of the metabolic syndrome are associated with an elevated 
CRP. We sought to investigate whether intensive statin therapy reduced CRP in these 
subgroups, more than standard dose statin therapy within the PROVE IT-TIMI 22 study. 
Methods: The effect of intensive (atorvastatin 80mg) vs standard (pravastatin 40 mg) 
statin therapy on CRP (n=3507) at 4 months after an ACS in smokers, diabetics and 
among individuals with components of the metabolic syndrome was assessed.
Results: Intensive statin therapy was associated with a lower CRP in each group (see 
table). In a multivariable model after accounting for treatment groups, a number of 
clinical factors remained associated with CRP: age (p<0.0001), female sex (p<0.0001), 
smoking (p<0.0001), BMI>25(p<0.0001), Triglyceride >150mg/dl (p=0.0005), HDL<50 
mg/dl (p=0.001), glucose (p=0.009), on treatment LDL (p<0.0001), % change in LDL from 
baseline (p=0.02) and intensive statin therapy (p<0.0001). 
Conclusion: Our data demonstrates that intensive statin therapy is effective at reducing 
CRP across many high-risk subgroups of ACS patients. Potential therapeutic areas to 
target for further reductions in CRP are control of non-LDL metabolic abnormalities and 
lifestyle modiﬁcation.
The effect of intensive statin therapy on 4 month CRP  
(median IQR) 






Female 3.44 (1.4,7.2) 2.22(1,5.1) <0.001
BMI >25
(Baseline) 2.2 (1.1,4.8) 1.42 (0.7,3.1) <0.001
Current Smokers 2.4 (1.2,5.6) 1.77 (0.8,3.6) <0.001
Diabetes
(baseline) 2.74 (1.3,5.5) 1.51 (0.7,3.5) <0.001
Glucose>110mg/dl






(on Tx 4 mth)
2.15
(1,4.5) 1.34 (0.7,3.1) <0.001
Triglyceride >150 mg/dl
(on Tx 4 mth) 2.39 (1.2,5.1) 1.68 (0.8,3.6) <0.001
BP >130/85
(On Tx at 4 mth) 2.56 (1.2,4.8) 1.39 (0.7,3.2) <0.001
2:15 p.m.
850-4 Use of Statins Is Associated With Decreased Risk 
of Bleeding in Patients With Unstable Coronary 
Syndromes Treated with Antiplatelet Therapy
Yochai Birnbaum, Salvatore Rosanio, Sabina Murphy, Mohammad Saeed, Atiar M. 
Rahman, Christopher P. Cannon, University of Texas Medical Branch, Galveston, 
Brigham and Women’s Hospital, Boston, MA
Background: Antiplatelet therapy improves outcome in patients with acute coronary 
syndrome (ACS), but increases bleeding rates. Independent of their lipid-lowering 
mechanism, statins upregulate the production of PGE2 and PGI2 which may protect 
the gastrointestinal (GI) tract. We studied whether statins reduce the risk of bleeding 
associated with antiplatelet therapy. 
Methods: Retrospective analysis of the Orboﬁban in Patients with Unstable coronary 
Syndromes (OPUS-TIMI-16) trial that compared orboﬁban (ORBO) and placebo in 10,288 
patients with ACS. All patients received ASA 162 mg/d. 
Results: GI bleeding occurred in 1.89% and 0.94% of the patient -/+ statins (p<.001). 
Statins were associated with less overall bleeding in both the ORBO (p=.001) and placebo 
(p=.017) groups (Fig. 1a). Severe and major GI bleeding occurred in 1.55% and 0.74% 
of the patients -/+ statins (p<.001). Statins were associated with less severe and major 
bleeding in both the ORBO (p=.001) and placebo (p=.043) groups (Fig. 1b). Logistic 
regression analysis showed that the use of statins (OR 0.57; 95% CI 0.38-0.85; p=.005), 
age >65 y (5.27; 3.53-7.87; p<.001), ORBO treatment (4.07; 2.45-6.77; p<.001), Killip 
≥2 (1.61; 1.05-2.51; p=.030), history of cardiovascular disease (1.99; 1.04-3.79; p=.036), 
and the use of calcium channel blocker (1.47; 1.05-2.07; p=.027) were independently 
associated with the risk of GI bleeding. 
Conclusions: Statins may protect against gastrointestinal bleeding in patients with ACS. 
2:30 p.m.
850-5 Predictors of Major Bleeding and Transfusion in 
SYNERGY: Effects of Pretreatment Variables and 
Treatment Assignment
Sunil V. Rao, Kenneth W. Mahaffey, Elliott Antman, Neal S. Kleiman, James J. Ferguson, 
Robert M. Califf, Richard C. Becker, Shaun G. Goodman, Philip E. Aylward, Duke Clinical 
Research Institute, Durham, NC
Background: In the SYNERGY trial (N=9978), enoxaparin was noninferior to 
unfractionated heparin in patients with acute coronary syndromes, but was associated 
with a modest increase in bleeding. We determined predictors of bleeding and transfusion 
among patients treated with enoxaparin or unfractionated heparin.
Methods: Predictive models for GUSTO severe bleeding, TIMI major bleeding, and 
transfusions were developed from baseline characteristics. Stepwise logistic regression 
was used to determine independent predictors of the three outcomes. Interactions 
between treatment arm and candidate predictors were considered.
Results: Independent predictors of the three outcomes are shown. Enoxaparin was not 
an independent predictor of bleeding in any model. No signiﬁcant interaction between 
treatment and other variables for GUSTO severe bleeding or transfusions was seen. 
However, for TIMI major bleeding there was a signiﬁcant interaction between creatinine 
and treatment such that patients with elevated creatinine treated with enoxaparin were 
more likely to have a TIMI major bleed.
Conclusions: Treatment with enoxaparin is not associated with GUSTO severe bleeding 
or transfusions, but is associated with TIMI major bleeding in patients with renal 
insufﬁciency. This emphasizes the need for careful dosing of enoxaparin in patients with 
abnormal renal function.
Independent predictors of bleeding and transfusions 
GUSTO severe bleeding TIMI major bleeding Blood transfusion










Age (per 10 yr increase) 1.22 (1.03-1.46) ST-segment depression 1.62 (1.39-1.89) ST-segment depression 1.58 (1.40-1.78)
Renal function (per 
5 mL/hr increase in 
creatinine clearance)
0.91 (0.85-0.97) Baseline hematocrit 1.38 (1.27 - 1.5) Baseline hemoglobin 0.75 (0.72-0.78)
Prior CABG 0.51 (0.34-0.77) Age (per 10 yr increase) 1.33 (1.21-1.48) Prior CABG 0.48 (0.40-0.57)
Region (Europe vs. 
others) 0.47 (0.31-0.71)
Renal function (per 
10 mg/dL increase 
in creatinine) and 
enoxaparin treatment
1.09 (1.05-1.13)
Prior CABG 0.48 (0.38-0.61)
2:45 p.m.
850-6 Enoxaparin Versus Unfractionated Heparin: 
Consequences of Treatment Duration on Efﬁcacy and 
Safety in SYNERGY
James J. Ferguson, Kenneth W. Mahaffey, Yao Huang, Paul Armstrong, Glenn Levine, 
Neal S. Kleiman, Shaun G. Goodman, Marc Cohen, Elliott Antman, Robert M. Califf, for 
the SYNERGY Investigators, Texas Heart Institute, Houston, TX, Duke Clinical Research 
Institute, Durham, NC
Background: SYNERGY randomized 9978 patients with non-ST-segment elevation acute 
coronary syndromes (NSTE ACS) managed with an early invasive strategy to enoxaparin 
or unfractionated heparin (UFH). Questions remain as to the effect of treatment duration 
on outcomes in patients coming rapidly to the catheterization laboratory. 
Methods: We evaluated death/myocardial infarction (MI) and TIMI major bleeding as 
functions of treatment duration for enoxaparin and UFH. Since 75% of patients received 
antithrombin treatment prior to enrollment and 12% received nonrandomized treatment 
after randomization (crossovers), only patients with consistent therapy (no prerandomization 
therapy or prerandomization therapy same as randomized and no postrandomization 
crossover) were included to avoid the confounding inﬂuences of changing therapy. 
Results: 4718 patients (47%) had consistent therapy during the entire hospitalization 
or before experiencing death/MI; 4700 (47%) had consistent therapy during the entire 
hospitalization or before experiencing a major TIMI bleed. The median time from 
randomization to catheterization was 22 hours; the median duration of therapy was 33.67 
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hours with UFH and 46.21 hours with enoxaparin. The incidence of death or MI at 30 days 
was 12.4% with enoxaparin and 14.2% with UFH (p=0.064), with no signiﬁcant effect 
of duration of therapy on outcome for either enoxaparin (p=0.249) or UFH (p=0.068). 
The incidence of TIMI major bleeding was 6.3% with enoxaparin and 5.8% with UFH 
(p=0.477). In patients assigned to enoxaparin, bleeding did not vary with duration 
of treatment (p=0.536); however, in UFH-assigned patients there was a signiﬁcant 
association between bleeding and duration of treatment (p=0.003), with bleeding rates 
tending to increase after approximately 3-4 days of therapy.
Conclusions: Enoxaparin and UFH have similar treatment effects regardless of the 
duration of treatment; longer duration with UFH (but not enoxaparin) is associated with an 
increased risk of bleeding. Enoxaparin is a safe and effective antithrombotic agent for both 
short and long durations of therapy in patients with NSTE ACS.
3:00 p.m.
850-7 Safety of Single Versus Multi Vessel Angioplasty 
for Patients with Unstable Angina and Multi Vessel 
Coronary Disease: a Report from the New York State 
Angioplasty Registry
James A. Kong, Robert Minutello, Steve S. Kim, Atul Sharma, Srhihari Naidu, Manish 
Parikh, Geoffrey Bergman, Shing C. Wong, Mun K. Hong, New York Hospital-Weill 
Cornell Medical Center, New York, NY
Background: Recent clinical trials support an early invasive management strategy for patients 
with unstable angina (UA). Many of these patients may have signiﬁcant lesions in multiple 
coronary arteries. However, the safety of multi vessel versus single vessel percutaneous 
coronary intervention (PCI) as a treatment strategy in UA has not been studied.
Methods: Using the 2000/2001 New York State Angioplasty Registry, we compared the in-
hospital clinical outcomes in patients with multivessel disease (>70% stenosis) who underwent 
either single versus multi vessel PCI for class III or IV UA without evidence of acute myocardial 
infarction (MI). Patients with previous MI, PCI, or coronary artery bypass surgery (CABG), and 
those presenting with hemodynamic instability or shock were excluded.
Results: Patients in the multi vessel PCI group were less likely to have peripheral 
vascular disease, renal insufﬁciency, and diabetes. There was no difference in the total 
number of lesions with >70% stenosis. A chronic total occlusion (CTO) was present more 
often in the single vessel PCI group, though a CTO was more likely to be treated in the 
multi vessel PCI group. There was no difference in death, CABG, stroke, renal failure, or 
stent thrombosis.
Conclusion: Despite the added complexity of multivessel PCI, there was no increase 
in adverse in-hospital outcomes in this group. In patients undergoing percutaneous 
revascularization for UA, multi vessel PCI is likely to be safe compared to single vessel 






Age (years) 66.1 +/- 12.0 64.8 +/- 12.3 0.002
Male sex (%) 63.7 64.3 NS
History of stroke (%) 5.4 4.2 NS
Peripheral vascular disease (%) 13.4 11.1 0.024
Diabetes mellitus (%) 29.0 25.4 0.010
Renal insufﬁciency (%)1 2.0 1.2 0.038
Congestive failure on admission (%) 5.2 5.2 NS
Angiographic and procedural 
characteristics
Ejection fraction (%) 54.5 +/- 10.8 55.4 +/- 10.4 0.008
Lesions >70% (per patient) 3.2 3.2 NS
GPIIb/IIIa inhibitor use (%) 58.5 63.5 0.001
CTO present (%) 37.9 17.5 <0.001
PCI for CTO (%) 8.2 10.4 0.015
Outcomes
Renal failure with dialysis (%) 0.1 0.2 NS
Stroke (%) 0.2 0.1 NS
Emergency CABG (%) 0.5 0.2 NS
Stent thrombosis (%) 0.6 0.2 NS
Death (%) 0.4 0.7 NS
MACE2 (%) 1.2 0.8 NS
1Renal insufﬁciency: serum creatinine >2.5 mg/dL, 2MACE: Major Adverse Cardiac 
Event (stroke, CABG, and death)
p value compared to placebo
3:15 p.m.
850-8 Intensity of Lipid Lowering With Statins and Brachial 
Artery Vascular Endothelium Reactivity After Acute 
Coronary Syndromes: The BRAVER Trial
Jocelyn Dupuis, Jean-Claude Tardif, Jean-Lucien Rouleau, Joseph Ricci, Malcolm 
Arnold, Eva Lonn, René Roux, Lawrence Title, Jean Diodati, Nickie Bonafede, Anna 
Woo, Christopher P. Cannon, Montreal Heart Institute, Montreal, PQ, Canada
Background. The time course and the differential effects of statin regimens on endothelial 
function after acute coronary syndromes (ACS) are unknown and could contribute to the 
superiority of a more intense strategy.
Methods. Subjects enrolled in the PROVE IT-TIMI 22 trial (n=50) underwent serial 
evaluation of vascular reactivity by high-resolution brachial ultrasound. Endothelium-
dependent ﬂow-mediated dilatation (FMD) was measured after reactive hyperemia while 
endothelium-independent dilatation was measured after 0.4 mg sublingual nitroglycerin 
(NMD). Evaluations were performed at baseline and at 48 hours, 1 month and 4 months 
after the initiation of pravastatin 40 mg (n=26) or atorvastatin 80 mg (n=24).
Results. Baseline lipid proﬁles and C-reactive protein were similar except for mildly higher 
LDL cholesterol in the atorvastatin group (104 ± 26 mg/dL vs. 90 ± 27 mg/dL, p<0.05). After 
4 months, atorvastatin therapy reduced total cholesterol by 22% and LDL cholesterol by 32% 
while pravastatin had no signiﬁcant effect. C-reactive protein decreased similarly in both groups. 
Brachial artery diameters prior to the determination of FMD and NMD were similar in both 
groups and at each time point of the trial. Both FMD and NMD increased signiﬁcantly after 4 
months only by 27% and 24% respectively, with no difference between groups. There was no 
correlation between the change in FMD and the change in lipids or C-reactive protein.
Conclusion. Statin therapy soon after ACS is associated with improvement of both 
endothelium-dependent and-independent vascular reactivity after 4 months. The 
improvement is unrelated to the reduction of lipids and is thus unlikely to contribute to the 
superiority of a more intense regimen.
ORAL CONTRIBUTIONS
858  Stable Cardiac Ischemic Syndromes: 
Novel Risk Stratiﬁcation Methods
Tuesday, March 08, 2005, 4:00 p.m.-5:00 p.m.
Orange County Convention Center, Room 414A
4:00 p.m.
858-3 Prognostic Implications in Patients With 
Angiographically Flow Limiting Coronary Artery 
Disease but a Normal Stress Echocardiogram: 
Incremental Value of Stress Echocardiography Over 
Coronary Angiography
Sripal Bangalore, Devi Gopinath, Ajay Shah, Utpal Patel, Nilo Ayuyao, Mutahir Khan, 
James Wilentz, Siu-Sun Yao, Farooq A. Chaudhry, St Luke’s-Roosevelt Hospital Center, 
New York, NY
Background: Data on the importance of normal stress echocardiogram in the presence 
of angiographically signiﬁcant CAD is limited.
Methods: We evaluated 290 patients (62 ± 11 years; 67% males) undergoing stress 
echocardiography (22% treadmill, 78% dobutamine) within a 3-month period of 
angiography without an intervening intervention. All patients had signiﬁcant CAD as 
deﬁned by coronary stenosis ≥70% in major epicardial vessels or its branches. Abnormal 
stress echocardiography was deﬁned as those with stress-induced ischemia (increase in 
wall-motion score of ≥1 grade). Followup (2.9 ± 1.3 years) for cardiac death (n = 21) and 
total mortality (n = 33) was obtained.
Results: Stress echocardiography effectively risk stratiﬁed normal vs. abnormal 
subgroups for endpoints of both cardiac death (Event rate 0.0%/year vs. 3.4%/year; p = 
0.003) and total mortality (Event rate 0.9%/year vs. 5.1%/year; p = 0.004; OR = 6.7; 95% 
CI = 1.6-28.9)(graph). Cox proportional hazard model showed incremental value of stress 
echocardiography over angiography (Global chi2 increased from 5.8 to 24.2 , p <0.0001 
for cardiac death and from 7.1 to 23.1, p <0.0001 for total mortality).
Conclusions: A normal stress echocardiography even in the presence of angiographically 
determined coronary stenosis is associated with benign prognosis (<1%event rate/year) 
and provides incremental value over angiography. Physiology (function) may be a better 
predictor of mortality rather than anatomical coronary stenosis.
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858-4 Usefulness of N-Terminal Pro-Brain Natriuretic Peptide 
for Predicting Moderate-to-Severe Myocardial Perfusion 
Defects in Patients With Stable Coronary Artery Disease
Gerald Vanzetto, Peggy Jacon, Alex Calizzano, Yannick Neuder, Malik Zine, Patrice Faure, 
Daniel Fagret, Jacques Machecourt, University Hospital of Grenoble, Grenoble, France
BACKGROUND: The prognostic value of NT-pro-brain natriuretic peptide (NTBNP) is 
demonstrated in patients (pts) with acute coronary syndromes but not in pts with stable 
coronary artery disease (SCAD). We determined the relationship between NTBNP and 
the extent of myocardial perfusion defects on exercise (EST) Tl201 SPECT in SCAD pts 
with normal ejection fraction (EF > 45%).
METHODS: 88 pts (79 men, 61+8 years) with known SCAD and no history of heart failure 
were included. Mean EF was 62+11%. NTBNP was measured at baseline, peak-EST, 
and 3 hours post-EST.
RESULTS: SPECT was normal in 33 pts (37%, group 1) and abnormal in 55 (63%, 
group 2 - ﬁxed defects n=33, reversible defects n=49). Group 2 pts had higher baseline, 
peak-EST and post-EST NTBNP values than group 1 (Table below). NTBNP baseline 
vs. post-EST variations were also higher in group 2. Post-EST NTBNP was predictive of 
perfusion abnormalities and moderate-to-severe ischemia (areas under the ROC curves 
= 0.71 and 0.61 respectively). A post-EST NTBNP <190 pmol/ml ruled-out moderate-
to-severe myocardial ischemia with a negative predictive value of 85%. The accuracy of 
combined EST and post-stress NTBNP was 74% for identifying the presence or absence 
of signiﬁcant ischemia.
CONCLUSION: A single post-EST NTBNP measure accurately predicts the presence 
or absence of signiﬁcant myocardial ischemia in SCAD and can be useful in centers 
without on site nuclear facilities for selecting pts requiring perfusion imaging as second 
line diagnostic or prognostic tool.
Group 1 Group 2
Baseline 107 (52-172) 183 (100-274)*
Peak-EST 119 (56-182) 201 (110-311)*
Post-EST 122 (59-195) 213 (108-326)*
Baseline- Post EST + 16 (6-25) + 23 (7-66)*
Value are medians (interquartile range). * p < 0.05 versus Group 1
4:30 p.m.
858-5 Brain Natriuretic peptide (BNP) Provides Incremental 
Data for Risk Stratiﬁcation of Diabetics: A Stress 
Echocardiography Study
Shrikanth P. Upadya, Sripal Bangalore, Tariqshah Syed, Asif Malik, Deborah Cantales, 
Amandeep Kalra, Lubna Rashid, Veerana Merla, Ranju Soni, Joseph Schappert, Farooq 
A. Chaudhry, St. Luke’s-Roosevelt Hospital, New York, NY
Background: In the absence of heart failure, Brain natriuretic peptide (BNP) is elevated 
in patients with coronary artery disease (CAD). Diabetics (DM) are known to have 
accelerated CAD and non invasive stress testing is commonly used for prognosticating 
and risk stratifying DM’s. We evaluated the effect of a pre stress BNP in DM’s referred for 
a stress echocardiogram (SE).
Methods: We measured BNP pre SE in 74 diabetic patients (mean age 63 ±14 yrs; 
54% males). Dobutamine stress echocardiogram was performed in 78% and exercise 
echocardiogram in 22% of patients. Echocardiogram readings were blinded to BNP levels. 
LV was divided as per the standard 16-segment model. Ischemia was deﬁned as new 
reversible wall motion abnormality and/or biphasic response. BNP levels were analyzed 
at Biosite Inc.
Results: Signiﬁcant variables are presented in the Table. Ischemia by SE was seen in 37 
patients (50%). Mean pre-stress BNP was higher in ischemics compared to non-ischemics 
(254.4 ± 451.4 vs. 37±62.2, p =0.006). When pre stress BNP was added to clinical risk 
factors (age, gender, race, body mass index, hypertension, hypercholesterolemia, 
family history of premature CAD, smoking) global chi square increased from 5.9 to 15.5 
(p<0.001) in predicting ischemia on SE.
Conclusions: Pre stress BNP has incremental value to clinical risk factors in predicting 
ischemia during SE in DM. An elevated baseline BNP in DM suggests the presence of 
CAD, requiring SE for risk stratiﬁaction and prognostiﬁcation.
Table 
Ischemics Non ischemics P value
Age 66 ± 12 59 ± 14 0.016
History of heart failure (%) 19 5 0.075
Hypertension (%) 87 81 NS
Prior myocardial infarction (%) 19 19 NS
LVEF (%) 49 ± 15 58 ± 4 0.002
Resting Wall Motion Index 1.5 ± 0.7 1.0 ± 0.2 <0.001
Stress Wall Motion Index 1.5 ± 0.9 1.1 ± 0.3 0.006




858-6 Occurrence of Atrial Fibrillation in Chronic Stable CAD 
Patients Is Common and Predictable of Unfavorable 
Outcome
Yinong Young-Xu, Shmuel Ravid, Lown Cardiovascular Foundation, Brookline, MA
Background: Atrial Fibrillation (AF) is associated with increased risk of morbidity and 
mortality. Coronary artery disease (CAD) is a known risk factor for AF. We studied the 
long-term incidence and the development of associated outcomes of AF in patients with 
chronic stable CAD.
Methods: The study cohort included patients with stable CAD followed prospectively. 
Episodes of AF were documented throughout the study. The outcomes of interest were 
cardiac death, nonfatal myocardial infarction (MI), heart failure (HF), unstable angina 
(UA), revascularization and stroke. We calculated incidence rate and estimated the odds 
ratios (ORs) and 95% conﬁdence intervals (CI).
Results: 449 subjects with a mean follow-up of four years were included in the analysis.. 
A total of 52 patients developed AF during follow-up (12%). In multivariate analysis 
the occurrence of AF was not predictable by prior MI, HF, ischemia, or left ventricular 
ejection fraction. Compared with those who did not develop AF, patients with AF were 
at signiﬁcantly higher risk for having stroke (OR, 5.7), HF (OR, 6.9), revascularization 
(OR, 11.2), UA (OR, 6.8), and nonfatal MI (OR, 8.7), even after adjustment for potential 
confounders such as age, hypertension, diabetes, drug usage, and medical treatments.
Conclusion: Development of AF in patients with CAD is relatively common and is 
associated with a signiﬁcant increase in the risk of HF, UA, nonfatal MI and revascularization 
in addition to the predictable higher risk of stroke. 
ORAL CONTRIBUTIONS
862  Coronary Artery Bypass Surgery: 
Still the Underutilized Therapy for 
Multivessel Disease in Diabetics
Tuesday, March 08, 2005, 4:00 p.m.-5:00 p.m.
Orange County Convention Center, Room 231A
4:00 p.m.
862-3 Differential Impact of Coronary Artery Bypass Graft 
Surgery and Diabetes on Cause of Death, a Long-Term 
Report from the BARI Study
David R. Holmes, Jr., Lauren Kim, Maria M. Brooks, Katherine M. Detre, Robert L. Frye, 
Mandeep Singh, Mayo Clinic, Rochester, MN, University of Pittsburgh, Pttisburgh, PA
Background: Evaluation of the cause of death may have implications for developing 
treatment strategies in patients with coronary artery disease (CAD).
Purpose: Evaluate cause of death in patients in the BARI study during long-term follow-
up and the effect of revascularization treatment and diabetes on cause of death.
Population: Of 3610 patients who received revascularization (PTCA or CABG) in 
the BARI trial and registry, 642 (18%) had diabetes. 621 patients (17%) had died at a 
mean follow-up of 7.8 years. All deaths were classiﬁed by an independent mortality and 
morbidity committee.
Results: Forty six percent (46%) of the deaths were due to cardiac causes; 17% were 
sudden cardiac deaths, 18% secondary to myocardial infarction, and 11% related to 
congestive heart failure or other cardiac causes. Of 642 diabetics in the study, 32% 
died compared to 14% of the 2968 patients who were not diabetic (p<.01). Death was 
more often due to cardiac causes among patients with diabetes compared to those 
without diabetes (51% versus 43%, p=.08), and the primary cause of death was more 
frequently congestive heart failure/other (16% versus 9%, p=.01). Using competing risks 
Cox proportional hazards models, diabetes was associated with higher rates of death 
for all causes, but the effect of diabetes on CHF/other cardiac death was signiﬁcantly 
greater compared to the effect of diabetes on other causes of death (RR=3.73 for CHF 
death vs RR=1.85 for the all other causes, p=.01). In these multivariate models, receiving 
CABG (time dependent variable) was associated with a signiﬁcant reduction in sudden 
cardiac death but was not signiﬁcantly associated with other causes of death (RR=0.61 
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for sudden cardiac death vs RR=0.97 for all other causes, p=.03).
Conclusion: Over a mean follow-up of 7.8 years, mortality was 17% in patients with 
established multivessel coronary artery disease who received revascularization. Death 
was due to cardiac causes in 46% of cases. Diabetes was associated with higher death 
rates for all causes of death, but the relative difference was most pronounced for death 
from congestive heart failure/other cardiac causes. Receiving CABG was associated with 
lower sudden death rates for all patients.
4:15 p.m.
862-4 Clinical Outcomes of Patients with Multivessel Disease 
Treated With Three or More Sirolimus-eluting Stents
Seung-Woon Rha, Awefork GebreEyesus, Pramod Kuchulakanti, Daniel A. Canos, 
George Aggrey, Jana Fournadjiev, Augusto D. Pichard, William O. Suddath, Kenneth M. 
Kent, Lowell F. Satler, Ron Waksman, Washington Hospital Center, Washington, DC
Background: Sirolimus-eluting stent (SES; CypherTM) implantation for single vessels is 
proven to be effective and durable. This study aimed to compare the clinical outcomes of 
3 or more SES implantations for multivessels to those of single SES implantation.
Methods: From our SES registry, we identiﬁed 31 patients (pts) with 71 lesions that were 
treated with 3 or more SES and 1013 pts that were treated with a single SES for various 
coronary lesions. The in-hospital, 30-day, and 6-month clinical outcomes of both groups 
were compared.
Results: Baseline characteristics were similar except for more history of diabetes mellitus 
(53.1% vs. 33.1%, P=0.02), renal insufﬁciency (22.6% vs. 8.4%, P=0.006), and restenotic 
lesions (14.1% vs. 7.2%, p=0.03) in the multiple SES group. The multiple SES group 
had a higher incidence of periprocedural CK-MB elevation (p=<0.02), abrupt closure, 
dissection, and renal failure. At 30 days and 6 months, the multiple SES group had a 
higher incidence of Q-wave and non-Q-wave myocardial infarction (MI) and TLR-MACE, 
TVR-MACE compared to the single SES group. (Table)
Conclusions: Patients with multivessel disease, requiring 3 or more SES, experience 
increased periprocedural and in-hospital complications and worse adverse clinical 
outcomes at 30 days and 6 months when compared to pts with single vessel that require 
single SES. Therefore, when 3 or more SES are needed for pts with multivessel disease, 
CABG should be considered as a revascularization alternative. 
Clinical Outcomes at 30 Days and 6 Months
Variables, % Multiple SES (n=31 pts)
Single SES 
(n=1013 pts) p Value
At 30 days 
Death 3.6 0.6 0.07
Q-wave MI 7.1 0.4 <0.001
Non-Q-wave MI 21.4 9.1 0.04
TVR-MACE 7.1 1.0 0.002
TLR-MACE 7.1 0.9 0.001
Subacute stent thrombosis 0.3 0.0 0.03
At 6 months 
Death 6.7 1.9 0.18
Q-wave MI 23.5 1.6 <0.001
Non-Q-wave MI 31.6 10.8 0.004
TVR-MACE 23.5 5.6 0.002
TLR-MACE 23.5 2.9 <0.001
TLR 6.7 1.1 0.04
TVR 6.7 2.8 0.37
4:30 p.m.
862-5 The Medicine Angioplasty Or Surgery Study (MASS 
Registry): Impact Of Diabetes On Long-term Prognosis 
In Patients With Single Or Multivesel Coronary Artery 
Disease. Five Years Of Follow-up.
Whady Hueb, Fernando Costa, Bernard J. Gerh, Neuza Lopes, Aecio Gois, Paulo Dutra, 
Desiderio Favarato, Jose R L Luces, Sergio A. Oliveira, Jose Ramires, Heart Institute 
(InCor) University of Sao Paulo, Sao Paulo, Brazil, Mayo Clinic, Rochester, MN
Background: Diabetes mellitus is a major cause of coronary artery disease (CAD).
Despite improvement in the management of patients with stable CAD diabetes remains a 
major adverse risk factor for increased morbidity and mortality. Although the frequent use 
of Coronary Artery Bypass Surgery (CABG) and Percutaneous Coronary
Intervention (PCI), there is no conclusive evidence that either treatment modality is
better then Medical Therapy (MT) alone for the treatment of single or
multivessel in patients with diabetes.
Methods: We compared MT, PCI and CABG in patients with single and multivessel 
disease in diabetic (399) and non-diabetic subjects (930). The composite primary end 
point was deﬁned as cardiac mortality; Q-wave myocardial infarction (MI); or refractory
angina requiring revascularization.
Results: A total of 1329 patients were assigned to either CABG (n=519), PCI (n= 414) 
or MT (n= 396). The ﬁve year survival rates were 88.2 % for CABG; 73.4 % for PCI and 
74.5 % for MT (p<0.0001) for diabetes and non diabetes patients. There was a signiﬁcant 
higher mortality in diabetic subjects compared to non-diabetics regardless of the tree 
therapeutic options (p <0.001). When stratiﬁed by the number of vessels disease, there 
was a signiﬁcant beneﬁt for CABG in patients with diabetes and multivessel disease 
versus single vessel (p=0.001).
Conclusion: All three therapeutic regimens resulted in a high rate of cardiac related 
death in diabetic comparing with non diabetic patients. However, we observed better 
outcome in the multivessel CAD diabetic patients undergoing to surgery regarding the 
primary end points in the 5 years of follow-up study..
4:45 p.m.
862-6 A Double-Blind, Placebo-Controlled, Crossover 
Study of the Safety of Intravenous Glyceryl Trinitrate 
After Administration of Sildenaﬁl Citrate to Men With 
Coronary Artery Disease
John D. Parker, Bradley A. Bart, David Webb, Michael J. Koren, Richard L. Siegel, Susan 
Nicholas, Mount Sinai and University Health Network Hospitals, Toronto, ON, Canada, 
Hennepin County Medical Center, Minneapolis, MN
Background: Nitrate and sildenaﬁl coadministration is contraindicated, and the ACC/AHA 
Expert Consensus Document does not recommend coadministration within 24 hours unless 
beneﬁts far outweigh risks. This double-blind study assessed intravenous (IV) glyceryl 
trinitrate (GTN) in men with coronary artery disease (CAD) who had taken sildenaﬁl.
Methods: 34 men (≥35 years) with a history of angina pectoris and CAD (>50% stenosis 
of ≥1 coronary artery) were randomized to a single dose of sildenaﬁl 100 mg or placebo 
(with crossover after 3-7 days) followed in 45 min by escalating doses of IV GTN.
Results: After sildenaﬁl, 2 men were discontinued following GTN 5 µg/min for asymptomatic 
hypotension and 1 for nausea. The maximum infusion rate at discontinuation for sildenaﬁl 
versus placebo was: median (range), 80 (0-160) versus 160 (20-160) µg/min; adjusted 
mean ± SE, 77±7 versus 127±7 (P<0.0001; ANOVA). GTN 160 µg/min was tolerated by 
8 (sildenaﬁl) and 19 (placebo) men. Maximum decreases in supine blood pressure (BP) 
and increases in supine heart rate (HR) were slightly greater for sildenaﬁl than placebo 
at most GTN doses (Table). Adverse events were mostly mild or moderate hypotension, 
headache, dizziness, and paresthesia. These events were not unexpected and are often 
associated with GTN alone.
Conclusions: Most men with CAD who have taken sildenaﬁl tolerate a low dose of IV 
GTN with gradual upward titration, while BP and HR are monitored closely. 
Difference in Adjusted Mean ± SE Changes From Baseline: Sildenaﬁl - Placebo



















 ‡ -4±3 -5±2 -6±2 ** 0.5±2 -7±4
DBP,
mmHg -1±2 -2±2 -2±2 -3±2 -2±2 -2±3 -0.7±3
HR,
bpm 0.5±2 0.1±0.7 -0.3±1 1±2 0.9±2 9±4
‡ 5±4
*32 men completed the study; the other 2 had SBP below protocol cutoff after sildenaﬁl.
†GTN dose was escalated every 10 min. Infusion was stopped when systolic BP (SBP) decreased either by 
>35 mm Hg from the pre-GTN measurement, or decreased to <100 mm Hg and was sustained for 1 min; or 
HR increased >25 bpm from the pre-GTN measurement, or increased to >100 bpm and was sustained for 1 
min; or if the subject, in the opinion of the investigator, suffered signiﬁcant hypotensive symptoms.
‡P<0.05, **P<0.01 (ANOVA); DBP=diastolic BP; bpm=beats/min.
ORAL CONTRIBUTIONS
872FO  Featured Oral Session... Antiplatelet 
Therapy in ST-Segment Elevation 
Myocardial Infarction
Wednesday, March 09, 2005, 8:30 a.m.-10:00 a.m.
Orange County Convention Center, Room 231A
8:45 a.m.
872-4 Upstream Administration of Abciximab Prior to 
Primary Angioplasty Improves Epicardial Patency and 
Myocardial Tissue Perfusion - Results From a Meta-
Analysis of 602 Cases
Jochen Goedicke, Marcus Denis Flather, Hans-Richard Arntz, Henrique Mesquita 
Gabriel, Lars Grip, Kurt Huber, Marko Noc, Gilles Montalescot, Eli Lilly, Critical Care 
Europe, Geneva, Switzerland, Clinical Trials and Evaluation Unit, Royal Brompton 
Hospital, London, United Kingdom
Background: The 2004 ACC/AHA guidelines on STEMI state that it is reasonable 
to start treatment with Abciximab (ABC) as early as possible before primary PCI. 
While there is ample evidence for peri-procedural (=late) application of ABC, data on 
upstream application (=early) is limited to several but small studies. This meta-analysis 
was performed to provide more robust information on surrogate parameters as well as 
estimates for potential beneﬁt on clinical outcomes.
Methods: 6 prospective studies that compared early and late start of ABC were identiﬁed. 
The investigators from ADMIRAL, BRIDGING, ERAMI, REOMOBILE, SWEDES and 
Zorman et al provided individual patient data to the co-ordinating center. Analyses 
were performed on the composite of death, reinfarction (re-MI) and target vessel 
revascularisation (TVR) at 30 days (primary outcome), death alone, major bleeding, TIMI 
ﬂow and ST-resolution (ST-RES) after PCI. Planned subgroup analyses were performed 
for PCI<3hrs or >=3hrs from symptom onset.
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Early Late p / OR (95% CI)
Median ABC to Angio (min, IQR) 50 (32 to 73)(246/260)
5 (-9 to 30)
(267/342) p=<0.001
Pre-PCI TIMI 2/3 42%(107/255)
29%
(98/337) p=0.001






ST-RES >=70% (PCI>=3hrs) 62%(53/85)
36%
(27/74) p=0.005




















Conclusions: Starting ABC early for primary PCI is feasible and appears safe. The 
incidence of death and the composite of death, re-MI and TVR appears lower with ABC 
started early. Early ABC improves epicardial patency prior to PCI, which is predominantly 
present in PCIs performed <3hrs from symptom onset. In delayed PCIs (>=3hrs from 
symptom onset) early ABC can restore myocardial tissue perfusion as assessed by post-
PCI ST-RES to a similar level to that observed with PCI <3hrs.
9:00 a.m.
872-5 Safety of Glycoprotein 2b/3a Inhibitors in Patients with 
Acute Myocardial Infarction requiring Percutaneous 
Coronary Intervention after Thrombolytic Therapy: A 
Report From The New York State Angioplasty Registry
Alexander J. Slotwiner, Robert M. Minutello, Atul Sharma, James A. Kong, Steve S. Kim, 
Mun K. Hong, Manish Parikh, Geoffrey Bergman, S. Chiu Wong, New York Presbyterian 
Hosp.-Weill Med. College of Cornell Univ., New York, NY
Background: Few studies have examined glycoprotein 2b/3a inhibitor (GPI) use in 
patients with acute myocardial infarction (AMI) who received antecedent thrombolytic 
therapy. Therefore, we sought to ascertain in-hospital outcomes in this patient cohort.
Methods: Using the 2000-2001 New York State PCI Database, we identiﬁed patients with 
AMI treated with thrombolytic therapy who subsequently underwent PCI with and without 
GPIs (N=1,053). All patients identiﬁed received thrombolytic therapy within 6 hours of PCI.
Results: Of 1,053 patients who underwent rescue angioplasty for AMI, 686 (65%) patients 
received GPI and 367 (35%) had not. There was no signiﬁcant difference in baseline 
characteristics. Similarly, there was no difference in inpatient clinical outcomes between 
the two groups with respect to death, emergent CABG, access site injury requiring 
surgical treatment, renal failure requiring dialysis, stent thrombosis, or length of hospital 
stay. Importantly, only 9 patients in the GPI group (1.3%) experienced a stroke post PCI, 
in comparison to 5 (1.4%) in the non-GPI group (p= NS).
Conclusion: The use of peri-procedural PCI GPIs after recent thrombolytic therapy does 
not pose an increased risk of major inpatient clinical adverse events, including stroke. It 
therefore appears safe to use a GPI during PCI in the setting of an AMI in a patient who 
received thrombolytics.





Death (%) 4.5 5.4 NS
Emergent CABG (%) 0.4 0.3 NS
Length of stay (days) 5.4 +/- 6.5 5.8 +/- 8.0 NS
Access site injury (%) 0.3 0.3 NS
Renal failure requiring dialysis (%) 0.4 0.5 NS
Stent thrombosis (%) 0.9 0.5 NS
Stroke (%) 1.3 1.3 NS
9:15 a.m.
872-6 CLARITY-TIMI 28: Primary Results
Marc S. Sabatine, Christopher P. Cannon, C. Michael Gibson, Jose Lopez-Sendon, 
Gilles Montalescot, Marc Claeys, Frank Cools, Carolyn H. McCabe, Eugene Braunwald, 
Brigham and Women’s Hospital, Boston, MA
Background: Although ﬁbrinolysis is effective in improving outcomes in ST-elevation 
myocardial infarction (STEMI), failure to achieve reperfusion and/or reocclusion of the 
infarct-related artery occur in substantial proportions of patients and are associated with 
a signiﬁcant increase in morbidity and mortality. We hypothesized that the addition of the 
oral antiplatelet agent clopidogrel, an adenosine diphosphate (ADP)-receptor antagonist, 
to standard ﬁbrinolytic therapy in patients with STEMI will improve reperfusion.
Methods: CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY) - Thrombolysis 
In Myocardial Infarction (TIMI) 28 is a multicenter, international, randomized, double-
blind, placebo-controlled trial enrolling 3500 patients between the ages of 18 and 75 with 
STEMI, presenting within 12 hours of symptom onset and in whom ﬁbrinolysis is planned. 
Subjects are randomized in a 1:1 ratio to receive clopidogrel (300 mg loading dose, then 
75 mg daily) or placebo. The choice of ﬁbrinolytic and anticoagulant is at the discretion 
of the treating physician, and all patients are to receive aspirin. Patients are scheduled 
to undergo angiography during the index hospitalization 48-192 hours after the start of 
study medication.
Results: The primary results will be ready for presentation at the ACC 2005. The primary 
endpoint is the composite of death or recurrent MI by the start of coronary angiography 
or an occluded infarct-related artery (TIMI Flow Grade 0 or 1) on the pre-discharge 
angiogram. Secondary endpoints are (1) Clinical: death, recurrent MI, or recurrent 
myocardial ischemia by the time of the start of coronary angiography; (2) Angiographic: 
TFG 0 or 1 in the infarct-related artery on the pre-discharge angiogram; and (3) 
Electrocardiographic: degree of ST segment resolution at 180 minutes. The primary safety 
endpoint is the rate of TIMI major bleeding.
Conclusions: CLARITY-TIMI 28 will help deﬁne the role of clopidogrel as a part of the 
pharmacologic reperfusion regimen in acute STEMI.
9:30 a.m.
872-7 Adjunctive Abciximab To Reperfusion Therapy In 
Patients With Acute St-segment Elevation Myocardial 
Infarction: A Meta-analysis Of Randomized Trials
Giuseppe De Luca, Harry Suryapranata, Gregg W. Stone, David Antoniucci, James E. 
Tcheng, Franz-Josef Neumann, Frans Van de Werf, Elliott M. Antman, Eric J. Topol, De 
Weezenlanden Hospital, Zwolle, The Netherlands
Background. The beneﬁts of abciximab in patients with ST-segment elevation myocardial 
infarction (STEMI) is still a matter of debate. The aim of this meta-analysis was to combine 
data from all randomized trials conducted with abciximab in STEMI.
Methods. We obtained results from all completed randomized trials with abciximab 
in STEMI, by formal searches of electronic databases (MEDLINE, Pubmed). Odds 
ratio (OR) and 95% conﬁdence intervals (95% CI) were reported. A ﬁrst analysis was 
performed according to the treatment strategy (primary angioplasty or thrombolysis). The 
ﬁnal analysis was conducted including all trials. The pooled odds ratio was calculated 
by the Mantel-Haenszel method, whereas the Breslow-Day test was used to examine 
heterogeneity across the studies.
Results. Fifteen studies were analyzed, involving 13,140 patients randomized to 
abciximab, and 14,910 to control. When compared to control group, abciximab was 
associated with a signiﬁcant reduction in long-term mortality in patients undergoing 
primary angioplasty (4.4% vs 6.1%, p=0.015), but not in those treated with thrombolysis 
(8.6% vs 8.3%, p=NS). Furthermore, abciximab was associated with a signiﬁcant 
reduction in 30-day reinfarction, both in primary angioplasty (1.0% vs 1.9%, p=0.026) 
and in thrombolysis trials (2.3% vs 3.5%, p<0.0001), and in all trials combined (2.1% vs 
3.3%, p<0.0001). Abciximab did not result in an increased risk of intracranial bleeding 
(0.65% vs 0.64%, p=NS), but was associated with an increased risk of major bleeding 
complications when combined with thrombolysis (5.4% vs 3.1%, p<0.0001), but not with 
primary angioplasty (4.9% vs 4.2%, p=NS).
Conclusions. This meta-analysis shows that, when compared to control group, adjunctive 
abciximab for STEMI is associated with a signiﬁcant reduction in long-term mortality in 
patients treated with primary angioplasty, but not in those receiving thrombolytic therapy. 
The 30-day reinfarction rate is signiﬁcantly reduced in patients treated with either 
thrombolysis or primary angioplasty. A higher risk of major bleeding complications is 
observed with abciximab in association with thrombolytic therapy.
9:45 a.m.
872-8 In-Hospital Adherence to Current Guidelines is not 
Optimal for Antiplatelet and Antithrombotic Therapies 
in Patients With Acute Myocardial Infarction: Insights 
From the International Valsartan in Acute Myocardial 
Infarction (VALIANT) Registry
Gustavo B.F. Oliveira, Rakhi Kilaru, Michael P. Hudson, Eric J. Velazquez, Duke Clinical 
Research Institute, Duke University Medical Center, Durham, NC, Henry Ford Hospital, 
Detroit, MI
Background. Current guidelines recommend aspirin (ASA) to all AMI patients (pts) 
on admission and indeﬁnitely after discharge; thienopyridines (Thieno) to pts with ASA 
intolerance, coronary stents, or NSTEMI; anticoagulation with either UFH or LMWH to 
NSTEMI pts; and GP IIb/IIIa inhibitors to NSTEMI pts and managed with percutaneous 
coronary intervention (PCI). Methods. We analyzed data from 4370 pts with STEMI or 
NSTEMI enrolled in the international VALIANT Registry from 1999-2001. Patterns of use 
of antiplatelets (AP) and antithrombins (AT) were assessed to determine actual adherence 
to guidelines. Early (<24h) and discharge use is displayed by type of AMI and by PCI/no-
PCI (Figure). Results. Among pts not treated with early or discharge ASA, 86% and 83%, 
respectively, did not receive any Thieno. In STEMI pts, 16% and 14% did not receive 
early AP and AT, respectively, and 14% were not discharged on AP. In NSTEMI pts, 21% 
and 24% did not receive early AP and AT, respectively, and 20% were not discharged on 
AP. No-PCI patients less frequently received AP upon discharge as compared to PCI-
managed pts (75% vs 95%, respectively, p<0.001).
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Conclusions. STEMI pts and those managed with PCI more frequently received early 
GP IIb/IIIa inhibitors and UFH, and ASA and Thieno both early and at discharge, than 
NSTEMI pts and no-PCI pts. Only LMWH was preferentially used in NSTEMI pts and 
in no-PCI pts. Despite guidelines, many eligible AMI pts do not receive AP and AT 
appropriately, and no-PCI pts are particularly undertreated.
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877-4 Intrinsic Inhibitors of Complement Activation 
Dramatically Limit Infarct Following Coronary Occlusion
Nikolay Vasilyev, Arman Askari, Feng Lin, Lisa Kuttner-Kondo, Maryann Fitzmaurice, 
Edward Medof, Marc S. Penn, Cleveland Clinic Foundation, Cleveland, OH, Case 
Western Reserve University, Cleveland, OH
Background: The extent of myocardial damage following coronary occlusion is 
determined not only by the area deprived of perfusion but also by hypoxic reperfusion 
injury extending from this site. Although complement has been implicated in this process, 
the role of the cell surface intrinsic complement regulators (which protect self cells from 
complement mediated damage) in limiting the extension is unstudied. Important among 
these regulators are decay accelerating factor (DAF) and CD59.
Methods: To address this issue we compared infarct size and mortality in wild type (WT) 
and mice targeted in the DAF, CD59 or both genes. After 30 min of ischemia and 60 
min of reperfusion following LAD occlusion, infarct size was assessed as percent area 
at risk (IS%AAR) using tetrazolium/Evan’s blue staining. To verify the involvement of 
complement, we assessed C3b and C9 deposition by immunohistochemistry.
Results: In Daf-/-CD59-/- mice, IS%AAR was markedly greater than in WT mice (62.3 ± 
4.0% (n=4) vs. 47.4 ± 2.3% (n=5), p<0.001). C3b and C9 deposition in microvasculature 
was greatly enhanced. To determine the relative importance of DAF and CD59, we 
compared IS%AAR in Daf-/- and CD59-/- mice. The absence of DAF had a signiﬁcantly 
greater effect (Daf-/-: 61.7 ± 6.0, n=9; CD59-/-: 53.2 ± 1.9, n=8, p<0.001).
Conclusion: These data establish that intrinsic complement regulators play a key role in 
protecting microvascular patency, and consequently attenuate infarct size in the course of 
infarction. They show that DAF plays a greater role than CD59 and open the possibility of 
developing new agents for therapeutic intervention in myocardial infarction patients.
11:00 a.m.
877-5 Angiotensin II Receptor Blockade With Losartan 
Reduces Apoptosis and Infarct Size Following 
Ischemia/reperfusion in the Rabbit Heart
Shinji Okubo, Patrick W. Fisher, Fadi Salloum, Ramzi Ockaili, Vijay Marwaha, Giuseppe 
Ambrosio, Michael L. Hess, Rakesh C. Kukreja, Virginia Commonwealth University 
Medical Center, Richmond, VA, University of Perugia School of Medicine, Perugia, Italy
Background: Recent studies suggest that cardiac renin angiotensin system is activated 
during acute myocardial ischemia. Formation of angiotensin II (A-II) may contribute to 
neutrophil activation, resulting in tissue injury during reﬂow. We hypothesized that blockade 
of A-II receptors with losartan may attenuate ischemia/reperfusion (IR) injury in vivo.
Methods: Three groups of rabbits (n=6/group) were treated with either saline, losartan 
5 mg/kg or 25 mg/kg iv 30 min prior to ischemia. All animals were subjected to regional 
ischemia by 30 min LAD occlusion with 3 hrs of reperfusion. Risk area (RA) was 
determined by injection of Evan’s blue. Infarct size (IS) was determined by morphometry 
of tetrazolium stained sections. Apoptotic Index ([TUNEL positive myocyte nuclei/total 
myocyte nuclei] x 100) was determined using TUNEL technique in cryosections from 
infarct border zone.
Results: RA was not signiﬁcantly different between groups (P>0.05). Losartan-treated 
rabbits exhibited a dose-dependent reduction in IS following IR. In contrast, mean arterial 
blood pressure (MAP) during reperfusion was signiﬁcantly lower in losartan group (5 mg/
kg) compared to saline. Apoptosis was increased in saline group compared to all groups, 
the most marked reduction being in losartan (5 mg/kg) vs. losartan (25 mg/kg). These 
results indicate that A-II receptor blockade exerts a potent anti-infarct and anti-apoptotic 
effect in rabbit heart, by a mechanism that is independent of MAP-lowering.
Effect of Losartan on Infarct Size, Mean Arterial  
Blood Pressure, and Apoptosis 
Group IS RA MAP Apoptotic Index
(% RA) (% LV) (mmHg) (%)
Saline 42.0±2 57±7 75±5 2.86±0.6
Losartan (5 mg/kg) 31.5±4* 48.0±7 52±3* 0.01±0.01*,#
Losartan (25 mg/kg) 13.7±1*,** 54.8±3 48±5* 0.43±0.3*
*P<0.05 vs. saline, **P<0.05 vs. losartan (5 mg/kg), #P<0.001 vs. losartan (25 mg/kg).
11:15 a.m.
877-6 Effects Of Ramipril, An Angiotensin Converting 
Enzyme Inhibitor, On Apoptotic Associated Molecular 
Expression In Ischemic Reperfused Myocardium
Zhong Jing Wang, How Sung Lee, Yi Zhun Zhu, National University of Singapore, 
Singapore, Singapore
Apoptosis has been emerged as a predominant mode contributed to cardiomyocyte loss 
with the pathophysiological consequences and may associate to the ventricular remodeling 
and left ventricular dysfunction after myocardial ischemia/reperfusion (I/R). Attenuation of 
cardiomyocyte apoptosis may be one of the cardioprotective mechanisms by Angiotensin 
Converting Enzyme inhibitors (ACEI) in preventing adverse cardiac hypertrophy/
remodeling and preservation of global left ventricular function. The purpose of this study 
was to globe identify the changes of myocardial apoptosis associated transcripts under 
the effects of ramipril, an ACEI, in the early I/R phase and speciﬁcally to further deﬁne 
these genes in myocardium. Using Affymetrix oligonucleotide microarray technology, we 
identiﬁed and analyzed several ACE mediated transcripts in reperfused myocardium. 103 
probe sets showed increase whereas 101 probe sets demonstrated decrease in 2-fold or 
more in ramipril treated sample. Among these probe set, four apoptotic transcripts which 
encoding Bcl-2, NF-κB, SOD-1 and CCAAT/enhancer binding protein-β (Cebp-β) were 
shown upregulation and eight apoptotic associated probe set which transcript to caspase-
3, caspase-1, Bax, Bad, Bcl-xS, TNFR-1, p53 and Gsk3-β were shown downregulation. 
The up- and down-regulation of these pro-apoptotic genes were further conﬁrmed and 
characteristic by semi-quantitative reverse-transcription-polymerase china reaction (RT-
PCR), immunobloting and immunohistochemistry in a time course. The caspase-3 activity 
was furthermore veriﬁed by caspase-3 activity assay (ﬂuorogenic AFC-DEVD method). 
The ﬁndings have provided a new insight into the mechanism of ACEI in the prevention of 
myocardial apoptosis following I/R injury.
11:30 a.m.
877-7 Nitroxyl Requires Calcitonin Gene-Related Peptide 
(CGRP) Signaling but not Protein Kinase C to Afford 
Early-Preconditioning Effect in Rat Heart.
Pasquale Pagliaro, Daniele Mancardi, Claudia Penna, Sandra Cappello, Carlo G. 
Tocchetti, David A. Wink, Gianni A. Losano, Nazareno Paolocci, Dipartimento di Scienze 
Cliniche e Biologiche dell’Universita di Torino, Orbassano, Italy, Johns Hopkins Medical 
Institutions, Baltimore, MD
Background: Donors of nitroxyl (HNO/NO-), the reduced form of nitric oxide (NO), induce 
early preconditioning (PC)-like effects in isolated rat hearts. Nitroxyl-induced protection 
is somehow larger than that afforded by equimolar doses of NO donors. Then, it is 
plausible to hypothesize that HNO and NO donors can use, at least in part, discrete 
signaling pathways to protect myocardium against reperfusion injury. Protein kinase C 
(PKC) activation is one of the tenets of NO-induced protection. On the other hand, in vivo 
HNO cardiotropic action appears to be linked to calcitonin gene-related peptide (CGRP) 
signaling pathway. CGRP blockade has been already shown to prevent NO/nitrate-
induced early-PC effect in rats. Here we tested whether nitroxyl early PC-like action is 
dependent upon PKC activation and assessed the involvement of CGRP receptors in 
HNO-induced myocardial protection. 
Methods: Isolated rat hearts were subjected to 30’ global ischemia followed by 120’ 
reperfusion. Infarct size (IS) was measured by staining myocardium with nitro-blue 
tetrazolium. 
Results: In controls, IS was 67±6% (n=9). Three cycles of PC (3’ global ischemia 
+ 5’ reperfusion each = IPC3) substantially reduced IS (32±5.5%, n=9, p<.01). In lieu 
of ischemic PC, the nitroxyl donor Angeli’s salt (AS, 1µM for 19’) similarly reduced IS 
(38±3.5%, p<.01 vs. control, n=8, p=NS vs IPC3). The PKC inhibitor GF109203X (0.5 
µM for 29’) co-infused with AS did not reverse the protection achieved with nitroxyl 
(IS=31±5.5%, n=5). In stark contrast, blockade of CGRP receptors by means of the 
selective antagonist CGRP8-37 infusion (0.1µM for 29’) completely abrogated nitroxyl-
induced cardiac protection (IS=63±9%, n=5, p=NS vs. controls). 
Conclusions: Herein, we demonstrate for the ﬁrst time that in isolated rat hearts the 
preconditioning effects of exogenous nitroxyl, similarly to NO/nitrate donors, involve a 
CGRP receptor-coupled pathway. However, differently from NO donors HNO does 
not require the activation of a PKC-dependent pathway to afford protection against 
reperfusion injury.
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877-8 Intra-Aortic Balloon Counterpulsation During 
Myocardial Reperfusion Increases Coronary Blood Flow 
and Myocardial Salvage: Experimental Study
Michalis Bonios, Argirios Ntalianis, Stavros Stavrakis, Stavros Drakos, Paraskevi 
Savvari, Dimitrios Koudoumas, Paraskevi Dolou, Charalampos Pierrakos, Apostolos 
Papalois, John Nanas, University of Athens, Athens, Greece
Background: The beneﬁcial effects of the IABP on the outcome of patients undergoing 
primary angioplasty in the setting of acute myocardial infarction have been controversial. 
We sought to investigate the effects of the IABP on the extent of infarct size, the no-
reﬂow phenomenon and coronary blood ﬂow (CBF) during reperfusion in an ischemia-
reperfusion experimental model.
Methods: A 30-ml IABP was placed in the descending aorta of 11 open-chest pigs. Each 
pig underwent occlusion of the mid left anterior descending (LAD) coronary artery for 1 h, 
followed by reperfusion for 2 h. The mean CBF, distal to the LAD occlusion site was measured 
with a transit-time ultrasound ﬂowmeter. In 6 experiments, IABP support was used during 
reperfusion. At the end of each experiment the infarcted (IA) and the no-reﬂow (NRA) area 
were also measured with the use of coloring matters (tetrazolium and thioﬂavine).
Results: The results are shown in the table. CBF at reperfusion was normalized with 
respect to baseline values (% of baseline CBF). 
Reperfusion
(min)
1 15 30 45 60 90 120
CBF
(ml/min) IABP yes 241+/-88% 240+/-63% 189+/-57% 155+/-43% 90+/-71% 87+/-43% 55+/-61%
IABP no 121+/-112% 73+/-105% 50+/-83% 51+/-75% 17+/-63% -0.07+/-45% -18+/-45%
p 0.06 0.01 0.01 0.03 0.05 0.05 0.01
NRA IABP yes 36.4%
IABP no 69.4%
p 0.01
IA IABP yes 36.7%
IABP no 72.0%
p 0.02
Conclusions: The IABP succeeded in reducing the infarct size and the no-reﬂow 
phenomenon, probably due to increased CBF during the reperfusion period.
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